,Unnamed: 0,Title,Status,Interventions,Gender,Age,Phases,Enrollment,Start Date,Completion Date,Locations,URL
0,0,Duvelisib to Combat COVID-19,Recruiting,Drug: Duvelisib|Procedure: Peripheral blood draw|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,28.0,"October 12, 2020","April 30, 2022",United States,https://ClinicalTrials.gov/show/NCT04372602
1,1,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Recruiting,Drug: Decitabine|Other: Placebo Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"September 14, 2020",July 2021,United States,https://ClinicalTrials.gov/show/NCT04482621
2,2,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Recruiting,Drug: Infliximab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,17.0,"June 1, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04425538
3,3,Safety & Performance Evaluation of Seraph 100 in Treatment of Pts With COVID-19,Not yet recruiting,Device: Seraph 100,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,42.0,"December 15, 2020","April 15, 2021",Netherlands,https://ClinicalTrials.gov/show/NCT04547257
4,4,Safety and Efficacy of C21 in Subjects With COVID-19,Completed,Drug: C21|Drug: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,106.0,"July 21, 2020","October 13, 2020",India,https://ClinicalTrials.gov/show/NCT04452435
5,5,Application of Desferal to Treat COVID-19,Recruiting,Drug: Deferoxamine,All,"3 Years to 99 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,50.0,April 2020,March 2021,"Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04333550
6,6,Dornase Alpha for the Treatment of COVID-19,Recruiting,Drug: Pulmozyme,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 25, 2020","September 25, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04432987
7,7,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"Active, not recruiting",Drug: Favipiravir|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,100.0,"March 25, 2020",July 2020,Italy,https://ClinicalTrials.gov/show/NCT04336904
8,8,Study of AZD1222 for the Prevention of COVID-19 in Japan,"Active, not recruiting",Drug: AZD1222|Drug: 0.9% (w/v) saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,256.0,"August 23, 2020","November 10, 2021",Japan,https://ClinicalTrials.gov/show/NCT04568031
9,9,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,Recruiting,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"May 22, 2020","August 22, 2020",Spain,https://ClinicalTrials.gov/show/NCT04445272
10,10,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,Recruiting,Biological: anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,131.0,"May 11, 2020","May 1, 2023",United States,https://ClinicalTrials.gov/show/NCT04354831
11,11,AZD1222 Vaccine for the Prevention of COVID-19,Suspended,Biological: AZD1222,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,100.0,"September 2, 2020","March 12, 2021",Russian Federation,https://ClinicalTrials.gov/show/NCT04540393
12,12,Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,Not yet recruiting,Drug: Tocilizumab|Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,310.0,"April 15, 2020","October 31, 2020",Malaysia,https://ClinicalTrials.gov/show/NCT04345445
13,13,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Recruiting,Drug: Emtricitabine/tenofovir|Drug: Colchicine Pill|Drug: Rosuvastatin|Other: Standard treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1200.0,"August 18, 2020","February 28, 2021",Colombia,https://ClinicalTrials.gov/show/NCT04359095
14,14,Inhaled Nitric Oxide for Preventing Progression in COVID-19,Recruiting,Drug: Nitric Oxide,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,42.0,"May 12, 2020","July 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04388683
15,15,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults",Recruiting,Drug: AZD7442|Drug: Placebo,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,1125.0,"December 2, 2020","January 4, 2022",Georgia,https://ClinicalTrials.gov/show/NCT04625972
16,16,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Recruiting,Dietary Supplement: Quercetin Phytosome,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"October 29, 2020","June 28, 2021",Pakistan,https://ClinicalTrials.gov/show/NCT04578158
17,17,A Trial of NT-I7 in COVID-19 (SPESELPIS),Recruiting,Drug: Double-Blind NT-I7|Drug: Double-Blind Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,30.0,August 2020,December 2021,United States,https://ClinicalTrials.gov/show/NCT04501796
18,18,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,Not yet recruiting,Device: Hyperbaric Oxygen Therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,48.0,April 2020,June 2020,United States,https://ClinicalTrials.gov/show/NCT04343183
19,19,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.",Recruiting,Drug: AZD7442|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,5000.0,"November 21, 2020","February 3, 2022",Belgium,https://ClinicalTrials.gov/show/NCT04625725
20,20,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,Recruiting,Drug: Clevudine|Drug: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 6, 2020","December 31, 2020","Korea, Republic of",https://ClinicalTrials.gov/show/NCT04347915
21,21,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,3170.0,"April 3, 2020","March 30, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04333407
22,22,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),Recruiting,Drug: Aprepitant injectable emulsion|Drug: Saline Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"July 20, 2020",March 2021,Puerto Rico,https://ClinicalTrials.gov/show/NCT04470622
23,23,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,Not yet recruiting,Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"August 15, 2020","February 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04452669
24,24,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),Recruiting,Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban,All,"18 Years and older   (Adult, Older Adult)",Phase 4,186.0,"October 13, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04406389
25,25,COVID-19 Convalescent Plasma (CCP) Transfusion,Recruiting,Biological: COVID Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,100.0,"June 1, 2020","May 31, 2022",United States,https://ClinicalTrials.gov/show/NCT04412486
26,26,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,"Active, not recruiting",Biological: Ad5-nCoV,All,"18 Years and older   (Adult, Older Adult)",Phase 1,149.0,"September 29, 2020","June 30, 2021",China,https://ClinicalTrials.gov/show/NCT04552366
27,27,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,Recruiting,Device: oxyhydrogen|Device: Oxygen,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,100.0,"February 15, 2020","August 1, 2020",China,https://ClinicalTrials.gov/show/NCT04336462
28,28,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Recruiting,Drug: Lambda 180 mcg S.C,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"August 5, 2020","December 31, 2021",Israel,https://ClinicalTrials.gov/show/NCT04534673
29,29,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,Recruiting,Drug: ABX464|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1034.0,"May 1, 2020","April 30, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04393038
30,30,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,Recruiting,Drug: Melatonin|Other: Placebo (Methylcellulose) capsule,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"November 6, 2020","March 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04474483
31,31,The Role of Resistant Starch in COVID-19 Infection,Recruiting,Drug: Dietary Supplement containing resistant starch|Dietary Supplement: Placebo Starch,All,"19 Years and older   (Adult, Older Adult)",Phase 3,1500.0,"June 3, 2020","June 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04342689
32,32,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,Recruiting,Drug: Tocilizumab|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,332.0,"September 10, 2020","March 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04479358
33,33,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,Recruiting,Drug: FT516,All,"18 Years to 76 Years   (Adult, Older Adult)",Phase 1,12.0,"May 14, 2020",January 2022,United States,https://ClinicalTrials.gov/show/NCT04363346
34,34,C5a Receptor Expression - COVID-19 (C5-COV),Recruiting,Other: draw blood,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"March 31, 2020",November 2020,France,https://ClinicalTrials.gov/show/NCT04369820
35,35,TXA127 for the Treatment of Severe COVID-19,Recruiting,Drug: TXA127|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,August 2020,December 2021,United States,https://ClinicalTrials.gov/show/NCT04401423
36,36,Genosvid Diagnostic Test for Early Detection of COVID-19,Recruiting,Other: exhaled breath sampling,All,"4 Years and older   (Child, Adult, Older Adult)",Not Applicable,1543.0,"April 1, 2020","December 31, 2020",Indonesia,https://ClinicalTrials.gov/show/NCT04558372
37,37,Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19,Not yet recruiting,Drug: Placebo|Drug: Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,51.0,"October 20, 2020","June 20, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04514302
38,38,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Recruiting,Drug: Standard Treatment|Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions,All,"10 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,200.0,"April 1, 2020","November 1, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04392141
39,39,Vitamin D Supplementation in Patients With COVID-19,Completed,Dietary Supplement: Vitamin D|Dietary Supplement: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240.0,"June 1, 2020","October 7, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04449718
40,40,DAS181 for Severe COVID-19: Compassionate Use,Completed,Drug: DAS181,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,4.0,"March 6, 2020","April 30, 2020",China,https://ClinicalTrials.gov/show/NCT04324489
41,41,Multi-site Adaptive Trials for COVID-19,Completed,Drug: SOC + Intravenous Famotidine|Drug: SOC + Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,233.0,"April 7, 2020","September 7, 2020",United States,https://ClinicalTrials.gov/show/NCT04370262
42,42,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,Not yet recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"August 20, 2020","December 31, 2020",Peru,https://ClinicalTrials.gov/show/NCT04497324
43,43,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Recruiting,Dietary Supplement: Oral supplement enriched in antioxidants|Dietary Supplement: cellulose-containing placebo capsules,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,40.0,"September 1, 2020","December 30, 2020",Saudi Arabia,https://ClinicalTrials.gov/show/NCT04323228
44,44,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,Biological: exchange blood transfusion from normal donor|Biological: plasma from convalescent patients with COVID-19|Drug: Methylene Blue 5 MG/ML,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,15.0,"May 20, 2020","September 1, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04376788
45,45,Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19),"Active, not recruiting","Drug: Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60.0,"February 6, 2020","January 31, 2021",China,https://ClinicalTrials.gov/show/NCT04664010
46,46,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,Procedure: CT-scan with minimal invasive autopsy,All,"Child, Adult, Older Adult",Not Applicable,45.0,"April 14, 2020",December 2020,Belgium,https://ClinicalTrials.gov/show/NCT04366882
47,47,Study of Open Label Losartan in COVID-19,Completed,Drug: Losartan,All,"18 Years and older   (Adult, Older Adult)",Phase 1,34.0,"April 4, 2020","August 17, 2020",United States,https://ClinicalTrials.gov/show/NCT04335123
48,48,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Active, not recruiting",Drug: Favipiravir|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,330.0,"April 23, 2020",July 2020,Russian Federation,https://ClinicalTrials.gov/show/NCT04434248
49,49,Dapagliflozin in Respiratory Failure in Patients With COVID-19,Recruiting,Drug: Dapagliflozin 10 MG|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900.0,"April 22, 2020",December 2020,Brazil,https://ClinicalTrials.gov/show/NCT04350593
50,50,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Recruiting,Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,80.0,"September 14, 2020",June 2021,France,https://ClinicalTrials.gov/show/NCT04372979
51,51,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,Recruiting,Biological: Convalescent Plasma|Other: Best Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,306.0,"November 6, 2020",November 2021,Jersey,https://ClinicalTrials.gov/show/NCT04456413
52,52,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Recruiting,Drug: CPI-006|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1,60.0,"July 1, 2020","August 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04464395
53,53,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,"Active, not recruiting",Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52.0,"April 9, 2020",April 2021,Jersey,https://ClinicalTrials.gov/show/NCT04343755
54,54,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19",Recruiting,Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,2104.0,"June 16, 2020","December 19, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04425629
55,55,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,Other: hyperimmune plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,49.0,"March 17, 2020","May 7, 2020",Italy,https://ClinicalTrials.gov/show/NCT04321421
56,56,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",Drug: Aprotinin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"June 11, 2020","August 31, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04527133
57,57,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease",Recruiting,Drug: Pamrevlumab|Drug: Placebo,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 2,130.0,"June 20, 2020",January 2021,United States,https://ClinicalTrials.gov/show/NCT04432298
58,58,Ivermectin for Severe COVID-19 Management,Completed,Drug: Ivermectin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,60.0,"May 11, 2020","September 2, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04646109
59,59,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,Terminated,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,148.0,"April 13, 2020","July 20, 2020",Canada,https://ClinicalTrials.gov/show/NCT04329611
60,60,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,Not yet recruiting,Dietary Supplement: Probiotics (2 strains 10x10^9 UFC)|Dietary Supplement: Placebo (potato starch and magnesium stearate),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84.0,"November 16, 2020",March 2021,Canada,https://ClinicalTrials.gov/show/NCT04621071
61,61,Treatment of Patients With COVID-19 With Convalescent Plasma,Recruiting,Biological: convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"June 1, 2020","May 22, 2022",Brazil,https://ClinicalTrials.gov/show/NCT04415086
62,62,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,Drug: Baricitinib (janus kinase inhibitor),All,"18 Years and older   (Adult, Older Adult)",Phase 2,800.0,"April 17, 2020",March 2022,Canada,https://ClinicalTrials.gov/show/NCT04321993
63,63,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19",Not yet recruiting,Biological: COVI-VAC|Other: Placebo,All,18 Years to 30 Years   (Adult),Phase 1,48.0,December 2020,May 2022,United Kingdom,https://ClinicalTrials.gov/show/NCT04619628
64,64,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Active, not recruiting",Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day,All,"18 Years and older   (Adult, Older Adult)",Phase 1,46.0,"May 12, 2020",November 2020,Spain,https://ClinicalTrials.gov/show/NCT04382066
65,65,Traditional Chinese Medicine for Severe COVID-19,Not yet recruiting,Drug: Traditional Chinese Medicine Prescription,All,"up to 85 Years   (Child, Adult, Older Adult)",Phase 3,50.0,March 2020,April 2020,China,https://ClinicalTrials.gov/show/NCT04323332
66,66,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,Recruiting,Biological: multipeptide cocktail,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,"November 27, 2020","December 20, 2021",Germany,https://ClinicalTrials.gov/show/NCT04546841
67,67,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Recruiting,Other: blood samples|Other: feces samples (COVI-BIOME ancillary study)|Other: sweat samples (COVIDOG ancillary study),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"March 31, 2020","March 31, 2022",France,https://ClinicalTrials.gov/show/NCT04352348
68,68,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),"Active, not recruiting",Biological: SARS-CoV-2 convalescent plasma,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,10.0,"April 10, 2020",December 2020,Sweden,https://ClinicalTrials.gov/show/NCT04390178
69,69,COVID-19 Ozanimod Intervention Study,Recruiting,Drug: Ozanimod|Other: Standard of care,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,48.0,"September 16, 2020","January 1, 2024",Canada,https://ClinicalTrials.gov/show/NCT04405102
70,70,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,Biological: Convalescent plasma,All,"Child, Adult, Older Adult",Phase 2,60.0,"August 18, 2020","December 31, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04528368
71,71,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,Recruiting,Drug: Interferon beta-1b|Drug: Clofazimine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,81.0,"July 14, 2020","September 30, 2021",China,https://ClinicalTrials.gov/show/NCT04465695
72,72,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,Biological: UC-MSCs|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"February 1, 2020","June 30, 2020",China,https://ClinicalTrials.gov/show/NCT04339660
73,73,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Recruiting,Drug: Lopinavir/ritonavir,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,300.0,"April 23, 2020",March 2021,Switzerland,https://ClinicalTrials.gov/show/NCT04364022
74,74,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"Active, not recruiting",Biological: AG0302-COVID19,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"August 31, 2020","September 30, 2021",Japan,https://ClinicalTrials.gov/show/NCT04527081
75,75,Colchicine in COVID-19: a Pilot Study,Recruiting,Drug: Colchicine 1 MG Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,308.0,"April 18, 2020","October 31, 2021",Italy,https://ClinicalTrials.gov/show/NCT04375202
76,76,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"Active, not recruiting",Biological: AG0301-COVID19,All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"June 29, 2020","July 31, 2021",Japan,https://ClinicalTrials.gov/show/NCT04463472
77,77,Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy,Withdrawn,Drug: Tofacitinib|Other: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,0.0,"July 6, 2020","October 18, 2020",United States,https://ClinicalTrials.gov/show/NCT04412252
78,78,Co-infection Management in COVID-19 Critically Ill,Completed,Diagnostic Test: FilmArray Pneumonia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,32.0,"March 23, 2020","April 24, 2020",Belgium,https://ClinicalTrials.gov/show/NCT04382092
79,79,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Withdrawn,Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2),All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,0.0,February 2020,April 2020,China,https://ClinicalTrials.gov/show/NCT04287686
80,80,Favipiravir Therapy in Adults With Mild COVID-19,Recruiting,Drug: Favipiravir|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,576.0,"July 23, 2020",June 2021,Saudi Arabia,https://ClinicalTrials.gov/show/NCT04464408
81,81,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Terminated,Other: home care monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,37.0,"April 21, 2020","June 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04361916
82,82,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Recruiting,Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days later,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,170.0,"March 4, 2020","December 31, 2021",France,https://ClinicalTrials.gov/show/NCT04385108
83,83,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,Recruiting,Biological: Prolastin|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"July 29, 2020",April 2021,Spain,https://ClinicalTrials.gov/show/NCT04495101
84,84,COVID-19 Plasma Collection,Recruiting,Other: Plasma Donation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"April 13, 2020","April 12, 2021",United States,https://ClinicalTrials.gov/show/NCT04344015
85,85,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Drug: SOC + IFX-1|Drug: SOC + Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,390.0,"March 31, 2020","August 31, 2021",Germany,https://ClinicalTrials.gov/show/NCT04333420
86,86,DAS181 for STOP COVID-19,Withdrawn,Drug: DAS181|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,0.0,"July 25, 2020","November 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04354389
87,87,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Not yet recruiting,Drug: Clazakizumab|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,May 2020,"August 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04381052
88,88,Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis,Not yet recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,"August 1, 2020",August 2022,Colombia,https://ClinicalTrials.gov/show/NCT04480632
89,89,A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),Recruiting,Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen|Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen|Biological: Low-dose placebo (18-59 years) & Two dose regimen|Biological: Low-dose placebo (18-59 years) & Three dose regimen|Biological: High-dose placebo (18-59 years) & Two dose regimen|Biological: High-dose placebo (18-59 years) & Three dose regimen|Biological: Low-dose placebo (60-85 years) & Two dose regimen|Biological: Low-dose placebo (60-85 years) & Three dose regimen|Biological: High-dose placebo (60-85 years) & Two dose regimen|Biological: High-dose placebo (60-85 years) & Three dose regimen,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,960.0,"November 17, 2020","November 18, 2021",China,https://ClinicalTrials.gov/show/NCT04640402
90,90,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)",Not yet recruiting,Other: Aerobic Exercise Training|Other: Education,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,90.0,"December 16, 2020","December 31, 2023",United States,https://ClinicalTrials.gov/show/NCT04595773
91,91,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,Recruiting,"Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,90.0,"February 21, 2020","August 31, 2022",China,https://ClinicalTrials.gov/show/NCT04324996
92,92,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),Recruiting,Biological: Group A (AG0302-COVID19)|Biological: Group A (Placebo)|Biological: Group B (AG0302-COVID19)|Biological: Group B (Placebo),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,500.0,"November 23, 2020","March 31, 2022",Japan,https://ClinicalTrials.gov/show/NCT04655625
93,93,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,Device: MLS Laser|Other: Regular Inpatient Medical Care,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,10.0,"April 30, 2020","July 16, 2020",United States,https://ClinicalTrials.gov/show/NCT04391712
94,94,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",Recruiting,Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,2970.0,"June 10, 2020","January 25, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04426695
95,95,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Other: plasma hyperimmune|Drug: standard therapy,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,400.0,"May 1, 2020","May 15, 2021",Italy,https://ClinicalTrials.gov/show/NCT04385043
96,96,Chloroquine Phosphate Prophylactic Use in Health Personnel Exposed to COVID-19 Patients,Not yet recruiting,Drug: Chloroquine phosphate,All,18 Years to 59 Years   (Adult),Phase 1,200.0,"July 27, 2020","January 31, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04443270
97,97,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Recruiting,Biological: SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,"May 7, 2020",December 2020,Sweden,https://ClinicalTrials.gov/show/NCT04384497
98,98,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Biological: Intravenous Immune Globulin|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 2, 2020",December 2020,Spain,https://ClinicalTrials.gov/show/NCT04432324
99,99,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Completed,Drug: Favipiravir|Drug: Standard of care,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,200.0,"May 21, 2020","August 20, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04542694
100,100,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,Recruiting,Biological: Lenzilumab|Other: Placebo|Drug: Remdesivir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200.0,"October 19, 2020","July 1, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04583969
101,101,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Biological: Liquid Alpha1-Proteinase Inhibitor (Human)|Drug: Placebo|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,November 2020,September 2021,United States,https://ClinicalTrials.gov/show/NCT04547140
102,102,Safety and Efficacy of Baricitinib for COVID-19,Not yet recruiting,Drug: Baricitinib,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2|Phase 3,80.0,November 2020,October 2021,United States,https://ClinicalTrials.gov/show/NCT04340232
103,103,Favipiravir in Hospitalized COVID-19 Patients,Not yet recruiting,Drug: Favipiravir|Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"April 20, 2020","May 5, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04359615
104,104,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),Recruiting,Biological: CoronaVac|Biological: Placebo,All,18 Years to 59 Years   (Adult),Phase 3,13000.0,"September 14, 2020","April 15, 2021",Turkey,https://ClinicalTrials.gov/show/NCT04582344
105,105,Losmapimod Safety and Efficacy in COVID-19,Recruiting,Drug: Losmapimod oral tablet|Drug: Placebo oral tablet,All,"50 Years and older   (Adult, Older Adult)",Phase 3,410.0,"August 28, 2020",November 2020,Brazil,https://ClinicalTrials.gov/show/NCT04511819
106,106,Azithromycin in Hospitalized COVID-19 Patients,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"April 20, 2020","May 5, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04359316
107,107,COVID-19 Treatment in South Africa,Recruiting,Other: Standard of care (Paracetamol)|Drug: Artesunate-amodiaquine|Drug: Pyronaridine-artesunate|Drug: Favipiravir plus Nitazoxanide|Drug: Sofosbuvir/daclatasvir,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,250.0,"September 3, 2020",January 2021,South Africa,https://ClinicalTrials.gov/show/NCT04532931
108,108,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),Recruiting,Biological: Convalescent anti-SARS-CoV-2 MBT Plasma|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 29, 2020",March 2021,Spain,https://ClinicalTrials.gov/show/NCT04547127
109,109,Vitamin D and COVID-19 Trial,Not yet recruiting,Dietary Supplement: vitamin D|Dietary Supplement: Placebo,All,"30 Years and older   (Adult, Older Adult)",Phase 3,2700.0,"December 1, 2020","March 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04536298
110,110,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"April 9, 2020","April 27, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04343768
111,111,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,Terminated,Drug: Acalabrutinib,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,8.0,"September 21, 2020","November 18, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04497948
112,112,The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial,Withdrawn,Drug: Hydroxychloroquine plus standard preventive measures|Drug: Placebo plus standard preventive measures,All,18 Years to 59 Years   (Adult),Phase 3,0.0,December 2020,May 2021,Philippines,https://ClinicalTrials.gov/show/NCT04364815
113,113,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,Behavioral: Positive COVID Test Result - Hypothetical Scenario|Behavioral: Negative COVID Test Result - Hypothetical Scenario|Behavioral: Unavailable COVID Test Result - Hypothetical Scenario,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,1400.0,"July 23, 2020","July 29, 2020",United States,https://ClinicalTrials.gov/show/NCT04459520
114,114,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"Active, not recruiting",Drug: Interferon beta-1a|Other: Placebo|Drug: Remdesivir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,969.0,"August 4, 2020","December 30, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04492475
115,115,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,85.0,"March 30, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04329832
116,116,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),Recruiting,Drug: Rivaroxaban|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"September 2, 2020",December 2020,Jersey,https://ClinicalTrials.gov/show/NCT04504032
117,117,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,Recruiting,Drug: Omegaven®|Drug: Sodium chloride,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"June 23, 2020","April 30, 2021",Sweden,https://ClinicalTrials.gov/show/NCT04647604
118,118,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Recruiting,Biological: convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,410.0,"August 25, 2020","December 31, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04388410
119,119,COVID-19 Antibody Plasma Research Study in Hospitalized Patients,Recruiting,Biological: High-titer Convalescent COVID-19 Plasma (CCP1)|Biological: Standard-titer Convalescent COVID-19 plasma (CCP2),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,56.0,"August 27, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04524507
120,120,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Recruiting,Biological: MSCs,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20.0,"January 27, 2020",December 2021,China,https://ClinicalTrials.gov/show/NCT04252118
121,121,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,Recruiting,Drug: BDB-001 Injection|Other: Conventional treatment,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,368.0,"July 23, 2020","August 7, 2022",China,https://ClinicalTrials.gov/show/NCT04449588
122,122,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Other: Placebo|Drug: Remdesivir|Drug: Baricitinib,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1034.0,"May 8, 2020","July 31, 2020",Denmark,https://ClinicalTrials.gov/show/NCT04401579
123,123,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Other: Placebo|Drug: Remdesivir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1062.0,"February 21, 2020","May 21, 2020",Denmark,https://ClinicalTrials.gov/show/NCT04280705
124,124,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,Recruiting,Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose|Biological: Two COVID-19 vaccine candidate (TMV-083) administrations - High dose|Biological: One COVID-19 vaccine candidate (TMV-083) administration - High dose|Other: Placebo,All,18 Years to 55 Years   (Adult),Phase 1,90.0,"August 10, 2020",October 2021,Belgium,https://ClinicalTrials.gov/show/NCT04497298
125,125,Study of Niclosamide in Moderate Hospitalized Coronavirus-19 (COVID-19) Patients,Recruiting,Drug: Niclosamide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,436.0,"October 7, 2020",June 2022,United States,https://ClinicalTrials.gov/show/NCT04603924
126,126,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),Recruiting,Drug: Baricitinib|Drug: Dexamethasone|Other: Placebo|Drug: Remdesivir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,1500.0,"November 24, 2020","June 30, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04640168
127,127,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Biological: Mesenchymal Stromal Cells|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"May 1, 2020","December 31, 2020",Spain,https://ClinicalTrials.gov/show/NCT04361942
128,128,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Terminated,Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,"June 16, 2020","December 1, 2020",Jersey,https://ClinicalTrials.gov/show/NCT04410354
129,129,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,Recruiting,Drug: Pyronaridine-Artesunate|Drug: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 2,76.0,"July 9, 2020",February 2021,"Korea, Republic of",https://ClinicalTrials.gov/show/NCT04475107
130,130,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Recruiting,Drug: Ciclesonide Metered Dose Inhaler [Alvesco],All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,94.0,"April 1, 2020","December 31, 2020","Korea, Republic of",https://ClinicalTrials.gov/show/NCT04330586
131,131,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Drug: Acalabrutinib,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,62.0,"June 13, 2020","November 16, 2020",India,https://ClinicalTrials.gov/show/NCT04380688
132,132,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,Recruiting,Other: Placebo|Drug: Remdesivir|Biological: Risankizumab,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200.0,"October 14, 2020","July 1, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04583956
133,133,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Drug: unfractionated Heparin|Drug: Unfractionated heparin nebulized|Drug: acetylsalicylic acid|Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,310.0,"July 8, 2020","April 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04466670
134,134,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"Active, not recruiting",Drug: Acalabrutinib,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,163.0,"June 12, 2020","November 23, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04346199
135,135,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,Recruiting,Drug: 0.5% Povidone Iodine|Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse|Drug: 1% Hydrogen Peroxide|Drug: 0.9% Normal Saline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,60.0,"October 1, 2020",November 2020,United States,https://ClinicalTrials.gov/show/NCT04603794
136,136,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan,All,"60 Years and older   (Adult, Older Adult)",Phase 3,1600.0,"April 25, 2020","June 1, 2021",France,https://ClinicalTrials.gov/show/NCT04359953
137,137,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Recruiting,Biological: SARS-CoV-2 antibody based IVIG therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,"June 19, 2020",March 2021,Pakistan,https://ClinicalTrials.gov/show/NCT04521309
138,138,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,Recruiting,Drug: Nafamostat Mesilate,All,"18 Years and older   (Adult, Older Adult)",Phase 3,186.0,"August 13, 2020","August 12, 2021",Senegal,https://ClinicalTrials.gov/show/NCT04390594
139,139,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,Recruiting,Device: Vielight RX Plus,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,280.0,"September 2, 2020","March 1, 2021",Canada,https://ClinicalTrials.gov/show/NCT04418505
140,140,Telmisartan for Treatment of COVID-19 Patients,Recruiting,Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400.0,"May 19, 2020","October 1, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04355936
141,141,Brainstem Dysfunction in COVID-19 Critically Ill Patients: a Prospective Observational Study,Not yet recruiting,Diagnostic Test: Brainstem Responses Assessment Sedation Score (BRASS)|Diagnostic Test: Electroencephalogram with EKG lead,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,September 2020,June 2021,France,https://ClinicalTrials.gov/show/NCT04527198
142,142,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Recruiting,Drug: Prazosin|Other: Standard of care,All,"45 Years to 85 Years   (Adult, Older Adult)",Phase 2,220.0,"May 13, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04365257
143,143,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),Recruiting,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1300.0,"May 12, 2020","March 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04466540
144,144,Interferon Beta 1a in Hospitalized COVID-19 Patients,Enrolling by invitation,Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine,All,"50 Years and older   (Adult, Older Adult)",Phase 4,40.0,"April 15, 2020","April 24, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04350671
145,145,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Drug: Tocilizumab Injection,All,"Child, Adult, Older Adult",Phase 2,400.0,"March 19, 2020","December 19, 2022",Italy,https://ClinicalTrials.gov/show/NCT04317092
146,146,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Completed,Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,45.0,"May 18, 2020","September 29, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04381884
147,147,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),Recruiting,Biological: Convalescent plasma,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,1200.0,"May 14, 2020","December 31, 2020",Canada,https://ClinicalTrials.gov/show/NCT04348656
148,148,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",Recruiting,Biological: AZD1222|Biological: Placebo,All,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,40000.0,"August 28, 2020","February 21, 2023",Argentina,https://ClinicalTrials.gov/show/NCT04516746
149,149,Atovaquone for Treatment of COVID-19,Recruiting,Drug: Experimental Group|Drug: Placebo Group,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"July 22, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04456153
150,150,Umifenovir in Hospitalized COVID-19 Patients,Enrolling by invitation,Drug: Umifenovir|Drug: Interferon-β 1a|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine|Drug: Standards of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"April 15, 2020","April 24, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04350684
151,151,Niclosamide for Mild to Moderate COVID-19,Recruiting,Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"October 1, 2020","February 12, 2021",United States,https://ClinicalTrials.gov/show/NCT04399356
152,152,Repurposing of Chlorpromazine in Covid-19 Treatment,Not yet recruiting,Drug: CHLORPROMAZINE (CPZ)|Combination Product: Standard of Care (SOC),All,"18 Years and older   (Adult, Older Adult)",Phase 3,40.0,"April 29, 2020","September 30, 2020",France,https://ClinicalTrials.gov/show/NCT04366739
153,153,Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,Not yet recruiting,Drug: Rivaroxaban|Other: Standard Of Care (SOC),All,"18 Years and older   (Adult, Older Adult)",Phase 3,400.0,"August 1, 2020","May 30, 2021",Germany,https://ClinicalTrials.gov/show/NCT04416048
154,154,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Recruiting,"Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Biological: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14|Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28|Biological: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#|Biological: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|Biological: Two doses of placebo at the schedule of day 0, 14 #High-dose group#|Biological: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#",All,"18 Years and older   (Adult, Older Adult)",Phase 1,216.0,"October 30, 2020","January 7, 2022",China,https://ClinicalTrials.gov/show/NCT04636333
155,155,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,Recruiting,Drug: Maraviroc 300 mg|Other: Standard care therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"June 26, 2020","December 20, 2020",Spain,https://ClinicalTrials.gov/show/NCT04441385
156,156,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1200.0,"April 14, 2020","November 30, 2020",France,https://ClinicalTrials.gov/show/NCT04328285
157,157,Crizanlizumab for Treating COVID-19 Vasculopathy,Recruiting,Drug: Crizanlizumab|Other: 0.9% saline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"July 9, 2020","January 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04435184
158,158,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,Completed,Drug: Sarilumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1912.0,"March 18, 2020","September 2, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04315298
159,159,PROLIFIC ChemoprophylaxisTrial (COVID-19),Recruiting,Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1000.0,"May 11, 2020",April 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04352933
160,160,Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults,Not yet recruiting,Drug: Maraviroc + Currently used therapy|Procedure: Curently used therapy for COVID-19 non-critical patients|Drug: Favipiravir + Currently used therapy|Drug: Maraviroc+Favipiravir+CT,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,100.0,November 2020,January 2021,Mexico,https://ClinicalTrials.gov/show/NCT04475991
161,161,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,Recruiting,Drug: Brequinar|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,"June 25, 2020",April 2021,Mexico,https://ClinicalTrials.gov/show/NCT04425252
162,162,Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,Not yet recruiting,Dietary Supplement: Vitamin D3 (cholecalciferol)|Dietary Supplement: Zinc (zinc gluconate)|Dietary Supplement: Zinc (zinc gluconate) & Vitamin D (cholecalciferol)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,700.0,"December 7, 2020","December 31, 2021",India,https://ClinicalTrials.gov/show/NCT04641195
163,163,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),Recruiting,Drug: Placebo|Drug: Ruxolitinib,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,500.0,"May 24, 2020","April 30, 2021",India,https://ClinicalTrials.gov/show/NCT04377620
164,164,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,"Active, not recruiting",Drug: Favipiravir|Drug: Standard of care (SOC)|Drug: standard concomitant therapy,All,18 Years to 60 Years   (Adult),Phase 3,168.0,"May 20, 2020",August 2020,Russian Federation,https://ClinicalTrials.gov/show/NCT04501783
165,165,Hydroxychloroquine in COVID-19 Patients,Recruiting,Drug: Hydroxychloroquine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,200.0,"March 21, 2020",August 2020,Saudi Arabia,https://ClinicalTrials.gov/show/NCT04394442
166,166,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Not yet recruiting,Drug: Sofosbuvir 400 MG plus Daclatasvir 200mg,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50.0,"September 4, 2020","September 3, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04535869
167,167,Dynamic Evaluation of COVID-19 Diagnostic Tests,Recruiting,Diagnostic Test: COVID-19 diagnostic test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,165.0,"July 13, 2020",December 2020,France,https://ClinicalTrials.gov/show/NCT04337996
168,168,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"Active, not recruiting",Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,342.0,"April 3, 2020",March 2021,Belgium,https://ClinicalTrials.gov/show/NCT04330638
169,169,Rapid Experimental Medicine for COVID-19,Recruiting,Drug: Nafamostat Mesilate|Drug: TD139|Other: Standard care,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,60.0,"July 3, 2020","December 3, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04473053
170,170,Lanadelumab for Treatment of COVID-19 Disease,Recruiting,Biological: lanadelumab|Other: regular care,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,80.0,"October 3, 2020","August 3, 2021",Netherlands,https://ClinicalTrials.gov/show/NCT04422509
171,171,COVID-19 Patient Positioning Pragmatic Trial,Enrolling by invitation,Other: Prone|Other: Usual Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"April 27, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04359797
172,172,A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19,Recruiting,Drug: MRx-4DP0004|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,June 2020,September 2020,United Kingdom,https://ClinicalTrials.gov/show/NCT04363372
173,173,Allocetra-OTS in COVID-19,"Active, not recruiting",Biological: Allocetra-OTS,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,5.0,"August 1, 2020",February 2021,Israel,https://ClinicalTrials.gov/show/NCT04513470
174,174,Leflunomide in Mild COVID-19 Patients,Recruiting,Drug: Leflunomide,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"May 5, 2020",February 2021,United States,https://ClinicalTrials.gov/show/NCT04361214
175,175,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,Recruiting,Drug: BI 764198|Drug: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 2,90.0,"November 3, 2020","May 5, 2021",United States,https://ClinicalTrials.gov/show/NCT04604184
176,176,Treating COVID-19 With Hydroxychloroquine (TEACH),Suspended,Drug: Hydroxychloroquine (HCQ)|Other: Pacebo: Calcium citrate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,626.0,"April 15, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04369742
177,177,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,Recruiting,Biological: Convalescent plasma,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1200.0,"June 24, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04418518
178,178,COPING With COVID-19( CWC-19),Withdrawn,Behavioral: Crisis management coaching,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0.0,"March 27, 2020","May 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04343690
179,179,Complementary Intervention for COVID-19,Recruiting,Dietary Supplement: Licorice extract,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,70.0,"January 1, 2020",January 2021,Egypt,https://ClinicalTrials.gov/show/NCT04487964
180,180,Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia,Recruiting,Drug: Methylprednisolone|Drug: Heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,268.0,"July 20, 2020","December 31, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04485429
181,181,Hypertonic Saline for COVID-19 Symptoms,Recruiting,Other: Wearing surgical face mask sprayed with hypertonic saline,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"July 1, 2020",May 2021,Saudi Arabia,https://ClinicalTrials.gov/show/NCT04465604
182,182,COVID-19: A POC Test Under Research & Evaluation,Recruiting,Diagnostic Test: Sample Collection/Performance Evaluation (A)|Diagnostic Test: Sample Collection/Performance Evaluation (B),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"April 30, 2020","April 30, 2022",United Kingdom,https://ClinicalTrials.gov/show/NCT04408066
183,183,Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).,Not yet recruiting,Drug: Olokizumab 64 mg|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,376.0,"June 30, 2020","January 29, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04452474
184,184,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,Recruiting,Drug: Apixaban 2.5 MG|Drug: Apixaban 5MG|Drug: Aspirin|Drug: Placebo,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 3,7000.0,"September 7, 2020",September 2021,United States,https://ClinicalTrials.gov/show/NCT04498273
185,185,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Completed,Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,372.0,"April 23, 2020","July 24, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04380519
186,186,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"Active, not recruiting",Drug: Sargramostim|Other: Control,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,80.0,"March 24, 2020","March 31, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04326920
187,187,Hyperbaric Oxygen for COVID-19 Patients,Terminated,Device: hyperbaric oxygen therapy (HBOT),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"April 6, 2020","May 29, 2020",United States,https://ClinicalTrials.gov/show/NCT04332081
188,188,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Recruiting,Radiation: Single fraction whole lung radiotherapy,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"May 10, 2020","August 30, 2022",Italy,https://ClinicalTrials.gov/show/NCT04377477
189,189,Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19,Recruiting,Drug: Plant Polyphenol|Dietary Supplement: Vitamin D3,All,"45 Years and older   (Adult, Older Adult)",Phase 2,200.0,"September 12, 2020",January 2021,United States,https://ClinicalTrials.gov/show/NCT04400890
190,190,A Pilot Study of Sildenafil in COVID-19,Recruiting,Drug: Sildenafil citrate tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10.0,"February 9, 2020","November 9, 2020",China,https://ClinicalTrials.gov/show/NCT04304313
191,191,Cardiovascular Effects of COVID-19,Recruiting,Drug: AT-001,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"April 8, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04365699
192,192,Abatacept for Patients With COVID-19 and Respiratory Distress,Withdrawn,Drug: Abatacept,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,0.0,August 2020,December 2020,Israel,https://ClinicalTrials.gov/show/NCT04477642
193,193,Convalescent Plasma in COVID-19 Elderly Patients,Completed,Biological: Convalescent plasma,All,65 Years and older   (Older Adult),Phase 2,21.0,"May 15, 2020","September 3, 2020",Italy,https://ClinicalTrials.gov/show/NCT04569188
194,194,Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,Recruiting,Drug: Zilucoplan®|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,81.0,"May 22, 2020",September 2021,Belgium,https://ClinicalTrials.gov/show/NCT04382755
195,195,SCB-2019 as COVID-19 Vaccine,Recruiting,Biological: SCB-2019|Biological: SCB-2019 with AS03 adjuvant|Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,150.0,"June 19, 2020","March 30, 2021",Australia,https://ClinicalTrials.gov/show/NCT04405908
196,196,Awake Prone Position for Early Hypoxemia in COVID-19,Enrolling by invitation,Other: Self-prone position recommendation|Other: Usual care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,560.0,"April 23, 2020",December 2020,Georgia,https://ClinicalTrials.gov/show/NCT04344587
197,197,Safety in Convalescent Plasma Transfusion to COVID-19,Recruiting,Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"May 8, 2020","April 30, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04333355
198,198,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Enrolling by invitation,Biological: Therapeutic plasma exchange (TPE)|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20.0,"July 17, 2020",October 2020,Georgia,https://ClinicalTrials.gov/show/NCT04441996
199,199,Camostat Mesylate in COVID-19 Outpatients,Recruiting,Drug: Camostat Mesilate|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,114.0,"June 19, 2020","May 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04353284
200,200,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,Other: Surgical facial mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6000.0,"April 2, 2020","June 2, 2020",Denmark,https://ClinicalTrials.gov/show/NCT04337541
201,201,Convalescent Plasma for the Treatment of COVID-19,Recruiting,Drug: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"April 15, 2020","April 14, 2021",United States,https://ClinicalTrials.gov/show/NCT04389710
202,202,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"Active, not recruiting",Drug: Gimsilumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,227.0,"April 12, 2020",March 2021,Georgia,https://ClinicalTrials.gov/show/NCT04351243
203,203,GRAd-COV2 Vaccine Against COVID-19,Recruiting,Biological: GRAd-COV2,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,90.0,"August 10, 2020","July 31, 2021",Italy,https://ClinicalTrials.gov/show/NCT04528641
204,204,SCIL-1Ra in COVID-19 Feasibility & PK/PD,Suspended,Drug: Anakinra 100Mg/0.67Ml Inj Syringe,All,"18 Years and older   (Adult, Older Adult)",Phase 2,5.0,"May 28, 2020","December 31, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04462757
205,205,A Randomized Trial of Anticoagulation Strategies in COVID-19,Terminated,Drug: Enoxaparin Higher Dose|Drug: Lower-dose prophylactic anticoagulation,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,77.0,"April 21, 2020","September 20, 2020",United States,https://ClinicalTrials.gov/show/NCT04359277
206,206,Administration of Chlorpromazine as a Treatment for COVID-19,Not yet recruiting,Drug: Chlorpromazine,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"August 1, 2020",November 2020,Egypt,https://ClinicalTrials.gov/show/NCT04354805
207,207,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Recruiting,Drug: Amiodarone|Drug: Verapamil,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2|Phase 3,804.0,"April 27, 2020","April 10, 2021",Poland,https://ClinicalTrials.gov/show/NCT04351763
208,208,Antiviral Agents Against COVID-19 Infection,Not yet recruiting,Drug: Atazanavir|Drug: Daclatasvir 60 mg|Drug: Sofusbuvir + Daclastavir 60 mg|Drug: Placebo Atazanavir|Drug: Placebo Daclatasvir 60 mg|Drug: Placebo Sofusbuvir + Daclatasvir 60 mg,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,1005.0,"December 1, 2020","April 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04468087
209,209,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Terminated,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,17.0,"April 22, 2020","October 12, 2020",Germany,https://ClinicalTrials.gov/show/NCT04340544
210,210,Tofacitinib for Treatment of Moderate COVID-19,"Active, not recruiting",Drug: Tofacitinib 10 mg|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,60.0,"July 29, 2020","March 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04415151
211,211,Accelerated Prone Position Ventilation of Patients With COVID-19,Recruiting,Procedure: Prone position ventilation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"May 11, 2020",December 2020,Denmark,https://ClinicalTrials.gov/show/NCT04384900
212,212,Etoposide in Patients With COVID-19 Infection,Recruiting,Drug: Etoposide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,64.0,"May 8, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04356690
213,213,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,Recruiting,Drug: OP-101|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"July 1, 2020","January 31, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04458298
214,214,Treatment of Angiotensin Peptide (1-7) for COVID-19,Recruiting,Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"April 25, 2020","September 30, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04375124
215,215,Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,Recruiting,Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Placebo,Male,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,100.0,"October 26, 2020",September 2022,United States,https://ClinicalTrials.gov/show/NCT04509999
216,216,Cyclosporine in Patients With Moderate COVID-19,Recruiting,Drug: Cyclosporine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"June 30, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04412785
217,217,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Recruiting,Dietary Supplement: Quercetin Prophylaxis|Dietary Supplement: Quercetin Treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"March 20, 2020","August 31, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04377789
218,218,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Recruiting,Drug: PF-06650833|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,68.0,"November 30, 2020","March 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04575610
219,219,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),Recruiting,Drug: Nitric Oxide,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"September 2, 2020",December 2020,Canada,https://ClinicalTrials.gov/show/NCT04383002
220,220,PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams,Not yet recruiting,Dietary Supplement: Placebo|Dietary Supplement: Vitamin D,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 3,2414.0,"November 30, 2020","June 30, 2021",Canada,https://ClinicalTrials.gov/show/NCT04483635
221,221,Ozone Auto-hemotherapy for COVID-19 Pneumonia,Not yet recruiting,Biological: Ozone auto-hemotherapy,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,208.0,"May 25, 2020","December 25, 2020",Spain,https://ClinicalTrials.gov/show/NCT04370223
222,222,A Study of LAM-002A for the Prevention of Progression of COVID-19,Recruiting,Drug: Apilimod Dimesylate Capsule|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,142.0,"July 15, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04446377
223,223,"Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs",Not yet recruiting,Other: Rehabilitation-focused program,All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,506.0,"November 1, 2021","October 31, 2024",United States,https://ClinicalTrials.gov/show/NCT04628039
224,224,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,Other: Prone Positioning|Other: Supine Positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"July 13, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04424797
225,225,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,Device: miniprobe Alveoflex,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,15.0,"August 1, 2020","September 1, 2021",Russian Federation,https://ClinicalTrials.gov/show/NCT04451889
226,226,Ramipril for the Treatment of COVID-19,Enrolling by invitation,Drug: Ramipril 2.5 MG Oral Capsule|Drug: Placebo oral capsule,All,"18 Years and older   (Adult, Older Adult)",Phase 2,560.0,"May 11, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04366050
227,227,Comparison of Two Different Doses of Bemiparin in COVID-19,Recruiting,Drug: Bemiparin sodium,All,"18 Years and older   (Adult, Older Adult)",Phase 3,164.0,"October 26, 2020","July 31, 2021",Spain,https://ClinicalTrials.gov/show/NCT04604327
228,228,Mesenchymal Stem Cell Infusion for COVID-19 Infection,Recruiting,Drug: Mesenchymal stem cells|Other: Placebo,All,"10 Years and older   (Child, Adult, Older Adult)",Phase 2,20.0,"May 1, 2020","September 30, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04444271
229,229,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Drug: Sirolimus|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"April 24, 2020",September 2020,United States,https://ClinicalTrials.gov/show/NCT04341675
230,230,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Recruiting,Drug: Prednisone,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,184.0,"June 23, 2020","December 30, 2020",Chile,https://ClinicalTrials.gov/show/NCT04451174
231,231,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Drug: Imatinib|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,204.0,"June 2, 2020","June 1, 2023",United States,https://ClinicalTrials.gov/show/NCT04394416
232,232,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,173.0,"April 9, 2020","November 13, 2020",United States,https://ClinicalTrials.gov/show/NCT04329923
233,233,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,Recruiting,Biological: COVID-19 Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80.0,"May 13, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04397757
234,234,Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial,Not yet recruiting,"Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Drug: Placebo",All,"60 Years and older   (Adult, Older Adult)",Phase 4,120.0,"October 27, 2020","December 31, 2021",Spain,https://ClinicalTrials.gov/show/NCT04361643
235,235,Desidustat in the Management of COVID-19 Patients,Recruiting,Drug: Desidustat|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"July 25, 2020","January 30, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04463602
236,236,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,Terminated,Drug: chloroquine|Other: standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,5.0,"June 1, 2020","September 1, 2020",Israel,https://ClinicalTrials.gov/show/NCT04333628
237,237,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,Recruiting,Drug: Tocilizumab|Drug: Placebo,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,300.0,"June 12, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04412772
238,238,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Completed,Other: Rehabilitation,All,28 Years to 45 Years   (Adult),Not Applicable,270.0,"March 11, 2020","April 26, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04365738
239,239,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,Recruiting,Drug: Lopinavir/Ritonavir 400 mg/100 mg|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"June 1, 2020","May 1, 2021",Israel,https://ClinicalTrials.gov/show/NCT04372628
240,240,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Drug: aerosolized DNase|Drug: NaCl,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 4, 2020","December 1, 2020",Sweden,https://ClinicalTrials.gov/show/NCT04541979
241,241,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,Device: Auricular percutaneous neurostimulation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"July 13, 2020","July 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04514627
242,242,A Study of Baricitinib (LY3009104) in Participants With COVID-19,Recruiting,Drug: Baricitinib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1400.0,"September 7, 2019","June 20, 2021",Argentina,https://ClinicalTrials.gov/show/NCT04421027
243,243,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),Recruiting,Biological: GAMUNEX-C|Drug: Standard Medical Treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"September 17, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04480424
244,244,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Drug: Treatment and prophylaxis|Other: Standard Public Health measures,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2300.0,"March 18, 2020","June 15, 2020",Spain,https://ClinicalTrials.gov/show/NCT04304053
245,245,Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients,Not yet recruiting,Drug: HCQ & AZ vs HCQ+SIR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,58.0,"May 1, 2020","September 1, 2020",Jordan,https://ClinicalTrials.gov/show/NCT04374903
246,246,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),Recruiting,Drug: Colchicine Tablets|Other: Current care per UCLA treating physicians,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,"May 1, 2020","April 25, 2021",United States,https://ClinicalTrials.gov/show/NCT04355143
247,247,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Recruiting,Drug: Therapeutic Anticoagulation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,462.0,"May 11, 2020",December 2020,Canada,https://ClinicalTrials.gov/show/NCT04362085
248,248,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,Diagnostic Test: diagnostic tests for COVID-19 infection,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,100.0,"May 8, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04372004
249,249,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,April 2020,June 2020,United States,https://ClinicalTrials.gov/show/NCT04351620
250,250,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),Recruiting,Drug: Camostat Mesilate|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"November 9, 2020",January 2021,Georgia,https://ClinicalTrials.gov/show/NCT04583592
251,251,Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients,Not yet recruiting,Drug: HCQ & AZ,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,200.0,"May 1, 2020","October 15, 2020",Jordan,https://ClinicalTrials.gov/show/NCT04354597
252,252,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,Recruiting,Drug: Zanubrutinib|Drug: Supportive Care|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,52.0,"July 6, 2020",April 2021,Brazil,https://ClinicalTrials.gov/show/NCT04382586
253,253,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Recruiting,Drug: Cholecalciferol,All,"Child, Adult, Older Adult",Phase 4,80.0,"April 4, 2020","December 30, 2020",Spain,https://ClinicalTrials.gov/show/NCT04552951
254,254,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin,All,"45 Years and older   (Adult, Older Adult)",Phase 3,1550.0,"April 2, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04334382
255,255,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,Biological: CCP,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,"August 12, 2020","August 12, 2021",United States,https://ClinicalTrials.gov/show/NCT04438057
256,256,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,Procedure: blood sampling,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,99.0,"April 9, 2020","May 14, 2020",France,https://ClinicalTrials.gov/show/NCT04367662
257,257,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Recruiting,Drug: PHR160 Spray|Drug: Placebo|Drug: Standard treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,224.0,"August 15, 2020","December 15, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04463420
258,258,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Completed,Drug: Povidone-Iodine|Drug: Essential oils|Other: Tap water,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"June 22, 2020","July 6, 2020",Malaysia,https://ClinicalTrials.gov/show/NCT04410159
259,259,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,Recruiting,Device: Viruxal Oral and Nasal Spray|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,128.0,"September 4, 2020",March 2021,Iceland,https://ClinicalTrials.gov/show/NCT04357990
260,260,Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients,Not yet recruiting,Drug: Ulinastatin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,160.0,December 2020,June 2021,United States,https://ClinicalTrials.gov/show/NCT04393311
261,261,"Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial",Not yet recruiting,Procedure: Extended sampling and procedures,All,"15 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,400.0,"April 28, 2020","April 14, 2026",Sweden,https://ClinicalTrials.gov/show/NCT04368013
262,262,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,Completed,Biological: COVID-19 convalescent hyperimmune plasma|Biological: Non-convalescent fresh frozen plasma (Standard plasma),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"May 1, 2020","September 23, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04392414
263,263,Convalescent Plasma as a Possible Treatment for COVID-19,Recruiting,Biological: Convalescent plasma|Biological: Placebo,All,"40 Years and older   (Adult, Older Adult)",Phase 2,50.0,"May 5, 2020","May 5, 2021",United States,https://ClinicalTrials.gov/show/NCT04442191
264,264,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,Recruiting,Drug: EC-18|Drug: Placebo EC-18,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 28, 2020",May 2022,"Korea, Republic of",https://ClinicalTrials.gov/show/NCT04500132
265,265,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"Active, not recruiting",Drug: HB-adMSC|Drug: Placebo,All,"Child, Adult, Older Adult",Phase 2,100.0,"June 30, 2020","October 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04362189
266,266,INB03 for the Treatment of Pulmonary Complications From COVID-19,Recruiting,Drug: INB03|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,366.0,"October 21, 2020",February 2021,United States,https://ClinicalTrials.gov/show/NCT04370236
267,267,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recruiting,Drug: RhACE2 APN01|Drug: Physiological saline solution,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,200.0,"April 30, 2020",December 2020,Austria,https://ClinicalTrials.gov/show/NCT04335136
268,268,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Completed,Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",Phase 3,108.0,"May 4, 2020","November 6, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04391127
269,269,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,Device: GO2 PEEP MOUTHPIECE,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2.0,"April 8, 2020","August 31, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04331366
270,270,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,Biological: SARS-CoV-2 Specific T Cells,All,"1 Year to 90 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,18.0,"July 1, 2020",December 2022,Singapore,https://ClinicalTrials.gov/show/NCT04457726
271,271,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Active, not recruiting",Drug: Favipiravir + Standard of Care|Drug: Standard of Care,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,50.0,"April 17, 2020","November 1, 2020",Jersey,https://ClinicalTrials.gov/show/NCT04358549
272,272,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Drug: Clazakizumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"July 13, 2020","July 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04494724
273,273,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Recruiting,Drug: Interferon beta-1a|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2900.0,"March 18, 2020","May 18, 2022",Canada,https://ClinicalTrials.gov/show/NCT04330690
274,274,Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,Recruiting,Behavioral: Exercise training,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"September 25, 2020","May 1, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04549337
275,275,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,"Active, not recruiting",Biological: Ampion|Other: Standard of Care,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 1,10.0,"July 27, 2020","November 13, 2020",United States,https://ClinicalTrials.gov/show/NCT04456452
276,276,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19),Recruiting,Drug: AT-527|Other: Placebo,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 2,190.0,"May 26, 2020",January 2021,Belgium,https://ClinicalTrials.gov/show/NCT04396106
277,277,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Completed,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,32.0,"April 4, 2020","June 5, 2020",United States,https://ClinicalTrials.gov/show/NCT04331795
278,278,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,"Active, not recruiting",Drug: Hydroxychloroquine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,228.0,"April 3, 2020","July 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04333225
279,279,"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19",Not yet recruiting,Dietary Supplement: 5-ALA-Phosphate + SFC (5-ALA + SFC),All,"21 Years and older   (Adult, Older Adult)",Not Applicable,40.0,November 2020,December 2020,Bahrain,https://ClinicalTrials.gov/show/NCT04542850
280,280,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),Recruiting,Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Clazakizumab|Drug: placebo for clazakizumab,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2|Phase 3,500.0,"April 16, 2020","December 31, 2020",Austria,https://ClinicalTrials.gov/show/NCT04351724
281,281,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,600.0,"April 13, 2020","December 10, 2021",United States,https://ClinicalTrials.gov/show/NCT04344444
282,282,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,700.0,"May 7, 2020","December 7, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04429867
283,283,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans,Recruiting,"Drug: Nitric Oxide lozenges, 30 mg|Drug: Placebo",All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,100.0,"November 1, 2020","July 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04601077
284,284,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,"Active, not recruiting",Other: Cash transfer,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,392.0,"April 20, 2020","December 30, 2020",Canada,https://ClinicalTrials.gov/show/NCT04359264
285,285,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,"Active, not recruiting",Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,9.0,"May 1, 2020","May 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04377659
286,286,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Recruiting,Device: CytoSorb-Therapy,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,24.0,"April 1, 2020",February 2021,Germany,https://ClinicalTrials.gov/show/NCT04344080
287,287,Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients,Not yet recruiting,Drug: Methotrexate,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42.0,"May 1, 2020","November 30, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04352465
288,288,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,Recruiting,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,All,"12 Years to 120 Years   (Child, Adult, Older Adult)",Phase 3,800.0,"August 13, 2020","December 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04486313
289,289,A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Drug: GNS561,All,"18 Years and older   (Adult, Older Adult)",Phase 2,178.0,"November 18, 2020","October 30, 2021",France,https://ClinicalTrials.gov/show/NCT04637828
290,290,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,Biological: WJ-MSCs,All,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,"March 16, 2020","September 30, 2020",Jordan,https://ClinicalTrials.gov/show/NCT04313322
291,291,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Drug: LY3819253|Drug: LY3832479|Drug: Placebo,All,18 Years to 64 Years   (Adult),Phase 2,500.0,"October 29, 2020","March 15, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04634409
292,292,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Recruiting,Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,45.0,"August 15, 2020",January 2021,United States,https://ClinicalTrials.gov/show/NCT04347954
293,293,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Recruiting,Radiation: Radiation therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"July 23, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04427566
294,294,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),"Active, not recruiting",Drug: Ivermectin Oral Product|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,476.0,"July 14, 2020","December 21, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04405843
295,295,A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients,Not yet recruiting,Drug: BAT2020,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,174.0,"October 20, 2020","August 18, 2021",United States,https://ClinicalTrials.gov/show/NCT04432766
296,296,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,Recruiting,Drug: Ivermectin Oral Product,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 12, 2020","October 31, 2020",Israel,https://ClinicalTrials.gov/show/NCT04429711
297,297,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate,All,"16 Years to 99 Years   (Child, Adult, Older Adult)",Phase 2,65.0,"March 11, 2020","April 30, 2020","Korea, Republic of",https://ClinicalTrials.gov/show/NCT04307693
298,298,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,Recruiting,Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,48.0,"April 9, 2020","May 9, 2020",United States,https://ClinicalTrials.gov/show/NCT04344236
299,299,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,Recruiting,Biological: Bactek-R,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,100.0,"June 10, 2020","July 31, 2021",Dominica,https://ClinicalTrials.gov/show/NCT04363814
300,300,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,Terminated,Drug: Hydroxychloroquine,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 3,17.0,"March 26, 2020","August 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04345692
301,301,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,Completed,Drug: Levilimab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,206.0,"April 29, 2020","August 3, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04397562
302,302,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),Recruiting,Drug: RBT-9 (90 mg)|Drug: 0.9% sodium chloride (normal saline),All,"18 Years and older   (Adult, Older Adult)",Phase 2,252.0,"August 5, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04364763
303,303,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,Recruiting,Drug: Convalesscent Plasma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,106.0,"August 30, 2020",February 2021,Germany,https://ClinicalTrials.gov/show/NCT04433910
304,304,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,"Active, not recruiting",Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"June 9, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04421404
305,305,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,Recruiting,Drug: Degarelix|Other: Saline,Male,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,198.0,"July 6, 2020","July 6, 2021",United States,https://ClinicalTrials.gov/show/NCT04397718
306,306,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,Completed,Drug: LY3819253|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,24.0,"May 28, 2020","August 26, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04411628
307,307,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Terminated,Drug: Chloroquine Sulfate|Drug: Hydroxychloroquine|Other: Standard supportive care,All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 4,25.0,"April 14, 2020","June 8, 2020",Netherlands,https://ClinicalTrials.gov/show/NCT04362332
308,308,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"Active, not recruiting",Drug: Peginterferon Lambda-1a|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,120.0,"April 24, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04331899
309,309,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,Recruiting,Drug: Nafamostat Mesilate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"September 25, 2020",March 2021,Russian Federation,https://ClinicalTrials.gov/show/NCT04623021
310,310,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Drug: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"April 28, 2020","April 28, 2025",Mexico,https://ClinicalTrials.gov/show/NCT04434131
311,311,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Drug: LY3819253|Drug: LY3832479|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,1200.0,"June 17, 2020","March 11, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04427501
312,312,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,Suspended,Drug: Hydroxychloroquine|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440.0,"April 3, 2020","October 30, 2020",Spain,https://ClinicalTrials.gov/show/NCT04331834
313,313,Study of the Safety of Prophylactic Vaccination With 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy Volunteers,Recruiting,Biological: hAd5-S-Fusion+N-ETSD vaccine,All,18 Years to 55 Years   (Adult),Phase 1,35.0,"October 19, 2020","November 19, 2021",United States,https://ClinicalTrials.gov/show/NCT04591717
314,314,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Recruiting,Drug: PUL-042 Inhalation Solution|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"June 9, 2020",March 2021,Georgia,https://ClinicalTrials.gov/show/NCT04313023
315,315,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"April 6, 2020","March 31, 2021",China,https://ClinicalTrials.gov/show/NCT04336254
316,316,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,Recruiting,Drug: RDV|Drug: Placebo to Match RDV,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1264.0,"September 18, 2020",January 2021,Denmark,https://ClinicalTrials.gov/show/NCT04501952
317,317,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",Recruiting,Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,276.0,"April 2, 2020",October 2020,Spain,https://ClinicalTrials.gov/show/NCT04332094
318,318,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Drug: Remdesivir|Drug: Standard of Care,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,4891.0,"March 6, 2020","June 30, 2020",China,https://ClinicalTrials.gov/show/NCT04292899
319,319,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19",Recruiting,Drug: Hydroxychloroquine|Drug: Mucodentol|Device: Personal protective equipment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180.0,"July 15, 2020","December 15, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04466280
320,320,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,Recruiting,Biological: Adsorbed COVID-19 (inactivated) Vaccine|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,13060.0,"July 21, 2020",October 2021,Brazil,https://ClinicalTrials.gov/show/NCT04456595
321,321,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Recruiting,Diagnostic Test: COVID 19 serology|Other: COVID 19 Self-Questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"September 9, 2020",September 2021,France,https://ClinicalTrials.gov/show/NCT04481633
322,322,#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Mannitol,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,800.0,"May 12, 2020",October 2020,Switzerland,https://ClinicalTrials.gov/show/NCT04385264
323,323,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,Completed,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline,All,"30 Years and older   (Adult, Older Adult)",Phase 4,18.0,"April 28, 2020","September 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04370782
324,324,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Recruiting,Drug: PUL-042 Inhalation Solution|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 16, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04312997
325,325,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Recruiting,Drug: Remdesivir (RDV)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,282.0,"September 14, 2020",April 2021,United States,https://ClinicalTrials.gov/show/NCT04539262
326,326,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19",Recruiting,Biological: bacTRL-Spike,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,October 2020,"February 28, 2022",Australia,https://ClinicalTrials.gov/show/NCT04334980
327,327,Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19,Recruiting,Drug: UNI911 INHALATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,44.0,"June 29, 2020","December 31, 2020",Denmark,https://ClinicalTrials.gov/show/NCT04576312
328,328,Tetrandrine Tablets Used in the Treatment of COVID-19,Enrolling by invitation,Drug: Tetrandrine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,60.0,"March 5, 2020","May 1, 2021",China,https://ClinicalTrials.gov/show/NCT04308317
329,329,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Recruiting,Drug: Ciclesonide|Drug: Placebo,All,"12 Years to 100 Years   (Child, Adult, Older Adult)",Phase 3,400.0,"June 8, 2020","December 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04377711
330,330,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,Recruiting,Drug: Nitazoxanide Tablets|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"May 25, 2020","July 31, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04348409
331,331,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,Recruiting,Drug: Remdesivir|Drug: Cenicriviroc|Drug: Icatibant|Drug: Razuprotafib|Drug: Apremilast,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1500.0,"July 31, 2020","November 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04488081
332,332,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,Recruiting,Drug: Telmisartan 40mg|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"July 1, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04360551
333,333,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,Drug: Clazakizumab 25 mg|Drug: Clazakizumab 12.5 mg|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,"March 31, 2020","July 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04343989
334,334,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Drug: Bivalirudin Injection|Drug: Standard treatment,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,100.0,"June 28, 2020","March 28, 2021",Qatar,https://ClinicalTrials.gov/show/NCT04445935
335,335,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,Recruiting,"Drug: RESP301, a Nitric Oxide generating solution|Other: Standard of Care",All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,300.0,"July 29, 2020","April 23, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04460183
336,336,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",Enrolling by invitation,Drug: HB-adMSCs|Drug: Placebos,All,"Child, Adult, Older Adult",Phase 2,100.0,"May 14, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04348435
337,337,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,Suspended,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,400.0,"April 23, 2020","June 30, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04329572
338,338,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,Device: Flow controlled ventilation (Evone-ventilator),All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,20.0,"May 28, 2020",August 2020,Qatar,https://ClinicalTrials.gov/show/NCT04399317
339,339,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Drug: Remdesivir|Drug: Standard of Care,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,1113.0,"March 15, 2020","June 26, 2020",China,https://ClinicalTrials.gov/show/NCT04292730
340,340,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)",Recruiting,Drug: Remdesivir,All,"up to 18 Years   (Child, Adult)",Phase 2|Phase 3,52.0,"July 21, 2020",February 2021,Italy,https://ClinicalTrials.gov/show/NCT04431453
341,341,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,Recruiting,Diagnostic Test: Diagnostic test for SARS-Cov2 for patients and health staff,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12000.0,"June 15, 2020","June 15, 2022",France,https://ClinicalTrials.gov/show/NCT04421625
342,342,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,Recruiting,Drug: Standard Therapy Protocol (STP)|Other: STP + Standard Plasma (SP)|Other: STP + COVID-19 Convalescent Plasma (CP),All,"18 Years and older   (Adult, Older Adult)",Phase 2,180.0,"June 15, 2020","December 15, 2021",Italy,https://ClinicalTrials.gov/show/NCT04428021
343,343,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients,Recruiting,Other: Blood and derivatives.|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,278.0,"April 3, 2020",July 2020,Spain,https://ClinicalTrials.gov/show/NCT04345523
344,344,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),Recruiting,Drug: Nitazoxanide|Drug: Placebo,All,18 Years to 59 Years   (Adult),Phase 2|Phase 3,135.0,"June 26, 2020","December 26, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04463264
345,345,Trial to Promote Recovery From COVID-19 With Endocrine Therapy,Not yet recruiting,Drug: Bicalutamide 150 Mg Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"January 4, 2021",December 2021,United States,https://ClinicalTrials.gov/show/NCT04374279
346,346,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Recruiting,Biological: Biological,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,150.0,"June 23, 2020","September 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04542967
347,347,Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T),Not yet recruiting,Drug: Dialyzable Leukocyte Extract|Drug: Placebo oral,All,"18 Years and older   (Adult, Older Adult)",Phase 2,562.0,May 2020,December 2020,Mexico,https://ClinicalTrials.gov/show/NCT04379479
348,348,Early Versus Delayed Intubation of Patients With COVID-19,Not yet recruiting,Other: Endotracheal intubation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"November 18, 2020","May 1, 2021",Greece,https://ClinicalTrials.gov/show/NCT04632043
349,349,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,Completed,Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)|Drug: COVID-19 standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,146.0,"April 4, 2020","July 14, 2020",United Arab Emirates,https://ClinicalTrials.gov/show/NCT04473170
350,350,Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection.,Withdrawn,Biological: vaccine BCG|Other: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,0.0,August 2020,November 2021,Colombia,https://ClinicalTrials.gov/show/NCT04362124
351,351,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",Completed,Drug: Povidone-Iodine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,"September 1, 2020","October 23, 2020",France,https://ClinicalTrials.gov/show/NCT04371965
352,352,Control of COVID-19 Outbreaks in Long Term Care,Recruiting,Drug: Favipiravir|Drug: Favipiravir Placebo,All,65 Years and older   (Older Adult),Phase 2,760.0,"October 16, 2020",March 2021,Canada,https://ClinicalTrials.gov/show/NCT04448119
353,353,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Recruiting,Drug: Azithromycin Capsule,All,"19 Years and older   (Adult, Older Adult)",Phase 3,800.0,"May 29, 2020","October 13, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04381962
354,354,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,Recruiting,Drug: Zavegepant (BHV-3500)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"April 25, 2020",April 2021,United States,https://ClinicalTrials.gov/show/NCT04346615
355,355,RAPA-501-Allo Off-the-Shelf Therapy of COVID-19,Not yet recruiting,Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,88.0,"December 30, 2020","June 1, 2022",Jersey,https://ClinicalTrials.gov/show/NCT04482699
356,356,Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19),Withdrawn,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,August 2020,September 2021,United States,https://ClinicalTrials.gov/show/NCT04363866
357,357,Pegylated Interferon Lambda Treatment for COVID-19,Enrolling by invitation,Drug: Pegylated interferon lambda,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"June 22, 2020","September 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04343976
358,358,Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial,Not yet recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120.0,October 2020,"June 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04382625
359,359,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Recruiting,Other: Media Intervention|Procedure: Meditation Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Procedure: Yoga,All,"up to 70 Years   (Child, Adult, Older Adult)",Phase 1,50.0,"June 17, 2020","July 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04482647
360,360,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,Recruiting,Radiation: Low Dose Radiotherapy,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,30.0,"July 24, 2020","April 5, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04534790
361,361,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Recruiting,Drug: Angiotensin Receptor Blockers,All,"18 Years and older   (Adult, Older Adult)",Phase 4,605.0,"June 19, 2020","April 30, 2021",Australia,https://ClinicalTrials.gov/show/NCT04394117
362,362,Stopping ACE-inhibitors in COVID-19,Recruiting,"Drug: ACE inhibitor, angiotensin receptor blocker",All,"18 Years and older   (Adult, Older Adult)",Phase 4,208.0,"April 15, 2020","May 15, 2022",Austria,https://ClinicalTrials.gov/show/NCT04353596
363,363,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,Recruiting,Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution|Drug: Enoxaparin,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,300.0,"May 22, 2020","October 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04427098
364,364,Immune Modulators for Treating COVID-19,Recruiting,Drug: Infliximab|Drug: Abatacept|Drug: Remdesivir|Drug: cenicriviroc,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2160.0,"October 15, 2020",September 2021,Jersey,https://ClinicalTrials.gov/show/NCT04593940
365,365,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Recruiting,Procedure: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"April 23, 2020","September 15, 2021",Greece,https://ClinicalTrials.gov/show/NCT04408209
366,366,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Completed,Drug: Plasma from COVID-19 convalescent patient|Drug: Human immunoglobulin,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",Phase 3,196.0,"May 6, 2020","November 26, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04381858
367,367,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Recruiting,Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells|Drug: Antibiotics|Drug: Hormones|Drug: Anticoagulant Therapy|Device: Оxygen therapy,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"May 2, 2020",December 2021,Ukraine,https://ClinicalTrials.gov/show/NCT04461925
368,368,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,"March 31, 2020","June 6, 2020",Italy,https://ClinicalTrials.gov/show/NCT04346355
369,369,Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients,Not yet recruiting,Drug: SnPP Protoporphyrin plus Sunlight exposure|Drug: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Other: placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,56.0,August 2020,November 2020,Egypt,https://ClinicalTrials.gov/show/NCT04371822
370,370,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,Recruiting,Drug: Bevacizumab,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,140.0,"March 17, 2020","July 31, 2020",China,https://ClinicalTrials.gov/show/NCT04305106
371,371,NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,Not yet recruiting,Biological: NestaCell®|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,June 2020,August 2020,Brazil,https://ClinicalTrials.gov/show/NCT04315987
372,372,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Active, not recruiting",Biological: BCG vaccine|Biological: Placebo,All,"60 Years and older   (Adult, Older Adult)",Phase 4,2014.0,"April 16, 2020",May 2021,Netherlands,https://ClinicalTrials.gov/show/NCT04417335
373,373,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Drug: methylprednisolone therapy|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,80.0,"January 26, 2020","April 13, 2020",China,https://ClinicalTrials.gov/show/NCT04244591
374,374,PEP Flute-selfcare in COVID-19,Recruiting,Device: PEP flute,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"October 6, 2020","April 30, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04530435
375,375,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Completed,Drug: Tocilizumab (TCZ)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450.0,"April 3, 2020","July 28, 2020",Canada,https://ClinicalTrials.gov/show/NCT04320615
376,376,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,Enrolling by invitation,Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 2,72.0,"June 16, 2020",November 2020,Bangladesh,https://ClinicalTrials.gov/show/NCT04407130
377,377,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"Active, not recruiting",Drug: Placebo|Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,379.0,"May 14, 2020","December 1, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04372186
378,378,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,Recruiting,Biological: Abatacept|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,129.0,"August 24, 2020","January 14, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04472494
379,379,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,Recruiting,Drug: MSTT1041A|Drug: MSTT1041A-matched Placebo|Drug: UTTR1147A|Drug: UTTR1147A-matched Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,390.0,"June 2, 2020","March 3, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04386616
380,380,Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients,Not yet recruiting,Other: Cardiorespiratory Exercise|Other: Modified Bai He Gu Jin Tang,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,172.0,"October 1, 2020","June 30, 2023",Hong Kong,https://ClinicalTrials.gov/show/NCT04572360
381,381,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Completed,Drug: Tociliuzumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"May 5, 2020","August 12, 2020",Jamaica,https://ClinicalTrials.gov/show/NCT04363736
382,382,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,Recruiting,Drug: LAU-7b|Drug: Placebo oral capsule,All,"18 Years and older   (Adult, Older Adult)",Phase 2,240.0,"June 29, 2020","May 30, 2021",Canada,https://ClinicalTrials.gov/show/NCT04417257
383,383,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Drug: Siltuximab|Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 15, 2020","May 20, 2020",Spain,https://ClinicalTrials.gov/show/NCT04329650
384,384,Convalescent Plasma for COVID-19 Close Contacts,Recruiting,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%),All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,May 2020,April 2021,United States,https://ClinicalTrials.gov/show/NCT04390503
385,385,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,Recruiting,Drug: Camostat,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,389.0,"September 25, 2020","August 31, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04455815
386,386,PET/CT Imaging in COVID-19 Patients,Enrolling by invitation,Drug: 18F-αvβ6-BP,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10.0,"May 1, 2020",May 2022,United States,https://ClinicalTrials.gov/show/NCT04376593
387,387,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine,All,"15 Years to 100 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,30.0,"April 4, 2020","May 20, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04331470
388,388,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Recruiting,Drug: Remdesivir|Drug: Tocilizumab|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,500.0,"June 16, 2020","December 1, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04409262
389,389,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Recruiting,Drug: Sarilumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"April 22, 2020","December 30, 2020",Spain,https://ClinicalTrials.gov/show/NCT04661527
390,390,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"Active, not recruiting",Drug: metenkefalin + tridecactide|Drug: The standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"May 1, 2020","December 31, 2020",Bosnia and Herzegovina,https://ClinicalTrials.gov/show/NCT04374032
391,391,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,Diagnostic Test: Lung ultrasound use in patients hospitalized with COVID,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,90.0,"July 1, 2020","December 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04542421
392,392,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Drug: BCG Vaccine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500.0,"March 25, 2020","April 30, 2021",Netherlands,https://ClinicalTrials.gov/show/NCT04328441
393,393,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,500.0,"April 14, 2020","August 15, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04315896
394,394,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Active, not recruiting",Biological: Inactivated SARS-CoV-2 vaccine (Vero cell)|Biological: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,3000.0,"September 16, 2020","December 1, 2021",Argentina,https://ClinicalTrials.gov/show/NCT04560881
395,395,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,Recruiting,Biological: MVC-COV1901,All,20 Years to 50 Years   (Adult),Phase 1,45.0,"October 7, 2020","June 30, 2021","National Taiwan University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04487210
396,396,Expressive Writing for COVID-19 Resilience for Parents,Completed,Behavioral: Expressive writing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,11.0,"May 27, 2020","August 2, 2020",United States,https://ClinicalTrials.gov/show/NCT04589117
397,397,Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia,Recruiting,Drug: Chloroquine Phosphate Tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"March 10, 2020","August 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04428268
398,398,"A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19",Not yet recruiting,Drug: Favipiravir|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,256.0,June 2020,September 2020,China,https://ClinicalTrials.gov/show/NCT04425460
399,399,Study of Sargramostim in Patients With COVID-19,Recruiting,Drug: Sargramostim|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"August 18, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04411680
400,400,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Suspended,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200.0,"April 3, 2020","October 30, 2020",Spain,https://ClinicalTrials.gov/show/NCT04325061
401,401,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Terminated,Behavioral: Intermittent prone positioning instructions|Behavioral: Usual care positioning with no instructions,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"April 29, 2020","August 6, 2020",United States,https://ClinicalTrials.gov/show/NCT04368000
402,402,Hydroxychloroquine for COVID-19,Recruiting,Drug: Hydroxychloroquine Sulfate|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,220.0,"March 29, 2020",February 2022,Germany,https://ClinicalTrials.gov/show/NCT04342221
403,403,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,Recruiting,Drug: Anti-SARS-CoV-2 convalescent plasma,All,"19 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,136.0,"September 21, 2020","June 30, 2021",Philippines,https://ClinicalTrials.gov/show/NCT04567173
404,404,Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients,Recruiting,Drug: Interferon-ß-1a|Combination Product: Standard of Care (SOC),All,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,"November 2, 2020",June 2021,Italy,https://ClinicalTrials.gov/show/NCT04449380
405,405,"Rapid, Onsite COVID-19 Detection",Enrolling by invitation,Device: Rapid Onsite COVID-19 Detection,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,10000.0,"July 13, 2020",July 2021,United States,https://ClinicalTrials.gov/show/NCT04460690
406,406,Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS,Recruiting,Drug: Losartan 50 mg and Spironolactone 25 mg pillules oral use,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,90.0,"September 11, 2020","October 30, 2022",France,https://ClinicalTrials.gov/show/NCT04643691
407,407,COVID-19 PrEP HCW HCQ Study,Completed,Drug: Hydroxychloroquine (HCQ),All,"18 Years and older   (Adult, Older Adult)",Phase 2,130.0,"April 3, 2020","October 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04354870
408,408,COVID-19: Salvage TOcilizumab as a Rescue Measure,Recruiting,Drug: iv Tocillizumab (TCZ),All,"18 Years and older   (Adult, Older Adult)",Phase 3,90.0,"August 14, 2020","December 31, 2021",Finland,https://ClinicalTrials.gov/show/NCT04577534
409,409,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Recruiting,Biological: serology test|Diagnostic Test: NG Biotech|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample,All,up to 17 Years   (Child),Not Applicable,1920.0,"July 29, 2020",December 2022,France,https://ClinicalTrials.gov/show/NCT04355533
410,410,Convalescent Plasma Treatment in COVID-19,Recruiting,Biological: Convalescent Plasma (CP)|Other: Drugs and supportive care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"April 26, 2020",September 2020,Pakistan,https://ClinicalTrials.gov/show/NCT04476888
411,411,Expressive Writing for COVID-19 Resilience,Completed,Behavioral: Expressive writing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,63.0,"May 26, 2020","August 17, 2020",United States,https://ClinicalTrials.gov/show/NCT04589104
412,412,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Recruiting,Other: Neuromuscular Electrical Stimulation|Other: Physical Therapy Exercise,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"April 17, 2020",July 2020,Italy,https://ClinicalTrials.gov/show/NCT04382729
413,413,"Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)",Not yet recruiting,"Drug: NT-I7|Drug: Placebo|Procedure: Blood for research purposes|Procedure: Blood for pharmacokinetic samples|Procedure: Nasopharyngeal, oropharyngeal, or saliva swab|Procedure: Blood for anti-drug antibody (ADA)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,42.0,"December 31, 2020","September 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04498325
414,414,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)|Drug: 0.9%sodium chloride,All,"18 Years and older   (Adult, Older Adult)",Phase 2,44.0,"April 28, 2020","February 28, 2021",United States,https://ClinicalTrials.gov/show/NCT04445285
415,415,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",Recruiting,Biological: BNT162b1|Biological: BNT162b2|Other: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,43998.0,"April 29, 2020","January 29, 2023",Argentina,https://ClinicalTrials.gov/show/NCT04368728
416,416,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19",Recruiting,Drug: Silmitasertib|Drug: SOC,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"December 3, 2020","February 11, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04663737
417,417,COVID-FISETIN: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation,Enrolling by invitation,Drug: Placebo|Drug: Fisetin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,70.0,"August 3, 2020",July 2021,United States,https://ClinicalTrials.gov/show/NCT04476953
418,418,Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica,Not yet recruiting,Biological: Convalescent Plasma Infusion,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,30.0,"December 1, 2020","December 1, 2021",Jamaica,https://ClinicalTrials.gov/show/NCT04644198
419,419,Colchicine in Moderate Symptomatic COVID-19 Patients,Recruiting,Drug: Colchicine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"July 14, 2020",December 2020,Bangladesh,https://ClinicalTrials.gov/show/NCT04527562
420,420,Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection,Not yet recruiting,Drug: NIVOLUMAB|Other: Routine standard of care,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,120.0,"June 15, 2020","September 15, 2021",France,https://ClinicalTrials.gov/show/NCT04413838
421,421,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,Behavioral: Cognitive and behavioral intervention.|Behavioral: Problem-solving and relationship improvement intervention.,All,30 Years to 60 Years   (Adult),Not Applicable,300.0,"February 1, 2020","January 31, 2022",China,https://ClinicalTrials.gov/show/NCT04463433
422,422,Antioxidant Therapy for COVID-19 Study,Not yet recruiting,Dietary Supplement: Antioxidation Therapy|Other: Standard of Care,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,90.0,"November 1, 2020","April 30, 2021",Niger,https://ClinicalTrials.gov/show/NCT04466657
423,423,Efficacy and Safety of Sirolimus in COVID-19 Infection,Recruiting,Drug: Sirolimus,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"August 15, 2020","November 30, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04461340
424,424,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2712.0,"May 14, 2020",November 2020,Italy,https://ClinicalTrials.gov/show/NCT04366960
425,425,Convalescent Plasma for Treatment of COVID-19: An Open Randomised Controlled Trial,Not yet recruiting,Biological: SARS-CoV-2 convalescent plasma|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,920.0,"December 3, 2020","February 1, 2022",Sweden,https://ClinicalTrials.gov/show/NCT04649879
426,426,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),Recruiting,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,All,"55 Years to 120 Years   (Adult, Older Adult)",Phase 3,800.0,"May 12, 2020","December 31, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04343248
427,427,The Protective Potential of Exercise Training on the Cardiopulmonary Morbidity After COVID-19,Not yet recruiting,Behavioral: High intensity interval training|Behavioral: Standard care,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"January 1, 2021","December 31, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04647734
428,428,Angiotensin 1-7 as a Therapy in the Treatment of COVID-19,Not yet recruiting,Drug: Angiotensin 1-7,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,November 2020,April 2024,Israel,https://ClinicalTrials.gov/show/NCT04605887
429,429,Role of Inflammasomes in COVID-19 Disease,Recruiting,Other: COVID-19 patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"May 11, 2020","June 12, 2021",France,https://ClinicalTrials.gov/show/NCT04385017
430,430,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia,Not yet recruiting,Radiation: Low dose Radiotherapy,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,13.0,October 2020,April 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04572412
431,431,Catalysing the Containment of COVID-19,Recruiting,Drug: Nitazoxanide|Drug: Placebo,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2|Phase 3,960.0,"August 27, 2020",August 2021,South Africa,https://ClinicalTrials.gov/show/NCT04523090
432,432,NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes,Not yet recruiting,Drug: NBT-NM108|Other: Usual Care Only,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 2,100.0,"October 1, 2020","March 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04540406
433,433,Fingolimod in COVID-19,Withdrawn,Drug: Fingolimod 0.5 mg,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,0.0,"February 22, 2020","July 1, 2020",China,https://ClinicalTrials.gov/show/NCT04280588
434,434,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,Recruiting,Drug: MAS825|Drug: Matching placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"June 7, 2020","April 9, 2021",United States,https://ClinicalTrials.gov/show/NCT04382651
435,435,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,Device: Continuous vital sign monitoring - Isansys Patient Status Engine|Other: Machine Learning/AI Algorithm,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,60.0,"July 11, 2020","February 1, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04581031
436,436,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,Recruiting,Drug: Nitazoxanide|Drug: Placebo|Dietary Supplement: Vitamin Super B-Complex,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,4000.0,"May 13, 2020","April 30, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04359680
437,437,Outpatient Use of Ivermectin in COVID-19,Not yet recruiting,Drug: Ivermectin Pill|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"October 1, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04530474
438,438,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,Recruiting,Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,July 2020,March 2021,United States,https://ClinicalTrials.gov/show/NCT04486482
439,439,Health Professional Exposure Assessment to Covid-19,Recruiting,Diagnostic Test: Diagnostic test Covid-19,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6000.0,"July 6, 2020",December 2020,France,https://ClinicalTrials.gov/show/NCT04429724
440,440,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Biological: Gam-COVID-Vac,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,38.0,"June 17, 2020","August 10, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04436471
441,441,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Recruiting,Other: Moxibustion plus Cupping,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60.0,"May 10, 2020",December 2021,China,https://ClinicalTrials.gov/show/NCT04374084
442,442,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 Moves Through the Body of Adult Participants Hospitalized With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Drug: ABBV-47D11|Drug: Placebo for ABBV-47D11,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,"November 27, 2020","May 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04644120
443,443,Core Warming of COVID-19 Patients,Withdrawn,Device: ensoETM device,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0.0,October 2020,December 2020,United States,https://ClinicalTrials.gov/show/NCT04426344
444,444,COVID-19 Virtual Care at Home,Recruiting,Other: Virtual Care at Home,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"August 17, 2020","December 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04420182
445,445,Enzalutamide Treatment in COVID-19,Recruiting,Drug: Enzalutamide Pill,All,"50 Years and older   (Adult, Older Adult)",Phase 2,500.0,"July 15, 2020","May 8, 2022",Sweden,https://ClinicalTrials.gov/show/NCT04475601
446,446,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19",Recruiting,Drug: Placebo Administration|Biological: Vaccine Therapy,All,18 Years to 55 Years   (Adult),Phase 1,129.0,"December 23, 2020","November 10, 2022",United States,https://ClinicalTrials.gov/show/NCT04639466
447,447,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,Not yet recruiting,Biological: UC-MSCs|Drug: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,48.0,"April 20, 2020","February 15, 2022",China,https://ClinicalTrials.gov/show/NCT04273646
448,448,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Recruiting,Drug: Nitazoxanide and atazanavir/ritonavir|Other: Standard of Care,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,98.0,"October 9, 2020","March 21, 2021",Niger,https://ClinicalTrials.gov/show/NCT04459286
449,449,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,Completed,Drug: Clarithromycin 500mg|Drug: Azithromycin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"April 1, 2020","July 30, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04622891
450,450,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,Recruiting,Biological: AdimrSC-2f,All,20 Years to 60 Years   (Adult),Phase 1,70.0,"August 24, 2020","March 20, 2021","National Taiwan University Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04522089
451,451,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,Recruiting,"Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28",All,3 Years to 17 Years   (Child),Phase 1|Phase 2,552.0,"October 31, 2020",September 2021,China,https://ClinicalTrials.gov/show/NCT04551547
452,452,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Biological: Convalescent Plasma,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,100.0,"August 14, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04513158
453,453,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19",Not yet recruiting,Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,34020.0,December 2020,March 2022,Brazil,https://ClinicalTrials.gov/show/NCT04659239
454,454,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,Recruiting,Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"July 2, 2020",December 2020,Georgia,https://ClinicalTrials.gov/show/NCT04414124
455,455,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Recruiting,Drug: Azithromycin|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2271.0,"May 22, 2020","December 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04332107
456,456,Convalescent Plasma Trial in COVID -19 Patients,Completed,Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"April 19, 2020","July 9, 2020",Bahrain,https://ClinicalTrials.gov/show/NCT04356534
457,457,Hyperimmune Plasma for Patients With COVID-19,Recruiting,Other: treated with hyperimmune plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"July 2, 2020","July 2, 2022",Italy,https://ClinicalTrials.gov/show/NCT04614012
458,458,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Placebo on a 0- and 28-day schedule|Biological: Placebo on a 0- and 14-day schedule,All,18 Years to 59 Years   (Adult),Phase 1|Phase 2,942.0,"May 15, 2020",September 2021,China,https://ClinicalTrials.gov/show/NCT04412538
459,459,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,Recruiting,Drug: Chloroquine phosphate|Other: Telemedicine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400.0,"April 16, 2020","December 31, 2020",Poland,https://ClinicalTrials.gov/show/NCT04331600
460,460,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Recruiting,Other: Best Practice|Biological: Mesenchymal Stem Cell,All,"18 Years and older   (Adult, Older Adult)",Phase 1,70.0,"July 29, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04565665
461,461,Intravenous Infusion of CAP-1002 in Patients With COVID-19,Recruiting,Biological: CAP-1002|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"November 15, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04623671
462,462,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Recruiting,Drug: Transfusion of COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"April 15, 2020","June 1, 2020",France,https://ClinicalTrials.gov/show/NCT04345991
463,463,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Terminated,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,1.0,"April 14, 2020","July 15, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04435808
464,464,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,Diagnostic Test: Conjunctival swab and nasopharyngeal swab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 17, 2020","March 31, 2021",Austria,https://ClinicalTrials.gov/show/NCT04444596
465,465,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years,Enrolling by invitation,Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Placebo on a 0- and 28-day schedule,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,471.0,"July 10, 2020",November 2021,China,https://ClinicalTrials.gov/show/NCT04470609
466,466,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"Active, not recruiting","Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28",All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,422.0,"May 22, 2020","May 30, 2021",China,https://ClinicalTrials.gov/show/NCT04383574
467,467,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of placebo at the emergency vaccination schedule|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of placebo at the routine vaccination schedule,All,18 Years to 59 Years   (Adult),Phase 1|Phase 2,744.0,"April 16, 2020","December 13, 2020",China,https://ClinicalTrials.gov/show/NCT04352608
468,468,TXA and Corona Virus 2019 (COVID19) in Outpatients,Recruiting,Drug: Tranexamic acid tablets|Drug: Placebo oral tablet,All,"19 Years and older   (Adult, Older Adult)",Phase 2,100.0,"June 1, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04338074
469,469,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans",Not yet recruiting,Biological: TY027|Other: 0.9% saline,All,"21 Years to 100 Years   (Adult, Older Adult)",Phase 3,1305.0,"December 4, 2020","December 30, 2021",Singapore,https://ClinicalTrials.gov/show/NCT04649515
470,470,Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,Drug: Cenicriviroc (CVC)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,183.0,"August 25, 2020","September 30, 2021",Germany,https://ClinicalTrials.gov/show/NCT04500418
471,471,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Recruiting,Device: Volatile Organic Compounds analysis,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"April 14, 2020","November 16, 2020",France,https://ClinicalTrials.gov/show/NCT04379154
472,472,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,Drug: Razuprotafib Subcutaneous Solution|Drug: Placebo Subcutaneous Solution,All,"18 Years and older   (Adult, Older Adult)",Phase 2,180.0,"October 21, 2020",February 2021,United States,https://ClinicalTrials.gov/show/NCT04511650
473,473,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Recruiting,Other: Probiorinse|Other: Saline solution,All,18 Years to 59 Years   (Adult),Not Applicable,40.0,"July 16, 2020","December 31, 2020",Canada,https://ClinicalTrials.gov/show/NCT04458519
474,474,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",Recruiting,Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80.0,"April 16, 2020","September 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04344457
475,475,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Recruiting,Diagnostic Test: Cytokines dosage|Diagnostic Test: Complement dosage,All,"Child, Adult, Older Adult",Not Applicable,200.0,"March 20, 2020",December 2020,Belgium,https://ClinicalTrials.gov/show/NCT04346017
476,476,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Recruiting,Drug: Iloprost|Drug: Isotonic saline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"June 15, 2020","May 31, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04420741
477,477,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Recruiting,Drug: Ruxolitinib Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"April 15, 2020","June 1, 2020",Mali,https://ClinicalTrials.gov/show/NCT04334044
478,478,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,426.0,"April 8, 2020","July 31, 2021",Netherlands,https://ClinicalTrials.gov/show/NCT04342182
479,479,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,Recruiting,Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Standard therapy of COVID-19,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"April 30, 2020","July 30, 2021",India,https://ClinicalTrials.gov/show/NCT04347174
480,480,The Vietnam Chloroquine Treatment on COVID-19,Recruiting,Drug: Chloroquine phosphate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,250.0,"April 7, 2020","April 1, 2022","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",https://ClinicalTrials.gov/show/NCT04328493
481,481,Treatment for COVID-19 in High-Risk Adult Outpatients,"Active, not recruiting",Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra],All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,300.0,"April 16, 2020",January 2021,United States,https://ClinicalTrials.gov/show/NCT04354428
482,482,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,Drug: Melatonin|Drug: The usual treatment,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,55.0,"May 12, 2020","September 25, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04409522
483,483,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Drug: Colchicine Tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"March 20, 2020","September 30, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04360980
484,484,Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness,Not yet recruiting,Biological: COVID-19 convalescent plasma treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"December 1, 2020","May 1, 2022",Poland,https://ClinicalTrials.gov/show/NCT04642014
485,485,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,Biological: BCG vaccine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1000.0,"October 1, 2020","October 1, 2022",Brazil,https://ClinicalTrials.gov/show/NCT04659941
486,486,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"Active, not recruiting",Drug: Progesterone 100 MG,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"April 27, 2020","April 17, 2021",United States,https://ClinicalTrials.gov/show/NCT04365127
487,487,CAPTION AI to Minimize Risk of COVID Exposure,Withdrawn,Device: Caption AI,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0.0,July 2020,"November 9, 2020",United States,https://ClinicalTrials.gov/show/NCT04336774
488,488,Fase I Clinical Trial on NK Cells for COVID-19,Not yet recruiting,Biological: Natural Killer Cells infusion,All,"18 Years and older   (Adult, Older Adult)",Phase 1,24.0,"January 2, 2021","March 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04634370
489,489,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Drug: EDP1815|Drug: Dapagliflozin|Drug: Ambrisentan|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1407.0,"July 3, 2020","June 15, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04393246
490,490,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),Recruiting,Drug: Anakinra 149 MG/ML Prefilled Syringe [Kineret],All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,180.0,"May 8, 2020",March 2021,Spain,https://ClinicalTrials.gov/show/NCT04443881
491,491,Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,Not yet recruiting,Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,104.0,"April 30, 2020","July 30, 2020",France,https://ClinicalTrials.gov/show/NCT04363060
492,492,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,Recruiting,Drug: Hydroxychloroquine + Metabolic cofactor supplementation|Drug: Hydroxychloroquine + Sorbitol,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,400.0,"September 21, 2020","March 31, 2021",Turkey,https://ClinicalTrials.gov/show/NCT04573153
493,493,Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients,Recruiting,Drug: Famotidine 20 MG,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Phase 3,200.0,"August 1, 2020","October 30, 2020",Bangladesh,https://ClinicalTrials.gov/show/NCT04504240
494,494,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Active, not recruiting",Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1.0,"May 14, 2020","June 4, 2021",United States,https://ClinicalTrials.gov/show/NCT04372017
495,495,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19",Recruiting,Biological: SAB-185|Other: Normal Saline,All,18 Years to 60 Years   (Adult),Phase 1,21.0,"August 20, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04469179
496,496,VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),Suspended,Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet,All,"216 Months and older   (Adult, Older Adult)",Phase 3,300.0,"April 30, 2020",August 2021,United States,https://ClinicalTrials.gov/show/NCT04363203
497,497,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)",Recruiting,Dietary Supplement: Investigational Product - ViraCide|Other: Placebo - Starch Powder Soft gels,All,"50 Years to 90 Years   (Adult, Older Adult)",Not Applicable,124.0,"September 16, 2020","January 30, 2021",India,https://ClinicalTrials.gov/show/NCT04596085
498,498,A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,Suspended,Drug: Remdesivir|Drug: Remdesivir placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,308.0,"February 12, 2020","April 27, 2020",China,https://ClinicalTrials.gov/show/NCT04252664
499,499,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Recruiting,Drug: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,94.0,"July 7, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04478019
500,500,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Recruiting,Biological: MSC|Drug: Control,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20.0,"August 1, 2020","December 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04611256
501,501,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,Recruiting,Biological: VIR-7831|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1360.0,"August 27, 2020",July 2021,Austria,https://ClinicalTrials.gov/show/NCT04545060
502,502,Asunercept in Patients With Severe COVID-19,Recruiting,Biological: Asunercept,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,"October 9, 2020",May 2021,Russian Federation,https://ClinicalTrials.gov/show/NCT04535674
503,503,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,Drug: favipiravir|Drug: Standard of care therapy,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,100.0,"April 18, 2020","June 20, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04349241
504,504,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,Other: blood sample,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,115.0,"April 22, 2020","February 22, 2021",France,https://ClinicalTrials.gov/show/NCT04371510
505,505,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Recruiting,Drug: GC4419|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"September 9, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04555096
506,506,"A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19",Recruiting,Drug: Galidesivir|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,132.0,"April 9, 2020","May 31, 2021",Brazil,https://ClinicalTrials.gov/show/NCT03891420
507,507,Tableted COVID-19 Therapeutic Vaccine,"Active, not recruiting",Biological: V-SARS,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"May 15, 2020","June 15, 2021",Canada,https://ClinicalTrials.gov/show/NCT04380532
508,508,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,Recruiting,Biological: BNT162b3,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,120.0,"September 9, 2020",December 2021,Germany,https://ClinicalTrials.gov/show/NCT04537949
509,509,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,Not yet recruiting,Biological: PSC-04,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,20.0,"December 15, 2020","January 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04486001
510,510,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,Drug: oral co-trimoxazole,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,94.0,"July 12, 2020","January 30, 2021",Bangladesh,https://ClinicalTrials.gov/show/NCT04470531
511,511,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,"Active, not recruiting",Biological: Administration of Equine immunoglobulin anti SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",Phase 2,26.0,"September 6, 2020","December 6, 2020",Costa Rica,https://ClinicalTrials.gov/show/NCT04610502
512,512,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,Enrolling by invitation,Drug: Favipiravir|Drug: Placebo|Other: Standard of care treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"July 12, 2020",July 2021,United States,https://ClinicalTrials.gov/show/NCT04346628
513,513,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,508.0,"April 12, 2020","January 31, 2021",China,https://ClinicalTrials.gov/show/NCT04341389
514,514,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,"Active, not recruiting",Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,30.0,"June 12, 2020","December 21, 2020",Jersey,https://ClinicalTrials.gov/show/NCT04412668
515,515,Silymarin in COVID-19 Pneumonia,Recruiting,Drug: Silymarin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50.0,"August 16, 2020","February 28, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04394208
516,516,Piclidenoson for Treatment of COVID-19,Not yet recruiting,Drug: Piclidenoson|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"January 6, 2021","July 6, 2021",Israel,https://ClinicalTrials.gov/show/NCT04333472
517,517,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Completed,Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"May 1, 2020","July 7, 2020",United States,https://ClinicalTrials.gov/show/NCT04358068
518,518,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,Recruiting,Device: Electric pad for human external pain therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,274.0,"August 27, 2020",June 2022,Mexico,https://ClinicalTrials.gov/show/NCT04363541
519,519,COVID-19 And Geko Evaluation: The CAGE Study,Not yet recruiting,Device: geko T3,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,December 2020,April 2021,Canada,https://ClinicalTrials.gov/show/NCT04651374
520,520,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Recruiting,Procedure: Awake prone positioning|Procedure: Standard oxygen therapy,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200.0,"May 3, 2020","December 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04477655
521,521,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Drug: Povidone-Iodine Nasal Spray and Gargle,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,300.0,"April 29, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04364802
522,522,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,Recruiting,Biological: Lenzilumab|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,300.0,"April 30, 2020",September 2020,Georgia,https://ClinicalTrials.gov/show/NCT04351152
523,523,A Study of LY3819253 (LY-CoV555) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,Recruiting,Drug: LY3819253|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2400.0,"August 2, 2020","June 29, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04497987
524,524,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Biological: Gam-COVID-Vac Lyo,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,38.0,"June 17, 2020","August 10, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04437875
525,525,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Biological: mRNA-1273,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,120.0,"March 16, 2020","November 22, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04283461
526,526,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Recruiting,Dietary Supplement: Probiotic|Dietary Supplement: Control,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,314.0,"April 24, 2020",October 2020,Spain,https://ClinicalTrials.gov/show/NCT04366180
527,527,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Completed,Other: convalescent plasma application to SARS-CoV-2 infected patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15.0,"March 31, 2020","June 30, 2020",Switzerland,https://ClinicalTrials.gov/show/NCT04389944
528,528,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,Drug: Sofosbuvir plus Ledipasvir,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,250.0,"April 15, 2020","July 23, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04530422
529,529,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,Enrolling by invitation,Other: Certified cloth face mask plus preventive information|Behavioral: Preventive information,All,"10 Years and older   (Child, Adult, Older Adult)",Not Applicable,66000.0,"July 20, 2020",August 2021,Guinea,https://ClinicalTrials.gov/show/NCT04471766
530,530,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,Recruiting,Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,1000.0,"May 8, 2020","July 30, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04411433
531,531,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,Recruiting,Drug: Bemiparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"June 4, 2020","March 31, 2021",Spain,https://ClinicalTrials.gov/show/NCT04420299
532,532,Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19,Not yet recruiting,Drug: Metformin|Drug: Naltrexone,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,80.0,November 2020,May 2021,United States,https://ClinicalTrials.gov/show/NCT04604678
533,533,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,Recruiting,Diagnostic Test: Nasal Swab|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Throat swab|Diagnostic Test: Fingerstick|Diagnostic Test: Saliva specimen,All,"Child, Adult, Older Adult",Not Applicable,400.0,"June 26, 2020","December 31, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04557046
534,534,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Drug: Brazilian Green Propolis Extract (EPP-AF)|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"June 2, 2020","August 30, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04480593
535,535,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Recruiting,Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,160.0,"April 1, 2020","April 30, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04336332
536,536,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Recruiting,Drug: Molgramostim nebuliser solution|Other: Placebo nebuliser solution,All,"18 Years and older   (Adult, Older Adult)",Phase 2,238.0,"September 24, 2020","December 25, 2022",Germany,https://ClinicalTrials.gov/show/NCT04569877
537,537,Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19,Not yet recruiting,Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"May 20, 2020","December 1, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04360122
538,538,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Drug: Povidone-Iodine 0.4% NI|Drug: Povidone-Iodine 0.5% NI|Drug: Povidone-Iodine 0.6% NI|Drug: Povidone-Iodine 0.5% NS|Drug: Povidone-Iodine 0.6% NS|Other: Placebo comparator: DW-NI|Other: Placebo comparator: DW-NS,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Phase 2,200.0,"July 1, 2020","October 30, 2020",Bangladesh,https://ClinicalTrials.gov/show/NCT04549376
539,539,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Drug: TJ003234|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,384.0,"April 11, 2020",December 2021,India,https://ClinicalTrials.gov/show/NCT04341116
540,540,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,Recruiting,Drug: Antroquinonol|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,174.0,"October 8, 2020","March 31, 2021",India,https://ClinicalTrials.gov/show/NCT04523181
541,541,Sildenafil in COVID-19,Recruiting,Drug: Sildenafil|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"August 19, 2020",March 2021,Chile,https://ClinicalTrials.gov/show/NCT04489446
542,542,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Recruiting,Drug: 1: ILT101|Drug: 2: Placebo Comparator,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"October 23, 2020","February 23, 2021",France,https://ClinicalTrials.gov/show/NCT04357444
543,543,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,Completed,Drug: Ivermectin and Doxycyline|Drug: Standard of care,All,"16 Years to 86 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,140.0,"July 1, 2020","October 14, 2020",Iraq,https://ClinicalTrials.gov/show/NCT04591600
544,544,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Not yet recruiting,Drug: Duvelisib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,August 2020,February 2022,Georgia,https://ClinicalTrials.gov/show/NCT04487886
545,545,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,Recruiting,Drug: AVIGAN|Drug: Placebo Comparator,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 3,780.0,"August 20, 2020","January 31, 2021",Kuwait,https://ClinicalTrials.gov/show/NCT04529499
546,546,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),Recruiting,Procedure: Biospecimen Collection|Other: Questionnaire Administration,All,"Child, Adult, Older Adult",Not Applicable,1500.0,"April 9, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04513990
547,547,TD-0903 for ALI Associated With COVID-19,Recruiting,Drug: TD-0903|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,222.0,"June 24, 2020",February 2021,"Moldova, Republic of",https://ClinicalTrials.gov/show/NCT04402866
548,548,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Completed,Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,20.0,"May 1, 2020","July 27, 2020",United States,https://ClinicalTrials.gov/show/NCT04358081
549,549,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,Procedure: Stellate Ganglion Block,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,5.0,"April 24, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04402840
550,550,Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19,Not yet recruiting,Biological: intradermal injection of BCG Vaccine|Other: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,900.0,"April 20, 2020","December 1, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04350931
551,551,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","Active, not recruiting",Biological: BNT162b2|Other: Placebo,All,"20 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,160.0,"October 21, 2020","November 30, 2021",Japan,https://ClinicalTrials.gov/show/NCT04588480
552,552,Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19,Not yet recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15.0,"July 6, 2020","April 1, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04452812
553,553,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",Other: Saliva collection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"July 28, 2020","June 27, 2021",United States,https://ClinicalTrials.gov/show/NCT04567953
554,554,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,Drug: IV Dexamethasone|Drug: Nasal Dexamethasone,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"July 14, 2020","July 31, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04513184
555,555,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),Recruiting,Drug: Molnupiravir|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1300.0,"October 19, 2020","December 2, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04575584
556,556,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",Recruiting,Drug: Baricitinib|Drug: Hydroxychloroquine|Drug: Placebo Administration,All,"18 Years and older   (Adult, Older Adult)",Phase 2,144.0,"May 1, 2020","May 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04373044
557,557,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),Recruiting,Drug: Molnupiravir|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1450.0,"October 19, 2020","November 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04575597
558,558,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Completed,Drug: HCQ|Other: Standard therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,325.0,"March 1, 2020","July 31, 2020",India,https://ClinicalTrials.gov/show/NCT04408456
559,559,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Active, not recruiting","Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|Other: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,100.0,"July 27, 2020","October 4, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04527575
560,560,BCG Vaccination to Prevent COVID-19,Recruiting,Drug: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Drug: Preservative-free saline,All,18 Years to 64 Years   (Adult),Phase 3,550.0,"December 7, 2020",April 2023,United States,https://ClinicalTrials.gov/show/NCT04632537
561,561,DISulfiram for COvid-19 (DISCO) Trial,Not yet recruiting,Drug: Disulfiram|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"December 1, 2020","June 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04485130
562,562,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,Recruiting,Drug: AZD1656|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,"August 12, 2020",March 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04516759
563,563,A Study of LY3127804 in Participants With COVID-19,Terminated,Drug: LY3127804|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,95.0,"April 20, 2020","October 12, 2020",India,https://ClinicalTrials.gov/show/NCT04342897
564,564,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","Active, not recruiting",Biological: V591|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,260.0,"August 27, 2020","April 26, 2022",Austria,https://ClinicalTrials.gov/show/NCT04498247
565,565,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,Recruiting,Drug: Fuzheng Huayu Tablet|Drug: Vitamin C tablets|Other: Placebo|Other: respiratory function rehabilitation training,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,160.0,"April 23, 2020",December 2021,China,https://ClinicalTrials.gov/show/NCT04279197
566,566,Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19,Not yet recruiting,Drug: Enzalutamide,Male,"50 Years and older   (Adult, Older Adult)",Phase 2,90.0,July 2020,December 2021,Switzerland,https://ClinicalTrials.gov/show/NCT04456049
567,567,The COVID-RASi Trial (COVID-19),Not yet recruiting,Drug: Angiotensin converting enzyme inhibitor|Drug: Angiotensin II Receptor Blockers,All,65 Years and older   (Older Adult),Phase 3,1155.0,"October 30, 2020",August 2022,Canada,https://ClinicalTrials.gov/show/NCT04591210
568,568,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,Recruiting,Drug: MR or M-M-R II ® vaccine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000.0,"September 4, 2020",August 2021,Canada,https://ClinicalTrials.gov/show/NCT04333732
569,569,"Favipiravir, Protease Inhibitors, Oseltamivir -Gpo, Hydroxychloroquine for Treatment of COVID-19",Recruiting,Drug: Oral,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",Phase 3,320.0,"August 19, 2020","December 31, 2021",Thailand,https://ClinicalTrials.gov/show/NCT04303299
570,570,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,Diagnostic Test: ENT exam|Diagnostic Test: Olfactometry|Diagnostic Test: Brain MRI,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"September 3, 2020","September 3, 2021",France,https://ClinicalTrials.gov/show/NCT04526054
571,571,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),Recruiting,Drug: FOY-305|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,110.0,"November 9, 2020","May 31, 2021",Japan,https://ClinicalTrials.gov/show/NCT04657497
572,572,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Recruiting,Biological: COVID-19 Convalescent Plasma,All,65 Years and older   (Older Adult),Phase 2|Phase 3,182.0,"May 27, 2020","June 30, 2021",Italy,https://ClinicalTrials.gov/show/NCT04374526
573,573,COVID-19 and Chilblains,Completed,Diagnostic Test: Biological sample collection,All,"Child, Adult, Older Adult",Not Applicable,269.0,"July 21, 2020","October 19, 2020",France,https://ClinicalTrials.gov/show/NCT04455308
574,574,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,Recruiting,Drug: Favipiravir|Drug: Oseltamivir 75mg,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,100.0,"April 16, 2020","October 30, 2020",Indonesia,https://ClinicalTrials.gov/show/NCT04558463
575,575,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,Recruiting,Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet|Other: Supportive tratment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,165.0,"April 13, 2020",May 2021,Spain,https://ClinicalTrials.gov/show/NCT04346147
576,576,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,Recruiting,Drug: Trimodulin|Other: Placebo (human albumin 1%),All,"18 Years and older   (Adult, Older Adult)",Phase 2,164.0,"October 6, 2020",March 2021,Spain,https://ClinicalTrials.gov/show/NCT04576728
577,577,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,Other: Remote controlled exercise|Other: Home exercise,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,122.0,"September 1, 2020",August 2022,Turkey,https://ClinicalTrials.gov/show/NCT04482634
578,578,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell)|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,45000.0,"July 16, 2020","September 16, 2021",Bahrain,https://ClinicalTrials.gov/show/NCT04510207
579,579,COVID-19 (VA CURES-1),Recruiting,Drug: Convalescent Plasma|Other: Masked Saline Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,702.0,"November 16, 2020","July 18, 2022",Georgia,https://ClinicalTrials.gov/show/NCT04539275
580,580,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,Device: Performing of lung ultrasound,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"June 15, 2020","June 15, 2021",France,https://ClinicalTrials.gov/show/NCT04432805
581,581,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Completed,Diagnostic Test: RT-qPCR test|Diagnostic Test: COVID-VIRO® test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"October 13, 2020","October 17, 2020",France,https://ClinicalTrials.gov/show/NCT04609969
582,582,LYT-100 in Post-acute COVID-19 Respiratory Disease,Not yet recruiting,Drug: LYT-100|Other: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,168.0,December 2020,December 2021,Romania,https://ClinicalTrials.gov/show/NCT04652518
583,583,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Recruiting,Other: Prone decubitus,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,404.0,"April 27, 2020","November 24, 2021",France,https://ClinicalTrials.gov/show/NCT04358939
584,584,Glucocorticoids in COVID-19 (CORTIVID),Recruiting,Drug: Methylprednisolone|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,72.0,"May 15, 2020",February 2021,Spain,https://ClinicalTrials.gov/show/NCT04438980
585,585,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Drug: Chloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,3217.0,"March 28, 2020","February 14, 2021",Colombia,https://ClinicalTrials.gov/show/NCT04627467
586,586,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,Drug: TD-0903|Drug: Placebo,All,18 Years to 50 Years   (Adult),Phase 1,54.0,"April 23, 2020","June 24, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04350736
587,587,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"Active, not recruiting",Biological: Adenovirus Type-5 Vectored COVID-19 Vaccine,All,"Child, Adult, Older Adult",Phase 1,89.0,"September 26, 2020","September 27, 2021",China,https://ClinicalTrials.gov/show/NCT04568811
588,588,Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19,Not yet recruiting,Biological: SARS-CoV-2 convalescent plasma treatment|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,236.0,July 2020,February 2021,Colombia,https://ClinicalTrials.gov/show/NCT04425837
589,589,Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Biological: BM-MSCs|Biological: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,April 2020,December 2020,China,https://ClinicalTrials.gov/show/NCT04346368
590,590,"Australasian COVID-19 Trial (ASCOT): An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)",Recruiting,Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2400.0,"July 28, 2020","December 31, 2022",Australia,https://ClinicalTrials.gov/show/NCT04483960
591,591,Pilot Randomized Controlled Trial: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19),Not yet recruiting,Drug: Fluoxetine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,40.0,September 2020,October 2021,United States,https://ClinicalTrials.gov/show/NCT04570449
592,592,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,Recruiting,Biological: Bacille Calmette-Guérin (BCG)|Other: Placebo Comparator,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"May 4, 2020","April 28, 2021",South Africa,https://ClinicalTrials.gov/show/NCT04379336
593,593,Efficacy and Safety of COVID-19 Convalescent Plasma,Recruiting,Biological: anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"April 30, 2020","April 29, 2021","Institute for Transfusion Medicine of RNM, Skopje, North Macedonia",https://ClinicalTrials.gov/show/NCT04397523
594,594,Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.,Not yet recruiting,Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,75.0,September 2020,June 2021,Colombia,https://ClinicalTrials.gov/show/NCT04395170
595,595,Oral 25-hydroxyvitamin D3 and COVID-19,Recruiting,Drug: Oral 25-Hydroxyvitamin D3,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,1500.0,"April 14, 2020","March 15, 2021","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04386850
596,596,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Not yet recruiting,"Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,January 2021,January 2023,France,https://ClinicalTrials.gov/show/NCT04427254
597,597,TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study),Not yet recruiting,Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1378.0,"July 31, 2020","November 15, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04405271
598,598,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),"Active, not recruiting",Drug: Sarilumab|Other: Standar of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"April 13, 2020",December 2020,Spain,https://ClinicalTrials.gov/show/NCT04357808
599,599,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,Dietary Supplement: Oxaloacetate Medical Food/Dietary Supplement,Female,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40.0,"October 15, 2020","June 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04592354
600,600,CLBS119 for Repair of COVID-19 Induced Pulmonary Damage,Recruiting,Biological: CLBS119,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,"October 5, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04522817
601,601,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Recruiting,Other: Discontinuation of ACEi/ARB|Other: Continuation of ACEi/ARB,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,215.0,"May 18, 2020",December 2020,Denmark,https://ClinicalTrials.gov/show/NCT04351581
602,602,CICERO- A Care Home Study of COVID-19,Not yet recruiting,Diagnostic Test: Q16 testing|Diagnostic Test: Nasopharyngeal swab and main laboratory,All,"18 Years to 130 Years   (Adult, Older Adult)",Not Applicable,50.0,"July 2, 2020","September 28, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04453553
603,603,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin|Other: Placebo Tablet|Other: Placebo capsules,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,456.0,"April 14, 2020","August 30, 2020",Qatar,https://ClinicalTrials.gov/show/NCT04349592
604,604,Vitamin D on Prevention and Treatment of COVID-19,Not yet recruiting,Dietary Supplement: Vitamin D,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,200.0,"April 10, 2020","June 30, 2020",Spain,https://ClinicalTrials.gov/show/NCT04334005
605,605,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),Completed,Biological: UC-MSCs|Biological: Saline containing 1% Human serum albumin（solution without UC-MSCs）,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,100.0,"March 5, 2020","July 9, 2020",China,https://ClinicalTrials.gov/show/NCT04288102
606,606,"COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7",Not yet recruiting,"Combination Product: Tomeka®|Drug: ""Vernonia amygdalina""",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,2000.0,November 2020,December 2022,Congo,https://ClinicalTrials.gov/show/NCT04537585
607,607,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3.0,"May 13, 2020","November 4, 2020","František Duška, Praha, Česká Republika, Czechia",https://ClinicalTrials.gov/show/NCT04339816
608,608,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,Recruiting,Drug: Brequinar|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"November 19, 2020","February 28, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04575038
609,609,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,Recruiting,Drug: Dexamethasone and Hydroxychloroquine|Drug: Hydroxychloroquine,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,122.0,April 2020,August 2020,France,https://ClinicalTrials.gov/show/NCT04347980
610,610,Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,Biological: Tigerase® and best available care|Other: Best available care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"June 1, 2020","July 20, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04459325
611,611,Home Pulse Oximeter Use in Patients With COVID-19,Completed,Device: Home Pulse Oximetry Monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,209.0,"March 20, 2020","April 22, 2020",United States,https://ClinicalTrials.gov/show/NCT04373161
612,612,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,Recruiting,Drug: Standard of Care (SOC) + ANG-3777|Drug: Standard Of Care (SOC) + Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"July 31, 2020",October 2020,Brazil,https://ClinicalTrials.gov/show/NCT04459676
613,613,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",Recruiting,Drug: Rivaroxaban|Other: Placebo|Other: Standard of Care (SOC),All,"18 Years and older   (Adult, Older Adult)",Phase 3,4000.0,"August 13, 2020","April 6, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04508023
614,614,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,"Active, not recruiting",Drug: Sodium Bicarbonate,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180.0,"August 1, 2020","November 1, 2020",Canada,https://ClinicalTrials.gov/show/NCT04374591
615,615,Nasal Irrigation to Reduce COVID-19 Morbidity,Enrolling by invitation,Other: Nasal lavage,All,"55 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"September 24, 2020","December 31, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04559035
616,616,ACTIV-3: Therapeutics for Inpatients With COVID-19,"Active, not recruiting",Drug: LY3819253|Drug: Placebo|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10000.0,"August 4, 2020",July 2021,Denmark,https://ClinicalTrials.gov/show/NCT04501978
617,617,Treat COVID-19 Patients With Regadenoson,Not yet recruiting,Drug: Regadenoson|Other: Placebo Control,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"November 1, 2020","January 31, 2022",United States,https://ClinicalTrials.gov/show/NCT04606069
618,618,Elmo Respiratory Support Project - COVID-19,Recruiting,Other: ELMO PROJECT AT COVID-19: STUDY IN HUMANS|Device: ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"August 2, 2020",December 2020,Brazil,https://ClinicalTrials.gov/show/NCT04470258
619,619,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),Recruiting,Diagnostic Test: Rapid Diagnostic Test vs PCR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1250.0,"September 25, 2020","December 31, 2020",Switzerland,https://ClinicalTrials.gov/show/NCT04613310
620,620,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,Recruiting,Device: Telerehabilitation,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 11, 2020",March 2021,Greece,https://ClinicalTrials.gov/show/NCT04368845
621,621,Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure,Not yet recruiting,Biological: Decidual Stromal Cells (DSC),All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20.0,"August 24, 2020","February 24, 2021",Canada,https://ClinicalTrials.gov/show/NCT04451291
622,622,"COVID-19 Vaccine Messaging, Part 1",Completed,Other: Control message|Other: Baseline message|Other: Personal freedom message|Other: Economic freedom message|Other: Self-interest message|Other: Community interest message|Other: Economic benefit message|Other: Guilt message|Other: Embarrassment message|Other: Anger message|Other: Trust in science message|Other: Not bravery message,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4000.0,"July 3, 2020","July 8, 2020",United States,https://ClinicalTrials.gov/show/NCT04460703
623,623,Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized),Not yet recruiting,Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment|Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment|Drug: Standard treatment,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1000.0,October 2020,December 2020,Egypt,https://ClinicalTrials.gov/show/NCT04353180
624,624,WHO COVID-19 Solidarity Trial for COVID-19 Treatments,Not yet recruiting,Drug: Remdesivir|Drug: Acalabrutinib|Drug: Interferon beta-1a|Other: Standard of Care,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,100.0,"December 1, 2020","December 31, 2021",Jamaica,https://ClinicalTrials.gov/show/NCT04647669
625,625,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Recruiting,Device: Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35.0,"June 1, 2020","July 1, 2021","Zan Mitrev Clinic, Skopje, North Macedonia",https://ClinicalTrials.gov/show/NCT04478539
626,626,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Completed,Device: Active PBMT/sMF|Device: Placebo PBMT/sMF,All,"15 Years and older   (Child, Adult, Older Adult)",Not Applicable,30.0,"May 18, 2020","September 17, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04386694
627,627,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 4,500.0,"April 8, 2020","May 8, 2021",Israel,https://ClinicalTrials.gov/show/NCT04377750
628,628,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,Recruiting,Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,60.0,"June 27, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04353206
629,629,Nebulized PL for Post-COVID-19 Syndrome,Recruiting,Biological: Nebulized Platelet Lysate|Other: Nebulized Sterile Saline,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,40.0,"December 8, 2020","December 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04487691
630,630,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Completed,Device: Spartan COVID-19 System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,27.0,"June 28, 2020","August 30, 2020",Canada,https://ClinicalTrials.gov/show/NCT04473248
631,631,FREEDOM COVID-19 Anticoagulation Strategy,Recruiting,Drug: Enoxaparin|Drug: Apixaban,All,"18 Years and older   (Adult, Older Adult)",Phase 4,3600.0,"September 8, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04512079
632,632,Convalescent Plasma in Outpatients With COVID-19,Enrolling by invitation,Biological: Convalescent Plasma|Biological: Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,600.0,"August 11, 2020",December 2022,Georgia,https://ClinicalTrials.gov/show/NCT04355767
633,633,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Recruiting,Dietary Supplement: L-citrulline|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"November 2, 2020","September 15, 2021",France,https://ClinicalTrials.gov/show/NCT04404426
634,634,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,Recruiting,Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"September 9, 2020","December 31, 2021",Australia,https://ClinicalTrials.gov/show/NCT04395768
635,635,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,Recruiting,Drug: Melphalan|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"April 30, 2020","October 30, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04380376
636,636,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device),All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"April 14, 2020",April 2022,France,https://ClinicalTrials.gov/show/NCT04344431
637,637,Convalescent Plasma for COVID-19 Patients,Enrolling by invitation,Biological: Convalescent COVID 19 Plasma,All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,10.0,"August 1, 2020","December 30, 2020","Vinmec Research Institute of Stem cell and Gene Technology, Hanoi, Vietnam",https://ClinicalTrials.gov/show/NCT04516954
638,638,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"June 11, 2020",February 2021,Sweden,https://ClinicalTrials.gov/show/NCT04412291
639,639,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Recruiting,Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH)|Drug: Low dose Low molecular weight heparin or Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,172.0,"November 12, 2020","September 30, 2021",Germany,https://ClinicalTrials.gov/show/NCT04542408
640,640,Convalescent Plasma for Severe COVID-19 Patients,Recruiting,Biological: Convalescent Plasma|Other: Best Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,160.0,"July 16, 2020",October 2021,Brazil,https://ClinicalTrials.gov/show/NCT04547660
641,641,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol,Not yet recruiting,Drug: Acebilustat|Drug: Camostat,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,240.0,January 2021,January 2022,United States,https://ClinicalTrials.gov/show/NCT04662086
642,642,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Drug: Interferon beta-1b|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"November 20, 2020","September 30, 2021",Hong Kong,https://ClinicalTrials.gov/show/NCT04647695
643,643,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,Recruiting,Biological: Mesenchymal stromal cells|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"September 15, 2020",January 2022,Spain,https://ClinicalTrials.gov/show/NCT04615429
644,644,Modulation of Hyperinflammation in COVID-19,Recruiting,Device: Control group|Device: SLEDD with a L-MOD,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"April 28, 2020",January 2021,Canada,https://ClinicalTrials.gov/show/NCT04353674
645,645,Low Dose Radiotherapy for COVID-19 Pneumonitis,Recruiting,Radiation: Radiotherapy,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,41.0,"May 1, 2020","September 8, 2020",Spain,https://ClinicalTrials.gov/show/NCT04420390
646,646,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,Not yet recruiting,Drug: Camostat|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,January 2021,January 2022,United States,https://ClinicalTrials.gov/show/NCT04662073
647,647,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID),Recruiting,Other: Respiratory rehabilitation program (RR).|Other: Respiratory tele-rehabilitation program (TRR).,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,118.0,December 2020,December 2022,France,https://ClinicalTrials.gov/show/NCT04634318
648,648,"Rapid Turnaround, Home-based Saliva Testing for COVID-19",Recruiting,Device: Saliva test kit,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3015.0,"November 20, 2020",April 2021,United States,https://ClinicalTrials.gov/show/NCT04568122
649,649,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol,Not yet recruiting,Drug: Acebilustat|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,January 2021,January 2022,United States,https://ClinicalTrials.gov/show/NCT04662060
650,650,Suloexide in the Treatment of Early Stages of COVID-19,Completed,Drug: Sulodexide|Drug: Placebo,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,243.0,"June 5, 2020","September 7, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04483830
651,651,Helmet Non-Invasive Ventilation for COVID-19 Patients,Not yet recruiting,Device: Helmet non-invasive ventilation,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,320.0,October 2020,January 2022,Saudi Arabia,https://ClinicalTrials.gov/show/NCT04477668
652,652,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Drug: Unfractionated heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,656.0,"June 1, 2020","June 1, 2021",Argentina,https://ClinicalTrials.gov/show/NCT04635241
653,653,Western Kenya Integrated COVID-19 Response,Recruiting,"Other: Training of youth, community health assistants and community health workers.|Other: Training clinicians in basic critical care and the management of severe COVID-19 cases",All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,200000.0,"May 18, 2020","December 19, 2020",Kenya,https://ClinicalTrials.gov/show/NCT04501458
654,654,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),Recruiting,Biological: GC5131|Other: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60.0,"September 20, 2020",August 2021,"Korea, Republic of",https://ClinicalTrials.gov/show/NCT04555148
655,655,Late Clinical Events Associated With COVID-19 Infection,Not yet recruiting,Other: Questionnaire|Other: Biocollection|Other: Follow-up visit,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,October 2020,August 2022,France,https://ClinicalTrials.gov/show/NCT04591613
656,656,LLLT Treatment of Lung Inflammation in COVID-19,Not yet recruiting,Device: Non-invasive red LLLT treatment to chest of patient.|Device: Sham Device Treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,64.0,"March 31, 2021","March 31, 2022",United States,https://ClinicalTrials.gov/show/NCT04524715
657,657,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With Salivette® Cortisol for Viral RNA Sampling for RT-qPCR,Recruiting,Diagnostic Test: Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"October 26, 2020","November 26, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04599959
658,658,Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen,Withdrawn,Drug: Opaganib,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,0.0,August 2020,June 2021,Israel,https://ClinicalTrials.gov/show/NCT04502069
659,659,Ivermectin to Prevent Hospitalizations in COVID-19,Recruiting,Drug: Ivermectin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,500.0,"August 19, 2020","January 31, 2021",Argentina,https://ClinicalTrials.gov/show/NCT04529525
660,660,Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologics,"Active, not recruiting",Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection,All,"22 Years to 72 Years   (Adult, Older Adult)",Early Phase 1,20.0,"July 18, 2020","January 28, 2021",United States,https://ClinicalTrials.gov/show/NCT03305341
661,661,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"April 14, 2020","April 30, 2021",Puerto Rico,https://ClinicalTrials.gov/show/NCT04355247
662,662,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,Recruiting,Device: Core Warming|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"August 19, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04494867
663,663,Favipiravir vs Hydroxychloroquine in COVID -19,Recruiting,Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients,All,"21 Years and older   (Adult, Older Adult)",Phase 2,150.0,"August 11, 2020","May 14, 2021",Bahrain,https://ClinicalTrials.gov/show/NCT04387760
664,664,COVID-19 Study of Safety and Tolerability of Alvelestat,Recruiting,Drug: Alvelestat|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15.0,"November 1, 2020","September 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04539795
665,665,Efficacy and Safety of Ovotransferrin in COVID-19 Patients,Not yet recruiting,Dietary Supplement: Ovotransferrin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"December 1, 2020","March 30, 2021",Italy,https://ClinicalTrials.gov/show/NCT04643054
666,666,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,Enrolling by invitation,Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,90.0,"October 1, 2020","December 30, 2021",Russian Federation,https://ClinicalTrials.gov/show/NCT04602442
667,667,Convalescent Plasma for COVID-19 Patients (CPCP),Not yet recruiting,Biological: Convalescent Plasma as Therapy for Covid-19 patients,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,44.0,"December 1, 2020","October 30, 2021","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",https://ClinicalTrials.gov/show/NCT04521036
668,668,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Completed,Drug: Ivermectin and Doxycycline|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,400.0,"June 1, 2020","September 10, 2020",Bangladesh,https://ClinicalTrials.gov/show/NCT04523831
669,669,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,Device: Hyperbaric oxygen therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"April 30, 2020","November 1, 2020",Israel,https://ClinicalTrials.gov/show/NCT04358926
670,670,IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19),Not yet recruiting,Biological: IC14|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,July 2020,September 2021,United States,https://ClinicalTrials.gov/show/NCT04391309
671,671,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,Recruiting,Drug: Dexamethasone injection|Drug: placebo|Procedure: conventional oxygen|Procedure: CPAP|Procedure: HFNO|Procedure: mechanical ventilation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,550.0,"April 10, 2020","December 31, 2020",France,https://ClinicalTrials.gov/show/NCT04344730
672,672,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,Drug: Dociparastat sodium|Drug: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,524.0,"June 3, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04389840
673,673,"Allocetra-OTS in COVID-19, Phase II",Recruiting,Biological: Allocetra-OTS,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24.0,"October 20, 2020",March 2021,Israel,https://ClinicalTrials.gov/show/NCT04590053
674,674,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,Recruiting,Biological: COVID-19 Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,"April 30, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04388527
675,675,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),Not yet recruiting,"Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28|Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28|Biological: Two doses of placebo at the schedule of day 0, 28（middle-dose group）|Biological: Two doses of placebo at the schedule of day 0, 28（high-dose group）|Biological: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）",All,"18 Years and older   (Adult, Older Adult)",Phase 1,168.0,"August 28, 2020","August 28, 2021",China,https://ClinicalTrials.gov/show/NCT04530656
676,676,Checkpoint Blockade in COVID-19 Pandemic,Recruiting,Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,24.0,"April 9, 2020","June 30, 2021",Spain,https://ClinicalTrials.gov/show/NCT04335305
677,677,Assesment of the Metabolomic Signature in COVID-19 Patients,Recruiting,Other: COVID-19 patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"August 7, 2020","October 7, 2021",France,https://ClinicalTrials.gov/show/NCT04497272
678,678,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,Recruiting,Drug: Thymalfasin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"September 10, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04487444
679,679,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,Recruiting,Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen,All,"18 Years and older   (Adult, Older Adult)",Phase 2,260.0,"April 18, 2020",April 2022,United States,https://ClinicalTrials.gov/show/NCT04338828
680,680,Bucillamine in Treatment of Patients With COVID-19,Enrolling by invitation,Drug: Bucillamine|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,1000.0,"November 27, 2020","May 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04504734
681,681,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"Active, not recruiting",Combination Product: AZD7442|Other: Placebo,All,18 Years to 55 Years   (Adult),Phase 1,60.0,"August 18, 2020","October 25, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04507256
682,682,DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19),Not yet recruiting,Drug: Doxycycline|Drug: Placebo,All,"46 Years and older   (Adult, Older Adult)",Phase 3,330.0,"June 1, 2020","December 1, 2020",France,https://ClinicalTrials.gov/show/NCT04371952
683,683,Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC ),Recruiting,Drug: Heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,3000.0,"May 20, 2020",January 2021,Brazil,https://ClinicalTrials.gov/show/NCT04372589
684,684,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Recruiting,Drug: TM5614|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,80.0,"November 16, 2020","June 30, 2022",United States,https://ClinicalTrials.gov/show/NCT04634799
685,685,Prevalence of Myocardial Scars on CMR After COVID-19 Infection,Recruiting,Device: Contrast-enhanced CMR|Diagnostic Test: Exercise test ECG|Biological: Blood sample|Diagnostic Test: Resting 12 lead ECG|Diagnostic Test: 24 hour Holter ECG,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,240.0,"June 13, 2020","April 13, 2021",France,https://ClinicalTrials.gov/show/NCT04636320
686,686,Using Travelan to Boost Immune Response in Vitro to COVID-19,"Active, not recruiting",Other: Travelan OTC,Male,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5.0,"November 1, 2020","December 31, 2020",Israel,https://ClinicalTrials.gov/show/NCT04643561
687,687,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,Recruiting,Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,40000.0,"September 15, 2020","January 30, 2022",Argentina,https://ClinicalTrials.gov/show/NCT04526990
688,688,Mild Hypothermia for COVID-19 ARDS,Recruiting,Other: Hypothermia Via Cooling Machine- Arctic Sun 5000,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,20.0,"May 18, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04570462
689,689,COVID Screening Strategies in Homeless Shelters,Recruiting,Diagnostic Test: COVID-19 Swab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"April 10, 2020",June 2020,Canada,https://ClinicalTrials.gov/show/NCT04438070
690,690,Efficacy and Safety of Corticosteroids in COVID-19,Completed,Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,86.0,"February 14, 2020","April 15, 2020",China,https://ClinicalTrials.gov/show/NCT04273321
691,691,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,Recruiting,Drug: ISIS 721744|Drug: Normal Saline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,110.0,"October 21, 2020",December 2021,Brazil,https://ClinicalTrials.gov/show/NCT04549922
692,692,Study to Evaluate the Effect of a Probiotic in COVID-19,Recruiting,Dietary Supplement: Probiotic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"May 4, 2020",May 2021,Spain,https://ClinicalTrials.gov/show/NCT04390477
693,693,Changes in Cellular Immune Profile During COVID-19 Infection,Recruiting,Other: Leukapheresis,All,18 Years to 60 Years   (Adult),Not Applicable,25.0,"April 15, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04470999
694,694,Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Not yet recruiting,Drug: Oxygen,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,234.0,October 2020,August 2022,Canada,https://ClinicalTrials.gov/show/NCT04500626
695,695,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Completed,Diagnostic Test: Passive Microwave Radiometry,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,195.0,"July 1, 2020","August 1, 2020",Kyrgyzstan,https://ClinicalTrials.gov/show/NCT04568525
696,696,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,"Active, not recruiting",Other: Saline Nasal Irrigation|Other: Saline with Baby Shampoo Nasal Irrigation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"May 1, 2020",June 2022,United States,https://ClinicalTrials.gov/show/NCT04347538
697,697,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Recruiting,Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo,All,"6 Years and older   (Child, Adult, Older Adult)",Phase 2,481.0,"September 24, 2020","October 20, 2022",China,https://ClinicalTrials.gov/show/NCT04566770
698,698,Randomised Study of Plasma Exchange in Severe COVID-19,Recruiting,Drug: OCTAPLAS,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,20.0,"October 16, 2020","November 1, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04623255
699,699,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Recruiting,Procedure: Ophthalmologic exam,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 7, 2020",May 2021,France,https://ClinicalTrials.gov/show/NCT04387292
700,700,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,Recruiting,Drug: NOX66,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"September 30, 2020",June 2021,"Moldova, Republic of",https://ClinicalTrials.gov/show/NCT04555213
701,701,A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19,Not yet recruiting,Drug: Defibrotide,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,42.0,"January 1, 2021","November 1, 2023",United States,https://ClinicalTrials.gov/show/NCT04652115
702,702,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,Recruiting,Diagnostic Test: Capillary Collection & Testing|Diagnostic Test: Venous Draw & Testing,All,"2 Years and older   (Child, Adult, Older Adult)",Not Applicable,200.0,"August 20, 2020","December 31, 2022",United States,https://ClinicalTrials.gov/show/NCT04597047
703,703,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet,All,"19 Years and older   (Adult, Older Adult)",Phase 4,90.0,"April 10, 2020","July 31, 2020",Slovenia,https://ClinicalTrials.gov/show/NCT04355026
704,704,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,Recruiting,Biological: Octagam 10%|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,208.0,"June 1, 2020","December 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04400058
705,705,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,Completed,Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C,Male,21 Years to 60 Years   (Adult),Phase 3,4257.0,"May 13, 2020","August 31, 2020",Singapore,https://ClinicalTrials.gov/show/NCT04446104
706,706,Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Respiratory Distress,Not yet recruiting,Device: Hyperbaric Oxygen Therapy (HBOT),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600.0,"November 16, 2020","December 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04619719
707,707,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Drug: Tofacitinib 10 mg|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,260.0,"September 16, 2020","January 31, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04469114
708,708,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Recruiting,Drug: N-acetylcysteine|Other: Peripheral Blood,All,"18 Years and older   (Adult, Older Adult)",Phase 2,84.0,"May 1, 2020",May 2022,United States,https://ClinicalTrials.gov/show/NCT04374461
709,709,Safe Return to Regular Clinical Operation After COVID-19 Pandemic,Not yet recruiting,Diagnostic Test: molecular testing for virus RNA using RT-PCR,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,400.0,"May 17, 2020","December 30, 2020",Saudi Arabia,https://ClinicalTrials.gov/show/NCT04377802
710,710,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Recruiting,Drug: Chloroquine or Hydroxychloroquine,All,"Child, Adult, Older Adult",Phase 2|Phase 3,200.0,"March 23, 2020","December 23, 2030",Egypt,https://ClinicalTrials.gov/show/NCT04353336
711,711,IMU-838 and Oseltamivir in the Treatment of COVID-19,Recruiting,Drug: IMU-838|Drug: Oseltamivir,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,120.0,"June 15, 2020",July 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04516915
712,712,Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4),Recruiting,Drug: theraputic heparin|Drug: prophylactic heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2000.0,"September 4, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04505774
713,713,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Completed,Drug: Ivermectin (IVM),All,"18 Years and older   (Adult, Older Adult)",Phase 1,16.0,"April 18, 2020","June 1, 2020",Iraq,https://ClinicalTrials.gov/show/NCT04343092
714,714,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,Other: patients COVID 19,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"June 1, 2020","June 1, 2021",France,https://ClinicalTrials.gov/show/NCT04418206
715,715,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,Recruiting,Drug: RTB101|Drug: Placebo,All,65 Years and older   (Older Adult),Phase 2,60.0,"October 13, 2020",February 2021,United States,https://ClinicalTrials.gov/show/NCT04584710
716,716,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"Active, not recruiting",Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),All,18 Years to 60 Years   (Adult),Phase 1,108.0,"March 16, 2020","December 20, 2022",China,https://ClinicalTrials.gov/show/NCT04313127
717,717,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"Active, not recruiting",Drug: CD24Fc|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,243.0,"April 8, 2020","December 30, 2020",Jersey,https://ClinicalTrials.gov/show/NCT04317040
718,718,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,Recruiting,Drug: Disulfiram|Drug: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 2,200.0,"November 20, 2020",April 2021,Brazil,https://ClinicalTrials.gov/show/NCT04594343
719,719,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,Biological: ConvP|Biological: FFP,All,"50 Years and older   (Adult, Older Adult)",Phase 3,690.0,"October 12, 2020","November 1, 2023",Netherlands,https://ClinicalTrials.gov/show/NCT04589949
720,720,Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients,Not yet recruiting,Drug: Angiotensin-(1-7)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,160.0,January 2021,June 2021,United States,https://ClinicalTrials.gov/show/NCT04570501
721,721,Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19),Recruiting,Drug: Pegylated Interferon-α2b|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"August 11, 2020","January 30, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04480138
722,722,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,Other: Baseline and during hospitalization blood samples|Other: Baseline blood sample,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"October 19, 2020",October 2021,France,https://ClinicalTrials.gov/show/NCT04613297
723,723,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Completed,Drug: Guduchi Ghan Vati,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,46.0,"May 1, 2020","August 18, 2020",India,https://ClinicalTrials.gov/show/NCT04542876
724,724,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,Recruiting,Drug: Atovaquone/Azithromycin,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 2,25.0,"April 20, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04339426
725,725,Effectiveness of Hydroxychloroquine in Covid-19 Patients,Not yet recruiting,Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets,All,18 Years to 50 Years   (Adult),Phase 3,75.0,"March 28, 2020","June 28, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04328272
726,726,Trial to Study the Benefit of Colchicine in Patients With COVID-19,Recruiting,Drug: Colchicine Tablets|Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,102.0,"April 30, 2020","November 20, 2020",Spain,https://ClinicalTrials.gov/show/NCT04350320
727,727,Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID),Not yet recruiting,Procedure: ECMO Implantation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"August 1, 2020","May 1, 2022",Germany,https://ClinicalTrials.gov/show/NCT04341285
728,728,Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,Device: BIOVITALS,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 1, 2020","January 31, 2022",Hong Kong,https://ClinicalTrials.gov/show/NCT04343794
729,729,COVID-19 SAFE Enrollment,"Active, not recruiting",Behavioral: Opt-out Recruitment Email|Behavioral: Opt-in Recruitment Email,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1200.0,"September 9, 2020",November 2020,United States,https://ClinicalTrials.gov/show/NCT04506268
730,730,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),Recruiting,"Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo",All,"18 Years and older   (Adult, Older Adult)",Phase 2,124.0,"July 1, 2020",December 2020,Jersey,https://ClinicalTrials.gov/show/NCT04409509
731,731,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,Recruiting,Biological: Ad26.COV2.S|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000.0,"November 15, 2020","May 11, 2023",Belgium,https://ClinicalTrials.gov/show/NCT04614948
732,732,Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,Not yet recruiting,Drug: Ruxolitinib,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,64.0,"April 20, 2020","January 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04331665
733,733,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,Not yet recruiting,Drug: Camostat Mesilate|Drug: Placebo|Other: Standard of Care Treatment,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,November 2020,April 2021,United States,https://ClinicalTrials.gov/show/NCT04524663
734,734,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,Completed,Other: Shanshamani Vati Plus,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,26.0,"October 8, 2020","November 3, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04621903
735,735,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,Recruiting,Biological: Ampion|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"October 28, 2020","March 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04606784
736,736,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,Drug: Camostat|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,150.0,"November 4, 2020","January 1, 2023",Belgium,https://ClinicalTrials.gov/show/NCT04625114
737,737,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,Device: Control swab|Device: Prototype swab,All,"up to 99 Years   (Child, Adult, Older Adult)",Not Applicable,40.0,"April 24, 2020","July 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04368260
738,738,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Not yet recruiting,Drug: Naltrexone|Dietary Supplement: NAD+,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60.0,November 2020,June 2021,United States,https://ClinicalTrials.gov/show/NCT04604704
739,739,Nudges to Improve Health Behaviors That Limit COVID-19 Spread,Terminated,Behavioral: Nudge,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,45.0,"July 27, 2020","September 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04379375
740,740,The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19,Not yet recruiting,Drug: Lucinactant,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,October 2020,April 2021,United States,https://ClinicalTrials.gov/show/NCT04389671
741,741,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,"Active, not recruiting",Device: Virtual reality therapy first|Device: Conventional therapy first,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,50.0,"June 18, 2020","December 1, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04537858
742,742,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600.0,"March 29, 2020",March 2022,United States,https://ClinicalTrials.gov/show/NCT04318444
743,743,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,Drug: Favipiravir|Drug: Only Standard Treatment,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,50.0,May 2020,July 2020,Bangladesh,https://ClinicalTrials.gov/show/NCT04402203
744,744,Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),Recruiting,Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1|Drug: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses),All,"18 Years and older   (Adult, Older Adult)",Phase 2,78.0,"May 4, 2020","August 4, 2020",Spain,https://ClinicalTrials.gov/show/NCT04435717
745,745,Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19,Recruiting,Biological: COVI-GUARD|Other: Standard of Care|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,"September 17, 2020",February 2021,United States,https://ClinicalTrials.gov/show/NCT04454398
746,746,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,Recruiting,Biological: Ad26.COV2.S|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,60000.0,"September 7, 2020","March 10, 2023",Argentina,https://ClinicalTrials.gov/show/NCT04505722
747,747,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",Recruiting,Drug: Opaganib|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,270.0,"August 21, 2020",February 2021,Brazil,https://ClinicalTrials.gov/show/NCT04467840
748,748,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),Recruiting,Drug: Remdesivir|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"September 4, 2020","January 31, 2021",Bangladesh,https://ClinicalTrials.gov/show/NCT04596839
749,749,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,Other: convalescent plasma,All,18 Years to 55 Years   (Adult),Not Applicable,2000.0,"May 1, 2020",April 2021,Pakistan,https://ClinicalTrials.gov/show/NCT04352751
750,750,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Recruiting,Device: Innova Lateral Flow Device,All,up to 17 Years   (Child),Not Applicable,400.0,"November 5, 2020","November 19, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04629157
751,751,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,Recruiting,Biological: F-652|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,38.0,"October 9, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04498377
752,752,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,Drug: Clazakizumab|Drug: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,30.0,"May 7, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04363502
753,753,Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Drug: poractant alfa,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,20.0,"May 29, 2020","January 30, 2021",France,https://ClinicalTrials.gov/show/NCT04384731
754,754,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"Active, not recruiting",Drug: Convalescent Plasma|Other: Standard Care Therapy,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,100.0,"May 9, 2020","August 9, 2021",India,https://ClinicalTrials.gov/show/NCT04374487
755,755,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Recruiting,Biological: Convalescent plasma transfusion,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,200.0,"June 6, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04502472
756,756,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,Recruiting,Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|Drug: Telmisartan 40Mg Oral Tablet|Drug: Atorvastatin 20 Mg Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,294.0,"November 27, 2020","March 26, 2021","Service des Maladies Infectieuses et Tropicales, Centre Hospitalier et Universitaire (CHU) Treichville, Abidjan, Côte D'Ivoire|Centre de Traitement des Maladies Infectieuses (CTMI), CHU de Yopougon, Abidjan, Côte D'Ivoire",https://ClinicalTrials.gov/show/NCT04466241
757,757,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,Recruiting,Drug: COVID-19 Convalscent Plasma,All,"15 Years to 85 Years   (Child, Adult, Older Adult)",Phase 1,300.0,"May 21, 2020","December 30, 2020",Kuwait,https://ClinicalTrials.gov/show/NCT04474340
758,758,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Completed,Other: CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|Other: placebo rinse,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,23.0,"June 18, 2020","October 23, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04563689
759,759,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,Recruiting,Drug: Icosapent ethyl,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,100.0,"June 4, 2020",December 2020,Canada,https://ClinicalTrials.gov/show/NCT04412018
760,760,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Recruiting,Device: Volatile Organic Compounds analysis|Other: Canine odor detection of Volatile Organic Compounds,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"October 21, 2020",October 2021,France,https://ClinicalTrials.gov/show/NCT04614883
761,761,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,"Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)",All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,20.0,"April 19, 2020","September 21, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04370288
762,762,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,Drug: Quercetin|Dietary Supplement: bromelain|Drug: Zinc|Drug: Vitamin C,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60.0,"June 20, 2020","July 30, 2020",Saudi Arabia,https://ClinicalTrials.gov/show/NCT04468139
763,763,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,Other: Moderate Intensity Aerobic Exercises,All,24 Years to 45 Years   (Adult),Not Applicable,30.0,"January 1, 2020","October 1, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04581291
764,764,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,400.0,"April 14, 2020","March 31, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04318015
765,765,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,Recruiting,Drug: Niclosamide suspension|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"October 8, 2020","February 14, 2021",Turkey,https://ClinicalTrials.gov/show/NCT04558021
766,766,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Recruiting,Drug: Tacrolimus|Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,84.0,"April 1, 2020","July 1, 2020",Spain,https://ClinicalTrials.gov/show/NCT04341038
767,767,"RCT,Double Blind, Placebo to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU",Not yet recruiting,Dietary Supplement: zinc gluconate and ascorbic acid,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50.0,"October 1, 2020","September 1, 2021",Bangladesh,https://ClinicalTrials.gov/show/NCT04558424
768,768,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,Recruiting,Device: CytoSorb,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,24.0,"May 3, 2020","December 1, 2020",Belgium,https://ClinicalTrials.gov/show/NCT04518969
769,769,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,Recruiting,Drug: Abivertinib|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"October 9, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04440007
770,770,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,Drug: liposomal lactoferrin,All,"20 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"April 15, 2020","July 2, 2020",Italy,https://ClinicalTrials.gov/show/NCT04475120
771,771,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Recruiting,Drug: intermediate dose Enoxaparin/ unfractionated heparin|Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin|Drug: Atorvastatin 20mg|Drug: Matched placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,600.0,"July 30, 2020","December 6, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04486508
772,772,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Recruiting,Biological: Infusion IV of Mesenchymal Stem cells,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10.0,"May 1, 2020","May 1, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04416139
773,773,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Recruiting,Device: RD-X19,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,60.0,"November 18, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04662671
774,774,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Drug: Interleukin-7|Drug: Placebo,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,48.0,"June 8, 2020","December 30, 2020",France,https://ClinicalTrials.gov/show/NCT04407689
775,775,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,Recruiting,Drug: Interleukin-7|Drug: Placebos,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,48.0,"May 14, 2020","December 30, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04379076
776,776,Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19,Not yet recruiting,Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole|Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid),All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2,45.0,"October 20, 2020","November 20, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04577378
777,777,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,Recruiting,"Dietary Supplement: Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension|Combination Product: Standard Therapy",All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"October 23, 2020",November 2021,Italy,https://ClinicalTrials.gov/show/NCT04568876
778,778,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 1|Biological: SARS-CoV-2 vaccine formulation 1 with adjuvant 2|Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 1|Biological: SARS-CoV-2 vaccine formulation 2 with adjuvant 2|Biological: SARS-CoV-2 vaccine formulation 2 without adjuvant|Biological: Placebo (0.9% normal saline),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,440.0,"September 3, 2020",October 2021,United States,https://ClinicalTrials.gov/show/NCT04537208
779,779,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Completed,Drug: 20 Mg Prednisone for 14 days|Drug: control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450.0,"April 1, 2020","July 30, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04551781
780,780,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,Recruiting,Biological: SBI-101,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,22.0,"November 19, 2020",July 2021,Mexico,https://ClinicalTrials.gov/show/NCT04445220
781,781,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,Diagnostic Test: Lung ultrasound,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"April 16, 2020","December 30, 2020",Belgium,https://ClinicalTrials.gov/show/NCT04338568
782,782,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,Recruiting,Device: COVID-19 barrier box,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"May 1, 2020","January 1, 2021",Canada,https://ClinicalTrials.gov/show/NCT04366141
783,783,"Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation",Not yet recruiting,Drug: nangibotide|Drug: placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,August 2020,March 2021,France,https://ClinicalTrials.gov/show/NCT04429334
784,784,Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,Terminated,Other: Let It Out (LIO)-C|Other: Neutral writing control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"May 26, 2020","August 31, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04386668
785,785,Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,Suspended,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,200.0,"April 20, 2020","July 31, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04348474
786,786,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,Drug: Colchicine|Drug: Prednisone tablet|Drug: standard of care,All,65 Years and older   (Older Adult),Phase 2|Phase 3,144.0,"October 22, 2020",October 2021,Spain,https://ClinicalTrials.gov/show/NCT04492358
787,787,Nebulised Heparin in Patients With Severe COVID-19,Recruiting,Drug: Nebulised unfractionated heparin (UFH),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,202.0,"November 1, 2020",June 2022,United States,https://ClinicalTrials.gov/show/NCT04545541
788,788,Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus,Withdrawn,Biological: UC-MSCs|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,0.0,"February 24, 2020","February 25, 2020",China,https://ClinicalTrials.gov/show/NCT04293692
789,789,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,Biological: COVID19 convalescent plasma infusion,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"April 18, 2020","February 25, 2021",Argentina,https://ClinicalTrials.gov/show/NCT04535063
790,790,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,Drug: Ruxolitinib|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,432.0,"May 2, 2020","October 17, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04362137
791,791,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",Recruiting,Drug: ATI-450|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,36.0,"July 20, 2020",July 2022,United States,https://ClinicalTrials.gov/show/NCT04481685
792,792,Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers,Not yet recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,582.0,July 2020,June 2022,Israel,https://ClinicalTrials.gov/show/NCT04438837
793,793,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,Recruiting,Biological: immune plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"May 15, 2020","December 31, 2020",Italy,https://ClinicalTrials.gov/show/NCT04622826
794,794,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Drug: Danoprevir+Ritonavir,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,10.0,"March 18, 2020","April 15, 2020",China,https://ClinicalTrials.gov/show/NCT04345276
795,795,Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Drug: Ganovo+ritonavir+/-Interferon nebulization,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,11.0,"February 17, 2020","March 19, 2020",China,https://ClinicalTrials.gov/show/NCT04291729
796,796,Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP),"Active, not recruiting",Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection,All,"22 Years to 72 Years   (Adult, Older Adult)",Early Phase 1,20.0,"July 20, 2020","November 28, 2020",United States,https://ClinicalTrials.gov/show/NCT03348670
797,797,Polyvalent Immunoglobulin in COVID-19 Related ARds,Recruiting,Drug: Human immunoglobulin|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,138.0,"April 11, 2020",June 2021,France,https://ClinicalTrials.gov/show/NCT04350580
798,798,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Drug: CYT107|Drug: Placebo,All,"25 Years to 80 Years   (Adult, Older Adult)",Phase 2,48.0,"September 15, 2020","March 31, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04442178
799,799,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,Recruiting,Drug: Isoflurane Inhalant Product|Drug: Sevoflurane inhalant product,All,"18 Years and older   (Adult, Older Adult)",Phase 3,752.0,"June 15, 2020","June 15, 2023",Canada,https://ClinicalTrials.gov/show/NCT04415060
800,800,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Active, not recruiting",Biological: Gam-COVID-Vac|Other: Placebo,All,18 Years to 60 Years   (Adult),Phase 3,100.0,"September 28, 2020","April 10, 2021",Belarus,https://ClinicalTrials.gov/show/NCT04564716
801,801,Efficacy of Nicotine in Preventing COVID-19 Infection in Caregivers,Recruiting,Drug: Nicotine patch|Drug: Placebo patch,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1633.0,"October 22, 2020",October 2021,France,https://ClinicalTrials.gov/show/NCT04583410
802,802,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting","Biological: SARS-CoV-2 rS - Phase 1|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|Other: Normal saline solution (NSS), Placebo - Phase 1|Other: Normal saline solution (NSS), Placebo - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2|Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2|Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2|Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2",All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 1|Phase 2,1419.0,"May 25, 2020","November 18, 2021",Australia,https://ClinicalTrials.gov/show/NCT04368988
803,803,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,Recruiting,Drug: Iota-Carrageenan,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400.0,"July 24, 2020","November 30, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04521322
804,804,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Completed,Diagnostic Test: rapid salivary test,All,"Child, Adult, Older Adult",Not Applicable,122.0,"April 16, 2020","July 31, 2020",Italy,https://ClinicalTrials.gov/show/NCT04357327
805,805,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Recruiting,Biological: Sample,Male,18 Years to 50 Years   (Adult),Not Applicable,50.0,"October 2, 2020",February 2022,France,https://ClinicalTrials.gov/show/NCT04584593
806,806,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",Drug: inhalable hydroxychloroquine (HCQ)|Drug: supportive and symptomatic treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"July 15, 2020","August 15, 2020",Canada,https://ClinicalTrials.gov/show/NCT04477083
807,807,Low Dose Radiation Therapy for Covid-19 Pneumonia,"Active, not recruiting",Radiation: Low dose radiation therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"June 13, 2020",September 2020,India,https://ClinicalTrials.gov/show/NCT04394793
808,808,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,Other: Convalescent SARS COVID-19 plasma|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,333.0,"May 15, 2020","September 27, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04383535
809,809,CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients,Recruiting,Drug: Camostat Mesylate|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,596.0,"December 3, 2020",March 2022,France,https://ClinicalTrials.gov/show/NCT04608266
810,810,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,Completed,Other: Prolectin-M; a (1-6)-alpha-D-Mannopyranose class|Other: Standard of Care,All,18 Years to 45 Years   (Adult),Not Applicable,10.0,"September 15, 2020","October 16, 2020",India,https://ClinicalTrials.gov/show/NCT04512027
811,811,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV),Terminated,Drug: Anakinra alone (stages 2b/3)|Drug: Anakinra and Ruxolitinib (overcome stage 3)|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2.0,"August 19, 2020","October 2, 2020",France,https://ClinicalTrials.gov/show/NCT04366232
812,812,Emergency Ventilator Splitting Between Two or More Patients (COVID-19),Not yet recruiting,Device: Emergency Ventilator Splitter,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4.0,December 2020,January 2021,United States,https://ClinicalTrials.gov/show/NCT04381013
813,813,S-Nitrosylation Therapy of COVID-19,Not yet recruiting,Drug: SNO|Drug: Nitrogen gas,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 1,21.0,"October 31, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04528771
814,814,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard,Recruiting,Biological: Mesenchymal Stromal Cells,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,"May 15, 2020",June 2021,Canada,https://ClinicalTrials.gov/show/NCT04400032
815,815,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,Recruiting,Biological: Mesenchymal cells|Drug: Standard of care,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,106.0,"May 7, 2020","May 31, 2021",Spain,https://ClinicalTrials.gov/show/NCT04366271
816,816,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine",Recruiting,Biological: UB-612,All,20 Years to 55 Years   (Adult),Phase 1,60.0,"September 25, 2020","August 31, 2021",China,https://ClinicalTrials.gov/show/NCT04545749
817,817,Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia,Not yet recruiting,Drug: Cyclosporin A,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,200.0,September 2020,"September 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04540926
818,818,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","Active, not recruiting",Drug: Fluvoxamine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,152.0,"April 10, 2020","October 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04342663
819,819,Sirolimus in COVID-19 Phase 1,Withdrawn,Drug: Sirolimus 1 MG/ML|Drug: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,0.0,"July 6, 2020",August 2021,United States,https://ClinicalTrials.gov/show/NCT04371640
820,820,Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial,Not yet recruiting,Biological: intravenous immunoglobulin therapy,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,60.0,"September 15, 2020","November 15, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04548557
821,821,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Recruiting,Drug: Omega 3/Nigella Sativa Oil|Drug: Omega 3/Nigella Sativa Oil/Indian Costus|Drug: Omega 3/Nigella Sativa Oil/Quinine pills|Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule|Drug: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|Drug: Active Comparator,All,25 Years to 40 Years   (Adult),Phase 2|Phase 3,200.0,"September 20, 2020","December 4, 2020",Saudi Arabia,https://ClinicalTrials.gov/show/NCT04553705
822,822,Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients,Recruiting,Drug: NuSepin® 0.1 mg|Drug: NuSepin® 0.2 mg|Drug: Placebo,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,60.0,"September 25, 2020","November 30, 2020",Romania,https://ClinicalTrials.gov/show/NCT04565379
823,823,COVID-19 Breastfeeding Guideline for African-Americans,Not yet recruiting,Behavioral: COVID-19 Breastfeeding Support,Female,18 Years to 45 Years   (Adult),Not Applicable,200.0,September 2020,June 2022,United States,https://ClinicalTrials.gov/show/NCT04476940
824,824,COVID-19 Prophylaxis South Africa (COVER HCW),Not yet recruiting,Drug: Nitazoxanide|Drug: Sofosbuvir/Daclatasvir,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,1950.0,December 2020,July 2021,South Africa,https://ClinicalTrials.gov/show/NCT04561063
825,825,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,Biological: Human Amniotic Fluid,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60.0,"October 28, 2020","September 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04497389
826,826,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,Recruiting,Drug: DFV890|Drug: Standard of Care (SoC),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,140.0,"May 27, 2020","December 25, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04382053
827,827,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,Recruiting,Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant|Other: Placebo,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 2,4400.0,"August 17, 2020",November 2021,South Africa,https://ClinicalTrials.gov/show/NCT04533399
828,828,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,700.0,"April 9, 2020","December 1, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04364893
829,829,"Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort",Not yet recruiting,Drug: Tinzaparin or unfractionated heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,808.0,"April 20, 2020","September 30, 2020",France,https://ClinicalTrials.gov/show/NCT04344756
830,830,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",Recruiting,Other: Obvio-19 app,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 29, 2020","December 31, 2021",France,https://ClinicalTrials.gov/show/NCT04437719
831,831,Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2,Recruiting,Drug: Nasal Spray,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,200.0,"August 8, 2020","August 8, 2021",United States,https://ClinicalTrials.gov/show/NCT04610801
832,832,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Drug: mometasone furoate nasal spray,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"August 8, 2020","November 3, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04484493
833,833,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom",Recruiting,Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant|Other: Placebo|Biological: Licensed seasonal influenza vaccine,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 3,15000.0,"September 28, 2020","January 14, 2022",United Kingdom,https://ClinicalTrials.gov/show/NCT04583995
834,834,Timing of Corticosteroids in COVID-19,Recruiting,Drug: Early-Dexamethasone|Drug: Late-Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,450.0,"August 26, 2020","January 1, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04530409
835,835,CoVID-19 Plasma in Treatment of COVID-19 Patients,Recruiting,Biological: Convalescent COVID 19 Plasma,All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,100.0,"April 28, 2020",August 2020,United States,https://ClinicalTrials.gov/show/NCT04355897
836,836,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,Recruiting,Drug: Melatonin intravenous|Drug: Placebo intravenous,All,"18 Years and older   (Adult, Older Adult)",Phase 2,18.0,"June 20, 2020","November 30, 2020",Spain,https://ClinicalTrials.gov/show/NCT04568863
837,837,"Hydroxychloroquine, Azithromycin in the Treatment of Covid-19",Not yet recruiting,Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,July 2020,March 2021,Tunisia,https://ClinicalTrials.gov/show/NCT04405921
838,838,Plasma Rich Antibodies From Recovered Patients From COVID19,Not yet recruiting,Other: Antibody-Rich Plasma from COVID-19 recovered patients,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20.0,"April 20, 2020",December 2020,Egypt,https://ClinicalTrials.gov/show/NCT04348877
839,839,Treatment With Pirfenidone for COVID-19 Related Severe ARDS,Recruiting,Drug: Pirfenidone|Other: Standard of care,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100.0,"November 8, 2020",December 2021,Israel,https://ClinicalTrials.gov/show/NCT04653831
840,840,Comparison of Two Corticosteroid Regimens for Post-COVID Diffuse Lung Disease,Recruiting,Drug: Medium dose prednisolone|Drug: Low dose prednisolone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"December 10, 2020","December 9, 2021",India,https://ClinicalTrials.gov/show/NCT04657484
841,841,Nigella Sativa in COVID-19,Recruiting,Dietary Supplement: Nigella sativa,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,200.0,"May 21, 2020","December 31, 2020",Saudi Arabia,https://ClinicalTrials.gov/show/NCT04401202
842,842,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),Recruiting,Drug: Bardoxolone methyl|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,440.0,"September 8, 2020","February 28, 2021",United States,https://ClinicalTrials.gov/show/NCT04494646
843,843,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",Other: Serology test follow-up,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450.0,"July 1, 2020","December 31, 2021",France,https://ClinicalTrials.gov/show/NCT04488484
844,844,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Active, not recruiting",Drug: Canakinumab|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,451.0,"April 30, 2020","December 22, 2020",France,https://ClinicalTrials.gov/show/NCT04362813
845,845,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"Active, not recruiting",Drug: HB-adMSCs,All,"Child, Adult, Older Adult",Phase 2,56.0,"April 22, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04349631
846,846,Exploring Brain Damages After COVID-19 Infection,Recruiting,Procedure: Auditory Evoked Potentials (AEP)|Procedure: Blink and Masseter Inhibitory Reflex,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,38.0,"May 19, 2020","November 19, 2021",France,https://ClinicalTrials.gov/show/NCT04405986
847,847,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.",Completed,Device: Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,5.0,"July 28, 2020","September 20, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04497623
848,848,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",Recruiting,Drug: IMU-838|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,230.0,"June 11, 2020",October 2020,Bulgaria,https://ClinicalTrials.gov/show/NCT04379271
849,849,Inhaled Ciclesonide for Outpatients With COVID19,Recruiting,Drug: Normal Saline intranasal,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,454.0,"September 14, 2020","March 25, 2021",Canada,https://ClinicalTrials.gov/show/NCT04435795
850,850,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,Recruiting,Behavioral: Self-management booklet (SWitCh: Stay well during COVID-19),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,548.0,"May 20, 2020","December 22, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04408157
851,851,Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection,Recruiting,Drug: Cholecalciferol|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,"November 12, 2020","February 28, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04636086
852,852,COVID-19 Anosmia Study,Recruiting,Drug: Omega-3 Fatty Acid Supplement|Drug: Placebo/Control,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,"July 15, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04495816
853,853,Early CPAP in COVID-19 Confirmed or Suspected Patients,Recruiting,Device: Continuous Positive Airway Pressure,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"May 7, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04390191
854,854,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,Recruiting,Drug: Triazavirin (Riamilovir)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,420.0,"September 8, 2020","December 31, 2021",South Africa,https://ClinicalTrials.gov/show/NCT04581915
855,855,Ayurveda as Prophylaxis for Suspected COVID-19 Patients,Not yet recruiting,Other: Ayurveda,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"June 10, 2020","October 1, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04395976
856,856,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Suspended,Drug: inhaled type I interferon|Drug: WFI water nebulization,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"September 20, 2020",April 2021,France,https://ClinicalTrials.gov/show/NCT04469491
857,857,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Completed,Other: severity of lung involvement with COVID-19.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,29.0,"June 5, 2020","September 5, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04577235
858,858,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Recruiting,Diagnostic Test: Biological Sample Collection,All,"12 Years and older   (Child, Adult, Older Adult)",Not Applicable,30.0,"April 30, 2020",June 2021,France,https://ClinicalTrials.gov/show/NCT04387955
859,859,A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Hydroxychloroquine (placebo)|Drug: Zinc|Drug: Zinc (Placebo),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,660.0,"May 4, 2020","July 31, 2020",Tunisia,https://ClinicalTrials.gov/show/NCT04377646
860,860,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Recruiting,Drug: Colchicine|Other: Local standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2500.0,"April 17, 2020","March 30, 2021",Argentina,https://ClinicalTrials.gov/show/NCT04328480
861,861,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Recruiting,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"August 27, 2020","February 17, 2022",Denmark,https://ClinicalTrials.gov/show/NCT04509973
862,862,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19",Recruiting,Biological: Gam-COVID-Vac|Other: placebo,All,"18 Years to 111 Years   (Adult, Older Adult)",Phase 3,40000.0,"September 7, 2020","May 1, 2021",Russian Federation,https://ClinicalTrials.gov/show/NCT04530396
863,863,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Active, not recruiting",Drug: BLD-2660,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"May 4, 2020","November 30, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04334460
864,864,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Drug: BIO101|Drug: Placebo,All,"55 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,310.0,"June 16, 2020",September 2021,Belgium,https://ClinicalTrials.gov/show/NCT04472728
865,865,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,Not yet recruiting,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,300.0,"January 1, 2021","March 31, 2023","University Hospital Brno, Brno, Czechia",https://ClinicalTrials.gov/show/NCT04663555
866,866,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Drug: Peginterferon Lambda-1A|Other: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,140.0,"May 13, 2020","November 30, 2020",Canada,https://ClinicalTrials.gov/show/NCT04354259
867,867,A Phase II/III Study of Sargramostim,Not yet recruiting,Drug: Sargramostim|Drug: Placebo,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"November 24, 2020","April 30, 2021",Japan,https://ClinicalTrials.gov/show/NCT04642950
868,868,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",Other: Standard of Care (SoC)|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,400.0,"June 29, 2020",November 2022,Germany,https://ClinicalTrials.gov/show/NCT04575064
869,869,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,600.0,"April 5, 2020","August 29, 2020",United States,https://ClinicalTrials.gov/show/NCT04393961
870,870,iNOPulse for COVID-19,Withdrawn,Drug: Inhaled nitric oxide (iNO)|Drug: Nitrogen gas|Drug: Oxygen gas,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"December 1, 2020","July 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04398290
871,871,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Recruiting,Diagnostic Test: Optical Coherence Tomography (OCT),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"June 1, 2020","December 31, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04410549
872,872,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Recruiting,Procedure: Therapeutic Plasma Exchange (TPE),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"July 25, 2020","December 29, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04457349
873,873,COVidIVERmectin: Ivermectin for Treatment of Covid-19,Recruiting,Drug: Ivermectin|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,102.0,"July 31, 2020",December 2020,Italy,https://ClinicalTrials.gov/show/NCT04438850
874,874,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,Other: Prone Positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 1, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04517123
875,875,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,Recruiting,Drug: Nuvastatic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,10.0,"September 1, 2020","September 30, 2020",India,https://ClinicalTrials.gov/show/NCT04542447
876,876,COVID-19 Nasal Swab Trial,Not yet recruiting,Device: CanSwab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72.0,December 2020,"February 28, 2021",Canada,https://ClinicalTrials.gov/show/NCT04649424
877,877,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,Drug: Fluoxetine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,2000.0,"May 1, 2020","October 20, 2021",United States,https://ClinicalTrials.gov/show/NCT04377308
878,878,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Biological: BBV152A - Phase I|Biological: BBV152B - Phase I|Biological: BBV152C - Phase I|Biological: Placebo - Phase I|Biological: BBV152A - Phase II|Biological: BBV152B - Phase II,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,755.0,"July 13, 2020","June 30, 2021",India,https://ClinicalTrials.gov/show/NCT04471519
879,879,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,Recruiting,Drug: Hydroxychloroquine|Other: Placebo|Radiation: Radiation therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,132.0,"May 7, 2020",May 2021,Jersey,https://ClinicalTrials.gov/show/NCT04381988
880,880,"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",Suspended,Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,27.0,"April 11, 2020",August 2020,France,https://ClinicalTrials.gov/show/NCT04341870
881,881,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Recruiting,Combination Product: Hyperbaric Oxygen,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"July 6, 2020","December 30, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04477954
882,882,Coronavirus Response - Active Support for Hospitalised Covid-19 Patients,Withdrawn,Drug: Aspirin|Drug: Losartan|Drug: Simvastatin,All,"40 Years and older   (Adult, Older Adult)",Phase 3,0.0,October 2020,August 2021,Niger,https://ClinicalTrials.gov/show/NCT04343001
883,883,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,Recruiting,Drug: Daily Vitamin D3|Drug: Daily placebo|Drug: Bolus vitamin D3|Drug: Bolus placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 4,140.0,"July 31, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04482673
884,884,Ketogenic Diet as Protective Factor During COVID-19,Recruiting,Dietary Supplement: Ketogenic diet with phytoextracts,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,28.0,"November 1, 2020","August 30, 2021",Italy,https://ClinicalTrials.gov/show/NCT04615975
885,885,Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,"Active, not recruiting",Drug: RTB101|Drug: Placebo,All,65 Years and older   (Older Adult),Phase 2,36.0,"July 11, 2020",January 2021,United States,https://ClinicalTrials.gov/show/NCT04409327
886,886,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Recruiting,Procedure: Prone positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,56.0,"September 3, 2020","June 30, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04589936
887,887,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Enrolling by invitation,Combination Product: Hydroxycloroquine and Azythromycine|Combination Product: Cospherunate/Azythromycine|Combination Product: Cospherunate/Phytomedicine/Azythromycien,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"June 1, 2020","September 30, 2020",Guinea,https://ClinicalTrials.gov/show/NCT04502342
888,888,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Terminated,Drug: Prednisone|Other: Control group,All,"18 Years and older   (Adult, Older Adult)",Phase 2,11.0,"April 21, 2020","August 18, 2020",France,https://ClinicalTrials.gov/show/NCT04344288
889,889,Donated Antibodies Working Against nCoV,Recruiting,Biological: Convalescent Plasma|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,483.0,"May 2, 2020","November 2, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04429854
890,890,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,"Active, not recruiting",Drug: Clazakizumab,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,17.0,"April 24, 2020","March 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04348500
891,891,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Recruiting,Drug: Heparin sodium|Drug: Enoxaparin,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,200.0,"June 1, 2020","June 1, 2021",Argentina,https://ClinicalTrials.gov/show/NCT04530578
892,892,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,Recruiting,Drug: EDP1815|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"August 26, 2020","December 21, 2020",Jersey,https://ClinicalTrials.gov/show/NCT04488575
893,893,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Drug: UNIKINON (Chloroquine phosphate) 200mg tablets,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,60.0,"April 6, 2020","April 30, 2021",Greece,https://ClinicalTrials.gov/show/NCT04344951
894,894,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Recruiting,Other: blood sampling|Other: additional blood tubes,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"May 5, 2020","October 22, 2020",France,https://ClinicalTrials.gov/show/NCT04355351
895,895,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,Recruiting,Drug: Favipiravir|Drug: Lopinavir/ Ritonavir|Other: Favipiravir Placebo|Other: Lopinavir/ Ritonavir Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,240.0,"September 24, 2020","March 1, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04499677
896,896,Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE),Withdrawn,Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"September 2, 2020","September 2, 2020",France,https://ClinicalTrials.gov/show/NCT04392128
897,897,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults",Recruiting,Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|Biological: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,216.0,"July 13, 2020",September 2021,Australia,https://ClinicalTrials.gov/show/NCT04495933
898,898,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Drug: Dornase Alfa Inhalation Solution [Pulmozyme]|Procedure: standard procedure,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"April 21, 2020","April 21, 2021",France,https://ClinicalTrials.gov/show/NCT04355364
899,899,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,Not yet recruiting,Biological: Recombinant new coronavirus vaccine (CHO cell) group|Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group,All,"18 Years and older   (Adult, Older Adult)",Phase 3,29000.0,December 2020,April 2022,China,https://ClinicalTrials.gov/show/NCT04646590
900,900,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10000.0,"March 24, 2020","March 24, 2025",Mexico,https://ClinicalTrials.gov/show/NCT04458948
901,901,Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19,Not yet recruiting,Drug: semaglutide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,"November 30, 2020","March 31, 2022",Brazil,https://ClinicalTrials.gov/show/NCT04615871
902,902,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30.0,"February 6, 2020","February 25, 2020",China,https://ClinicalTrials.gov/show/NCT04261517
903,903,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,Recruiting,Dietary Supplement: Natural Honey|Other: Standard Care,All,"5 Years to 75 Years   (Child, Adult, Older Adult)",Phase 3,1000.0,"April 15, 2020","January 15, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04323345
904,904,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,"Active, not recruiting",Drug: Octagam,All,"18 Years and older   (Adult, Older Adult)",Phase 4,34.0,"April 28, 2020","November 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04411667
905,905,Convalescent Plasma in Pediatric COVID-19,Recruiting,Biological: Convalescent Plasma (CP)|Drug: Standard COVID-19 therapies,All,"up to 22 Years   (Child, Adult)",Early Phase 1,50.0,July 2020,June 2022,Georgia,https://ClinicalTrials.gov/show/NCT04458363
906,906,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,Recruiting,Combination Product: Immunofree tablets and Reginmune capsule,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"August 7, 2020","October 30, 2020",India,https://ClinicalTrials.gov/show/NCT04494204
907,907,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Drug: Enoxaparin Prophylactic Dose|Drug: Heparin Infusion|Drug: Heparin SC|Drug: Enoxaparin/Lovenox Intermediate Dose,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,100.0,"May 2, 2020",April 2021,United States,https://ClinicalTrials.gov/show/NCT04367831
908,908,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection,Not yet recruiting,Biological: Gam-COVID-Vac|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1600.0,December 2020,September 2021,India,https://ClinicalTrials.gov/show/NCT04640233
909,909,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,Recruiting,Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Drug: Placebo 250 cc 24 hours continuous infusion for 15 days,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"April 8, 2020","January 15, 2021",Spain,https://ClinicalTrials.gov/show/NCT04348383
910,910,Tenecteplase in Patients With COVID-19,Recruiting,Drug: Tenecteplase|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"September 25, 2020",April 2021,United States,https://ClinicalTrials.gov/show/NCT04505592
911,911,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Completed,Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,29.0,"April 20, 2020","May 30, 2020",India,https://ClinicalTrials.gov/show/NCT04346446
912,912,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,Recruiting,Drug: mavrilimumab|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,573.0,"July 27, 2020",April 2021,Brazil,https://ClinicalTrials.gov/show/NCT04447469
913,913,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,Recruiting,Drug: Dexamethasone|Drug: Methylprednisolone,All,"20 Years to 80 Years   (Adult, Older Adult)",Phase 3,60.0,"August 2, 2020","November 30, 2020",Bangladesh,https://ClinicalTrials.gov/show/NCT04499313
914,914,Different PEEP Settings of COVID-19 Induced ARDS,Completed,Other: Gas exchanges at different PEEP|Other: lung mechanics at different PEEP|Other: Hemodynamics changes at different PEEP,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20.0,"March 5, 2020","March 25, 2020",China,https://ClinicalTrials.gov/show/NCT04359251
915,915,Covid-19 Associated Coagulopathy,Recruiting,Drug: Intermediate dose thromboprophylaxis|Drug: Standard of Care thromboprophylaxis,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,170.0,"May 6, 2020","April 16, 2021",United States,https://ClinicalTrials.gov/show/NCT04360824
916,916,HFNT vs. COT in COVID-19,Not yet recruiting,Device: High Flow Nasal Therapy|Device: Conventional Oxygen Therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,364.0,"January 10, 2021","March 1, 2022",Italy,https://ClinicalTrials.gov/show/NCT04655638
917,917,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,Completed,Drug: XC221|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,118.0,"July 25, 2020","October 29, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04487574
918,918,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Completed,Biological: COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,58.0,"May 4, 2020","August 17, 2020",Chile,https://ClinicalTrials.gov/show/NCT04375098
919,919,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure",Recruiting,Drug: INO-4800|Device: CELLECTRA® 2000|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,6578.0,"November 30, 2020",September 2022,Jordan,https://ClinicalTrials.gov/show/NCT04642638
920,920,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,Recruiting,Drug: Rivaroxaban 10 MG,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,320.0,"October 16, 2020","June 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04662684
921,921,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,"Active, not recruiting",Drug: Clarithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,"May 6, 2020","May 6, 2022",Greece,https://ClinicalTrials.gov/show/NCT04398004
922,922,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,Recruiting,Dietary Supplement: Zinc Picolinate|Dietary Supplement: Resveratrol|Dietary Supplement: Zinc Picolinate Placebo|Dietary Supplement: Resveratrol Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"September 8, 2020",June 2022,United States,https://ClinicalTrials.gov/show/NCT04542993
923,923,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Recruiting,Device: Transcutaneous Auricular Vagus Nerve Stimulation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"June 27, 2020","November 1, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04379037
924,924,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Recruiting,"Drug: Patch, Nicotine|Drug: Patch, Placebo",All,"18 Years and older   (Adult, Older Adult)",Phase 3,220.0,November 2020,November 2021,France,https://ClinicalTrials.gov/show/NCT04598594
925,925,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Completed,Drug: Nitazoxanide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,392.0,"June 8, 2020","September 5, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04552483
926,926,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Biological: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)|Biological: Standard of care (SOC) plus placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,600.0,"September 21, 2020","July 31, 2022",South Africa,https://ClinicalTrials.gov/show/NCT04516811
927,927,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,Recruiting,Drug: Dipyridamole,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,"May 3, 2020","May 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04424901
928,928,Safety and Immunity of Covid-19 aAPC Vaccine,Recruiting,Biological: Pathogen-specific aAPC,All,"6 Months to 80 Years   (Child, Adult, Older Adult)",Phase 1,100.0,"February 15, 2020","December 31, 2024",China,https://ClinicalTrials.gov/show/NCT04299724
929,929,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,Drug: Dexamethasone 2 MG/ML|Drug: Methylprednisolone Injection,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,100.0,"May 30, 2020","July 1, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04603729
930,930,Covid-19 Messaging to Underserved Communities - 2nd Experiment,"Active, not recruiting",Behavioral: Acknowledgement Racial Injustice AMA|Behavioral: African American Sender Acknowledgement|Behavioral: African American Sender in Informational Videos.|Behavioral: Racial Inequality Highlighted|Behavioral: AMA Acknowledgement Drug Pricing|Behavioral: White Sender in Acknowledgement|Behavioral: White Sender in Informational Videos|Behavioral: No Racial Inequality Highlighting|Behavioral: Placebo videos,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20000.0,"July 31, 2020",September 2021,United States,https://ClinicalTrials.gov/show/NCT04502056
931,931,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,Recruiting,Other: Sampling of tissue,All,"Child, Adult, Older Adult",Not Applicable,90.0,"May 7, 2020","December 31, 2022",Belgium,https://ClinicalTrials.gov/show/NCT04445597
932,932,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,Diagnostic Test: Direct Antigen Tests for COVID-19,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 24, 2020","September 24, 2020",United States,https://ClinicalTrials.gov/show/NCT04568356
933,933,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Recruiting,Drug: T3 solution for injection|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 29, 2020","May 31, 2021",Greece,https://ClinicalTrials.gov/show/NCT04348513
934,934,Detection of COVID-19 Using Breath Analysis - Validation Study,Not yet recruiting,Diagnostic Test: Breath Biopsy Analysis,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,4000.0,"November 12, 2020","February 28, 2021",Israel,https://ClinicalTrials.gov/show/NCT04602949
935,935,Test and Treat COVID 65plus+,"Active, not recruiting",Drug: Hydroxychloroquine|Other: Placebo,All,65 Years and older   (Older Adult),Phase 2|Phase 3,350.0,"April 21, 2020","May 1, 2021",Germany,https://ClinicalTrials.gov/show/NCT04351516
936,936,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,Recruiting,Drug: dapansutrile capsules|Drug: placebo capsules,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"September 25, 2020",February 2021,Switzerland,https://ClinicalTrials.gov/show/NCT04540120
937,937,Early Detection of COVID-19 Using Breath Analysis,Suspended,Diagnostic Test: Breath biopsy sampling using the ReCIVA Breath Sampler,All,18 Years to 55 Years   (Adult),Not Applicable,50.0,"September 22, 2020","December 30, 2020",Israel,https://ClinicalTrials.gov/show/NCT04602884
938,938,The Açaí Berry COVID-19 Anti-Inflammation Trial,Recruiting,Dietary Supplement: Açaí palm berry extract - natural product|Other: Placebo,All,"40 Years and older   (Adult, Older Adult)",Phase 2,480.0,"August 4, 2020",May 2021,Canada,https://ClinicalTrials.gov/show/NCT04404218
939,939,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Completed,Drug: HCQ,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,540.0,"April 10, 2020","May 31, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04491994
940,940,Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children,Recruiting,Biological: Convalescent plasma (CP),All,"up to 18 Years   (Child, Adult)",Phase 2,100.0,"October 7, 2020","May 1, 2022",Canada,https://ClinicalTrials.gov/show/NCT04377568
941,941,Plasma Therapy of COVID-19 in Severely Ill Patients,Recruiting,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma),All,"18 Years and older   (Adult, Older Adult)",Phase 2,219.0,"April 21, 2020",April 2021,Brazil,https://ClinicalTrials.gov/show/NCT04359810
942,942,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Recruiting,Biological: blood samples,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"May 19, 2020","January 19, 2021",France,https://ClinicalTrials.gov/show/NCT04361344
943,943,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Other: convalescent plasma from recovered COVID 19 donor,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,575.0,"April 18, 2020","April 11, 2021",Saudi Arabia,https://ClinicalTrials.gov/show/NCT04347681
944,944,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,Recruiting,Procedure: AN69-Oxiris|Procedure: AN69-Standard,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,35.0,"October 2, 2020","March 30, 2022",Mexico,https://ClinicalTrials.gov/show/NCT04597034
945,945,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,Drug: Eculizumab,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,120.0,"April 16, 2020","December 31, 2020",France,https://ClinicalTrials.gov/show/NCT04346797
946,946,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Recruiting,Diagnostic Test: Breath Biopsy,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,108.0,"July 3, 2020","January 30, 2021",Israel,https://ClinicalTrials.gov/show/NCT04602871
947,947,"Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.",Not yet recruiting,Drug: Nivolumab Injection,All,"18 Years and older   (Adult, Older Adult)",Phase 2,92.0,"April 15, 2020","September 30, 2020",France,https://ClinicalTrials.gov/show/NCT04343144
948,948,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Not yet recruiting,Drug: Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|Drug: Placebo of NICOTINE Transdermal patch,All,"18 Years and older   (Adult, Older Adult)",Phase 3,220.0,November 2020,June 2022,France,https://ClinicalTrials.gov/show/NCT04608201
949,949,Nebulised Dornase Alfa for Treatment of COVID-19,Recruiting,Drug: Dornase Alfa Inhalation Solution [Pulmozyme],All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,50.0,"June 16, 2020","November 1, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04359654
950,950,COVID-19 and Lung Ultrasound Utility,Recruiting,Device: Butterfly iQ,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,100.0,"September 15, 2020",September 2021,Canada,https://ClinicalTrials.gov/show/NCT04591158
951,951,Washed Microbiota Transplantation for Patients With 2019-nCoV Infection,Withdrawn,Other: washed microbiota transplantation|Other: placebo,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Not Applicable,0.0,"February 5, 2020","April 30, 2020",China,https://ClinicalTrials.gov/show/NCT04251767
952,952,Ivermectin in Adults With Severe COVID-19.,Recruiting,Drug: Ivermectin|Other: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,100.0,"December 7, 2020",March 2021,Colombia,https://ClinicalTrials.gov/show/NCT04602507
953,953,Face Masks to Reduce COVID-19 in Bangladesh,Recruiting,Device: Face mask|Behavioral: Face mask awareness,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450000.0,"November 15, 2020","February 28, 2021",Bangladesh,https://ClinicalTrials.gov/show/NCT04630054
954,954,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,Recruiting,Biological: CK0802|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,45.0,"September 29, 2020","September 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04468971
955,955,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",Device: Oxygen Therapy|Procedure: Physical Therapy,All,21 Years to 40 Years   (Adult),Not Applicable,60.0,"March 15, 2020","June 23, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04368923
956,956,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,Recruiting,Drug: SNG001|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,820.0,"March 16, 2020","May 31, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04385095
957,957,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Drug: Remdesivir|Drug: Remdesivir placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,237.0,"February 6, 2020","April 10, 2020",China,https://ClinicalTrials.gov/show/NCT04257656
958,958,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,Recruiting,Drug: Cyclosporine|Drug: Standard treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,120.0,"April 16, 2020",December 2020,Spain,https://ClinicalTrials.gov/show/NCT04392531
959,959,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,Diagnostic Test: Blood group determination|Diagnostic Test: Antibody titration|Dietary Supplement: Probiotic,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"April 14, 2020",December 2020,Belgium,https://ClinicalTrials.gov/show/NCT04462627
960,960,Aggrenox To Treat Acute Covid-19,Recruiting,Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Other: Standard of care,All,"19 Years and older   (Adult, Older Adult)",Phase 3,132.0,"October 21, 2020","December 15, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04410328
961,961,Ivermectin In Treatment of COVID 19 Patients,Recruiting,Drug: Ivermectin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 9, 2020","September 1, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04425707
962,962,Treatment of Covid-19 Using Infrared and/or Vitamin C,Not yet recruiting,Other: Infrared Energy and Dietary Supplement,All,"Child, Adult, Older Adult",Not Applicable,400.0,"October 30, 2020","July 10, 2021",Canada,https://ClinicalTrials.gov/show/NCT04584437
963,963,Growth Hormone in Obese Cases With Covid-19,Withdrawn,Drug: Growth Hormone|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0.0,"October 26, 2020","December 20, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04532554
964,964,ACTIV-2: A Study for Outpatients With COVID-19,Recruiting,Drug: LY3819253|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,2000.0,"August 19, 2020",February 2021,Georgia,https://ClinicalTrials.gov/show/NCT04518410
965,965,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,Recruiting,Drug: Bempegaldesleukin|Drug: Standard of Care|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,"November 13, 2020","March 27, 2021",United States,https://ClinicalTrials.gov/show/NCT04646044
966,966,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Recruiting,Drug: Mavrilimumab|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"September 2, 2020",August 2021,United States,https://ClinicalTrials.gov/show/NCT04463004
967,967,COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL,Not yet recruiting,Other: Questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,7911.0,October 2020,October 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04542031
968,968,Efficacy of Iodine Complex Against COVID-19 Patients,Recruiting,Drug: Iodine Complex|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"July 14, 2020","September 30, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04473261
969,969,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Recruiting,Biological: COVID-19 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"July 16, 2020",August 2021,United States,https://ClinicalTrials.gov/show/NCT04432272
970,970,Covid-19 Breath Test,Recruiting,Diagnostic Test: Breath Test & Cheek Swab,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,250.0,"June 29, 2020","June 14, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04459962
971,971,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",Completed,Drug: IVIG,All,"18 Years and older   (Adult, Older Adult)",Phase 3,76.0,"May 7, 2020","September 15, 2020",Ukraine,https://ClinicalTrials.gov/show/NCT04500067
972,972,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Terminated,Drug: Tocilizumab (TCZ)|Drug: Placebo,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 2,5.0,"April 26, 2020","September 27, 2020",Switzerland,https://ClinicalTrials.gov/show/NCT04335071
973,973,Lactoferrin for Prevention of COVID-19 in Health Care Workers,Not yet recruiting,Dietary Supplement: Bovine Lactoferrin|Dietary Supplement: Maltodextrin,All,18 Years to 59 Years   (Adult),Phase 2,336.0,"September 1, 2020","November 1, 2021",Peru,https://ClinicalTrials.gov/show/NCT04526821
974,974,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,Diagnostic Test: COVID-19 PCR and Serology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"May 13, 2020","July 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04392323
975,975,IFN Beta-1b and Ribavirin for Covid-19,Recruiting,Drug: Interferon beta-1b|Drug: Ribavirin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,96.0,"July 29, 2020","August 1, 2022",Hong Kong,https://ClinicalTrials.gov/show/NCT04494399
976,976,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Terminated,Drug: Hydroxychloroquine (HCQ),All,"18 Years and older   (Adult, Older Adult)",Phase 3,7.0,"April 3, 2020","May 28, 2020",France,https://ClinicalTrials.gov/show/NCT04522466
977,977,CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19,Not yet recruiting,Drug: Edoxaban Tablets|Drug: Colchicine Tablets,All,"18 Years and older   (Adult, Older Adult)",Phase 3,420.0,"October 1, 2020","December 31, 2021",Switzerland,https://ClinicalTrials.gov/show/NCT04516941
978,978,DIgital Online SuPport for COVID-19 StrEss,Recruiting,Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,600.0,"April 8, 2020",December 2021,Germany,https://ClinicalTrials.gov/show/NCT04324190
979,979,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,Drug: Losartan,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1372.0,"October 9, 2020","June 30, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04606563
980,980,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Recruiting,Other: questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,134.0,"June 11, 2020","June 11, 2022",France,https://ClinicalTrials.gov/show/NCT04561154
981,981,Baricitinib Therapy in COVID-19,Completed,Drug: Baricitinib 4 MG Oral Tablet,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,12.0,"March 16, 2020","April 7, 2020",Italy,https://ClinicalTrials.gov/show/NCT04358614
982,982,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,Recruiting,Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,194.0,"April 20, 2020",August 2020,France,https://ClinicalTrials.gov/show/NCT04334850
983,983,Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,Not yet recruiting,Drug: Oxytocin|Drug: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,145.0,"September 1, 2020","December 31, 2020",France,https://ClinicalTrials.gov/show/NCT04386447
984,984,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Recruiting,Drug: Ruxolitinib,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 22, 2020","August 31, 2021",Germany,https://ClinicalTrials.gov/show/NCT04338958
985,985,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","Active, not recruiting",Drug: INM005|Drug: Placebo,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2|Phase 3,242.0,"July 27, 2020",December 2020,Argentina,https://ClinicalTrials.gov/show/NCT04494984
986,986,Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel,Withdrawn,Biological: BACMUNE (MV130)|Other: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,0.0,October 2020,December 2021,Mexico,https://ClinicalTrials.gov/show/NCT04452643
987,987,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Recruiting,Drug: Sofosbuvir|Drug: Daclatasvir,All,"Child, Adult, Older Adult",Phase 2|Phase 3,100.0,"July 1, 2020","April 10, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04497649
988,988,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Recruiting,Other: Prone position|Other: Supine position,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,18.0,"October 1, 2020",May 2021,France,https://ClinicalTrials.gov/show/NCT04543760
989,989,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,Recruiting,Drug: Masitinib|Drug: Isoquercetin|Drug: Best Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"June 1, 2020",June 2021,France,https://ClinicalTrials.gov/show/NCT04622865
990,990,Clinical Trial to Evaluate the Efficacy of Food Supplement Manremyc® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,Recruiting,Dietary Supplement: Manremyc|Dietary Supplement: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,315.0,"July 14, 2020",December 2021,Spain,https://ClinicalTrials.gov/show/NCT04452773
991,991,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"Active, not recruiting",Biological: VXA-CoV2-1,All,18 Years to 54 Years   (Adult),Phase 1,35.0,"September 21, 2020",October 2021,United States,https://ClinicalTrials.gov/show/NCT04563702
992,992,Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19,Recruiting,Drug: Enoxaparin,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300.0,"July 27, 2020","July 31, 2021",Italy,https://ClinicalTrials.gov/show/NCT04646655
993,993,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,Recruiting,Drug: XCEL-UMC-BETA|Other: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"May 13, 2020",December 2020,Spain,https://ClinicalTrials.gov/show/NCT04390139
994,994,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,Biological: recovered covid 19 patients plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,30.0,"May 29, 2020","September 1, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04530370
995,995,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,Recruiting,Biological: SARS-CoV-2 convalescent plasma|Biological: Plasma from a volunteer donor,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1344.0,"June 3, 2020","January 31, 2023",India,https://ClinicalTrials.gov/show/NCT04373460
996,996,Inspiratory Muscle Training in COVID-19 Patients,Not yet recruiting,Device: inspiratory muscle traiing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"November 1, 2020","June 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04595097
997,997,Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients,Not yet recruiting,Drug: Tranexamic acid|Drug: Placebo oral tablet,All,"19 Years and older   (Adult, Older Adult)",Phase 2,60.0,"September 30, 2021","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04338126
998,998,Contrast Enhanced Ultrasound in COVID-19,Recruiting,Drug: Sulfur hexafluoride lipid-type A microspheres,All,up to 17 Years   (Child),Phase 3,30.0,December 2020,December 2022,United States,https://ClinicalTrials.gov/show/NCT04640038
999,999,The Effect of Melatonin and Vitamin C on COVID-19,Not yet recruiting,Dietary Supplement: Vitamin C|Dietary Supplement: melatonin|Dietary Supplement: Placebo|Other: Symptom Survey,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"September 18, 2020","December 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04530539
1000,1000,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Recruiting,Other: Intervention group_rehabilitation program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"July 30, 2020","November 30, 2021",France,https://ClinicalTrials.gov/show/NCT04466800
1001,1001,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",Recruiting,Drug: anti-SARS-CoV-2 IgY|Drug: Placebo,All,18 Years to 45 Years   (Adult),Phase 1,48.0,"September 18, 2020",December 2020,Australia,https://ClinicalTrials.gov/show/NCT04567810
1002,1002,Hydrocortisone for COVID-19 and Severe Hypoxia,"Active, not recruiting",Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"April 17, 2020","June 8, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04348305
1003,1003,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,Diagnostic Test: Transpulmonary pressure measurements,All,up to 17 Years   (Child),Not Applicable,10.0,"May 21, 2020","January 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04519411
1004,1004,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Recruiting,Biological: Biological test,All,"Child, Adult, Older Adult",Not Applicable,500.0,"May 31, 2020","May 31, 2021",France,https://ClinicalTrials.gov/show/NCT04363385
1005,1005,Early Treatment of Cytokine Storm Syndrome in Covid-19,Recruiting,Drug: Anakinra|Drug: Normal saline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,30.0,"July 29, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04362111
1006,1006,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Drug: Ravulizumab|Drug: Baricitinib|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1167.0,"May 8, 2020","May 1, 2022",United Kingdom,https://ClinicalTrials.gov/show/NCT04390464
1007,1007,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Recruiting,Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs,All,"6 Months to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,100.0,"March 24, 2020","December 31, 2024",China,https://ClinicalTrials.gov/show/NCT04276896
1008,1008,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,Device: gammaCore® (Vagus nerve stimulation),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"April 20, 2020","July 31, 2020",Spain,https://ClinicalTrials.gov/show/NCT04368156
1009,1009,OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,Suspended,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab,All,"50 Years and older   (Adult, Older Adult)",Phase 3,640.0,"May 7, 2020","February 7, 2021",France,https://ClinicalTrials.gov/show/NCT04365582
1010,1010,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,Biological: Convalescent Plasma|Drug: Standard of Care,All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,67.0,"June 1, 2020","December 31, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04438694
1011,1011,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",Recruiting,Drug: BGB DXP593|Drug: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,30.0,"September 8, 2020","June 15, 2021",Australia,https://ClinicalTrials.gov/show/NCT04532294
1012,1012,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,Drug: unfractionated Heparin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"June 29, 2020",July 2021,Brazil,https://ClinicalTrials.gov/show/NCT04487990
1013,1013,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Recruiting,Device: KELEA Excellerated Water|Device: Water Without an Elevated Level of KELEA,All,"Child, Adult, Older Adult",Not Applicable,100.0,"October 1, 2020","November 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04490824
1014,1014,Repeat Testing for SARS-CoV-2,Enrolling by invitation,Device: Saliva Assay,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,10000.0,"September 29, 2020",September 2021,United States,https://ClinicalTrials.gov/show/NCT04579549
1015,1015,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Completed,Other: Physical Exercises,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,20.0,"July 3, 2020","October 3, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04445376
1016,1016,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Recruiting,Drug: Hydroxychloroquine Sulfate 200 MG|Other: Placebo,All,18 Years to 60 Years   (Adult),Phase 2,200.0,"May 1, 2020","September 25, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04359537
1017,1017,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Recruiting,Device: Biosensors,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,214.0,"April 22, 2020","December 20, 2025",Norway,https://ClinicalTrials.gov/show/NCT04335097
1018,1018,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Completed,Diagnostic Test: Performance of the test antigenic and test RT-PCR,All,"up to 18 Years   (Child, Adult)",Not Applicable,500.0,"October 1, 2020","November 25, 2020",France,https://ClinicalTrials.gov/show/NCT04583189
1019,1019,Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS,Recruiting,Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of Care,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,20.0,"May 1, 2018","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT03376854
1020,1020,Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients,Not yet recruiting,Dietary Supplement: Acacia Senegal|Dietary Supplement: Pectin,All,"5 Years to 90 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,110.0,"June 1, 2020","September 1, 2020",Sudan,https://ClinicalTrials.gov/show/NCT04381871
1021,1021,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,Recruiting,Biological: Convalescent Plasma|Other: Saline solution,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"April 17, 2020","April 30, 2023",United States,https://ClinicalTrials.gov/show/NCT04364737
1022,1022,Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome,Not yet recruiting,Device: Hyperbaric oxygen|Device: Sham,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,"January 1, 2021","January 1, 2023",Israel,https://ClinicalTrials.gov/show/NCT04647656
1023,1023,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Combination Product: Hydroxychloroquine/Azithromycine|Combination Product: Quinquina-Stevia/Azythromycin|Combination Product: 4Plants/Azythromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,231.0,"June 1, 2020","September 30, 2020",Guinea,https://ClinicalTrials.gov/show/NCT04501965
1024,1024,Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS),Not yet recruiting,Biological: MSC,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,October 2020,July 2021,Germany,https://ClinicalTrials.gov/show/NCT04377334
1025,1025,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Recruiting,Procedure: Biological samples specific to research|Procedure: Clinical examination|Procedure: Telephone follow-up,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,57.0,"April 27, 2020","October 27, 2021",France,https://ClinicalTrials.gov/show/NCT04354610
1026,1026,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",Device: Test Group: experimental - UVC Therapy applied,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50.0,"June 26, 2020","May 4, 2021",Turkey,https://ClinicalTrials.gov/show/NCT04642326
1027,1027,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,Recruiting,Biological: BM-Allo.MSC|Biological: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,45.0,"August 3, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04397796
1028,1028,"A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease",Not yet recruiting,Drug: Anakinra +/- Ruxolitinib (stages 2b/3)|Drug: Anakinra and Ruxolitinib (Advanced stage 3)|Drug: Tocilizumab +/- ruxolitinib (stages 2b/3)|Drug: Tocilizumab and Ruxolitinib (Advanced stage 3)|Other: Standard of care,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,216.0,"September 1, 2020","November 1, 2022",France,https://ClinicalTrials.gov/show/NCT04424056
1029,1029,Furosemide as Supportive Therapy for COVID-19 Respiratory Failure,Not yet recruiting,Drug: Nebulized Furosemide|Drug: Nebulized Saline,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,640.0,"October 19, 2020","October 1, 2021",Canada,https://ClinicalTrials.gov/show/NCT04588792
1030,1030,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Recruiting,Drug: Vitamin D|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1264.0,"August 11, 2020","December 28, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04411446
1031,1031,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Recruiting,Other: PSG,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25.0,"April 28, 2020","December 28, 2020",France,https://ClinicalTrials.gov/show/NCT04371029
1032,1032,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Recruiting,Other: Usual Care|Other: APPS,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"June 14, 2020","September 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04547283
1033,1033,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Biological: Convalescent plasma,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,20.0,"May 20, 2020","October 30, 2020",Bangladesh,https://ClinicalTrials.gov/show/NCT04403477
1034,1034,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Drug: Berberine|Drug: Montmorrillonite,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,76.0,"February 8, 2020","April 23, 2020",China,https://ClinicalTrials.gov/show/NCT04479202
1035,1035,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,Recruiting,Other: Health supplements,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"August 13, 2020","April 30, 2022",Hong Kong,https://ClinicalTrials.gov/show/NCT04581018
1036,1036,COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes,Not yet recruiting,Drug: Fisetin|Drug: Placebo,All,65 Years and older   (Older Adult),Phase 2,150.0,December 2020,December 2023,United States,https://ClinicalTrials.gov/show/NCT04537299
1037,1037,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,Recruiting,Drug: BTL-TML-COVID|Drug: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 2,40.0,"July 30, 2020","February 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04522830
1038,1038,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Other: Mesenchymal stromal cell-based therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,"July 1, 2020","October 31, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04525378
1039,1039,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Drug: Pulmozyme|Drug: Placebo,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 2,60.0,"July 5, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04402944
1040,1040,Convalescent Plasma in the Treatment of Covid-19,Recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"April 25, 2020","February 28, 2022",Sweden,https://ClinicalTrials.gov/show/NCT04600440
1041,1041,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Drug: Pyridostigmine Bromide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,436.0,"April 4, 2020","April 30, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04343963
1042,1042,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,Not yet recruiting,"Diagnostic Test: Assessing antibody responses, neutralizing capacity and memory B-cell function",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,150.0,"July 31, 2020",July 2021,Belgium,https://ClinicalTrials.gov/show/NCT04469634
1043,1043,Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient,Not yet recruiting,Drug: Drug COVID19-0001-USR|Drug: normal saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60.0,"November 2, 2020","January 29, 2021",Colombia,https://ClinicalTrials.gov/show/NCT04595136
1044,1044,Mesenchymal Stem Cells for the Treatment of COVID-19,Completed,Biological: PrimePro|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"April 24, 2020","September 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04573270
1045,1045,IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation,Not yet recruiting,Drug: IVIG,All,"18 Years and older   (Adult, Older Adult)",Phase 4,10.0,"November 1, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04616001
1046,1046,Can the Electronic Nose Smell COVID-19?,Completed,Device: Aeonose,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,219.0,"April 6, 2020","July 1, 2020",Netherlands,https://ClinicalTrials.gov/show/NCT04475562
1047,1047,A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure,Not yet recruiting,Drug: RLS-0071|Drug: Placebo,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,42.0,October 2020,July 2021,United States,https://ClinicalTrials.gov/show/NCT04574869
1048,1048,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",Recruiting,Biological: Kamada Anti-SARS-CoV-2,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12.0,"August 5, 2020",February 2021,Israel,https://ClinicalTrials.gov/show/NCT04550325
1049,1049,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,Diagnostic Test: chest x-ray,All,up to 7 Hours   (Child),Not Applicable,20.0,"May 30, 2020","October 30, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04470739
1050,1050,Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite,Withdrawn,Drug: Sodium Nitrite|Drug: Normal Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"July 22, 2020","August 15, 2020",United States,https://ClinicalTrials.gov/show/NCT04401527
1051,1051,Low Dose Radiotherapy in COVID-19 Pneumonia,"Active, not recruiting",Radiation: Low Dose Radiotherapy,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5.0,"May 4, 2020",December 2020,"Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04390412
1052,1052,Efficacy of Ivermectin in COVID-19,Recruiting,Drug: Ivermectin 6 MG Oral Tablet (2 tablets),All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,100.0,"April 15, 2020",July 2020,Pakistan,https://ClinicalTrials.gov/show/NCT04392713
1053,1053,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,Biological: Blood samples collection|Other: Saliva collection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75.0,"May 25, 2020","November 25, 2020",France,https://ClinicalTrials.gov/show/NCT04373200
1054,1054,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",Recruiting,Biological: SCTA01|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,33.0,"July 24, 2020","January 15, 2021",China,https://ClinicalTrials.gov/show/NCT04483375
1055,1055,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Recruiting,Drug: Dexamethasone (high dose),All,"18 Years and older   (Adult, Older Adult)",Phase 3,284.0,"May 21, 2020","January 31, 2021",Argentina,https://ClinicalTrials.gov/show/NCT04395105
1056,1056,Inspiratory Muscle Training in Patients With COVID-19,Terminated,Device: power breathe,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,55.0,"June 1, 2020","October 23, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04603963
1057,1057,A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection,Enrolling by invitation,Drug: Clazakizumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,December 2020,December 2020,United States,https://ClinicalTrials.gov/show/NCT04659772
1058,1058,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,Recruiting,Other: Standard Oxygen Delivery System|Other: Double-Trunk Mask|Other: Surgical Mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,27.0,"November 13, 2020","November 13, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04629989
1059,1059,The Effects of Multi-modality Physiotherapy in Delaying or Preventing COVID-19 Patient From Admitting to ICU,Not yet recruiting,Device: Threshold IMT device|Other: Conventional physical therapy,All,21 Years to 60 Years   (Adult),Not Applicable,38.0,"November 1, 2020","April 6, 2021",Kuwait,https://ClinicalTrials.gov/show/NCT04617119
1060,1060,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,"Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum",All,"Child, Adult, Older Adult",Phase 2|Phase 3,1800.0,"April 11, 2020","September 14, 2020",United States,https://ClinicalTrials.gov/show/NCT04349410
1061,1061,Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Not yet recruiting,Other: questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1800.0,October 2020,December 2021,France,https://ClinicalTrials.gov/show/NCT04581746
1062,1062,Ivermectin in Treatment of COVID-19,Recruiting,Drug: Ivermectin,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"May 31, 2020","August 15, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04445311
1063,1063,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy,Recruiting,Drug: Hydroxychloroquine|Drug: Placebo,Female,"Child, Adult, Older Adult",Phase 3,714.0,"May 13, 2020","August 1, 2021",Spain,https://ClinicalTrials.gov/show/NCT04410562
1064,1064,Convalescent Plasma for Patients With COVID-19,Recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"May 4, 2020","August 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04385199
1065,1065,Can the Electronic Nose Smell COVID-19 Antibodies?,Completed,Device: Aeonose,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,222.0,"April 6, 2020","July 1, 2020",Netherlands,https://ClinicalTrials.gov/show/NCT04475575
1066,1066,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Recruiting,Procedure: Auricular neuromodulation|Procedure: Control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"April 9, 2020",March 2021,France,https://ClinicalTrials.gov/show/NCT04341415
1067,1067,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,"Active, not recruiting",Dietary Supplement: Vitamin D,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,6200.0,"October 27, 2020","June 30, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04579640
1068,1068,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"April 28, 2020","March 31, 2021",Switzerland,https://ClinicalTrials.gov/show/NCT04345848
1069,1069,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,Behavioral: Mental imagery,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250.0,"August 19, 2020","December 1, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04583449
1070,1070,The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19,Recruiting,Biological: CYP-001,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,"August 24, 2020","March 31, 2021",Australia,https://ClinicalTrials.gov/show/NCT04537351
1071,1071,Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers,Completed,Other: Serologic testing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"May 6, 2020","July 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04383587
1072,1072,Lung Irradiation for COVID-19 Pneumonia,Recruiting,Radiation: Phase 1|Radiation: Phase 2,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,48.0,June 2020,November 2020,United States,https://ClinicalTrials.gov/show/NCT04393948
1073,1073,Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Not yet recruiting,Radiation: Lung Low Dose Radiation,All,65 Years and older   (Older Adult),Not Applicable,41.0,"October 1, 2020","March 31, 2021",Spain,https://ClinicalTrials.gov/show/NCT04414293
1074,1074,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,9.0,"April 16, 2020","December 15, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04456361
1075,1075,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,Recruiting,Drug: Icosapent ethyl (IPE)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2000.0,"August 14, 2020",January 2021,Argentina,https://ClinicalTrials.gov/show/NCT04460651
1076,1076,Prophylactic Ivermectin in COVID-19 Contacts,Completed,Drug: Ivermectin Tablets,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2|Phase 3,340.0,"May 31, 2020","July 27, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04422561
1077,1077,New Antiviral Drugs for Treatment of COVID-19,Not yet recruiting,"Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :",All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,100.0,October 2020,May 2022,Egypt,https://ClinicalTrials.gov/show/NCT04392427
1078,1078,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Recruiting,Drug: Enoxaparin Prefilled Syringe [Lovenox],All,"up to 18 Years   (Child, Adult)",Phase 2,38.0,"June 2, 2020","October 15, 2022",United States,https://ClinicalTrials.gov/show/NCT04354155
1079,1079,Ivermectin and Doxycycine in COVID-19 Treatment,Recruiting,Drug: Ivermectin|Drug: Doxycycline|Drug: Chloroquine,All,"Child, Adult, Older Adult",Phase 2|Phase 3,200.0,"June 1, 2020","December 3, 2030",Egypt,https://ClinicalTrials.gov/show/NCT04403555
1080,1080,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,Biological: blood test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"September 22, 2020",March 2021,France,https://ClinicalTrials.gov/show/NCT04563676
1081,1081,A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,"Active, not recruiting",Combination Product: INOpulse|Combination Product: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"July 12, 2020",June 2021,Mexico,https://ClinicalTrials.gov/show/NCT04421508
1082,1082,Saved From COVID-19,Recruiting,Drug: Chloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,350.0,April 2020,April 2021,United States,https://ClinicalTrials.gov/show/NCT04349371
1083,1083,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,Device: Life2000® Ventilator,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"August 28, 2020",October 2020,United States,https://ClinicalTrials.gov/show/NCT04581161
1084,1084,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,"Active, not recruiting",Drug: Remdesivir-HU,All,"12 Years to 100 Years   (Child, Adult, Older Adult)",Phase 3,2000.0,"October 12, 2020","November 30, 2021",Hungary,https://ClinicalTrials.gov/show/NCT04610541
1085,1085,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER),Recruiting,Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,70.0,"July 24, 2020",July 2025,United States,https://ClinicalTrials.gov/show/NCT04629105
1086,1086,"Safety of TY027, a Treatment for COVID-19, in Humans","Active, not recruiting",Biological: TY027|Other: 0.9% Saline,All,21 Years to 50 Years   (Adult),Phase 1,32.0,"June 9, 2020",February 2021,Singapore,https://ClinicalTrials.gov/show/NCT04429529
1087,1087,Efficacy of Faviprevir in COVID-19 Treatment,Recruiting,Drug: Favipiravir|Drug: Placebos,All,"Child, Adult, Older Adult",Phase 2|Phase 3,90.0,"April 20, 2020","December 1, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04351295
1088,1088,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,Dietary Supplement: Vitamin C,All,"Child, Adult, Older Adult",Not Applicable,500.0,"March 13, 2020","March 13, 2021",Italy,https://ClinicalTrials.gov/show/NCT04323514
1089,1089,Asymptomatic COVID-19 Trial,Withdrawn,Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo,All,"20 Years and older   (Adult, Older Adult)",Phase 2,0.0,"May 5, 2020",April 2021,Jersey,https://ClinicalTrials.gov/show/NCT04374552
1090,1090,Use of Remote Monitoring for COVID-19 Patient,Recruiting,Device: LifeSignals Biosensor 1AX*|Other: Standard of Care,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,300.0,"September 1, 2020","June 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04425720
1091,1091,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Recruiting,Drug: Linagliptin tablet|Drug: Insulin,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,28.0,"August 1, 2020","September 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04542213
1092,1092,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Recruiting,Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,308.0,"April 26, 2020","April 26, 2021",Israel,https://ClinicalTrials.gov/show/NCT04401293
1093,1093,Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19,Not yet recruiting,Drug: Artemisinin / Artesunate|Other: placebo,All,18 Years to 60 Years   (Adult),Phase 2,22.0,December 2020,April 2021,Saudi Arabia,https://ClinicalTrials.gov/show/NCT04387240
1094,1094,"Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia",Withdrawn,Drug: HCQ|Drug: Azithromycin|Drug: Doxycycline|Dietary Supplement: Zinc,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,0.0,"May 15, 2020","July 15, 2020",Tunisia,https://ClinicalTrials.gov/show/NCT04528927
1095,1095,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,Other: Respiratory Training|Other: Aerobic training,All,35 Years to 45 Years   (Adult),Not Applicable,80.0,"July 2, 2020","January 20, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04613050
1096,1096,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Active, not recruiting",Procedure: Therapeutic Plasma Exchange|Drug: Ruxolitinib,All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Phase 2,20.0,"April 30, 2020","December 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04374149
1097,1097,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine",Recruiting,"Biological: IIBR-100, low dose (prime)|Biological: IIBR-100 medium dose (prime)|Biological: IIBR-100 high-dose (prime)|Biological: IIBR-100 low-dose (prime-boost)|Other: Saline Placebo",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,1040.0,"October 28, 2020","June 1, 2022",Israel,https://ClinicalTrials.gov/show/NCT04608305
1098,1098,Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Recruiting,Drug: TriCor® 145mg tablets|Other: Usual Care|Other: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,50.0,"December 13, 2020","December 1, 2021",Israel,https://ClinicalTrials.gov/show/NCT04661930
1099,1099,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,Recruiting,Drug: Ibrutinib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,46.0,"June 6, 2020","April 16, 2021",Israel,https://ClinicalTrials.gov/show/NCT04375397
1100,1100,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,Recruiting,Drug: Ivermectin|Drug: Camostat Mesilate|Dietary Supplement: Artemesia annua|Drug: Artesunate,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,240.0,"May 1, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04374019
1101,1101,Tocilizumab Treatment in Patients With COVID-19,"Active, not recruiting",Drug: Tocilizumab,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,200.0,"June 1, 2020","August 1, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04363853
1102,1102,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,Drug: Ciclesonide Inhalation Aerosol,All,"18 Years and older   (Adult, Older Adult)",Phase 2,446.0,"May 29, 2020","December 31, 2020",Sweden,https://ClinicalTrials.gov/show/NCT04381364
1103,1103,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Active, not recruiting",Other: blood sample,All,"Child, Adult, Older Adult",Not Applicable,1000.0,"March 16, 2020","October 16, 2021",France,https://ClinicalTrials.gov/show/NCT04304690
1104,1104,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Recruiting,Drug: Inhaled ILOPROST,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"May 23, 2020","May 31, 2021",Qatar,https://ClinicalTrials.gov/show/NCT04445246
1105,1105,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Recruiting,Drug: Cholecalciferol,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,400.0,"July 15, 2020",July 2021,Mexico,https://ClinicalTrials.gov/show/NCT04535791
1106,1106,Use of Convalescent Plasma for COVID-19,Recruiting,Biological: Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,700.0,"July 14, 2020","July 31, 2022",Georgia,https://ClinicalTrials.gov/show/NCT04408040
1107,1107,Sarilumab for Patients With Moderate COVID-19 Disease,Recruiting,Biological: SARILUMAB,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"April 10, 2020",April 2023,United States,https://ClinicalTrials.gov/show/NCT04359901
1108,1108,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,Recruiting,Drug: Favipiravir,All,"18 Years and older   (Adult, Older Adult)",Phase 2,190.0,"August 1, 2020",November 2020,Australia,https://ClinicalTrials.gov/show/NCT04445467
1109,1109,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Active, not recruiting",Drug: Vit D,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"June 15, 2020","September 10, 2020",India,https://ClinicalTrials.gov/show/NCT04459247
1110,1110,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Recruiting,Biological: Convalescent Plasma|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,400.0,"June 14, 2020","May 30, 2021",India,https://ClinicalTrials.gov/show/NCT04425915
1111,1111,Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers,Not yet recruiting,Biological: RUTI® vaccine|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,315.0,"July 30, 2020",December 2020,Spain,https://ClinicalTrials.gov/show/NCT04453488
1112,1112,The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,Recruiting,Drug: Ivermectin|Drug: Nitazoxanide with ivermectin|Drug: Ivermectin wth chloroquine,All,"Child, Adult, Older Adult",Phase 2|Phase 3,300.0,"June 16, 2020","December 1, 2030",Egypt,https://ClinicalTrials.gov/show/NCT04351347
1113,1113,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,Recruiting,Dietary Supplement: 300 mg of omega3-FA,All,"35 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"December 5, 2020","March 30, 2021",Jordan,https://ClinicalTrials.gov/show/NCT04658433
1114,1114,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Recruiting,Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,164.0,"May 29, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04344600
1115,1115,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Drug: Chloroquine|Drug: zinc,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200.0,"June 23, 2020","October 1, 2030",Egypt,https://ClinicalTrials.gov/show/NCT04447534
1116,1116,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Recruiting,Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,30.0,"March 15, 2020","June 10, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04399746
1117,1117,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Active, not recruiting",Drug: Hydroxychloroquine Sulfate (HCQ),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,44.0,"April 14, 2020","April 8, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04345653
1118,1118,Oscillation and Lung Expansion Therapy in Patients With COVID-19,Recruiting,Device: MetaNeb® System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"September 28, 2020","January 1, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04582214
1119,1119,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Recruiting,Drug: Pirfenidone|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,148.0,"August 1, 2020","August 1, 2021",Spain,https://ClinicalTrials.gov/show/NCT04607928
1120,1120,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,Completed,Drug: Sofosbuvir and Ledipasvir|Drug: Nitazoxanide,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 4,240.0,"July 15, 2020","October 30, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04498936
1121,1121,Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS,Not yet recruiting,Drug: Rapamycin|Drug: Placebo,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,January 2021,January 2023,United States,https://ClinicalTrials.gov/show/NCT04482712
1122,1122,Mother-infant Bonding During COVID-19,Recruiting,Behavioral: Family Nurture Intervention (FNI),All,up to 72 Hours   (Child),Not Applicable,280.0,"August 13, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04531618
1123,1123,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,Procedure: Ophthalmologic exam,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,23.0,"April 27, 2020","July 29, 2020",France,https://ClinicalTrials.gov/show/NCT04385810
1124,1124,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Not yet recruiting,Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,466.0,"August 1, 2020","August 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04472611
1125,1125,Trial of Hydroxychloroquine In Covid-19 Kinetics,Terminated,Drug: Hydroxychloroquine|Other: Placebo,All,"19 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,58.0,"April 17, 2020","July 8, 2020",United States,https://ClinicalTrials.gov/show/NCT04353271
1126,1126,Efficacy of Tocilizumab on Patients With COVID-19,"Active, not recruiting",Drug: Tocilizumab|Drug: Placebos,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,243.0,"April 20, 2020","October 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04356937
1127,1127,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,Diagnostic Test: Peripheral venous ultrasound,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"August 4, 2020","September 15, 2021",France,https://ClinicalTrials.gov/show/NCT04616846
1128,1128,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,Other: questionnaire,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"September 1, 2020",September 2022,France,https://ClinicalTrials.gov/show/NCT04554264
1129,1129,COVID-19 Pandemic and Parents of Disabled Children,Completed,Other: Difficulties lived by disabled children's parents in the period of COVID-19 pandemic,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,309.0,"July 5, 2020","September 15, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04525742
1130,1130,"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia",Not yet recruiting,Drug: Tocilizumab Injection|Drug: Deferoxamine,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,260.0,"September 4, 2020","October 4, 2020",Tunisia,https://ClinicalTrials.gov/show/NCT04361032
1131,1131,COVID-19 Search in Conjunctival Cells,Completed,Diagnostic Test: conjunctival swab,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"March 26, 2020","May 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04364594
1132,1132,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,Completed,Behavioral: Online support Group,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,32.0,"April 3, 2020","August 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04379661
1133,1133,Baricitinib Compared to Standard Therapy in Patients With COVID-19,Not yet recruiting,Drug: Baricitinib Oral Tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,126.0,"May 20, 2020","July 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04393051
1134,1134,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Recruiting,Biological: Convalescent Plasma from COVID-19 donors,All,"15 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,100.0,"April 7, 2020","April 6, 2021",Chile,https://ClinicalTrials.gov/show/NCT04384588
1135,1135,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Recruiting,Biological: BCG vaccine (Freeze-dried),All,"60 Years to 80 Years   (Adult, Older Adult)",Phase 3,2175.0,"July 1, 2020",May 2021,India,https://ClinicalTrials.gov/show/NCT04475302
1136,1136,Convalescent Plasma vs. Standard Plasma for COVID-19,Enrolling by invitation,Biological: Convalescent Plasma|Biological: Standard Donor Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,500.0,"April 8, 2020","August 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04344535
1137,1137,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )",Recruiting,Biological: avdoralimab|Other: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,168.0,"April 27, 2020","December 31, 2020",France,https://ClinicalTrials.gov/show/NCT04371367
1138,1138,Anakinra for COVID-19 Respiratory Symptoms,Suspended,Drug: Anakinra plus oSOC|Drug: oSOC,All,"18 Years and older   (Adult, Older Adult)",Phase 3,71.0,"April 27, 2020","November 3, 2020",France,https://ClinicalTrials.gov/show/NCT04364009
1139,1139,Lessening Organ Dysfunction With VITamin C - COVID-19,Recruiting,Drug: Vitamin C|Drug: Control,All,"18 Years and older   (Adult, Older Adult)",Phase 3,800.0,"August 14, 2020",January 2022,Canada,https://ClinicalTrials.gov/show/NCT04401150
1140,1140,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1000.0,"April 3, 2020",April 2022,France,https://ClinicalTrials.gov/show/NCT04341207
1141,1141,"Efficacy, Safety, and Immunogenicity of an Inactivated Vaccine Against COVID-19 in High Infection Risk Adults",Recruiting,Biological: SARS-CoV-2 inactivated vaccine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,2300.0,"November 27, 2020",March 2022,Chile,https://ClinicalTrials.gov/show/NCT04651790
1142,1142,Use of UC-MSCs for COVID-19 Patients,Completed,Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,"April 25, 2020","October 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04355728
1143,1143,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,"Active, not recruiting",Drug: Treamid|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"September 8, 2020",November 2020,Russian Federation,https://ClinicalTrials.gov/show/NCT04527354
1144,1144,QuadraMune(TM) for Prevention of COVID-19,Recruiting,Dietary Supplement: QuadraMune(TM),All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,500.0,"June 8, 2020","November 8, 2020",United States,https://ClinicalTrials.gov/show/NCT04421391
1145,1145,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),Not yet recruiting,Biological: Mesenchymal Stromal Cells|Other: Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,30.0,December 2020,September 2022,United States,https://ClinicalTrials.gov/show/NCT04345601
1146,1146,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects",Recruiting,Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody),All,"15 Years to 45 Years   (Child, Adult)",Phase 1,40.0,"June 5, 2020","December 11, 2020",China,https://ClinicalTrials.gov/show/NCT04441918
1147,1147,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,Recruiting,Drug: Pacritinib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,364.0,"May 22, 2020","October 31, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04404361
1148,1148,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,Completed,Diagnostic Test: Data collection and rhinopharyngeal swab,All,up to 15 Years   (Child),Not Applicable,605.0,"April 14, 2020","June 1, 2020",France,https://ClinicalTrials.gov/show/NCT04318431
1149,1149,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,Drug: Heparin|Drug: 0.9% Sodium-chloride,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,"June 1, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04397510
1150,1150,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Completed,Device: COViage,All,"Child, Adult, Older Adult",Not Applicable,290.0,"March 10, 2020","June 4, 2020",United States,https://ClinicalTrials.gov/show/NCT04423991
1151,1151,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,"Active, not recruiting",Drug: NP-120 (Ifenprodil),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,682.0,"August 5, 2020",February 2022,Australia,https://ClinicalTrials.gov/show/NCT04382924
1152,1152,Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,Recruiting,Drug: Renin-angiotensin system inhibitors,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,240.0,"July 25, 2020","February 14, 2022",Brazil,https://ClinicalTrials.gov/show/NCT04493359
1153,1153,"Anakinra, COVID-19, Cytokine Storm",Not yet recruiting,Drug: Anakinra|Drug: 0.9% Saline,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2,100.0,November 2020,February 2022,United States,https://ClinicalTrials.gov/show/NCT04603742
1154,1154,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,Not yet recruiting,Drug: allogeneic mesenchymal stem cell|Other: Placebo,All,"19 Years and older   (Adult, Older Adult)",Phase 1,9.0,"October 26, 2020","January 31, 2021",Indonesia,https://ClinicalTrials.gov/show/NCT04535856
1155,1155,A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19),Recruiting,Drug: PTC299|Other: SOC|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,380.0,"July 9, 2020","January 30, 2021",Australia,https://ClinicalTrials.gov/show/NCT04439071
1156,1156,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,Procedure: alveolar recruitment,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,10.0,"May 6, 2020","June 1, 2021",Hungary,https://ClinicalTrials.gov/show/NCT04360837
1157,1157,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),Recruiting,Device: TCC-COVID mHealth solution,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"May 20, 2020","May 19, 2021",Australia,https://ClinicalTrials.gov/show/NCT04399109
1158,1158,Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia,Not yet recruiting,Biological: Allogeneic NK transfer,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,10.0,"April 13, 2020","November 10, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04344548
1159,1159,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Completed,Device: Hydrogen Oxygen Generator with Nebulizer|Other: Standard-of-care,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,90.0,"January 21, 2020","March 23, 2020",China,https://ClinicalTrials.gov/show/NCT04378712
1160,1160,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,Recruiting,Drug: Unfractionated Heparin IV|Drug: Enoxaparin 1 mg/kg|Drug: Clopidogrel|Drug: Unfractionated heparin SC|Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution,All,"18 Years and older   (Adult, Older Adult)",Phase 4,750.0,"August 5, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04409834
1161,1161,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,Recruiting,Biological: IMM-101|Other: Observation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500.0,"June 25, 2020","March 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04442048
1162,1162,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,"Active, not recruiting",Drug: Ivermectin|Drug: Placebo,All,18 Years to 59 Years   (Adult),Phase 2,24.0,"July 31, 2020","December 30, 2020",Spain,https://ClinicalTrials.gov/show/NCT04390022
1163,1163,Will Hydroxychloroquine Impede or Prevent COVID-19,Recruiting,Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,3000.0,"April 7, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04341441
1164,1164,Camostat With Bicalutamide for COVID-19,Not yet recruiting,Drug: Camostat Mesilate|Drug: Bicalutamide 150 mg,All,"60 Years and older   (Adult, Older Adult)",Phase 1,60.0,January 2021,January 2023,United States,https://ClinicalTrials.gov/show/NCT04652765
1165,1165,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,Diagnostic Test: Serological testing,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3500.0,"May 12, 2020","May 12, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04426292
1166,1166,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),Recruiting,Biological: V590|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,252.0,"October 29, 2020","December 13, 2021",United States,https://ClinicalTrials.gov/show/NCT04569786
1167,1167,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE",Recruiting,Drug: IgIV,All,75 Years and older   (Older Adult),Phase 2,35.0,"May 5, 2020","May 5, 2021",France,https://ClinicalTrials.gov/show/NCT04403269
1168,1168,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,Other: Mindfulness based intervention,All,"Child, Adult, Older Adult",Not Applicable,1000.0,"March 10, 2020","April 26, 2020",Spain,https://ClinicalTrials.gov/show/NCT04555005
1169,1169,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults",Recruiting,Drug: GX-19|Drug: Saline,All,18 Years to 50 Years   (Adult),Phase 1|Phase 2,210.0,"June 17, 2020","June 17, 2022","Korea, Republic of",https://ClinicalTrials.gov/show/NCT04445389
1170,1170,Hydrogen-oxygen Gas Mixture Inhalation in Patients With Convalescent Coronavirus Disease 2019 (COVID-19),Not yet recruiting,"Device: Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Device: OLO-1 Medical Molecular Sieve Oxygen Generator",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,198.0,"October 31, 2020","December 31, 2021",China,https://ClinicalTrials.gov/show/NCT04594460
1171,1171,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198","Active, not recruiting",Drug: BRII-198|Drug: Placebo,All,18 Years to 49 Years   (Adult),Phase 1,17.0,"July 13, 2020",March 2021,China,https://ClinicalTrials.gov/show/NCT04479644
1172,1172,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196","Active, not recruiting",Drug: BRII-196|Drug: Placebo,All,18 Years to 49 Years   (Adult),Phase 1,16.0,"July 12, 2020",March 2021,China,https://ClinicalTrials.gov/show/NCT04479631
1173,1173,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,Recruiting,Drug: Almitrine|Drug: Placebo,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,212.0,"September 3, 2020",December 2020,France,https://ClinicalTrials.gov/show/NCT04357457
1174,1174,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic: A Prospective Randomized Trial,Recruiting,Behavioral: Telemedicine visit|Behavioral: In-person postoperative visit,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,70.0,"September 28, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04652674
1175,1175,Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),Withdrawn,Drug: Hydroxychloroquine|Drug: Azithromycin,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,0.0,"May 5, 2020","July 15, 2020",Tunisia,https://ClinicalTrials.gov/show/NCT04351919
1176,1176,Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge,Not yet recruiting,Biological: IN01 vaccine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,"December 1, 2020",June 2022,Spain,https://ClinicalTrials.gov/show/NCT04537130
1177,1177,Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients,Not yet recruiting,Other: Systemic indirect endovenous ozone therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50.0,July 2020,December 2020,Spain,https://ClinicalTrials.gov/show/NCT04359303
1178,1178,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",Recruiting,Drug: EIDD-2801|Drug: Placebo (PBO),All,"18 Years and older   (Adult, Older Adult)",Phase 2,204.0,"June 16, 2020","February 28, 2021",United States,https://ClinicalTrials.gov/show/NCT04405570
1179,1179,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Recruiting,Device: mouthrinse with bêta-cyclodextrin and citrox|Device: mouthrinse without bêta-cyclodextrin and citrox,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,206.0,"April 27, 2020","December 20, 2020",France,https://ClinicalTrials.gov/show/NCT04352959
1180,1180,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Recruiting,Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,72.0,"April 23, 2020",December 2021,Spain,https://ClinicalTrials.gov/show/NCT04366245
1181,1181,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,Recruiting,Drug: Favipiravir,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 3,150.0,"October 7, 2020",June 2021,Hungary,https://ClinicalTrials.gov/show/NCT04600999
1182,1182,Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19,Not yet recruiting,Biological: UCMSCs|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,21.0,"March 1, 2021","June 1, 2024",United States,https://ClinicalTrials.gov/show/NCT04490486
1183,1183,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19",Recruiting,Biological: MVA-SARS-2-S vaccinations (days 0 & 28),All,18 Years to 55 Years   (Adult),Phase 1,30.0,"October 5, 2020",May 2021,Germany,https://ClinicalTrials.gov/show/NCT04569383
1184,1184,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,Recruiting,Drug: GLS-1200|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,225.0,"June 1, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04408183
1185,1185,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,Drug: Azithromycin 500 milligram (mg) oral Tablet|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 27, 2020","December 27, 2020",Austria,https://ClinicalTrials.gov/show/NCT04369365
1186,1186,HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19,Withdrawn,Drug: Hydroxychloroquine and Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"June 30, 2020","October 30, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04575558
1187,1187,Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection,Withdrawn,Drug: Treatment with Dexmedetomidine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0.0,"April 20, 2020","November 20, 2020",France,https://ClinicalTrials.gov/show/NCT04350086
1188,1188,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Recruiting,Drug: Mavrilimumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"May 20, 2020","May 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04492514
1189,1189,Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19,Not yet recruiting,Drug: Placebo|Drug: DuACT,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,40.0,December 2020,March 2021,South Africa,https://ClinicalTrials.gov/show/NCT04563208
1190,1190,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Recruiting,Other: Ketogenic diet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 1, 2020","May 30, 2021",Italy,https://ClinicalTrials.gov/show/NCT04492228
1191,1191,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,Drug: Oseltamivir|Drug: Azithromycin|Biological: Umbilical Cord Mesenchymal Stem Cells,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 1,40.0,July 2020,September 2020,Indonesia,https://ClinicalTrials.gov/show/NCT04457609
1192,1192,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Active, not recruiting",Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,26.0,"April 27, 2020",October 2021,Spain,https://ClinicalTrials.gov/show/NCT04366323
1193,1193,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,Recruiting,Drug: Intramuscular injection|Biological: Intramuscular vaccine,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,30612.0,"November 19, 2020","April 30, 2022",Canada,https://ClinicalTrials.gov/show/NCT04636697
1194,1194,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Recruiting,Other: Best Practice|Radiation: Low Dose Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,52.0,"June 12, 2020","May 30, 2022",Georgia,https://ClinicalTrials.gov/show/NCT04433949
1195,1195,Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19),Not yet recruiting,Drug: Alisporivir|Other: Standard of care (SOC),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,100.0,"November 1, 2020","August 4, 2021",France,https://ClinicalTrials.gov/show/NCT04608214
1196,1196,Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection,Not yet recruiting,Drug: Human Ezrin Peptide 1 (HEP1)|Drug: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20.0,"December 20, 2020","April 1, 2021","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04627233
1197,1197,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,Recruiting,Biological: VPM1002|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3626.0,"June 24, 2020","July 1, 2021",Canada,https://ClinicalTrials.gov/show/NCT04439045
1198,1198,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Drug: Mavrilimumab|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"May 20, 2020","May 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04399980
1199,1199,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",Recruiting,Drug: AK119|Drug: Placebo,All,18 Years to 55 Years   (Adult),Phase 1,32.0,September 2020,April 2021,New Zealand,https://ClinicalTrials.gov/show/NCT04516564
1200,1200,Is Adipose Tissue a Reservoir for SARS-Cov2 Spread in Covid-19 Patients?,Not yet recruiting,Procedure: biopsies of subcutaneous adipose tissue,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,5.0,"July 1, 2020","July 9, 2021",France,https://ClinicalTrials.gov/show/NCT04427878
1201,1201,Telmisartan in Respiratory Failure Due to COVID-19,Recruiting,Drug: Telmisartan,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,August 2020,April 2021,Mexico,https://ClinicalTrials.gov/show/NCT04510662
1202,1202,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,Recruiting,Drug: Senicapoc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,46.0,"April 24, 2020","December 31, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04594668
1203,1203,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,Recruiting,Drug: Ensifentrine Dose 1|Drug: Placebo pMDI,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,45.0,"August 28, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04527471
1204,1204,hCT-MSCs for COVID19 ARDS,Recruiting,Biological: human cord tissue mesenchymal stromal cells,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"June 18, 2020","July 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04399889
1205,1205,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),Recruiting,Other: Meditation (1 x 20-minute guided audio training),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,624.0,"October 28, 2020",March 2021,Australia,https://ClinicalTrials.gov/show/NCT04602312
1206,1206,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Recruiting,Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo,All,20 Years to 50 Years   (Adult),Phase 4,400.0,"April 15, 2020","June 30, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04351191
1207,1207,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Recruiting,Diagnostic Test: AAZ Covid-19 rapid test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"April 25, 2020","October 25, 2020",France,https://ClinicalTrials.gov/show/NCT04525417
1208,1208,Telemedicine in Outpatient Covid-19 Patients,Recruiting,Device: Withings ScanWatch,All,40 Years to 59 Years   (Adult),Not Applicable,600.0,"September 18, 2020",March 2021,Germany,https://ClinicalTrials.gov/show/NCT04471636
1209,1209,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Recruiting,Drug: LEAF-4L6715,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,90.0,"April 14, 2020","December 31, 2020",France,https://ClinicalTrials.gov/show/NCT04378920
1210,1210,Estrogen Patch for COVID-19 Symptoms,Recruiting,Drug: Estradiol patch,All,"18 Years and older   (Adult, Older Adult)",Phase 2,110.0,"April 20, 2020","November 15, 2020",United States,https://ClinicalTrials.gov/show/NCT04359329
1211,1211,Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel,Not yet recruiting,Drug: Ivermectin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,550.0,"September 7, 2020","December 16, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04527211
1212,1212,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Recruiting,Drug: Ruxolitinib|Drug: Fostamatinib|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,456.0,"October 2, 2020","July 31, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04581954
1213,1213,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),Recruiting,Drug: Anakinra,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"April 15, 2020","April 15, 2022",Greece,https://ClinicalTrials.gov/show/NCT04357366
1214,1214,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,Recruiting,Drug: Trans Sodium Crocetinate|Drug: Normal saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,224.0,"September 10, 2020","December 14, 2021",Romania,https://ClinicalTrials.gov/show/NCT04573322
1215,1215,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,Recruiting,Drug: Autophagy inhibitor (GNS651)|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,219.0,"April 15, 2020",August 2021,France,https://ClinicalTrials.gov/show/NCT04333914
1216,1216,Investigation of Safety and Efficacy of CARDIO Softgels in Former Smokers and Asthma Patients With COVID-19 Infection,Not yet recruiting,Dietary Supplement: Best Standard of Care + CARDIO|Dietary Supplement: Best Standard of Care,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100.0,"August 31, 2020","August 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04465513
1217,1217,Interferon Lambda Therapy for COVID-19,Not yet recruiting,Drug: Peginterferon Lambda-1A,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66.0,September 2020,May 2021,United States,https://ClinicalTrials.gov/show/NCT04388709
1218,1218,COVID-19 Seroprevalence Study in French Guiana,Recruiting,Procedure: Blood sample,All,"Child, Adult, Older Adult",Not Applicable,1500.0,"July 15, 2020","July 15, 2021",French Guiana,https://ClinicalTrials.gov/show/NCT04490850
1219,1219,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Recruiting,Other: Respiratory and psychological rehabilitation,All,"50 Years and older   (Adult, Older Adult)",Not Applicable,108.0,"October 26, 2020","March 30, 2021",Peru,https://ClinicalTrials.gov/show/NCT04649736
1220,1220,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Recruiting,Drug: Sargramostim|Other: Normal Saline 0.9%,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 2,30.0,"June 2, 2020",June 2022,Singapore,https://ClinicalTrials.gov/show/NCT04400929
1221,1221,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",Recruiting,Diagnostic Test: Blood sample for serological test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1800.0,"April 17, 2020",August 2021,France,https://ClinicalTrials.gov/show/NCT04441684
1222,1222,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,Completed,Drug: Nitazoxanide|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"April 19, 2020","October 2, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04561219
1223,1223,BCG Vaccination to Protect Healthcare Workers Against COVID-19,Recruiting,Drug: BCG Vaccine|Drug: 0.9%NaCl,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10078.0,"March 30, 2020","March 30, 2022",Australia,https://ClinicalTrials.gov/show/NCT04327206
1224,1224,Coronavirus (COVID-19) ACEi/ARB Investigation,Suspended,Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker,All,"60 Years and older   (Adult, Older Adult)",Phase 4,2414.0,"April 30, 2020","December 1, 2021",Ireland,https://ClinicalTrials.gov/show/NCT04330300
1225,1225,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection,Recruiting,Other: Rehabilitation by Eccentric exercises|Other: Rehabilitation by Concentric exercises,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,120.0,"June 5, 2020","December 5, 2021",France,https://ClinicalTrials.gov/show/NCT04649086
1226,1226,Ravulizumab and COVID-19,Not yet recruiting,Drug: Ravulizumab,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,32.0,November 2020,November 2021,United States,https://ClinicalTrials.gov/show/NCT04570397
1227,1227,Relationship Between Biological Profiles and Clinical Evolutions Within the Same Cluster COVID-19 (COVIDCOLLECT),Not yet recruiting,"Biological: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine",All,"Child, Adult, Older Adult",Not Applicable,100.0,November 2020,February 2022,France,https://ClinicalTrials.gov/show/NCT04597736
1228,1228,Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.,Completed,Device: N-95 Respirator|Device: Cloth Face Mask|Diagnostic Test: Graded exercise test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"June 1, 2020","August 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04415879
1229,1229,Novel Regimens in COVID-19 Treatment,Recruiting,Drug: Nitazoxanide,All,"18 Years and older   (Adult, Older Adult)",Phase 3,160.0,"May 8, 2020","December 1, 2030",Egypt,https://ClinicalTrials.gov/show/NCT04382846
1230,1230,Rhu-pGSN for Severe Covid-19 Pneumonia,Recruiting,Drug: Recombinant human plasma gelsolin (Rhu-pGSN)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"July 30, 2020","October 30, 2020",Spain,https://ClinicalTrials.gov/show/NCT04358406
1231,1231,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,Recruiting,Drug: BCG-10 vaccine|Drug: 0.9% saline,All,"25 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"July 7, 2020",April 2021,Poland,https://ClinicalTrials.gov/show/NCT04648800
1232,1232,Honey & Nigella Sativa Trial Against COVID-19,Completed,Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 3,313.0,"April 30, 2020","August 30, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04347382
1233,1233,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),"Active, not recruiting",Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2,45.0,"April 24, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04365153
1234,1234,Mouth Rinses for Inactivation of COVID-19,Not yet recruiting,Drug: 1.5-2% w/v Hydrogen Peroxide|Drug: 0.12% Chlorhexidine Gluconate|Drug: 21% Ethanol plus essential oils|Drug: 1% w/v Povidone-iodide|Drug: 0.075% Cetylpyridinium Chloride|Other: Saline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,480.0,December 2020,September 2023,United States,https://ClinicalTrials.gov/show/NCT04584684
1235,1235,RAS and Coagulopathy in COVID19,Recruiting,Biological: TRV027|Other: sodium chloride 0.9%,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,60.0,"October 9, 2020",May 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04419610
1236,1236,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic,"Active, not recruiting",Other: PRO-SERO-COV,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,550.0,"June 1, 2020",December 2021,France,https://ClinicalTrials.gov/show/NCT04426006
1237,1237,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Recruiting,Diagnostic Test: SARS-CoV2 serum antibody testing,All,"21 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"May 5, 2020","October 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04389294
1238,1238,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Dietary Supplement: Vitamins|Drug: Telmisartan|Drug: Ciclesonide,All,"50 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,615.0,"July 29, 2020","August 31, 2021",France,https://ClinicalTrials.gov/show/NCT04356495
1239,1239,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,Recruiting,Procedure: Conventional oxygen therapy|Procedure: High flow nasal cannula,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,196.0,"August 11, 2020","July 28, 2021",Colombia,https://ClinicalTrials.gov/show/NCT04609462
1240,1240,Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19,Not yet recruiting,Drug: ACEIs|Drug: Conventional treatment,All,"Child, Adult, Older Adult",Phase 3,60.0,"April 15, 2020","December 1, 2029",Egypt,https://ClinicalTrials.gov/show/NCT04345406
1241,1241,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Recruiting,Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"April 24, 2020",April 2021,Israel,https://ClinicalTrials.gov/show/NCT04362176
1242,1242,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,Diagnostic Test: Ejaculated semen sample,Male,18 Years to 50 Years   (Adult),Not Applicable,20.0,"August 31, 2020","August 31, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04391829
1243,1243,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,Other: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"April 24, 2020","February 28, 2021",France,https://ClinicalTrials.gov/show/NCT04413864
1244,1244,Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19),Not yet recruiting,Drug: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,231.0,June 2020,December 2021,Colombia,https://ClinicalTrials.gov/show/NCT04391101
1245,1245,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Completed,Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"July 20, 2020","October 20, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04491240
1246,1246,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Recruiting,Drug: ArtemiC|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"May 8, 2020",January 2021,India,https://ClinicalTrials.gov/show/NCT04382040
1247,1247,Prasugrel in Severe COVID-19 Pneumonia,Not yet recruiting,Drug: Prasugrel Hydrochloride 10 MG Oral Tablet|Drug: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,128.0,July 2020,January 2021,Italy,https://ClinicalTrials.gov/show/NCT04445623
1248,1248,Outpatient Treatment With CoVid-19 With Prexablu,Recruiting,Drug: Sublingual Methylene blue|Other: Control patients,All,"18 Years and older   (Adult, Older Adult)",Phase 1,46.0,"October 12, 2020","December 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04619290
1249,1249,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,Drug: Colchicine|Drug: Standard treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,180.0,"April 3, 2020","September 30, 2020",Gibraltar,https://ClinicalTrials.gov/show/NCT04326790
1250,1250,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Recruiting,Drug: Anakinra|Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"April 2, 2020","April 1, 2022",Greece,https://ClinicalTrials.gov/show/NCT04339712
1251,1251,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 2,11.0,"April 17, 2020","June 26, 2020",United States,https://ClinicalTrials.gov/show/NCT04335552
1252,1252,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,Drug: NK-1R antagonist,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,100.0,"June 15, 2020","August 30, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04468646
1253,1253,A Study of Quintuple Therapy to Treat COVID-19 Infection,Recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"June 22, 2020",September 2021,United States,https://ClinicalTrials.gov/show/NCT04334512
1254,1254,Protective Role of Inhaled Steroids for Covid-19 Infection,Recruiting,Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,436.0,"April 13, 2020","January 13, 2022",France,https://ClinicalTrials.gov/show/NCT04331054
1255,1255,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,Drug: low-molecular-weight heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,"August 1, 2020","December 31, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04584580
1256,1256,Prayer in Commbate to Corona Virus - Covid -19,Recruiting,Other: PRAYER,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"August 1, 2020",January 2021,Brazil,https://ClinicalTrials.gov/show/NCT04631380
1257,1257,Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella Sativa in COVID-19 Patients,Recruiting,Drug: Nigella Sativa / Black Cumin|Drug: Ivermectin Injectable Solution|Other: Placebo|Drug: Zinc,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"July 14, 2020","September 30, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04472585
1258,1258,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,Diagnostic Test: Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,24.0,"June 30, 2020","June 30, 2021",Italy,https://ClinicalTrials.gov/show/NCT04463849
1259,1259,Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients,Recruiting,Device: Therapeutic plasma exchange,All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,10.0,"September 11, 2020","August 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04592705
1260,1260,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,829.0,"March 31, 2020","October 8, 2020",United States,https://ClinicalTrials.gov/show/NCT04328961
1261,1261,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Recruiting,Biological: Convalescent anti-SARS-CoV-2 MBT plasma|Other: Control Group,All,"50 Years and older   (Adult, Older Adult)",Phase 2,474.0,"October 30, 2020",October 2021,Spain,https://ClinicalTrials.gov/show/NCT04621123
1262,1262,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Active, not recruiting",Biological: BCG vaccine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,908.0,"July 21, 2020","January 1, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04461379
1263,1263,FAvipiravir and HydroxyChloroquine Combination Therapy,Recruiting,Combination Product: Favipiravir and Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,520.0,"May 21, 2020",November 2021,Saudi Arabia,https://ClinicalTrials.gov/show/NCT04392973
1264,1264,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,Recruiting,Drug: Colchicine plus symptomatic treatment (paracetamol)|Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations),All,"60 Years and older   (Adult, Older Adult)",Phase 3,954.0,"August 19, 2020","December 31, 2021",Spain,https://ClinicalTrials.gov/show/NCT04416334
1265,1265,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),Not yet recruiting,Other: blood sample,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"October 15, 2020","October 15, 2022",France,https://ClinicalTrials.gov/show/NCT04568707
1266,1266,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",Recruiting,Drug: Metformin Glycinate|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"July 14, 2020","March 31, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04625985
1267,1267,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Recruiting,Drug: Methotrexate-LDE phase 1|Drug: Methotrexate-LDE phase 2|Drug: Placebo-LDE phase 2,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,100.0,"October 27, 2020","July 15, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04610567
1268,1268,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,Not yet recruiting,Other: Best Practice|Drug: Leflunomide|Drug: Placebo Administration,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"September 18, 2020","September 18, 2022",United States,https://ClinicalTrials.gov/show/NCT04532372
1269,1269,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Active, not recruiting",Drug: L-ascorbic acid,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"April 16, 2020","October 15, 2020",United States,https://ClinicalTrials.gov/show/NCT04357782
1270,1270,Adolescents With COVID-19/MIS-C at HCFMUSP,Enrolling by invitation,Behavioral: Home-based exercise training,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,100.0,"September 24, 2020","April 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04659486
1271,1271,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,Recruiting,Drug: P2Et (Caesalpinia spinosa extract)|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"September 30, 2020",June 2021,Colombia,https://ClinicalTrials.gov/show/NCT04410510
1272,1272,Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore,Withdrawn,Drug: Hydroxychloroquine,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,0.0,April 2020,August 2020,United States,https://ClinicalTrials.gov/show/NCT04350450
1273,1273,Home-based Exercise in COVID-19 Survivors,Recruiting,Other: Exercise training,All,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60.0,"September 26, 2020","December 21, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04615052
1274,1274,COVID-19 Serology and Immunosenescence,Recruiting,Biological: blood sample,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,330.0,"September 18, 2020",November 2021,France,https://ClinicalTrials.gov/show/NCT04563650
1275,1275,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Completed,Drug: Bromhexine Hydrochloride,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,"May 14, 2020","August 31, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04405999
1276,1276,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Recruiting,Behavioral: Simha Kriya|Behavioral: Reading a Book,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30000.0,"May 22, 2020","December 31, 2020",Israel,https://ClinicalTrials.gov/show/NCT04498442
1277,1277,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","Active, not recruiting",Biological: Intramuscular Vaccine,All,18 Years to 55 Years   (Adult),Phase 1,180.0,"July 10, 2020","December 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04450004
1278,1278,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Adult Population In Peru",Recruiting,Biological: Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan,All,18 Years to 60 Years   (Adult),Phase 3,6000.0,"September 10, 2020","September 1, 2021",Peru,https://ClinicalTrials.gov/show/NCT04612972
1279,1279,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,Not yet recruiting,Behavioral: Lift,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"December 1, 2020","September 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04581200
1280,1280,FEnofibRate as a Metabolic INtervention for COVID-19,Enrolling by invitation,Other: Fenofibrate|Other: Placebo|Other: Usual care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"August 18, 2020","August 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04517396
1281,1281,Helmet CPAP Versus HFNC in COVID-19,Recruiting,Device: Helmet CPAP|Device: HFNC,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"June 3, 2020",May 2021,Sweden,https://ClinicalTrials.gov/show/NCT04395807
1282,1282,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,Recruiting,Drug: lopinavir/ritonavir|Drug: Losartan|Drug: Placebos,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,4000.0,"April 6, 2020","April 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04328012
1283,1283,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Recruiting,Diagnostic Test: Lung impedance technique,All,"18 Years to 95 Years   (Adult, Older Adult)",Not Applicable,50.0,"April 28, 2020","April 28, 2021",Israel,https://ClinicalTrials.gov/show/NCT04406493
1284,1284,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults",Recruiting,"Biological: Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|Biological: Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1040.0,"October 31, 2020","May 31, 2021",China,https://ClinicalTrials.gov/show/NCT04617483
1285,1285,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,Other: Essential Oil Blend|Other: Control Blend,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,65.0,"October 1, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04495842
1286,1286,Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,Not yet recruiting,Drug: Ivermectin Pill|Drug: Combined ART/hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,80.0,July 2020,November 2021,Thailand,https://ClinicalTrials.gov/show/NCT04435587
1287,1287,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19,Recruiting,Radiation: Low Dose Radiation Therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,10.0,"April 23, 2020","October 23, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04366791
1288,1288,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19",Not yet recruiting,Biological: mRNA-1273|Biological: Placebo,All,12 Years to 17 Years   (Child),Phase 2|Phase 3,3000.0,"November 30, 2020","June 30, 2022",Jordan,https://ClinicalTrials.gov/show/NCT04649151
1289,1289,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur",Recruiting,Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)|Diagnostic Test: Nasopharyngeal swabs,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2800.0,"April 28, 2020","April 28, 2021",France,https://ClinicalTrials.gov/show/NCT04369066
1290,1290,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Biological: mRNA-1273|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000.0,"July 27, 2020","October 27, 2022",Georgia,https://ClinicalTrials.gov/show/NCT04470427
1291,1291,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),"Active, not recruiting",Biological: COVID 19 Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,350.0,"March 20, 2020",June 2022,United States,https://ClinicalTrials.gov/show/NCT04554992
1292,1292,Anti-SARS Cov-2 T Cell Infusions for COVID 19,Recruiting,Biological: Dose Finding Phase (MTD)|Biological: Partially HLA-matched SARS-CoVSTs|Other: Routine care (no SARS-CoVSTs),All,"18 Years and older   (Adult, Older Adult)",Phase 1,58.0,"November 4, 2020","August 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04401410
1293,1293,Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year,Not yet recruiting,Drug: Lopinavir/Ritonavir|Drug: Placebo Administration|Other: Questionnaire Administration,All,"18 Years and older   (Adult, Older Adult)",Phase 2,75.0,"November 1, 2020","November 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04455958
1294,1294,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,Recruiting,Diagnostic Test: CTUS examination,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 22, 2020","September 22, 2020",France,https://ClinicalTrials.gov/show/NCT04372680
1295,1295,Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,Recruiting,Drug: Janus Kinase Inhibitor (ruxolitinib)|Other: Placebo,All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 2|Phase 3,200.0,"July 17, 2020","December 31, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04477993
1296,1296,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,Recruiting,Drug: Ivermectin|Drug: Placebo,Male,18 Years to 45 Years   (Adult),Early Phase 1,24.0,"September 22, 2020",May 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04632706
1297,1297,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,Recruiting,Drug: BMS-986253,All,"18 Years and older   (Adult, Older Adult)",Phase 2,138.0,"April 16, 2020",September 2022,United States,https://ClinicalTrials.gov/show/NCT04347226
1298,1298,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Completed,Other: Standard interface|Device: Double-Trunk Mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,12.0,"April 9, 2020","May 1, 2020",Belgium,https://ClinicalTrials.gov/show/NCT04346420
1299,1299,Vitamin D Testing and Treatment for COVID 19,Completed,Dietary Supplement: Vitamin D3,All,"18 Years and older   (Adult, Older Adult)",Phase 1,41.0,"May 19, 2020","November 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04407286
1300,1300,Early CPAP in COVID-19 Patients With Respiratory Failure.,Suspended,Device: CPAP treatment,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,900.0,October 2020,"November 9, 2020",Italy,https://ClinicalTrials.gov/show/NCT04326075
1301,1301,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,Recruiting,Other: Postural Positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,"May 25, 2020","May 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04344561
1302,1302,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,Recruiting,Device: Bedside lung ultrasound,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"May 10, 2020","September 10, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04399681
1303,1303,The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients,Not yet recruiting,Drug: Sitagliptin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,170.0,"December 29, 2020","December 30, 2021",Italy,https://ClinicalTrials.gov/show/NCT04365517
1304,1304,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml,All,"50 Years and older   (Adult, Older Adult)",Phase 3,1000.0,"June 15, 2020","April 14, 2021",Switzerland,https://ClinicalTrials.gov/show/NCT04400799
1305,1305,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Active, not recruiting",Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,500.0,"September 11, 2020","July 31, 2021",Russian Federation,https://ClinicalTrials.gov/show/NCT04540419
1306,1306,Clinical Trial of Sarilumab in Adults With COVID-19,Not yet recruiting,Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,120.0,"April 27, 2020","July 27, 2020",Spain,https://ClinicalTrials.gov/show/NCT04357860
1307,1307,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Recruiting,Drug: CERC-002|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,82.0,"June 9, 2020",November 2020,India,https://ClinicalTrials.gov/show/NCT04412057
1308,1308,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,Drug: Chloroquine|Drug: Hydroxychloroquine|Other: standard care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,142.0,"April 16, 2020","September 3, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04420247
1309,1309,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,Diagnostic Test: CT-scan|Diagnostic Test: EEG|Diagnostic Test: EP|Diagnostic Test: Pulse oximetry|Diagnostic Test: Blood tests,All,18 Years to 60 Years   (Adult),Not Applicable,51.0,"May 22, 2020","October 29, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04405544
1310,1310,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,Recruiting,Biological: BCG-Denmark|Biological: Saline,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1050.0,"December 3, 2020",March 2022,Cape Verde,https://ClinicalTrials.gov/show/NCT04641858
1311,1311,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"April 22, 2020","November 30, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04338698
1312,1312,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,Recruiting,Biological: BBV152|Biological: Placebo,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,25800.0,"November 25, 2020","March 1, 2022",India,https://ClinicalTrials.gov/show/NCT04641481
1313,1313,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Recruiting,Drug: Cholecalciferol,All,1 Month to 17 Years   (Child),Phase 3,40.0,"July 15, 2020",April 2021,Mexico,https://ClinicalTrials.gov/show/NCT04502667
1314,1314,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Recruiting,Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,165.0,"May 15, 2020","February 28, 2021",United States,https://ClinicalTrials.gov/show/NCT04311697
1315,1315,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Recruiting,Other: Prolonged Proned Positioning|Other: Traditional Proning Arm,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,52.0,"November 10, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04581811
1316,1316,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",Biological: Biological: mRNA-1273: 50 mcg|Other: Placebo|Biological: Biological: mRNA-1273: 100 mcg,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"May 29, 2020",August 2021,Georgia,https://ClinicalTrials.gov/show/NCT04405076
1317,1317,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Recruiting,Drug: Camostat Mesilate|Drug: Artemisia Annua Leaf,All,"18 Years and older   (Adult, Older Adult)",Phase 2,360.0,"October 5, 2020",February 2021,Canada,https://ClinicalTrials.gov/show/NCT04530617
1318,1318,Cod Liver Oil for Covid-19 Prevention Study,Recruiting,Dietary Supplement: Cod liver oil|Dietary Supplement: Corn oil (placebo),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,80000.0,"November 10, 2020",May 2023,Norway,https://ClinicalTrials.gov/show/NCT04609423
1319,1319,A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19,Withdrawn,Drug: Hydroxychloroquine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,0.0,"May 5, 2020","September 25, 2020",United States,https://ClinicalTrials.gov/show/NCT04379492
1320,1320,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Recruiting,Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo,All,20 Years to 50 Years   (Adult),Phase 4,400.0,"April 14, 2020","June 30, 2021",Pakistan,https://ClinicalTrials.gov/show/NCT04346667
1321,1321,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Recruiting,Biological: Cell therapy protocol 1|Biological: Cell therapy protocol 2,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"April 5, 2020","December 10, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04366063
1322,1322,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Recruiting,Behavioral: Therapy Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72.0,"May 19, 2020","April 19, 2022",United States,https://ClinicalTrials.gov/show/NCT04385901
1323,1323,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,Recruiting,Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP),All,"12 Months and older   (Child, Adult, Older Adult)",Phase 3,220.0,"April 30, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04361253
1324,1324,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,Diagnostic Test: Saliva collection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130.0,"April 16, 2020","May 17, 2020",France,https://ClinicalTrials.gov/show/NCT04367545
1325,1325,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19,Enrolling by invitation,Device: V/Q Vest,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24.0,"August 11, 2020",April 2021,Georgia,https://ClinicalTrials.gov/show/NCT04369599
1326,1326,Prone Positioning for Patients on General Medical Wards With COVID19,Recruiting,Other: Prone positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,350.0,"May 15, 2020","December 11, 2020",Canada,https://ClinicalTrials.gov/show/NCT04383613
1327,1327,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,Recruiting,Biological: PLX-PAD,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,40.0,November 2020,March 2022,Germany,https://ClinicalTrials.gov/show/NCT04614025
1328,1328,"Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine","Active, not recruiting",Biological: QazCovid-in® - COVID-19 inactivated vaccine|Other: Placebo,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1|Phase 2,244.0,"September 19, 2020","December 7, 2020",Kazakhstan,https://ClinicalTrials.gov/show/NCT04530357
1329,1329,Efficacy and Safety of Itolizumab in COVID-19 Complications,Completed,"Drug: Itolizumab IV infusion|Drug: Best supportive care"" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,30.0,"May 1, 2020","July 8, 2020",India,https://ClinicalTrials.gov/show/NCT04475588
1330,1330,Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium,Not yet recruiting,Drug: Valproate|Drug: Quetiapine|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20.0,"November 1, 2021","November 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04513314
1331,1331,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,"Active, not recruiting",Drug: Cannabidiol,All,24 Years to 60 Years   (Adult),Phase 2|Phase 3,120.0,"June 16, 2020","December 16, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04504877
1332,1332,Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19,Withdrawn,Drug: Chloroquine or hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"May 1, 2020","June 30, 2021",South Africa,https://ClinicalTrials.gov/show/NCT04360759
1333,1333,"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2",Not yet recruiting,Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,30000.0,November 2020,"December 30, 2022",Georgia,https://ClinicalTrials.gov/show/NCT04611802
1334,1334,Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19,Suspended,Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,300.0,"February 27, 2020",January 2021,China,https://ClinicalTrials.gov/show/NCT04278963
1335,1335,Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients,Not yet recruiting,Behavioral: Doctorgram Patient Kit,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,January 2021,December 2021,United States,https://ClinicalTrials.gov/show/NCT04480411
1336,1336,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,Biological: Convalescent plasma|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,60.0,"May 18, 2020","October 31, 2020",Indonesia,https://ClinicalTrials.gov/show/NCT04380935
1337,1337,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Biological: convalescent plasma,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,90.0,"May 20, 2020",December 2020,Mexico,https://ClinicalTrials.gov/show/NCT04356482
1338,1338,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",Recruiting,Biological: PLX-PAD|Biological: Placebo,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,140.0,"October 1, 2020",March 2022,Georgia,https://ClinicalTrials.gov/show/NCT04389450
1339,1339,Methylene Blue Treatment of COVID-19,Not yet recruiting,Drug: Methylene Blue|Drug: Control Test,All,"18 Years and older   (Adult, Older Adult)",Phase 2,64.0,November 2020,"December 31, 2022",Switzerland,https://ClinicalTrials.gov/show/NCT04635605
1340,1340,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,Recruiting,Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,40000.0,"April 29, 2020",April 2021,Indonesia,https://ClinicalTrials.gov/show/NCT04303507
1341,1341,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Recruiting,Device: Cytokine Adsorption,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"April 17, 2020",July 2020,Spain,https://ClinicalTrials.gov/show/NCT04361526
1342,1342,The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection,Not yet recruiting,"Procedure: Sphenopalatine Ganglion Block with Local Anesthetic|Procedure: Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)|Procedure: ""Sham""-block with Placebo (Isotone NaCl)",All,"18 Years and older   (Adult, Older Adult)",Phase 3,60.0,December 2020,November 2021,Denmark,https://ClinicalTrials.gov/show/NCT04636034
1343,1343,Rehabilitation for People With COVID-19 in ICU,Not yet recruiting,Other: Pulmonary and Motor Rehabilitation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,92.0,"May 10, 2020","September 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04381338
1344,1344,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Recruiting,Device: Digital oximeter monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"June 22, 2020","June 22, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04587921
1345,1345,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,Procedure: Prone Positioning|Procedure: Standard of care.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"July 11, 2020","September 11, 2021",Ireland,https://ClinicalTrials.gov/show/NCT04347941
1346,1346,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),Recruiting,Biological: Mesenchymal stromal cells|Other: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,30.0,"July 30, 2020","December 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04466098
1347,1347,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Recruiting,Drug: Ivermectin|Drug: Placebo,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,68.0,"August 28, 2020","January 28, 2021",Peru,https://ClinicalTrials.gov/show/NCT04635943
1348,1348,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,Recruiting,Dietary Supplement: Nicotinamide riboside|Dietary Supplement: Placebo,All,70 Years and older   (Older Adult),Phase 2,100.0,"June 1, 2020","May 1, 2022",Denmark,https://ClinicalTrials.gov/show/NCT04407390
1349,1349,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,Recruiting,Drug: Broncho-Vaxom®,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,1000.0,"August 24, 2020","June 30, 2021",Australia,https://ClinicalTrials.gov/show/NCT04496245
1350,1350,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Recruiting,Other: Solution-Focused Support Program,All,18 Years to 45 Years   (Adult),Not Applicable,60.0,"July 1, 2020","December 30, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04609722
1351,1351,Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD,Recruiting,Drug: SARS-CoV-2 plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,90.0,"April 7, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04411602
1352,1352,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,Recruiting,Device: HCFWO|Other: Standard Care Plus Monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,December 2020,November 2021,Israel,https://ClinicalTrials.gov/show/NCT04654481
1353,1353,Maraviroc in Patients With Moderate and Severe COVID-19,Recruiting,Drug: Maraviroc,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,16.0,"September 21, 2020",January 2021,United States,https://ClinicalTrials.gov/show/NCT04435522
1354,1354,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Recruiting,Diagnostic Test: diagnostic,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 7, 2020","August 31, 2021",France,https://ClinicalTrials.gov/show/NCT04460534
1355,1355,Sofosbuvir in Treatment of COVID 19,Recruiting,Drug: sofosbuvir|Drug: Sofosbuvir ledipsavir|Drug: Daclatasvir,All,"Child, Adult, Older Adult",Phase 2|Phase 3,60.0,"August 1, 2020","August 31, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04460443
1356,1356,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19",Recruiting,Biological: CVnCoV 6 μg|Biological: CVnCoV 12 μg|Biological: Hepatitis A vaccine|Biological: Pneumococcal vaccine|Biological: CVnCoV 12μg,All,"18 Years and older   (Adult, Older Adult)",Phase 2,660.0,"September 28, 2020","November 9, 2021",Panama,https://ClinicalTrials.gov/show/NCT04515147
1357,1357,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19,Recruiting,Other: Blood sample and data record,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,270.0,"May 28, 2020","October 28, 2022",France,https://ClinicalTrials.gov/show/NCT04376840
1358,1358,Bacillus Calmette-guérin Vaccination to Prevent COVID-19,Recruiting,Biological: BCG vaccine|Biological: Placebo,All,"50 Years and older   (Adult, Older Adult)",Phase 4,900.0,"May 26, 2020","May 25, 2021",Greece,https://ClinicalTrials.gov/show/NCT04414267
1359,1359,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Recruiting,Drug: Bacille Calmette-Guérin (BCG)|Drug: Placebo,All,"60 Years and older   (Adult, Older Adult)",Phase 4,5200.0,"August 25, 2020",April 2021,Netherlands,https://ClinicalTrials.gov/show/NCT04537663
1360,1360,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,Device: Dexcom G6,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,72.0,"May 25, 2020","May 25, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04430608
1361,1361,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Recruiting,Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"May 31, 2020",February 2021,United States,https://ClinicalTrials.gov/show/NCT04391179
1362,1362,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Recruiting,Drug: Naltrexone|Drug: Ketamine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"April 29, 2020",August 2021,United States,https://ClinicalTrials.gov/show/NCT04365985
1363,1363,Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada,Not yet recruiting,Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo,All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 1|Phase 2,696.0,"August 1, 2020","December 30, 2021",Canada,https://ClinicalTrials.gov/show/NCT04398147
1364,1364,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,Recruiting,Biological: Ravulizumab|Other: Best Supportive Care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,270.0,"May 11, 2020",July 2021,France,https://ClinicalTrials.gov/show/NCT04369469
1365,1365,Nasal Photodisinfection COVID Proof of Concept Study,Recruiting,Other: Methylene-Blue Photodisinfection,All,"Child, Adult, Older Adult",Not Applicable,100.0,"July 10, 2020","May 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04615936
1366,1366,Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients,Not yet recruiting,Drug: Pentoxifylline|Drug: Placebo,All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,200.0,"December 13, 2020","December 30, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04433988
1367,1367,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19,Not yet recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,86.0,"April 20, 2020","October 1, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04346329
1368,1368,Measles Vaccine in HCW,Recruiting,Drug: Measles-Mumps-Rubella Vaccine|Drug: Placebos,All,18 Years to 50 Years   (Adult),Phase 3,200.0,"July 13, 2020","November 1, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04357028
1369,1369,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,18.0,"February 16, 2020","June 1, 2020",China,https://ClinicalTrials.gov/show/NCT04273763
1370,1370,Proactive Care of Ambulatory COVID19 Patients,Not yet recruiting,Other: consultation|Drug: Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,64.0,"April 29, 2020",July 2020,France,https://ClinicalTrials.gov/show/NCT04371107
1371,1371,Study of Famotidine With Vitamins C and D for Pandemic Coronavirus,Not yet recruiting,Drug: Famotidine 20 MG,All,"18 Years and older   (Adult, Older Adult)",Phase 4,216.0,"December 1, 2020","July 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04565392
1372,1372,Assessment of Safety and Efficacy of CCP,"Active, not recruiting",Biological: COVID Convalescent Plasma,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,136.0,"June 16, 2020","October 31, 2020",Uganda,https://ClinicalTrials.gov/show/NCT04542941
1373,1373,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",Recruiting,Drug: PLN-74809|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,36.0,"October 22, 2020","October 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04565249
1374,1374,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults,Not yet recruiting,Biological: CVnCoV|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,36500.0,"November 30, 2020","March 4, 2023",Germany,https://ClinicalTrials.gov/show/NCT04652102
1375,1375,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,Recruiting,Drug: Placebo|Drug: Ivermectin|Drug: Losartan,All,"18 Years and older   (Adult, Older Adult)",Phase 2,176.0,"July 23, 2020",February 2021,Brazil,https://ClinicalTrials.gov/show/NCT04447235
1376,1376,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),Recruiting,Biological: Vaccinated with polio vaccine (IPV),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,25.0,"November 15, 2020","January 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04639375
1377,1377,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,Biological: BCG|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1000.0,"August 10, 2020",August 2023,Brazil,https://ClinicalTrials.gov/show/NCT04369794
1378,1378,HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial,Not yet recruiting,Drug: Hydroxychloroquine Pre-Exposure Prophylaxis|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,374.0,"April 24, 2020","August 24, 2020",United States,https://ClinicalTrials.gov/show/NCT04352946
1379,1379,Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia,Recruiting,Drug: Favipiravir|Drug: Azithromycin,All,18 Years to 59 Years   (Adult),Phase 3,210.0,"October 15, 2020","December 31, 2020",Indonesia,https://ClinicalTrials.gov/show/NCT04613271
1380,1380,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Completed,Behavioral: Tele-interventions related to diabetes management and mental well-being,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,149.0,"April 17, 2020","September 20, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04344210
1381,1381,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),Not yet recruiting,Drug: CORVax|Drug: IL-12 plasmid|Device: Cliniporator,All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,December 2020,May 2022,United States,https://ClinicalTrials.gov/show/NCT04627675
1382,1382,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,Recruiting,Diagnostic Test: Pulmonary function testing,All,"18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,140.0,"May 18, 2020","August 18, 2025",France,https://ClinicalTrials.gov/show/NCT04519320
1383,1383,High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy,Not yet recruiting,Drug: Enoxaparin,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,300.0,June 2020,June 2021,Italy,https://ClinicalTrials.gov/show/NCT04408235
1384,1384,Zofin (Organicell Flow) for Patients With COVID-19,Recruiting,Biological: Zofin|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"September 8, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04384445
1385,1385,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Recruiting,Drug: Valsartan (Diovan)|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 4,651.0,"April 17, 2020",December 2021,Netherlands,https://ClinicalTrials.gov/show/NCT04335786
1386,1386,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Recruiting,Diagnostic Test: biological samples day of delivery,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"May 17, 2020","December 31, 2020",France,https://ClinicalTrials.gov/show/NCT04402918
1387,1387,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Recruiting,Biological: CAStem,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,9.0,"January 27, 2020",December 2020,China,https://ClinicalTrials.gov/show/NCT04331613
1388,1388,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,Recruiting,Dietary Supplement: Omnibiotic AAD|Dietary Supplement: Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,108.0,"September 24, 2020",December 2022,Austria,https://ClinicalTrials.gov/show/NCT04420676
1389,1389,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,Biological: Convalescent Plasma|Other: Placebo,All,65 Years and older   (Older Adult),Not Applicable,165.0,"June 4, 2020","November 2, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04479163
1390,1390,Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,Suspended,Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,116.0,November 2020,"June 30, 2021",China,https://ClinicalTrials.gov/show/NCT04310865
1391,1391,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Recruiting,Drug: Sevoflurane|Drug: Propofol,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 4,50.0,"April 16, 2020","April 30, 2021",Spain,https://ClinicalTrials.gov/show/NCT04359862
1392,1392,Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS,Not yet recruiting,Drug: Aviptadil 67μg|Drug: Placebo 0.9% NaCl solution,All,"18 Years and older   (Adult, Older Adult)",Phase 1,80.0,January 2021,March 2022,Switzerland,https://ClinicalTrials.gov/show/NCT04536350
1393,1393,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Recruiting,Other: Psychoeducational intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,66.0,"May 1, 2020",April 2023,Denmark,https://ClinicalTrials.gov/show/NCT04351789
1394,1394,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,Behavioral: e-Psychotherapy,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,80.0,"June 15, 2020",May 2021,Canada,https://ClinicalTrials.gov/show/NCT04476667
1395,1395,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Recruiting,Drug: Convalescent Plasma,All,"16 Years and older   (Child, Adult, Older Adult)",Phase 2,100.0,"May 5, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04392232
1396,1396,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,Other: Questionnaire,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,248.0,"July 21, 2020",August 2021,France,https://ClinicalTrials.gov/show/NCT04487171
1397,1397,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Recruiting,Radiation: Low dose radiation 35 cGy|Radiation: High dose radiation 100 cGy,All,"50 Years and older   (Adult, Older Adult)",Phase 2,100.0,"August 28, 2020","December 31, 2022",India,https://ClinicalTrials.gov/show/NCT04466683
1398,1398,Mindfulness During COVID-19,Recruiting,Behavioral: Mindfulness session(s),All,"Child, Adult, Older Adult",Not Applicable,200.0,"March 22, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04319445
1399,1399,Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Not yet recruiting,Other: samling of oropharynx and nasopharynx,All,"Child, Adult, Older Adult",Not Applicable,30.0,"April 20, 2020","May 20, 2020",Belgium,https://ClinicalTrials.gov/show/NCT04361448
1400,1400,Convalescent Plasma in the Treatment of COVID 19,Completed,Biological: Convalescent Plasma,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,48.0,"April 10, 2020","August 13, 2020",United States,https://ClinicalTrials.gov/show/NCT04343261
1401,1401,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,Recruiting,Biological: Emapalumab|Biological: Anakinra,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,54.0,"April 2, 2020",December 2020,Italy,https://ClinicalTrials.gov/show/NCT04324021
1402,1402,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Recruiting,Biological: Convalescent plasma,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,36.0,"June 25, 2020",June 2021,Argentina,https://ClinicalTrials.gov/show/NCT04468009
1403,1403,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,Recruiting,Drug: Rayaldee 30Mcg Extended-Release (ER) Capsule|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,160.0,"October 26, 2020",April 2021,United States,https://ClinicalTrials.gov/show/NCT04551911
1404,1404,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,Drug: Enoxaparin,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,130.0,"June 20, 2020","December 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04508439
1405,1405,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,Completed,Procedure: Therapeutic Plasma exchange|Biological: Convalescent Plasma|Drug: Tocilizumab|Drug: Remdesivir|Biological: Mesenchymal stem cell therapy,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,600.0,"April 1, 2020","July 20, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04492501
1406,1406,MSCs in COVID-19 ARDS,Recruiting,Biological: Remestemcel-L|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,300.0,"April 30, 2020",April 2022,Georgia,https://ClinicalTrials.gov/show/NCT04371393
1407,1407,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Enrolling by invitation,Diagnostic Test: qRT-PCR and serology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"September 24, 2020","May 30, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04527614
1408,1408,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Recruiting,Drug: N-acetylcysteine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200.0,"September 23, 2020","May 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04419025
1409,1409,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,"Active, not recruiting",Drug: Vitamin C|Drug: Vitamin E|Drug: Melatonin|Drug: N-acetyl cysteine|Drug: Pentoxifylline,All,"Child, Adult, Older Adult",Not Applicable,11.0,"August 19, 2020","November 15, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04570254
1410,1410,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Biological: Convalescent Plasma|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"September 1, 2020","September 1, 2022",Belgium,https://ClinicalTrials.gov/show/NCT04558476
1411,1411,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,Drug: Ivermectin,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50.0,"April 25, 2020","July 25, 2020",India,https://ClinicalTrials.gov/show/NCT04373824
1412,1412,COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2,Not yet recruiting,Other: Physiology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"October 4, 2020","May 4, 2023",Belgium,https://ClinicalTrials.gov/show/NCT04524156
1413,1413,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Biological: Human Amniotic Fluid,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10.0,"March 20, 2020","March 20, 2021",United States,https://ClinicalTrials.gov/show/NCT04319731
1414,1414,Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care,Suspended,Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C,All,"45 Years and older   (Adult, Older Adult)",Phase 4,13.0,"March 30, 2020","May 27, 2022",United States,https://ClinicalTrials.gov/show/NCT04334967
1415,1415,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,Behavioral: Personalized health education|Behavioral: General health education,All,"60 Years and older   (Adult, Older Adult)",Not Applicable,7576.0,"April 1, 2020","August 21, 2021",Hungary,https://ClinicalTrials.gov/show/NCT04321928
1416,1416,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,Recruiting,Biological: CT-P59/Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,1020.0,"September 25, 2020",September 2021,"Korea, Republic of",https://ClinicalTrials.gov/show/NCT04602000
1417,1417,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,"Active, not recruiting",Behavioral: Immediate vs. delayed provision of antibody test results,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1700.0,"September 14, 2020",December 2020,India,https://ClinicalTrials.gov/show/NCT04620798
1418,1418,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","Active, not recruiting",Biological: CT-P59,All,18 Years to 60 Years   (Adult),Phase 1,18.0,"September 4, 2020","December 23, 2020","Korea, Republic of",https://ClinicalTrials.gov/show/NCT04593641
1419,1419,Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID),Not yet recruiting,Drug: captopril 25mg,All,"18 Years and older   (Adult, Older Adult)",Phase 2,230.0,"May 5, 2020",August 2020,France,https://ClinicalTrials.gov/show/NCT04355429
1420,1420,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,10.0,"April 13, 2020",August 2020,Mexico,https://ClinicalTrials.gov/show/NCT04357106
1421,1421,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Enrolling by invitation,Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,152.0,"March 31, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04338009
1422,1422,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,Drug: Anluohuaxian,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,750.0,"April 1, 2020","December 1, 2020",China,https://ClinicalTrials.gov/show/NCT04334265
1423,1423,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,"Active, not recruiting",Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1363.0,"April 22, 2020",January 2021,United States,https://ClinicalTrials.gov/show/NCT04334148
1424,1424,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,Drug: Favipiravir,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,210.0,"April 1, 2020","September 15, 2020",China,https://ClinicalTrials.gov/show/NCT04333589
1425,1425,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Recruiting,Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,150.0,"March 8, 2020",May 2020,China,https://ClinicalTrials.gov/show/NCT04310228
1426,1426,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1700.0,"April 27, 2020","June 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04363450
1427,1427,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,129.0,"May 8, 2020","July 21, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04403685
1428,1428,"A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19",Recruiting,Biological: NGM621|Biological: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,48.0,"November 8, 2020",September 2021,Australia,https://ClinicalTrials.gov/show/NCT04582318
1429,1429,Hydroxychloroquine to Prevent SARS-CoV-2 Infection,Not yet recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,320.0,June 2020,October 2020,Peru,https://ClinicalTrials.gov/show/NCT04414241
1430,1430,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",Recruiting,Drug: Drug: NA-831|Combination Product: NA-831 and Atazanavir|Combination Product: NA-831and Dexamethasone|Combination Product: Atazanavir and Dexamethasone,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,525.0,"October 15, 2020","February 15, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04452565
1431,1431,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Recruiting,Drug: Defibrotide,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,12.0,"October 1, 2020","October 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04530604
1432,1432,"OD-doxy-PNV-COV Old Drug "" DOXY "" for Prevention of New Virus Virus OD-doxy-PNV",Recruiting,Drug: Doxycyclin,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,1100.0,"November 20, 2020","March 1, 2021",Tunisia,https://ClinicalTrials.gov/show/NCT04584567
1433,1433,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,Recruiting,Drug: Hyperbaric oxygen,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2|Phase 3,200.0,"June 3, 2020","December 31, 2022",Germany,https://ClinicalTrials.gov/show/NCT04327505
1434,1434,Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19),Not yet recruiting,Drug: Mavrilimumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,"May 22, 2020","November 22, 2020",Italy,https://ClinicalTrials.gov/show/NCT04397497
1435,1435,Host-pathogen Interactions During SARS-CoV-2 Infection,Recruiting,Biological: Blood sample|Biological: Low or upper respiratory tract sample|Biological: Stool collection or fecal swab|Genetic: Blood sample for whole genome sequencing|Other: phone call,All,"up to 70 Years   (Child, Adult, Older Adult)",Not Applicable,450.0,"May 5, 2020","June 5, 2021",France,https://ClinicalTrials.gov/show/NCT04376476
1436,1436,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Biological: CONVALESCENT PLASMA,All,"18 Years and older   (Adult, Older Adult)",Phase 2,1.0,"May 1, 2020","September 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04393727
1437,1437,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Completed,Device: COViage,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,197.0,"March 24, 2020","May 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04390516
1438,1438,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,Recruiting,Procedure: Prone Positioning (PP),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,596.0,"November 10, 2020","June 1, 2021",Canada,https://ClinicalTrials.gov/show/NCT04402879
1439,1439,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Recruiting,Radiation: Low Dose Radiation Therapy (LD-RT)|Other: Sham irradiation,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,22.0,"November 2, 2020",November 2021,Switzerland,https://ClinicalTrials.gov/show/NCT04598581
1440,1440,Anti-Androgen Treatment for COVID-19,Recruiting,Drug: Dutasteride|Drug: Nitazoxanide|Drug: Azithromycin|Drug: Proxalutamide,Male,"50 Years and older   (Adult, Older Adult)",Not Applicable,381.0,"July 2, 2020","January 31, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04446429
1441,1441,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Recruiting,Behavioral: 1: Prone positioning|Behavioral: 2: No instruction regarding positioning,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,500.0,"June 26, 2020",January 2021,France,https://ClinicalTrials.gov/show/NCT04366856
1442,1442,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Recruiting,Diagnostic Test: Blood sample,Female,"up to 45 Years   (Child, Adult)",Not Applicable,20.0,"June 24, 2020","June 15, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04425317
1443,1443,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Active, not recruiting",Drug: Ruxolitinib administration,All,"18 Years and older   (Adult, Older Adult)",Phase 2,15.0,"July 1, 2020",July 2021,Germany,https://ClinicalTrials.gov/show/NCT04359290
1444,1444,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,479.0,"April 2, 2020","July 23, 2020",Israel,https://ClinicalTrials.gov/show/NCT04332991
1445,1445,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Recruiting,Behavioral: General Communication Message|Behavioral: Focused/Targeted Message|Behavioral: Best Message Alone|Behavioral: Best Message + Augmented Message or Implementation Strategy,All,"5 Years to 90 Years   (Child, Adult, Older Adult)",Not Applicable,2500.0,"November 20, 2020","September 21, 2022",United States,https://ClinicalTrials.gov/show/NCT04565509
1446,1446,COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia,Not yet recruiting,Device: Helmet Continuous Positive Airway Pressure (CPAP)|Device: High Flow Nasal Oxygen (HFNO),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"February 15, 2021","May 15, 2022",United States,https://ClinicalTrials.gov/show/NCT04381923
1447,1447,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,Recruiting,Device: SCD,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30.0,"September 10, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04395911
1448,1448,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients",Recruiting,Other: Magnetic Resonance Spectroscopy (MRS).,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"September 8, 2020",May 2022,France,https://ClinicalTrials.gov/show/NCT04546737
1449,1449,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,"Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine",All,"18 Years and older   (Adult, Older Adult)",Phase 2,152.0,"March 26, 2020","December 31, 2020",France,https://ClinicalTrials.gov/show/NCT04366089
1450,1450,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,Recruiting,Biological: Convalescent anti-SARS-CoV-2 plasma|Other: Infusion placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1100.0,"May 1, 2020","June 15, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04345289
1451,1451,Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease,Not yet recruiting,Dietary Supplement: Lactoferrin (Apolactoferrin)|Drug: Placebo of excipient(s) will be administered,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,516.0,"June 1, 2020","September 30, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04412395
1452,1452,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Recruiting,Biological: Serology SARS-CoV2|Behavioral: Data collection,All,"Child, Adult, Older Adult",Not Applicable,400.0,"June 19, 2020",September 2021,France,https://ClinicalTrials.gov/show/NCT04442087
1453,1453,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,Recruiting,Drug: agenT-797,All,"18 Years and older   (Adult, Older Adult)",Phase 1,55.0,"September 21, 2020","October 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04582201
1454,1454,COVID-19 Convalescent Plasma,"Active, not recruiting",Biological: anti-SARS-CoV-2 convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,10.0,"April 10, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04340050
1455,1455,DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19),Not yet recruiting,Drug: DAS181|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,280.0,July 2020,September 2022,China,https://ClinicalTrials.gov/show/NCT04298060
1456,1456,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,"Diagnostic Test: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine",All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,200.0,"April 16, 2020",April 2021,United States,https://ClinicalTrials.gov/show/NCT04348864
1457,1457,Double Therapy With IFN-beta 1b and Hydroxychloroquine,Completed,Drug: Interferon Beta-1B|Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"April 9, 2020","July 7, 2020",Hong Kong,https://ClinicalTrials.gov/show/NCT04350281
1458,1458,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),Recruiting,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 2,2300.0,"May 14, 2020",March 2021,Italy,https://ClinicalTrials.gov/show/NCT04363827
1459,1459,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),Recruiting,Drug: LSALT peptide|Drug: Placebo,All,"45 Years to 80 Years   (Adult, Older Adult)",Phase 2,60.0,"October 14, 2020","June 30, 2021",Turkey,https://ClinicalTrials.gov/show/NCT04402957
1460,1460,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"Active, not recruiting",Drug: Placebos|Drug: Leronlimab (700mg),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,86.0,"April 1, 2020","August 31, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04343651
1461,1461,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,Recruiting,Behavioral: Daily Coping Toolkit,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,"May 1, 2020",April 2021,United States,https://ClinicalTrials.gov/show/NCT04398277
1462,1462,Glycine Supplement for Severe COVID-19,Recruiting,Dietary Supplement: Glycine,All,"Child, Adult, Older Adult",Not Applicable,82.0,"August 20, 2020","June 30, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04443673
1463,1463,Monovalent Recombinant COVID19 Vaccine,Recruiting,Biological: COVID19 vaccine|Biological: Saline,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40.0,"June 30, 2020","July 1, 2021",Australia,https://ClinicalTrials.gov/show/NCT04453852
1464,1464,Convalescent Plasma Therapy for COVID-19 Patients,"Active, not recruiting",Biological: convalescent plasma,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Early Phase 1,20.0,"May 1, 2020","December 30, 2020",Mali,https://ClinicalTrials.gov/show/NCT04565197
1465,1465,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Drug: Collagen-Polyvinylpyrrolidone,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,90.0,"August 19, 2020","June 19, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04517162
1466,1466,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil],All,"20 Years to 79 Years   (Adult, Older Adult)",Not Applicable,33.0,"April 1, 2020","May 31, 2020","Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan",https://ClinicalTrials.gov/show/NCT04384380
1467,1467,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption),All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,30.0,"March 27, 2020","November 26, 2020",Germany,https://ClinicalTrials.gov/show/NCT04324528
1468,1468,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Biological: ChAdOx1 nCoV-19|Biological: MenACWY|Biological: ChAdOx1 nCoV-19 full boost|Biological: ChAdOx1 nCoV-19 half boost|Biological: MenACWY boost|Drug: Paracetamol|Biological: ChAdOx1 nCoV-19 0.5mL boost,All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,1090.0,"April 23, 2020",October 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04324606
1469,1469,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Not yet recruiting,Other: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATION,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 14, 2020","April 14, 2022",France,https://ClinicalTrials.gov/show/NCT04349618
1470,1470,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Suspended,Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,122.0,"April 17, 2020","July 15, 2020",France,https://ClinicalTrials.gov/show/NCT04344379
1471,1471,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,Device: Nitric Oxide delivered via LungFit™ system,All,"22 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20.0,"June 13, 2020","September 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04397692
1472,1472,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,Not yet recruiting,Biological: BNT162b2|Other: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,960.0,December 2020,December 2021,China,https://ClinicalTrials.gov/show/NCT04649021
1473,1473,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),Recruiting,Drug: Placebos|Drug: Leronlimab (700mg),All,"18 Years and older   (Adult, Older Adult)",Phase 2,390.0,"April 15, 2020","April 1, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04347239
1474,1474,Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19,Recruiting,Drug: azoximer bromide|Other: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,394.0,"April 29, 2020",April 2021,Russian Federation,https://ClinicalTrials.gov/show/NCT04381377
1475,1475,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Recruiting,Behavioral: Behaviour Change Technique Intervention to Improve Quality of Life,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,969.0,"May 22, 2020","December 31, 2022",United Kingdom,https://ClinicalTrials.gov/show/NCT04522128
1476,1476,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",Drug: Oseltamivir|Drug: hormones|Device: oxygen therapy|Procedure: mesenchymal stem cells,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,60.0,"March 1, 2020","December 31, 2022",China,https://ClinicalTrials.gov/show/NCT04371601
1477,1477,Community Health Workers Against COVID19,Enrolling by invitation,Other: community health worker support|Other: care as usual,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,140.0,"May 21, 2020","October 30, 2020",Belgium,https://ClinicalTrials.gov/show/NCT04426305
1478,1478,Sevoflurane in COVID-19 ARDS (SevCov),Recruiting,Drug: Sevoflurane|Drug: Intravenous drug,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,64.0,"April 23, 2020","March 31, 2021",Switzerland,https://ClinicalTrials.gov/show/NCT04355962
1479,1479,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),Not yet recruiting,Drug: Oral-B Mouth Sore mouthwash|Drug: Crest Pro-Health Multi-Protection mouthwash|Drug: CloSYS mouthwash|Drug: Distilled water|Drug: Listerine Mouthwash Product,All,"18 Years and older   (Adult, Older Adult)",Phase 2,150.0,"December 7, 2020","November 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04409873
1480,1480,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine",Recruiting,Biological: SARS-CoV-2 vaccine (inactivated)|Biological: Placebo,All,18 Years to 59 Years   (Adult),Phase 3,1620.0,"August 10, 2020",September 2021,Indonesia,https://ClinicalTrials.gov/show/NCT04508075
1481,1481,Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption),All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,80.0,"September 1, 2020","October 31, 2021",Germany,https://ClinicalTrials.gov/show/NCT04385771
1482,1482,Tocilizumab in COVID-19 Lahore General Hospital,Recruiting,Drug: Tocilizumab,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Phase 1,50.0,"May 1, 2020","December 30, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04560205
1483,1483,Phase 1 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered as a Single Dose or a Repeat Dose in Healthy Adults,Recruiting,Biological: COVID-HIGIV|Other: Placebo (saline),All,18 Years to 60 Years   (Adult),Phase 1,56.0,December 2020,September 2021,United States,https://ClinicalTrials.gov/show/NCT04661839
1484,1484,The Impact of Camostat Mesilate on COVID-19 Infection,Recruiting,Drug: Camostat Mesilate|Drug: Placebo oral tablet,All,"18 Years to 110 Years   (Adult, Older Adult)",Phase 1|Phase 2,580.0,"April 4, 2020","May 1, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04321096
1485,1485,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""",Recruiting,Drug: Hydroxychloroquine Sulfate Tablets|Drug: Lopinavir/ Ritonavir Oral Tablet|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1968.0,"June 3, 2020","November 28, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04403100
1486,1486,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Recruiting,Other: EIT-Group|Other: ARDSNet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,128.0,"May 8, 2020","December 1, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04497454
1487,1487,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,Other: prone position,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,400.0,"August 28, 2020","August 28, 2022",France,https://ClinicalTrials.gov/show/NCT04363463
1488,1488,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,Completed,Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir,All,"16 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,40.0,"March 29, 2020","May 25, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04376814
1489,1489,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Active, not recruiting",Biological: BNT162b1|Other: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,144.0,"July 28, 2020",August 2021,China,https://ClinicalTrials.gov/show/NCT04523571
1490,1490,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Recruiting,Other: Pulmonary Rehabilitation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 30, 2020",January 2021,Turkey,https://ClinicalTrials.gov/show/NCT04642040
1491,1491,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Recruiting,Biological: BCG-Denmark|Biological: Saline,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 3,1500.0,"May 18, 2020","August 1, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04373291
1492,1492,A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19,Not yet recruiting,Biological: EQ001|Biological: EQ001 Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,800.0,November 2020,June 2021,Colombia,https://ClinicalTrials.gov/show/NCT04605926
1493,1493,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Recruiting,Other: Physiotherapy,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,34.0,"May 27, 2020","December 1, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04402983
1494,1494,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,Behavioral: Unified Protocol for COVID-19 Parenting Stress (UP-COVID)|Behavioral: SHG,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"May 15, 2020","November 17, 2020",United States,https://ClinicalTrials.gov/show/NCT04431856
1495,1495,Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,"Active, not recruiting",Drug: TNKase,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,45.0,"September 8, 2020","June 30, 2022",United States,https://ClinicalTrials.gov/show/NCT04558125
1496,1496,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,Drug: Plasma,All,18 Years to 60 Years   (Adult),Phase 2,10.0,"May 1, 2020","July 28, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04332380
1497,1497,The Containing Coronavirus Disease 19 (COVID-19) Trial,Recruiting,Biological: Peginterferon beta-1a,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 3,1240.0,"December 1, 2020",December 2021,Chile,https://ClinicalTrials.gov/show/NCT04552379
1498,1498,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Not yet recruiting,Drug: FX06|Drug: Placebo of FX06,All,"18 Years and older   (Adult, Older Adult)",Phase 2,50.0,November 2020,July 2021,France,https://ClinicalTrials.gov/show/NCT04618042
1499,1499,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),Recruiting,Biological: NasoVAX|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,96.0,"September 29, 2020",February 2021,United States,https://ClinicalTrials.gov/show/NCT04442230
1500,1500,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Recruiting,Device: FFP2|Device: Facial mask|Device: MFS,All,18 Years to 60 Years   (Adult),Not Applicable,10.0,May 2020,May 2020,Belgium,https://ClinicalTrials.gov/show/NCT04375774
1501,1501,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Recruiting,Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC),All,"18 Years to 84 Years   (Adult, Older Adult)",Phase 2,270.0,"April 24, 2020","September 28, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04380961
1502,1502,M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia,Recruiting,Drug: M5049|Drug: Placebo,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,150.0,"July 29, 2020","November 13, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04448756
1503,1503,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Recruiting,Drug: Selinexor|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,230.0,"April 17, 2020","August 31, 2020",Austria,https://ClinicalTrials.gov/show/NCT04349098
1504,1504,"REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19, the REHSCU Study",Not yet recruiting,Drug: Remimazolam,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,30.0,"November 1, 2020","May 1, 2021",France,https://ClinicalTrials.gov/show/NCT04611425
1505,1505,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Recruiting,Dietary Supplement: Viusid and Asbrip,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80.0,"May 4, 2020","August 7, 2020",Ecuador,https://ClinicalTrials.gov/show/NCT04407182
1506,1506,"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus",Recruiting,Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,250.0,"April 11, 2020","December 11, 2020",Israel,https://ClinicalTrials.gov/show/NCT04355052
1507,1507,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),Recruiting,Other: rapid serological test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"July 21, 2020",March 2021,France,https://ClinicalTrials.gov/show/NCT04492410
1508,1508,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Active, not recruiting",Drug: Cannabidiol|Other: PLACEBO,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,100.0,"July 6, 2020","December 16, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04467918
1509,1509,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Recruiting,Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,4000.0,"April 15, 2020","December 31, 2020",Spain,https://ClinicalTrials.gov/show/NCT04334928
1510,1510,Early Intervention in COVID-19: Favipiravir Verses Standard Care,Recruiting,Drug: Favipiravir|Other: Standard of care management,All,"18 Years and older   (Adult, Older Adult)",Phase 3,450.0,"May 1, 2020","March 31, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04373733
1511,1511,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19",Recruiting,Biological: INO-4800|Device: CELLECTRA® 2000|Other: Saline-sodium citrate (SSC) buffer,All,19 Years to 64 Years   (Adult),Phase 1|Phase 2,160.0,"July 15, 2020","February 22, 2022","Korea, Republic of",https://ClinicalTrials.gov/show/NCT04447781
1512,1512,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,Biological: Intravenous Infusions of Stem Cells,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,20.0,"June 1, 2020","June 30, 2021",Pakistan,https://ClinicalTrials.gov/show/NCT04437823
1513,1513,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,Procedure: Medical Ozone procedure,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,90.0,"April 8, 2020","October 8, 2020",Italy,https://ClinicalTrials.gov/show/NCT04388514
1514,1514,Anakinra in the Management of COVID-19 Infection,Recruiting,Drug: Anakinra|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,80.0,"October 30, 2020","October 30, 2021",Qatar,https://ClinicalTrials.gov/show/NCT04643678
1515,1515,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Recruiting,Drug: Melatonin 2mg|Drug: Placebo oral tablet,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,450.0,"April 20, 2020",December 2020,Spain,https://ClinicalTrials.gov/show/NCT04353128
1516,1516,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Recruiting,Dietary Supplement: Lactobaciltus rhamnosus GG|Dietary Supplement: Lactobaciltus rhamnosus GG Placebo,All,"1 Year and older   (Child, Adult, Older Adult)",Not Applicable,1000.0,"June 24, 2020","May 25, 2022",United States,https://ClinicalTrials.gov/show/NCT04399252
1517,1517,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,Recruiting,Device: Soterix taVNS model 0125-LTE Stimulator - Active-Active Group|Device: Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,30.0,"November 19, 2020",June 2021,United States,https://ClinicalTrials.gov/show/NCT04638673
1518,1518,A Study of Combination Therapies to Treat COVID-19 Infection,Not yet recruiting,Drug: hydroxychloroquine|Drug: Azithromycin|Drug: Ritonavir|Drug: Lopinavir,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,200.0,July 2020,December 2021,United States,https://ClinicalTrials.gov/show/NCT04459702
1519,1519,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Completed,"Other: ""Calm"" is a mindfulness meditation mobile app",Female,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,101.0,"April 13, 2020","November 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04329533
1520,1520,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study",Not yet recruiting,Drug: Single high dose vitamin D|Drug: Placebo|Drug: Treatment as usual vitamin D,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"December 1, 2020","June 30, 2021",Switzerland,https://ClinicalTrials.gov/show/NCT04525820
1521,1521,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,Device: Calm Meditation App,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,328.0,"May 15, 2020","October 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04374786
1522,1522,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,Recruiting,Drug: Nitazoxanide|Drug: Placebo Nitazoxanide|Drug: Ribavirin|Drug: Placebo Ribavirin|Drug: Hydroxychloroquine|Drug: Placebo Hydroxychloroquine,All,"21 Years and older   (Adult, Older Adult)",Phase 2,70.0,"December 2, 2020",April 2021,Jersey,https://ClinicalTrials.gov/show/NCT04605588
1523,1523,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Recruiting,Biological: Umbilical Cord Lining Stem Cells (ULSC)|Other: Placebo (carrier control),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,60.0,"July 23, 2020","November 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04494386
1524,1524,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,Drug: Plasma|Drug: Standard Therapy,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2|Phase 3,92.0,"August 8, 2020","November 15, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04332835
1525,1525,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,Recruiting,Drug: Part 1 - TL-895|Drug: Part 2 - TL-895|Drug: Part 2 - Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,146.0,"July 9, 2020",July 2021,Georgia,https://ClinicalTrials.gov/show/NCT04419623
1526,1526,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",Completed,Diagnostic Test: Rapid detection test|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Stool collection,All,"1 Month and older   (Child, Adult, Older Adult)",Not Applicable,600.0,"June 2, 2020","October 2, 2020",France,https://ClinicalTrials.gov/show/NCT04413968
1527,1527,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.",Recruiting,Drug: PF-07304814|Drug: Placebo,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1,56.0,"September 9, 2020","April 20, 2021",United States,https://ClinicalTrials.gov/show/NCT04535167
1528,1528,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,"Active, not recruiting",Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,29.0,"May 5, 2020","April 5, 2021",United States,https://ClinicalTrials.gov/show/NCT04374565
1529,1529,Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),Withdrawn,Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"April 30, 2020","November 4, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04361461
1530,1530,"Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",Terminated,Drug: Pemziviptadil (PB1046)|Drug: Low Dose (10 mg) Control,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,54.0,"July 15, 2020","December 2, 2020",United States,https://ClinicalTrials.gov/show/NCT04433546
1531,1531,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,Drug: vadadustat|Drug: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"August 22, 2020","August 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04478071
1532,1532,STerOids in COVID-19 Study,Recruiting,Drug: Budesonide dry powder inhaler,All,"18 Years and older   (Adult, Older Adult)",Phase 2,478.0,"July 16, 2020","December 30, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04416399
1533,1533,The MentalPlus® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,Recruiting,Device: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19,All,"8 Years to 88 Years   (Child, Adult, Older Adult)",Not Applicable,200.0,"November 8, 2020","December 29, 2023",Brazil,https://ClinicalTrials.gov/show/NCT04632719
1534,1534,Cyclosporine For The Treatment Of COVID-19(+),Recruiting,Drug: Cyclosporine|Other: Standard of Care Treatment,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,75.0,"November 23, 2020","November 23, 2025",United States,https://ClinicalTrials.gov/show/NCT04492891
1535,1535,A Study of ResCure™ to Treat COVID-19 Infection,Not yet recruiting,Biological: ResCure™,All,"18 Years and older   (Adult, Older Adult)",Phase 1,50.0,July 2020,November 2021,United States,https://ClinicalTrials.gov/show/NCT04395716
1536,1536,Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,Drug: Losartan|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,200.0,"April 13, 2020","April 1, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04312009
1537,1537,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,600.0,"June 22, 2020",September 2021,United States,https://ClinicalTrials.gov/show/NCT04335084
1538,1538,Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,Enrolling by invitation,Behavioral: MenCare+/Bandebereho fathers'/couples' group education,All,26 Years to 40 Years   (Adult),Not Applicable,1000.0,June 2020,August 2020,Rwanda,https://ClinicalTrials.gov/show/NCT04442152
1539,1539,Randomised Evaluation of COVID-19 Therapy,Recruiting,Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab|Biological: Immunoglobulin|Drug: Synthetic neutralising antibodies|Drug: Aspirin|Drug: Colchicine,All,"Child, Adult, Older Adult",Phase 2|Phase 3,20000.0,"March 19, 2020",December 2031,United Kingdom,https://ClinicalTrials.gov/show/NCT04381936
1540,1540,Trial of Treatments for COVID-19 in Hospitalized Adults,Recruiting,Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3100.0,"March 22, 2020",March 2023,Austria,https://ClinicalTrials.gov/show/NCT04315948
1541,1541,Losartan for Patients With COVID-19 Not Requiring Hospitalization,"Active, not recruiting",Drug: Losartan|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,580.0,"April 9, 2020","April 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04311177
1542,1542,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Drug: EIDD-2801|Drug: Placebo (PB0),All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"June 16, 2020","March 12, 2021",United States,https://ClinicalTrials.gov/show/NCT04405739
1543,1543,Nebulised Rt-PA for ARDS Due to COVID-19,Recruiting,Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA),All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2,24.0,"April 22, 2020","January 14, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04356833
1544,1544,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Recruiting,Drug: Methylprednisolone Injectable Product,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200.0,"May 1, 2020","December 30, 2020",Mali,https://ClinicalTrials.gov/show/NCT04559113
1545,1545,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,"Active, not recruiting",Drug: Budesonide Nasal|Other: Physiological serum,All,"18 Years and older   (Adult, Older Adult)",Phase 3,120.0,"May 18, 2020","May 25, 2021",France,https://ClinicalTrials.gov/show/NCT04361474
1546,1546,DUR-928 in Subjects With SARS-CoV-2 With Acute Liver or Kidney Injury,Recruiting,Drug: DUR-928|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,80.0,"September 21, 2020",October 2021,Jersey,https://ClinicalTrials.gov/show/NCT04447404
1547,1547,Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19,Recruiting,"Drug: Cannabis, Medical",All,"7 Years and older   (Child, Adult, Older Adult)",Phase 2,200000.0,"December 1, 2018","December 31, 2025",United States,https://ClinicalTrials.gov/show/NCT03944447
1548,1548,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,Behavioral: RECHARGE|Behavioral: Self Study,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,160.0,"August 28, 2020","June 1, 2021",Switzerland,https://ClinicalTrials.gov/show/NCT04531774
1549,1549,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,54.0,"May 27, 2020","November 15, 2020",United States,https://ClinicalTrials.gov/show/NCT04652648
1550,1550,Trial of Combination Therapy to Treat COVID-19 Infection,Recruiting,Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,300.0,"December 9, 2020",July 2021,United States,https://ClinicalTrials.gov/show/NCT04482686
1551,1551,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",Recruiting,Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir,All,"18 Years and older   (Adult, Older Adult)",Phase 4,400.0,"February 1, 2020","July 1, 2020",China,https://ClinicalTrials.gov/show/NCT04255017
1552,1552,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",Recruiting,Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,"February 1, 2020","July 1, 2020",China,https://ClinicalTrials.gov/show/NCT04254874
1553,1553,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Recruiting,Drug: Colchicine,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,310.0,"April 20, 2020","December 21, 2020",Italy,https://ClinicalTrials.gov/show/NCT04322565
1554,1554,Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,Drug: Ibrutinib|Other: Quality-of-Life Assessment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,134.0,"December 31, 2020","May 1, 2025",United States,https://ClinicalTrials.gov/show/NCT04665115
1555,1555,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,Recruiting,Drug: APL-9|Other: Vehicle Control,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,66.0,"May 28, 2020",November 2020,Brazil,https://ClinicalTrials.gov/show/NCT04402060
1556,1556,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,Enrolling by invitation,Biological: Biological: oral polio vaccine|Biological: Comparable Placebo|Drug: NA-831|Drug: Comparable Placebo of drug|Combination Product: Combination of oral polio vaccine and NA-831|Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug,All,"18 Years and older   (Adult, Older Adult)",Phase 3,3600.0,"November 1, 2020","December 31, 2022",New Zealand,https://ClinicalTrials.gov/show/NCT04540185
1557,1557,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Enrolling by invitation,Behavioral: Shared Decision Making,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,800.0,"September 10, 2020","May 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04548531
1558,1558,The COGCOV Study in ICU Patients,Recruiting,Behavioral: Neurocognitive assessment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"October 7, 2020","February 28, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04593069
1559,1559,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Completed,Other: Pulmonary Physiotherapy Techniques,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40.0,"April 2, 2020","May 30, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04357340
1560,1560,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Recruiting,Drug: Ophtamesone,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,250.0,"August 1, 2020","October 15, 2020",Iraq,https://ClinicalTrials.gov/show/NCT04569825
1561,1561,OPV as Potential Protection Against COVID-19,Enrolling by invitation,Biological: oral polio vaccine + information|Behavioral: Information,All,"50 Years and older   (Adult, Older Adult)",Phase 4,3400.0,"July 15, 2020",June 2021,Guinea,https://ClinicalTrials.gov/show/NCT04445428
1562,1562,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Recruiting,Drug: Linagliptin 5 MG,All,"18 Years and older   (Adult, Older Adult)",Phase 3,100.0,"October 1, 2020","September 30, 2021",Israel,https://ClinicalTrials.gov/show/NCT04371978
1563,1563,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,Drug: virgin coconut oil (VCO)|Other: placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"June 1, 2020","December 31, 2020",Indonesia,https://ClinicalTrials.gov/show/NCT04594330
1564,1564,Tocilizumab for Patients With Cancer and COVID-19 Disease,Suspended,Biological: Tocilizumab,All,"2 Years and older   (Child, Adult, Older Adult)",Phase 2,217.0,"May 28, 2020","April 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04370834
1565,1565,Effects of DPP4 Inhibition on COVID-19,Not yet recruiting,Drug: Linagliptin|Drug: Insulin regimen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,20.0,"January 30, 2021","December 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04341935
1566,1566,Birth Experience During COVID-19 Confinement,Recruiting,Other: Self-administered questionnaires,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,927.0,"April 16, 2020","October 1, 2021",France,https://ClinicalTrials.gov/show/NCT04348929
1567,1567,"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020",Recruiting,Behavioral: Chat-based support|Behavioral: AWARD plus COVID-specific advice|Behavioral: AWARD advice|Behavioral: COVID-19 related health warning leaflet|Behavioral: Health warning leaflet|Behavioral: SMS-based support|Behavioral: Referral card|Behavioral: COSH Self-help smoking cessation booklet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,842.0,"June 13, 2020","June 30, 2022",China,https://ClinicalTrials.gov/show/NCT04399967
1568,1568,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,Other: Yoga,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"May 20, 2020","December 31, 2020",Jersey,https://ClinicalTrials.gov/show/NCT04414371
1569,1569,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",Other: SARS-Cov-2 infection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,54.0,"April 8, 2020","June 9, 2021",Italy,https://ClinicalTrials.gov/show/NCT04343053
1570,1570,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Not yet recruiting,Biological: Mesenchymal stem cell,All,"20 Years and older   (Adult, Older Adult)",Phase 1,6.0,September 2020,December 2021,Japan,https://ClinicalTrials.gov/show/NCT04522986
1571,1571,ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic,Recruiting,Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,554.0,"April 9, 2020","August 9, 2020",France,https://ClinicalTrials.gov/show/NCT04329195
1572,1572,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,Other: Prone position,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,248.0,"May 13, 2020",June 2021,Spain,https://ClinicalTrials.gov/show/NCT04391140
1573,1573,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,Recruiting,Biological: CYNK-001,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,86.0,"May 13, 2020","June 30, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04365101
1574,1574,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",Recruiting,Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir,All,18 Years to 55 Years   (Adult),Phase 3,60.0,"February 1, 2020","July 1, 2020",China,https://ClinicalTrials.gov/show/NCT04261270
1575,1575,"Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box""",Recruiting,Device: Aerosol Box|Device: Intubation Box,All,"Child, Adult, Older Adult",Not Applicable,30.0,"May 15, 2020","December 30, 2020",Malaysia,https://ClinicalTrials.gov/show/NCT04385576
1576,1576,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Terminated,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,70.0,"March 25, 2020","August 17, 2020",Canada,https://ClinicalTrials.gov/show/NCT04421664
1577,1577,Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN),Not yet recruiting,Diagnostic Test: carotid-femoral pulse-wave velocity,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,360.0,September 2020,June 2032,France,https://ClinicalTrials.gov/show/NCT04558450
1578,1578,TOFAcitinib in SARS-CoV2 Pneumonia,Not yet recruiting,Drug: Tofacitinib,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50.0,"April 10, 2020","July 10, 2020",Italy,https://ClinicalTrials.gov/show/NCT04332042
1579,1579,The New Silicone N99 Half-Piece Respirator,Completed,Device: Fit test|Device: Filtration Test,All,18 Years to 60 Years   (Adult),Not Applicable,43.0,"May 1, 2020","May 31, 2020",Thailand,https://ClinicalTrials.gov/show/NCT04454606
1580,1580,Remdesivir vs Chloroquine in Coronavirus Disease,Recruiting,Drug: Chloroquine or hydroxychloroquine|Drug: Remdesivir,All,"Child, Adult, Older Adult",Phase 2|Phase 3,120.0,"June 16, 2020",December 2029,Egypt,https://ClinicalTrials.gov/show/NCT04345419
1581,1581,"This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19",Recruiting,Drug: ADM03820|Other: Placebo,All,18 Years to 55 Years   (Adult),Phase 1,40.0,"December 4, 2020","September 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04592549
1582,1582,University of Utah COVID-19 Hydrochloroquine Trial,Recruiting,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,"April 4, 2020",April 2022,United States,https://ClinicalTrials.gov/show/NCT04342169
1583,1583,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,Recruiting,Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,700.0,"March 28, 2020",November 2020,Norway,https://ClinicalTrials.gov/show/NCT04321616
1584,1584,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Enrolling by invitation,Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"May 11, 2020","June 30, 2021",Belarus,https://ClinicalTrials.gov/show/NCT04382547
1585,1585,Clinical Use of Stem Cells for the Treatment of Covid-19,Recruiting,Biological: MSC Treatment|Biological: Saline Control,All,40 Years to 60 Years   (Adult),Phase 1|Phase 2,30.0,"April 1, 2020",September 2020,Turkey,https://ClinicalTrials.gov/show/NCT04392778
1586,1586,Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,Not yet recruiting,Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,March 2020,November 2020,Italy,https://ClinicalTrials.gov/show/NCT04316728
1587,1587,"Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2",Not yet recruiting,Drug: metformin glycinate|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"November 30, 2020","March 31, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04626089
1588,1588,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,Biological: Convalescent Plasma,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,30.0,"March 28, 2020","September 30, 2020","Iran, Islamic Republic of",https://ClinicalTrials.gov/show/NCT04327349
1589,1589,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","Active, not recruiting",Behavioral: Brief educational video,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2500.0,"May 8, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04373135
1590,1590,Telerehabilitation After Coronavirus,Recruiting,Other: Aerobic Exercise Training|Behavioral: Patient Education|Other: Respiratory Exercise Training,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,36.0,"June 19, 2020","December 19, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04473898
1591,1591,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,Recruiting,Drug: Methylprednisolone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,100.0,"February 1, 2020","July 1, 2020",China,https://ClinicalTrials.gov/show/NCT04263402
1592,1592,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Recruiting,Drug: Alteplase 50 MG [Activase],All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60.0,"May 14, 2020",November 2021,Israel,https://ClinicalTrials.gov/show/NCT04357730
1593,1593,Convalescent Plasma Therapy in Patients With COVID-19,Completed,Biological: Convalescent plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 1,10.0,"May 1, 2020","June 22, 2020",Indonesia,https://ClinicalTrials.gov/show/NCT04407208
1594,1594,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Recruiting,Procedure: Human biological samples,All,"Child, Adult, Older Adult",Not Applicable,1300.0,"March 23, 2020","March 23, 2022",French Guiana,https://ClinicalTrials.gov/show/NCT04328129
1595,1595,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,Recruiting,Drug: Therapeutic anticoagulation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,462.0,"July 4, 2020","December 31, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04444700
1596,1596,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants",Recruiting,Biological: SAB-185|Other: Normal saline,All,18 Years to 60 Years   (Adult),Phase 1,28.0,"August 5, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04468958
1597,1597,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Recruiting,Biological: BCG-Denmark|Biological: Saline,All,65 Years to 110 Years   (Older Adult),Phase 3,1900.0,"September 15, 2020",March 2022,Denmark,https://ClinicalTrials.gov/show/NCT04542330
1598,1598,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Recruiting,Other: NaCl Solution,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,405.0,"June 23, 2020","October 31, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04382131
1599,1599,Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact,Not yet recruiting,Behavioral: psychological assessment,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,April 2020,June 2020,France,https://ClinicalTrials.gov/show/NCT04366817
1600,1600,Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,Not yet recruiting,Drug: Nebulised heparin,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,September 2020,January 2022,Ireland,https://ClinicalTrials.gov/show/NCT04511923
1601,1601,Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,Recruiting,Drug: Nintedanib 150 MG [Ofev]|Other: Placebo,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 3,250.0,"October 29, 2020",December 2021,France,https://ClinicalTrials.gov/show/NCT04541680
1602,1602,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,Procedure: Robot Assisted Percutaneous Cardiovascular Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"April 27, 2020","April 27, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04379453
1603,1603,Investigating a Vaccine Against COVID-19,Recruiting,Biological: ChAdOx1 nCoV-19 (Abs 260)|Biological: MenACWY vaccine|Biological: ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|Biological: Two dose MenACWY vaccine|Biological: ChAdOx1 nCoV-19 (qPCR)|Biological: ChAdOx1 nCoV-19 0.5mL prime plus boost|Biological: Two dose MenACWY vaccine min. 4 weeks apart|Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Biological: Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,12390.0,"May 28, 2020",September 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04400838
1604,1604,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),Recruiting,Biological: MultiStem|Biological: Placebo,All,"18 Years to 89 Years   (Adult, Older Adult)",Phase 2|Phase 3,400.0,"April 28, 2020",August 2022,United States,https://ClinicalTrials.gov/show/NCT04367077
1605,1605,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,Other: EPIC risk score display,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,1200.0,"May 15, 2020","May 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04570488
1606,1606,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,"Active, not recruiting",Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,47.0,"April 6, 2020","April 6, 2022",France,https://ClinicalTrials.gov/show/NCT04333368
1607,1607,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Recruiting,Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Drug: Group 2: control group with enoxaparin 40mg/d,All,"18 Years and older   (Adult, Older Adult)",Phase 4,600.0,"June 21, 2020",December 2020,Brazil,https://ClinicalTrials.gov/show/NCT04394377
1608,1608,A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19,Suspended,Drug: SNDX-6352|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,186.0,"May 30, 2020","November 15, 2020",United States,https://ClinicalTrials.gov/show/NCT04415073
1609,1609,Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19),Recruiting,Biological: Human umbilical cord derived CD362 enriched MSCs|Biological: Placebo (Plasma-Lyte 148),All,"16 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,75.0,"January 7, 2019",October 2022,Ireland,https://ClinicalTrials.gov/show/NCT03042143
1610,1610,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Recruiting,Other: Best Practice|Drug: Ibrutinib,All,"18 Years and older   (Adult, Older Adult)",Phase 2,72.0,"July 22, 2020","December 31, 2022",United States,https://ClinicalTrials.gov/show/NCT04439006
1611,1611,Improving Thinking in Everyday Life After Covid-19,Recruiting,Behavioral: Speed of Processing Training|Behavioral: Instrumental Activities of Daily Living Shaping|Behavioral: Transfer Package from CI Therapy|Other: Usual Care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,40.0,"November 1, 2020",November 2024,United States,https://ClinicalTrials.gov/show/NCT04644172
1612,1612,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,106.0,"June 5, 2020","July 1, 2021",Spain,https://ClinicalTrials.gov/show/NCT04380818
1613,1613,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,140.0,"May 11, 2020","August 20, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04340349
1614,1614,RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM,Recruiting,Drug: Doxycycline|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"June 22, 2020",July 2021,United States,https://ClinicalTrials.gov/show/NCT04433078
1615,1615,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Drug: Darunavir and Cobicistat,All,"Child, Adult, Older Adult",Phase 3,30.0,"January 30, 2020","December 31, 2020",China,https://ClinicalTrials.gov/show/NCT04252274
1616,1616,Remote Monitoring of Cancer Patients With Suspected Covid-19,Not yet recruiting,Device: Patient Status Engine,All,"18 Years and older   (Adult, Older Adult)",Phase 1,30.0,June 2020,October 2020,United Kingdom,https://ClinicalTrials.gov/show/NCT04397705
1617,1617,BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization,Recruiting,Drug: Bromhexine and Spironolactone|Drug: Base therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 3,80.0,"May 16, 2020","August 23, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04424134
1618,1618,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,"Active, not recruiting",Drug: Nitric Oxide-Sessions|Drug: Nitric Oxide-Continuous and Sessions,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"July 24, 2020","September 17, 2021",Russian Federation,https://ClinicalTrials.gov/show/NCT04476992
1619,1619,The Use of Lung Ultrasonography in COVID-19 Patients,Recruiting,Behavioral: mechanical ventilator settings and position,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 26, 2020","August 10, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04432051
1620,1620,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Recruiting,Drug: Nitric Oxide,All,"18 Years and older   (Adult, Older Adult)",Phase 2,70.0,"March 21, 2020","April 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04305457
1621,1621,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Recruiting,Other: Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,4000.0,"May 20, 2020","October 30, 2020",France,https://ClinicalTrials.gov/show/NCT04401046
1622,1622,Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention,Withdrawn,Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe|Device: Ultrasound of the lower limbs,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0.0,"May 2, 2020","July 10, 2020",France,https://ClinicalTrials.gov/show/NCT04520620
1623,1623,COVID-19 Ad Intervention,Not yet recruiting,Behavioral: Social Distancing Advertisements,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,52500.0,"September 29, 2020","July 28, 2022",United States,https://ClinicalTrials.gov/show/NCT04555122
1624,1624,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Drug: Ruxolitinib plus simvastatin|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,94.0,"April 12, 2020","May 13, 2020",Spain,https://ClinicalTrials.gov/show/NCT04348695
1625,1625,Understanding Reactions to Emotional Material in the Media During COVID-19,Recruiting,Behavioral: Simple cognitive task intervention|Behavioral: Attention Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,66.0,"October 28, 2020","January 15, 2021",Sweden,https://ClinicalTrials.gov/show/NCT04608097
1626,1626,"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.",Not yet recruiting,Drug: Baricitinib,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,200.0,"May 16, 2020","July 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04320277
1627,1627,Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals,Withdrawn,Drug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tablet,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,0.0,"April 28, 2020","July 15, 2020",Tunisia,https://ClinicalTrials.gov/show/NCT04349228
1628,1628,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,Recruiting,Behavioral: Remote Cognitive Behavioral Therapy for Insomnia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"June 7, 2020",November 2021,United States,https://ClinicalTrials.gov/show/NCT04409743
1629,1629,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,Enrolling by invitation,Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,520.0,"April 8, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04342728
1630,1630,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Recruiting,Behavioral: HADS|Behavioral: a survey,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,200.0,"May 18, 2020","January 1, 2021",Belgium,https://ClinicalTrials.gov/show/NCT04406181
1631,1631,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Recruiting,Biological: blood tests|Biological: Nasopharyngeal swabs|Biological: Stools,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"June 11, 2020",December 2023,France,https://ClinicalTrials.gov/show/NCT04584541
1632,1632,Timing of Tracheotomy in Covid-19 Patients,Recruiting,Procedure: Tracheotomy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180.0,"June 4, 2020","February 1, 2021",Sweden,https://ClinicalTrials.gov/show/NCT04412356
1633,1633,"Hydroxychloroquine, Azithromycin and Zinc for the Treatment of COVID-19 in the Outpatient Setting",Not yet recruiting,Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Sulfate 220 MG|Drug: Placebo,All,"30 Years and older   (Adult, Older Adult)",Phase 4,750.0,November 2020,May 2021,United States,https://ClinicalTrials.gov/show/NCT04621461
1634,1634,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,Completed,Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 2,152.0,"April 8, 2020","June 8, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04342650
1635,1635,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Completed,Behavioral: Ultra Brief Online Mindfulness-based Intervention|Behavioral: Control,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,161.0,"April 1, 2020","June 30, 2020",Malaysia,https://ClinicalTrials.gov/show/NCT04536441
1636,1636,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,Recruiting,Other: Tele-medicine platform,All,"Child, Adult, Older Adult",Not Applicable,200.0,"March 31, 2020","October 1, 2020",Romania,https://ClinicalTrials.gov/show/NCT04325867
1637,1637,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Recruiting,Other: ICU Recovery + Physical Therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"May 1, 2020","May 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04412330
1638,1638,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",Recruiting,Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab|Drug: Vitamin C|Drug: Therapeutic anticoagulation|Drug: Simvastatin|Biological: Convalescent plasma|Other: Protocolised mechanical ventilation strategy|Drug: Eritoran|Drug: Apremilast|Drug: Aspirin|Drug: Clopidogrel|Drug: Prasugrel|Drug: Ticagrelor,All,"18 Years and older   (Adult, Older Adult)",Phase 4,7100.0,"April 11, 2016",December 2023,Australia,https://ClinicalTrials.gov/show/NCT02735707
1639,1639,Yoga Pranayama Adjuvant to Treat Burden COVID-19,Not yet recruiting,Behavioral: morning Yoga-based breathing support|Behavioral: pre_lunch Yoga-based breathing support|Behavioral: pre_dinner Yoga-based breathing support,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,1000.0,"August 15, 2020","September 30, 2021",Italy,https://ClinicalTrials.gov/show/NCT04413747
1640,1640,Plasma Adsorption in Patients With Confirmed COVID-19,Recruiting,Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"May 20, 2020","December 1, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04358003
1641,1641,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Completed,Device: Intravenous access|Device: Intraosseous access,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,41.0,"January 12, 2020","February 25, 2020",Poland,https://ClinicalTrials.gov/show/NCT04366297
1642,1642,CBD Oil for Reducing Emotional Impact of COVID-19,Recruiting,Dietary Supplement: CBD Isolate|Dietary Supplement: Full Spectrum CBD Oil|Dietary Supplement: Placebo Oil,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"December 4, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04603781
1643,1643,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),"Active, not recruiting",Biological: COVID-19 Specific T Cell derived exosomes (CSTC-Exo),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,60.0,"May 1, 2020","May 31, 2021",Turkey,https://ClinicalTrials.gov/show/NCT04389385
1644,1644,Fostamatinib for Hospitalized Adults With COVID-19,Recruiting,Drug: Placebo|Drug: fostamatinib,All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,"October 8, 2020","December 15, 2020",United States,https://ClinicalTrials.gov/show/NCT04579393
1645,1645,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab,All,"18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,15.0,"April 21, 2020","April 21, 2021",Spain,https://ClinicalTrials.gov/show/NCT04394182
1646,1646,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,"Active, not recruiting",Diagnostic Test: pulmonary anomalies 4 months after documented COVID-19 pneumonia,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,73.0,"May 28, 2020",May 2022,France,https://ClinicalTrials.gov/show/NCT04422613
1647,1647,COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial,Recruiting,Drug: Colchicine|Drug: Ruxolitinib 5 MG|Drug: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Other: standard therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,70.0,"May 8, 2020","August 23, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04403243
1648,1648,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,"Active, not recruiting",Behavioral: Peer Resilience Champion|Behavioral: Enriched Survey Feedback,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,882.0,"July 27, 2020",February 2022,Canada,https://ClinicalTrials.gov/show/NCT04373382
1649,1649,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Recruiting,Other: Collection of samples,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"June 16, 2020",June 2021,France,https://ClinicalTrials.gov/show/NCT04361396
1650,1650,Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device,Not yet recruiting,Device: Hemopurifier,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,October 2020,August 2021,United States,https://ClinicalTrials.gov/show/NCT04595903
1651,1651,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 3,299.0,"April 13, 2020","July 22, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04327401
1652,1652,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Terminated,Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,7.0,"April 11, 2020","June 8, 2020",France,https://ClinicalTrials.gov/show/NCT04345861
1653,1653,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,Recruiting,Drug: XAV-19|Drug: Placebo,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,414.0,"September 1, 2020",December 2021,France,https://ClinicalTrials.gov/show/NCT04453384
1654,1654,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Recruiting,Drug: Canakinumab|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,116.0,"October 23, 2020",September 2023,Switzerland,https://ClinicalTrials.gov/show/NCT04510493
1655,1655,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","Active, not recruiting",Biological: Gam-COVID-Vac,All,"60 Years to 111 Years   (Adult, Older Adult)",Phase 2,110.0,"October 22, 2020","December 31, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04587219
1656,1656,The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19,Recruiting,Drug: Nintedanib|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,120.0,November 2020,July 2021,Israel,https://ClinicalTrials.gov/show/NCT04619680
1657,1657,Remdesivir in COVID-19 Lahore General Hospital,Recruiting,Drug: Remdesivir,All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Early Phase 1,30.0,"June 1, 2020","November 30, 2020",Mali,https://ClinicalTrials.gov/show/NCT04560231
1658,1658,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Completed,Drug: Bevacizumab Injection,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,27.0,"February 15, 2020","May 2, 2020",China,https://ClinicalTrials.gov/show/NCT04275414
1659,1659,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",Recruiting,Diagnostic Test: COVID 19 diagnostic test by PCR,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,3600.0,"April 17, 2020",April 2022,France,https://ClinicalTrials.gov/show/NCT04360811
1660,1660,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Completed,Procedure: Therapeutic Plasma Exchange,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,280.0,"April 1, 2020","July 31, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04485169
1661,1661,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,Recruiting,Biological: Otilimab|Biological: Placebo|Drug: Standard of care,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 2,800.0,"May 28, 2020","December 21, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04376684
1662,1662,Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19,Enrolling by invitation,Behavioral: Cognitive Behavioral Brief-Telepsychotherapy|Behavioral: Brief Interpersonal Telepsychotherapy|Behavioral: Telepsychoeducation,All,"Child, Adult, Older Adult",Not Applicable,999.0,"November 5, 2020","July 20, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04635618
1663,1663,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Recruiting,Procedure: Awake Prone Positioning|Procedure: Standard care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,346.0,"May 15, 2020","December 31, 2020",Canada,https://ClinicalTrials.gov/show/NCT04395144
1664,1664,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Not yet recruiting,Behavioral: Phone-call screening and management by a medical student/general practitioner tandem,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,22000.0,April 2020,December 2020,France,https://ClinicalTrials.gov/show/NCT04359875
1665,1665,Tele-health Enabled Clinical Trial for COVID-19,Not yet recruiting,Drug: Vitamin D3 or Placebo|Device: Doctella telehealth monitoring,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,110.0,"August 1, 2020","August 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04489628
1666,1666,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns",Recruiting,Diagnostic Test: identify SARS-CoV-2 infection by serology|Biological: collection of biological samples,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,2200.0,"May 4, 2020","August 31, 2021",France,https://ClinicalTrials.gov/show/NCT04355234
1667,1667,High Flow Nasal Cannula HFNC In Covid-19 Patients,Recruiting,Device: High flow nasal cannula HFNC,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30.0,"May 1, 2020","December 30, 2020",Mali,https://ClinicalTrials.gov/show/NCT04560257
1668,1668,COVID-19 Health Messaging to Underserved Communities,Completed,Behavioral: Messaging,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15475.0,"May 13, 2020","May 24, 2020",United States,https://ClinicalTrials.gov/show/NCT04371419
1669,1669,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,Recruiting,Behavioral: Intervention program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,102.0,"May 25, 2020","March 25, 2021",Spain,https://ClinicalTrials.gov/show/NCT04394169
1670,1670,eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19,"Active, not recruiting",Behavioral: eHealth +counselling contacts|Behavioral: eHealth|Behavioral: Usual care,All,"20 Years to 69 Years   (Adult, Older Adult)",Not Applicable,122.0,"March 6, 2019","October 31, 2020",Finland,https://ClinicalTrials.gov/show/NCT04587414
1671,1671,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Recruiting,Drug: Povidone-Iodine|Drug: Normal saline,All,"18 Years and older   (Adult, Older Adult)",Phase 1,40.0,May 2020,August 2020,United Kingdom,https://ClinicalTrials.gov/show/NCT04393792
1672,1672,"General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to COVID-19",Not yet recruiting,Behavioral: Medical Music|Behavioral: Narrative Writing|Behavioral: Prolonged Exposure Therapy|Behavioral: Interpersonal Psychotherapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,November 2020,September 2021,United States,https://ClinicalTrials.gov/show/NCT04626050
1673,1673,A Study of Auxora in Patients With Critical COVID-19 Pneumonia,Not yet recruiting,Drug: CM4620-IE (Injectable Emulsion)|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,36.0,December 2020,April 2021,United States,https://ClinicalTrials.gov/show/NCT04661540
1674,1674,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Recruiting,Drug: Auxora|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400.0,"April 8, 2020",April 2021,Puerto Rico,https://ClinicalTrials.gov/show/NCT04345614
1675,1675,GERAS Frailty Rehabilitation at Home During COVID-19,Recruiting,Behavioral: Socialization|Behavioral: Virtual Group Exercise|Combination Product: Nutrition Consult and Protein Supplementation|Behavioral: Medication Review,All,65 Years and older   (Older Adult),Not Applicable,70.0,"August 26, 2020",May 2021,Canada,https://ClinicalTrials.gov/show/NCT04500366
1676,1676,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Recruiting,Drug: Dornase Alfa Inhalation Solution,All,"18 Years and older   (Adult, Older Adult)",Phase 3,20.0,"June 19, 2020","May 31, 2022",United States,https://ClinicalTrials.gov/show/NCT04402970
1677,1677,COVID-19 and the Healthy Minds Program for Educators,Recruiting,Behavioral: Healthy Minds Program Foundations Training,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"June 14, 2020","June 30, 2022",United States,https://ClinicalTrials.gov/show/NCT04426318
1678,1678,W-SUDs for COVID-19,Recruiting,Other: Woebot Substance Use Disorder,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,160.0,"June 22, 2020","August 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04460027
1679,1679,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Recruiting,Behavioral: Emotion Regulation Training via Telehealth,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 1, 2020",January 2023,United States,https://ClinicalTrials.gov/show/NCT04615416
1680,1680,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Recruiting,Procedure: Direct laryngoscopy|Procedure: Vie Scope laryngoscopy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"March 20, 2020","May 20, 2020",Poland,https://ClinicalTrials.gov/show/NCT04365608
1681,1681,Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19,Enrolling by invitation,Behavioral: Telepsychoeducation with personalized videos|Behavioral: Telepsychoeducation without personalized videos,All,"Child, Adult, Older Adult",Not Applicable,2200.0,"November 5, 2020","July 20, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04632082
1682,1682,MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay,Not yet recruiting,Device: MejoraCare,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,96.0,"December 9, 2020","December 9, 2021",Paraguay,https://ClinicalTrials.gov/show/NCT04659746
1683,1683,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Drug: Lopinavir/ritonavir,All,"18 Months and older   (Child, Adult, Older Adult)",Phase 3,1220.0,"April 17, 2020","March 31, 2022",Canada,https://ClinicalTrials.gov/show/NCT04321174
1684,1684,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Recruiting,Drug: Enoxaparin,All,"18 Years and older   (Adult, Older Adult)",Phase 4,602.0,"May 13, 2020",November 2021,France,https://ClinicalTrials.gov/show/NCT04373707
1685,1685,Serology COVID-19 From the Cornwall Hospital Union,Completed,Biological: Serological test|Biological: Serum test,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2587.0,"May 4, 2020","November 16, 2020",France,https://ClinicalTrials.gov/show/NCT04363593
1686,1686,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,Not yet recruiting,Drug: Immunoglobulin of cured patients|Drug: γ-Globulin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"March 17, 2020","May 31, 2020",China,https://ClinicalTrials.gov/show/NCT04264858
1687,1687,Health cAre woRkers exposeD to COVID-19,Recruiting,Behavioral: EMDR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,900.0,"November 20, 2020","August 20, 2022",France,https://ClinicalTrials.gov/show/NCT04570202
1688,1688,Provider Burnout During COVID-19,Recruiting,Behavioral: Coping strategies video,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250.0,"April 29, 2020","October 29, 2020",United States,https://ClinicalTrials.gov/show/NCT04370938
1689,1689,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,Recruiting,Drug: Colchicine|Drug: Interferon-Beta|Drug: Aspirin|Drug: Rivaroxaban,All,"18 Years and older   (Adult, Older Adult)",Phase 3,4000.0,"April 21, 2020","June 30, 2021",Armenia,https://ClinicalTrials.gov/show/NCT04324463
1690,1690,Active Pregnancy Against COVID-19,Recruiting,Other: Exercise program|Other: Healthy lifestyle advise,Female,18 Years to 50 Years   (Adult),Not Applicable,280.0,"August 1, 2020","December 31, 2023",Spain,https://ClinicalTrials.gov/show/NCT04563065
1691,1691,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,Recruiting,Other: Assembled mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"July 15, 2020",May 2025,United States,https://ClinicalTrials.gov/show/NCT04416919
1692,1692,The COVID-19 and Healthcare Workers: An Active Intervention,Recruiting,Other: Video-Based intervention,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,1200.0,"October 21, 2020","January 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04497415
1693,1693,Addressing COVID-19 Mental Health Problems Among US Veterans,Recruiting,Other: A short video intervention|Other: A vignette intervention,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,200.0,"July 6, 2020","October 26, 2020",United States,https://ClinicalTrials.gov/show/NCT04484207
1694,1694,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,Completed,Other: Exercise Group,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,170.0,"April 1, 2020","June 10, 2020",Greece,https://ClinicalTrials.gov/show/NCT04381000
1695,1695,Reducing Burnout Among Frontline Healthcare Workers During COVID-19,Not yet recruiting,Behavioral: Virtual Peer Support Platform|Behavioral: Control Period,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1080.0,"January 15, 2021",July 2021,Canada,https://ClinicalTrials.gov/show/NCT04474080
1696,1696,COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS),Not yet recruiting,Behavioral: Simulation Intervention|Behavioral: Control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,84.0,"December 15, 2020","November 15, 2022",United States,https://ClinicalTrials.gov/show/NCT04614844
1697,1697,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Recruiting,Other: specific exercise rehabilitation treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"August 7, 2020","May 7, 2022",France,https://ClinicalTrials.gov/show/NCT04569266
1698,1698,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Recruiting,"Diagnostic Test: COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)",All,"3 Years and older   (Child, Adult, Older Adult)",Not Applicable,500.0,"July 12, 2020","November 30, 2020",France,https://ClinicalTrials.gov/show/NCT04511949
1699,1699,Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions,Not yet recruiting,Behavioral: Virtual-Care Cognitive Behavioural Therapy,All,12 Years to 17 Years   (Child),Not Applicable,20.0,"June 1, 2020","June 1, 2021",Canada,https://ClinicalTrials.gov/show/NCT04408027
1700,1700,Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),"Active, not recruiting",Behavioral: HOPE intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"March 20, 2020","September 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04376515
1701,1701,LIBERATE Trial in COVID-19,Recruiting,Drug: Ibuprofen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,230.0,"May 26, 2020","September 25, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04334629
1702,1702,COVID-19 Health Professional Impact Study,Not yet recruiting,Other: Survey|Diagnostic Test: SARS-CoV-2 antibody test,All,"Child, Adult, Older Adult",Not Applicable,3000.0,"November 1, 2020","December 31, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04527432
1703,1703,Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,"Active, not recruiting",Biological: VPM1002|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,59.0,"May 25, 2020","May 1, 2021",Germany,https://ClinicalTrials.gov/show/NCT04387409
1704,1704,3D Telemedicine During COVID-19: Cohort Study,Not yet recruiting,Other: 3D Telemedicine,All,"1 Year to 95 Years   (Child, Adult, Older Adult)",Not Applicable,50.0,"September 1, 2020","January 1, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04444323
1705,1705,Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),Recruiting,Drug: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Other: Placebo|Drug: Remdesivir,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"October 8, 2020",July 2021,Denmark,https://ClinicalTrials.gov/show/NCT04546581
1706,1706,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Drug: Conestat alfa,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,120.0,"August 6, 2020",July 2021,Switzerland,https://ClinicalTrials.gov/show/NCT04414631
1707,1707,Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,Enrolling by invitation,Other: SCH Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,"April 21, 2020","May 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04464486
1708,1708,Reducing Food Insecurity During COVID-19,Not yet recruiting,Other: Produce prescription program|Other: Grocery store gift cards,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,250.0,January 2021,October 2022,United States,https://ClinicalTrials.gov/show/NCT04652596
1709,1709,CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.,Not yet recruiting,Other: Community popular opinion leader (POL) based intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"January 6, 2021","October 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04646616
1710,1710,Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff,Recruiting,Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,2944.0,"January 21, 2020",June 2020,China,https://ClinicalTrials.gov/show/NCT04320238
1711,1711,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,Drug: Aspirin 100mg,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2|Phase 3,128.0,"February 10, 2020",June 2020,China,https://ClinicalTrials.gov/show/NCT04365309
1712,1712,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,Completed,Other: SPIN-CHAT Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,172.0,"April 9, 2020","July 24, 2020",Canada,https://ClinicalTrials.gov/show/NCT04335279
1713,1713,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,Diagnostic Test: Low-dose Chest CT,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,230.0,"April 25, 2020","May 22, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04379531
1714,1714,3D Telemedicine During COVID-19: Non-clinical Validation,Not yet recruiting,Other: 3D Telemedicine|Other: 2D Telemedicine,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,40.0,"July 31, 2020","January 31, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04444297
1715,1715,Treating COVID-19 With a Bidirectional Oxygenation Valve,Recruiting,Device: bidirectional oxygenation mouthpiece,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"March 27, 2020","March 27, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04326452
1716,1716,Inhaled Ibuprofen to Treat COVID-19,Recruiting,Drug: Inhaled Hypertonic ibuprofen,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"May 1, 2020",January 2021,Argentina,https://ClinicalTrials.gov/show/NCT04382768
1717,1717,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,Recruiting,Other: Exercise|Behavioral: Psychological and Behaviour Change Support|Other: Nutrition,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1100.0,"May 29, 2020","November 30, 2022",United Kingdom,https://ClinicalTrials.gov/show/NCT04425616
1718,1718,NO Prevention of COVID-19 for Healthcare Providers,Recruiting,Drug: Inhaled nitric oxide gas,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,470.0,"April 7, 2020","April 7, 2022",United States,https://ClinicalTrials.gov/show/NCT04312243
1719,1719,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Completed,Drug: Tirofiban Injection|Drug: Clopidogrel|Drug: Acetylsalicylic acid|Drug: Fondaparinux,All,"18 Years and older   (Adult, Older Adult)",Phase 2,5.0,"April 6, 2020","April 23, 2020",Italy,https://ClinicalTrials.gov/show/NCT04368377
1720,1720,UVA Light Device to Treat COVID-19,Recruiting,Device: UV Light Treatment,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,5.0,"October 30, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04572399
1721,1721,Viral Specific T-cells for Treatment of COVID-19,Not yet recruiting,Biological: Viral Specific T-cells (VSTs),All,"Child, Adult, Older Adult",Phase 2,100.0,January 2021,June 2025,United States,https://ClinicalTrials.gov/show/NCT04406064
1722,1722,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,Biological: Blood sample,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,2000.0,"May 28, 2020","January 27, 2021",France,https://ClinicalTrials.gov/show/NCT04408131
1723,1723,Can the Prediction Market Improve Predictions of COVID-19?,Completed,Other: Prediction Market,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,560.0,"May 15, 2020","May 17, 2020",Singapore,https://ClinicalTrials.gov/show/NCT04410692
1724,1724,Handling Oxygenation Targets in COVID-19,Recruiting,Drug: Oxygen,All,"18 Years and older   (Adult, Older Adult)",Phase 4,780.0,"August 25, 2020","March 1, 2024",Denmark,https://ClinicalTrials.gov/show/NCT04425031
1725,1725,Blood Donor Recruitment During Epidemic of COVID-19,Completed,Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information,All,18 Years to 60 Years   (Adult),Not Applicable,19491.0,"March 13, 2020","April 3, 2020",China,https://ClinicalTrials.gov/show/NCT04306055
1726,1726,Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study,Recruiting,Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL,All,"Child, Adult, Older Adult",Phase 3,250.0,"May 23, 2019","December 28, 2021",Australia,https://ClinicalTrials.gov/show/NCT03808922
1727,1727,Impact of COVID-19 on Mental Health of Patients With Skin Picking,Enrolling by invitation,Behavioral: Internet-based Cognitive Behavioral Therapy|Other: Quality of life promotion,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"August 11, 2020",March 2021,Brazil,https://ClinicalTrials.gov/show/NCT04522492
1728,1728,Use of RDS MultiSense® in Post-ICU Patients in the COVID-19 Era,Not yet recruiting,Other: Remote Automated Monitoring System,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,January 2021,June 2022,France,https://ClinicalTrials.gov/show/NCT04661423
1729,1729,BIO 300 Oral Suspension in Discharged COVID-19 Patients,Recruiting,Drug: BIO 300 Oral Suspension|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,66.0,"November 11, 2020",May 2022,United States,https://ClinicalTrials.gov/show/NCT04482595
1730,1730,IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.,Not yet recruiting,Drug: Experimental drug,All,70 Years and older   (Older Adult),Phase 2,99.0,"September 1, 2020","December 1, 2021",France,https://ClinicalTrials.gov/show/NCT04357613
1731,1731,"REmotely Monitored, Mobile Health Supported High Intensity Interval Training for Survivors of COVID-19",Not yet recruiting,"Behavioral: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"January 1, 2021","February 1, 2023",United States,https://ClinicalTrials.gov/show/NCT04664101
1732,1732,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Completed,Behavioral: blood donation SMS,All,18 Years to 60 Years   (Adult),Not Applicable,456517.0,"April 30, 2020","May 10, 2020",China,https://ClinicalTrials.gov/show/NCT04370886
1733,1733,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,Recruiting,Behavioral: Anxiety Reduction Training|Behavioral: Kundalini Yoga and Anxiety Reduction Training|Behavioral: Meditation and Anxiety Reduction Training,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,360.0,"May 25, 2020","January 30, 2022",United States,https://ClinicalTrials.gov/show/NCT04386291
1734,1734,An Approach to Screening for COVID-19 at Vancouver Airport,Recruiting,Diagnostic Test: Rapid Antigen Test,All,"19 Years to 80 Years   (Adult, Older Adult)",Not Applicable,900.0,"November 23, 2020","April 30, 2021",Canada,https://ClinicalTrials.gov/show/NCT04665193
1735,1735,Impact of Colchicine in Hospitalized Colombian Patients With COVID-19,Not yet recruiting,Drug: Colchicine 0.5 MG|Combination Product: CONTROL GROUP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,128.0,"November 30, 2020",March 2021,Colombia,https://ClinicalTrials.gov/show/NCT04539873
1736,1736,Effects of Fuzheng Huayu Tablets on COVID-19,Completed,Drug: Fuzheng Huayu tablet,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,66.0,"February 1, 2020","April 15, 2020",China,https://ClinicalTrials.gov/show/NCT04645407
1737,1737,Improving Activity Engagement Among Persons With SCI During COVID-19,Not yet recruiting,Other: WebEx Physical Activity Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"September 15, 2020","October 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04408287
1738,1738,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults",Recruiting,Biological: CVnCoV Vaccine|Drug: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,284.0,"June 18, 2020",October 2021,Belgium,https://ClinicalTrials.gov/show/NCT04449276
1739,1739,Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers,Not yet recruiting,Drug: Apo-Hydroxychloroquine|Drug: Matched Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1100.0,"May 1, 2020","August 30, 2020",Canada,https://ClinicalTrials.gov/show/NCT04371523
1740,1740,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","Active, not recruiting",Drug: REGN10933+REGN10987|Drug: Placebo,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,974.0,"July 26, 2020","October 25, 2021",United States,https://ClinicalTrials.gov/show/NCT04519437
1741,1741,Psychological Symptoms and Families of COVID-19 Patients,Recruiting,Behavioral: Written Summary of Rounds,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 14, 2020","September 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04501445
1742,1742,Hydroxychloroquine in Outpatient Adults With COVID-19,Terminated,Drug: Hydroxychloroquine SAR321068|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,8.0,"April 12, 2020","May 26, 2020",Belgium,https://ClinicalTrials.gov/show/NCT04333654
1743,1743,Virtual Mindfulness Rounds in the Time of COVID-19 Pandemic,Not yet recruiting,Other: Mindfulness Rounds,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30.0,January 2021,June 2022,United States,https://ClinicalTrials.gov/show/NCT04431297
1744,1744,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Completed,Other: HIT-exercise|Other: Sham intervention,Female,48 Years to 60 Years   (Adult),Not Applicable,21.0,"March 14, 2020","October 30, 2020",Germany,https://ClinicalTrials.gov/show/NCT04420806
1745,1745,External Dead Space in Ventilated COVID-19 Patients,Recruiting,Other: Removal of dead space filter,All,"Child, Adult, Older Adult",Not Applicable,40.0,"June 9, 2020","November 7, 2020",Sweden,https://ClinicalTrials.gov/show/NCT04424082
1746,1746,Medical Masks vs N95 Respirators for COVID-19,Recruiting,Device: Medical Mask|Device: N95 respirator,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,576.0,"April 1, 2020","April 1, 2021",Canada,https://ClinicalTrials.gov/show/NCT04296643
1747,1747,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,Drug: Hydroxychloroquine|Drug: Ivermectin,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,400.0,"July 20, 2020",April 2021,Brazil,https://ClinicalTrials.gov/show/NCT04384458
1748,1748,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Recruiting,Drug: Nitazoxanide 500Mg Oral Tablet,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,150.0,"May 21, 2020","December 31, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04406246
1749,1749,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),Recruiting,Diagnostic Test: NG test|Diagnostic Test: Blood test|Behavioral: Self-questionnary,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,13000.0,"May 29, 2020","October 10, 2020",France,https://ClinicalTrials.gov/show/NCT04416308
1750,1750,Impact Nerium Oleander on Symptoms and Mortality: A Feasibility Study,Enrolling by invitation,Other: Proprietary extract of Nerium oleander,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"May 20, 2020","September 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04486144
1751,1751,Intravascular Access in Suspected/Confirmed COVID-19 Patient,"Active, not recruiting",Device: NIO® (Intraosseous access)|Device: Standard of Care (Intravenous access),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"April 14, 2020","May 20, 2020",Poland,https://ClinicalTrials.gov/show/NCT04366947
1752,1752,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,Recruiting,Behavioral: Emotional Support Plan|Behavioral: Daily Monitoring,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"August 12, 2020","March 31, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04460677
1753,1753,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Recruiting,Behavioral: Computer task questionnaires,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3000.0,"December 16, 2020","February 28, 2021",United States,https://ClinicalTrials.gov/show/NCT04377100
1754,1754,Recruit Blood Donors Via SMS During Epidemic of COVID-19 （Repeat Trial）,Enrolling by invitation,Behavioral: blood donation SMS,All,18 Years to 60 Years   (Adult),Not Applicable,506517.0,"May 31, 2020","June 12, 2020",China,https://ClinicalTrials.gov/show/NCT04410458
1755,1755,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,Behavioral: Contain COVID Anxiety SSI|Behavioral: Remain COVID Free SSI,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,"August 19, 2020","October 15, 2020",United States,https://ClinicalTrials.gov/show/NCT04459455
1756,1756,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support,Not yet recruiting,Behavioral: VR for psychoeducation and relaxation|Behavioral: Text material for psychoeducation and audio for relaxation techniques,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,90.0,"November 1, 2020","November 1, 2021",Italy,https://ClinicalTrials.gov/show/NCT04611399
1757,1757,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Recruiting,Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine,All,"5 Years and older   (Child, Adult, Older Adult)",Phase 4,86.0,"April 6, 2020","December 30, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04341493
1758,1758,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Drug: Tocilizumab,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 2,38.0,"March 12, 2020",May 2020,Italy,https://ClinicalTrials.gov/show/NCT04315480
1759,1759,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Enrolling by invitation,Behavioral: blood donation SMS,All,18 Years to 60 Years   (Adult),Not Applicable,403535.0,"June 13, 2020","June 30, 2020",China,https://ClinicalTrials.gov/show/NCT04431180
1760,1760,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,Recruiting,Behavioral: Reward Re-Training|Behavioral: Supportive Therapy,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60.0,"December 1, 2020","March 30, 2022",United States,https://ClinicalTrials.gov/show/NCT04661410
1761,1761,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,Recruiting,Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,"April 15, 2020",August 2020,Italy,https://ClinicalTrials.gov/show/NCT04346589
1762,1762,Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis,Not yet recruiting,Drug: topical steroids and cyclosporin-A,All,"Child, Adult, Older Adult",Not Applicable,12.0,"June 30, 2020",July 2020,Kuwait,https://ClinicalTrials.gov/show/NCT04451239
1763,1763,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,Diagnostic Test: Serological tests will be applied on patients blood sampling,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,550.0,"April 9, 2020","April 9, 2024",France,https://ClinicalTrials.gov/show/NCT04341142
1764,1764,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Recruiting,Device: Freestyle Libre 14 day CGM system|Device: Accuchek Inform II platform,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,50.0,"June 12, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04417270
1765,1765,Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.,Recruiting,Drug: Vitamin D|Drug: PLACEBO,All,"Child, Adult, Older Adult",Phase 3,108.0,"November 9, 2020","November 9, 2021",Spain,https://ClinicalTrials.gov/show/NCT04621058
1766,1766,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Recruiting,Behavioral: Trauma-informed yoga video recording,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"July 21, 2020",October 2020,United States,https://ClinicalTrials.gov/show/NCT04453514
1767,1767,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,Device: COVSurf Drug Delivery System|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24.0,"June 18, 2020","November 16, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04362059
1768,1768,COVID-19: Laser Interferometry for Rapid Single Coronavirus Detection,Not yet recruiting,Diagnostic Test: Novel laser inferometry test for CORONA virus,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,250.0,June 2020,December 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04401644
1769,1769,Evaluation of Aerosol in a Dental Clinic,Not yet recruiting,Device: High volume evacuation (HVE)|Device: Extraoral vacuum aspirator (EVA)|Device: External evacuation device (EED)|Drug: Hydrogen Peroxide,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50.0,"December 1, 2020","December 1, 2022",United States,https://ClinicalTrials.gov/show/NCT04659928
1770,1770,The Doctors for Coronavirus Prevention Project Thanksgiving Messaging Campaign,Not yet recruiting,Behavioral: Facebook Ads on the importance of staying safe during the Thanksgiving holiday,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20000000.0,"November 14, 2020","November 26, 2021",United States,https://ClinicalTrials.gov/show/NCT04644328
1771,1771,Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix (NanoDx-CoV-19),Recruiting,Device: sample of blood and saliva,All,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,200.0,"October 15, 2020","December 31, 2021",France,https://ClinicalTrials.gov/show/NCT04597216
1772,1772,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,Completed,Other: Farmalarm,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"March 31, 2020","May 18, 2020",Spain,https://ClinicalTrials.gov/show/NCT04423289
1773,1773,A Clinical Study to Evaluate MW33 Injection,"Active, not recruiting",Combination Product: MW33 injection|Combination Product: MW33 injection placebo,All,18 Years to 45 Years   (Adult),Phase 1,42.0,"August 7, 2020",December 2020,China,https://ClinicalTrials.gov/show/NCT04533048
1774,1774,Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers,Completed,Drug: inhaled hydroxychloroquine,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,12.0,"September 15, 2020","November 1, 2020",Netherlands,https://ClinicalTrials.gov/show/NCT04497519
1775,1775,Intranasal Heparin Tolerability Study,"Active, not recruiting",Drug: Intranasal heparin sodium (porcine),All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,6.0,"October 9, 2020",November 2020,United States,https://ClinicalTrials.gov/show/NCT04490239
1776,1776,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Recruiting,Drug: Colchicine|Drug: Usual Care,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,70.0,"April 26, 2020","June 14, 2020",United States,https://ClinicalTrials.gov/show/NCT04363437
1777,1777,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Completed,Other: Chiropractic care (one visit)|Other: Chiropractic care (more than one visit),All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,723.0,"May 2, 2020","May 27, 2020",Spain,https://ClinicalTrials.gov/show/NCT04573361
1778,1778,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Recruiting,Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,346.0,"April 2, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04325906
1779,1779,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Completed,Biological: Anti-SARS-CoV-2 IgT seropositivity,All,"5 Years and older   (Child, Adult, Older Adult)",Not Applicable,2006.0,"June 26, 2020","July 24, 2020",France,https://ClinicalTrials.gov/show/NCT04448769
1780,1780,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,Enrolling by invitation,Dietary Supplement: PreserVision AREDS formulation gel tabs|Dietary Supplement: Centrum Adult (under 50) multivitamin,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,4500.0,"September 28, 2020","May 14, 2021",United States,https://ClinicalTrials.gov/show/NCT04551339
1781,1781,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Recruiting,Device: Limbix Spark|Other: Psychoeducation,All,"13 Years to 21 Years   (Child, Adult)",Not Applicable,410.0,"July 20, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04524598
1782,1782,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,Enrolling by invitation,Other: Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,350.0,"October 14, 2020",December 2020,Canada,https://ClinicalTrials.gov/show/NCT04602832
1783,1783,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19",Recruiting,Device: Virtual Reality,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,40.0,"August 1, 2020","January 1, 2021",Netherlands,https://ClinicalTrials.gov/show/NCT04505761
1784,1784,ChulaCov19 mRNA Vaccine in Healthy Adults,Not yet recruiting,Biological: ChulaCov19 mRNA vaccine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,96.0,January 2021,June 2021,Thailand,https://ClinicalTrials.gov/show/NCT04566276
1785,1785,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,Recruiting,"Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"May 12, 2020","November 1, 2022",Canada,https://ClinicalTrials.gov/show/NCT04384965
1786,1786,Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP,Recruiting,Device: Low flow ECMO driving by CVVH machine,All,"14 Years and older   (Child, Adult, Older Adult)",Not Applicable,10.0,"February 20, 2020","October 15, 2020",China,https://ClinicalTrials.gov/show/NCT04340414
1787,1787,Renin Angiotensin System - CoronaVirus,Recruiting,Other: blood draw,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"April 3, 2020","July 31, 2020",France,https://ClinicalTrials.gov/show/NCT04337008
1788,1788,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Recruiting,Other: Staff Wellbeing Centres,All,"Child, Adult, Older Adult",Not Applicable,45.0,"May 25, 2020","November 30, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04410016
1789,1789,"Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",Recruiting,Behavioral: Dialectical Behavioral Therapy (DBT) Skills,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"September 12, 2020","December 15, 2020",Jersey,https://ClinicalTrials.gov/show/NCT04558411
1790,1790,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,Not yet recruiting,Other: EXTRA-CVD Virtual Care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75.0,February 2021,August 2022,United States,https://ClinicalTrials.gov/show/NCT04661813
1791,1791,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,Recruiting,Other: Caring Contacts,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"August 4, 2020",March 2021,Canada,https://ClinicalTrials.gov/show/NCT04456062
1792,1792,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,Terminated,Drug: Hydroxychloroquine|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,259.0,"April 1, 2020","June 18, 2020",France,https://ClinicalTrials.gov/show/NCT04325893
1793,1793,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,Biological: BCG GROUP|Other: PLACEBO GROUP,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1120.0,"May 20, 2020","February 20, 2021",France,https://ClinicalTrials.gov/show/NCT04384549
1794,1794,Sarilumab COVID-19,Completed,Drug: Sarilumab SAR153191|Drug: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,420.0,"March 28, 2020","September 2, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04327388
1795,1795,Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,Recruiting,"Device: MagPro X100 Stimulator, B70 Fluid-Cooled Coil",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"June 9, 2020",December 2022,Canada,https://ClinicalTrials.gov/show/NCT04427137
1796,1796,Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,Recruiting,Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,44.0,"September 4, 2020","September 4, 2021",United States,https://ClinicalTrials.gov/show/NCT04379518
1797,1797,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,Behavioral: Online Intervention Mental Health COVID-19,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,128.0,"May 20, 2020","January 15, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04468893
1798,1798,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,Other: blood sample,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,115.0,"April 22, 2020","October 22, 2020",France,https://ClinicalTrials.gov/show/NCT04369456
1799,1799,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,Biological: Plasma exchange|Drug: Standar medical treatmen,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,116.0,"April 29, 2020","August 29, 2021",Spain,https://ClinicalTrials.gov/show/NCT04374539
1800,1800,Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,Recruiting,Other: Exercise training group,All,"10 Years to 19 Years   (Child, Adult)",Not Applicable,140.0,July 2020,June 2021,Brazil,https://ClinicalTrials.gov/show/NCT04458246
1801,1801,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,"Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)",All,"14 Years to 80 Years   (Child, Adult, Older Adult)",Not Applicable,150.0,"January 22, 2020","January 22, 2021",China,https://ClinicalTrials.gov/show/NCT04251871
1802,1802,Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak,Not yet recruiting,Behavioral: online mindfulness group,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"August 1, 2020","July 30, 2021",Hong Kong,https://ClinicalTrials.gov/show/NCT04346082
1803,1803,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,Biological: Convalescent plasma|Drug: Hydroxychloroquin with Azithromycin,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,49.0,"April 3, 2020","June 1, 2020",Iraq,https://ClinicalTrials.gov/show/NCT04441424
1804,1804,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,Completed,Device: non-contact magnetically-controlled capsule endoscopy,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,40.0,"March 26, 2020","May 20, 2020",China,https://ClinicalTrials.gov/show/NCT04389333
1805,1805,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Recruiting,Other: physiological effects of awake prone position in COVID 19 patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"April 4, 2020","January 31, 2021",France,https://ClinicalTrials.gov/show/NCT04632602
1806,1806,The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19,Not yet recruiting,Behavioral: Behavioral: OCAT-sham|Behavioral: Behavioral: OCAT|Other: psycho-education video,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,100.0,"April 20, 2020",August 2020,Belgium,https://ClinicalTrials.gov/show/NCT04367636
1807,1807,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Recruiting,Behavioral: Mindfulness intervention|Behavioral: Non-Mindfulness intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,"August 26, 2020",December 2020,Malaysia,https://ClinicalTrials.gov/show/NCT04394013
1808,1808,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin,All,"18 Years and older   (Adult, Older Adult)",Phase 3,630.0,"April 1, 2020","August 30, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04322123
1809,1809,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Recruiting,Other: CHEST CT SCAN,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"June 8, 2020","November 8, 2021",France,https://ClinicalTrials.gov/show/NCT04483752
1810,1810,Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama,Not yet recruiting,"Behavioral: Intervention, TBN",All,15 Years to 17 Years   (Child),Not Applicable,4.0,"January 1, 2021","June 30, 2023",United States,https://ClinicalTrials.gov/show/NCT04604743
1811,1811,Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),Recruiting,Drug: Eltrombopag|Drug: rhTPO,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,120.0,"August 31, 2020",August 2022,China,https://ClinicalTrials.gov/show/NCT04516837
1812,1812,Breastfeeding Education in the Time of COVID-19,Recruiting,Behavioral: Telesimulation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,39.0,"July 31, 2020","September 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04519216
1813,1813,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting","Behavioral: Transitional Online Peer Support Group (n=20)|Other: Control Group (pharmacotherapy and/or psychotherapy, n=10)",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"August 25, 2020",December 2020,Canada,https://ClinicalTrials.gov/show/NCT04445324
1814,1814,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,Completed,Drug: SAR443122|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,68.0,"July 17, 2020","October 23, 2020",Argentina,https://ClinicalTrials.gov/show/NCT04469621
1815,1815,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,Recruiting,Behavioral: Assigned Strategies: Opt-in|Behavioral: Assigned Strategies: Active Choice|Behavioral: Assigned Strategies: Enhanced Active Choice|Behavioral: Choice of Assignment: Opt-in|Behavioral: Choice of Assignment: Active Choice|Behavioral: Choice of Assignment: Enhanced Active Choice,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,145.0,"September 7, 2020",December 2020,Canada,https://ClinicalTrials.gov/show/NCT04488796
1816,1816,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,Completed,"Behavioral: Training for Awareness, Resilience, and Action (TARA)",All,"14 Years to 18 Years   (Child, Adult)",Not Applicable,21.0,"October 18, 2019","May 20, 2020",United States,https://ClinicalTrials.gov/show/NCT04548544
1817,1817,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Drug: Ruconest,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,120.0,"November 30, 2020","November 30, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04530136
1818,1818,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Recruiting,Biological: Anti-SARS-CoV-2 Human Convalescent Plasma,All,"1 Month to 18 Years   (Child, Adult)",Phase 1,30.0,"May 28, 2020","May 28, 2022",United States,https://ClinicalTrials.gov/show/NCT04377672
1819,1819,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Device: ECCO2R,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"May 3, 2020","October 1, 2021",Germany,https://ClinicalTrials.gov/show/NCT04351906
1820,1820,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,Recruiting,Drug: NORS (Nitric Oxide Releasing Solution),All,"19 Years and older   (Adult, Older Adult)",Phase 2,200.0,"May 8, 2020","September 30, 2020",Canada,https://ClinicalTrials.gov/show/NCT04337918
1821,1821,COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic,Not yet recruiting,Behavioral: COMPASS|Behavioral: Standard charity resources,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"September 28, 2020","June 1, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04535778
1822,1822,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Recruiting,Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use,All,"18 Years to 90 Years   (Adult, Older Adult)",Early Phase 1,10.0,"March 25, 2020","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04326036
1823,1823,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,Not yet recruiting,Behavioral: Online Intervention Grief COVID-19,All,18 Years to 60 Years   (Adult),Not Applicable,42.0,"December 15, 2020","June 1, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04638842
1824,1824,Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,Recruiting,Behavioral: Simple cognitive task intervention|Behavioral: Attention Placebo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,164.0,"September 30, 2020","August 1, 2021",Sweden,https://ClinicalTrials.gov/show/NCT04460014
1825,1825,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,Recruiting,"Biological: SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|Drug: Normal Saline",All,65 Years to 100 Years   (Older Adult),Early Phase 1,250.0,"September 1, 2020","September 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04523246
1826,1826,Convalescent Antibodies Infusion in COVID 19 Patients,Not yet recruiting,Biological: Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,June 2020,September 2020,Italy,https://ClinicalTrials.gov/show/NCT04418531
1827,1827,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine,All,"18 Years and older   (Adult, Older Adult)",Phase 3,440.0,"March 28, 2020","June 14, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04321278
1828,1828,A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole,Recruiting,Drug: Acalabrutinib Treatment A|Drug: Acalabrutinib Treatment B|Drug: Acalabrutinib Treatment C|Drug: Acalabrutinib Treatment D,All,18 Years to 55 Years   (Adult),Phase 1,40.0,"October 12, 2020","November 30, 2020",Germany,https://ClinicalTrials.gov/show/NCT04564040
1829,1829,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,"Active, not recruiting",Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,320.0,"April 8, 2020",December 2020,Russian Federation,https://ClinicalTrials.gov/show/NCT04346693
1830,1830,ASC Therapy for Patients With Severe Respiratory COVID-19,Withdrawn,Drug: Stem Cell Product,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,0.0,"April 20, 2020","April 30, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04341610
1831,1831,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Recruiting,Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"Child, Adult, Older Adult",Phase 2,226.0,"April 6, 2020","March 31, 2021",Denmark,https://ClinicalTrials.gov/show/NCT04322396
1832,1832,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Recruiting,Behavioral: Digital Health Online Platform,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"May 20, 2020",January 2021,Canada,https://ClinicalTrials.gov/show/NCT04400305
1833,1833,Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine,Recruiting,Biological: Flucelvax|Biological: Fluvirin|Biological: Fluzone High Dose,All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,"October 2, 2019","December 31, 2025",United States,https://ClinicalTrials.gov/show/NCT04025580
1834,1834,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,Behavioral: Patient-centred advice on Telephone Consultation in TB Patients:,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 20, 2020","December 20, 2020",Pakistan,https://ClinicalTrials.gov/show/NCT04412239
1835,1835,Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19,Recruiting,Drug: Pioglitazone 30 mg|Other: standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,76.0,"September 18, 2020","April 10, 2021",Spain,https://ClinicalTrials.gov/show/NCT04535700
1836,1836,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",Drug: Sarilumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,239.0,"March 27, 2020","December 31, 2021",France,https://ClinicalTrials.gov/show/NCT04324073
1837,1837,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,"Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU",All,65 Years and older   (Older Adult),Phase 3,260.0,"April 15, 2020",May 2021,France,https://ClinicalTrials.gov/show/NCT04344041
1838,1838,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,Recruiting,Biological: Plasma|Other: Best Available Therapy,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,"April 27, 2020","May 30, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04358783
1839,1839,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Recruiting,Drug: Amlodipine,All,"18 Years and older   (Adult, Older Adult)",Phase 4,1000.0,"October 23, 2020","July 31, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04559074
1840,1840,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,Recruiting,Biological: ARCT-021 Dose 1|Biological: ARCT-021 Dose 2|Biological: ARCT-021 Dose 3|Biological: ARCT-021 Dose 4|Biological: ARCT-021 Dose Regimen 1|Biological: ARCT-021 Dose Regimen 2|Other: Placebo,All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,92.0,"August 4, 2020",January 2021,Singapore,https://ClinicalTrials.gov/show/NCT04480957
1841,1841,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,Recruiting,Drug: Camostat Mesilate|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,264.0,"July 28, 2020","September 15, 2022",United States,https://ClinicalTrials.gov/show/NCT04470544
1842,1842,"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19",Enrolling by invitation,Device: FamilyChildCare (provisional name of app),All,"3 Years to 99 Years   (Child, Adult, Older Adult)",Not Applicable,270.0,December 2020,September 2021,United States,https://ClinicalTrials.gov/show/NCT04453657
1843,1843,Somerset and South Essex Coronavirus Antigen Testing,Not yet recruiting,Diagnostic Test: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,June 2020,August 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04403906
1844,1844,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,Recruiting,Drug: L-Citrulline|Drug: Placebo,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60.0,"October 15, 2020","December 28, 2021",United States,https://ClinicalTrials.gov/show/NCT04570384
1845,1845,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,Recruiting,Drug: VIB7734|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,48.0,"August 28, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04526912
1846,1846,The COVID-19 Pandemic and Exercise Study,"Active, not recruiting",Behavioral: Yoga group|Behavioral: High Intensity Interval Training group|Behavioral: Combination,All,18 Years to 64 Years   (Adult),Not Applicable,334.0,"June 1, 2020",November 2020,Canada,https://ClinicalTrials.gov/show/NCT04400279
1847,1847,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,Recruiting,Drug: Group A HCQ|Drug: Group B Control,All,"50 Years to 75 Years   (Adult, Older Adult)",Phase 2,850.0,"April 7, 2020","June 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04353037
1848,1848,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,Drug: Tocilizumab|Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,69.0,"March 1, 2020","August 5, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04519385
1849,1849,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,Recruiting,Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,80.0,"May 20, 2020","December 20, 2020",Mexico,https://ClinicalTrials.gov/show/NCT04405310
1850,1850,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,Recruiting,Drug: Colchicine|Drug: Placebo oral tablet,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,174.0,"May 27, 2020","April 27, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04367168
1851,1851,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Recruiting,Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,216.0,"April 20, 2020","October 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04320056
1852,1852,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Recruiting,Device: VibroLUNG,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,200.0,"March 22, 2020","February 1, 2021",Kazakhstan,https://ClinicalTrials.gov/show/NCT04435353
1853,1853,Virtual Pain Care Management (COVID-19),Recruiting,Other: VCPM,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60.0,"October 1, 2020","June 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04539821
1854,1854,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Recruiting,Dietary Supplement: Probiotics|Other: Placebo,All,18 Years to 60 Years   (Adult),Not Applicable,300.0,"August 19, 2020","January 31, 2021",Mexico,https://ClinicalTrials.gov/show/NCT04517422
1855,1855,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic,All,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,670.0,"May 9, 2020","September 10, 2021",Sweden,https://ClinicalTrials.gov/show/NCT04341922
1856,1856,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Not yet recruiting,Other: Telerehabilitation,All,65 Years and older   (Older Adult),Not Applicable,30.0,"August 20, 2020","December 31, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04334434
1857,1857,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,Device: gammaCore® Sapphire (non-invasive vagus nerve stimulator)|Other: Standard of care therapies,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"May 8, 2020","December 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04382391
1858,1858,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,Enrolling by invitation,Drug: Tradipitant|Drug: Placebo,All,"18 Years to 90 Years   (Adult, Older Adult)",Phase 3,300.0,"April 13, 2020","August 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04326426
1859,1859,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Recruiting,Drug: Ivermectin|Other: Standard treatment for COVID-19,All,"18 Years and older   (Adult, Older Adult)",Phase 2,64.0,"July 1, 2020","July 1, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04431466
1860,1860,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,Enrolling by invitation,Drug: Hydroxychloroquine|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 3,988.0,"April 30, 2020","January 30, 2022",Canada,https://ClinicalTrials.gov/show/NCT04374942
1861,1861,Incidence of Covid-19 in School Children,Withdrawn,Diagnostic Test: RT-PCR Covid-19,All,3 Years to 10 Years   (Child),Not Applicable,0.0,"May 15, 2020",September 2020,France,https://ClinicalTrials.gov/show/NCT04377737
1862,1862,Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19,Not yet recruiting,Drug: Inactivated convalescent plasma|Drug: Support treatment,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,"June 20, 2020","December 30, 2020",Colombia,https://ClinicalTrials.gov/show/NCT04385186
1863,1863,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,Recruiting,"Diagnostic Test: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics",Male,18 Years to 60 Years   (Adult),Not Applicable,250.0,"July 10, 2020",July 2021,France,https://ClinicalTrials.gov/show/NCT04487639
1864,1864,"Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT",Recruiting,Drug: [18F]FP-R01-MG-F2,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,30.0,"November 8, 2017","April 14, 2023",United States,https://ClinicalTrials.gov/show/NCT03183570
1865,1865,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Recruiting,Other: Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,26.0,"October 1, 2020",September 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT04455360
1866,1866,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Completed,Other: Individualised Ayurveda,All,18 Years to 60 Years   (Adult),Not Applicable,18.0,"February 26, 2020","March 30, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04345549
1867,1867,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,Completed,Behavioral: Intervention App,All,"18 Years and older   (Adult, Older Adult)",Phase 3,560.0,"May 5, 2020","August 24, 2020",Spain,https://ClinicalTrials.gov/show/NCT04393818
1868,1868,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Recruiting,Other: Interview by psychologists,All,6 Years to 17 Years   (Child),Not Applicable,40.0,"May 5, 2020",January 2021,France,https://ClinicalTrials.gov/show/NCT04416360
1869,1869,Finding Wellness in the Pandemic,Recruiting,Behavioral: Trauma Informed Yoga|Behavioral: Trauma Informed Psychotherapy,Female,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,200.0,"November 1, 2020","April 30, 2021",Canada,https://ClinicalTrials.gov/show/NCT04615741
1870,1870,NK Cells Treatment for COVID-19,Recruiting,Biological: NK Cells,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30.0,"February 15, 2020","December 30, 2020",China,https://ClinicalTrials.gov/show/NCT04280224
1871,1871,Exploring Interventions for Glue Ear During Covid-19,Not yet recruiting,Device: Bone conduction headphones,All,3 Years to 11 Years   (Child),Not Applicable,20.0,"June 22, 2020","June 1, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04427631
1872,1872,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,Recruiting,Drug: Veru-111,All,"18 Years and older   (Adult, Older Adult)",Phase 2,40.0,"June 18, 2020","January 18, 2021",Jersey,https://ClinicalTrials.gov/show/NCT04388826
1873,1873,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Recruiting,"Other: Collection of blood, salivary and nasopharyngeal samples.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"November 23, 2020","November 1, 2021",France,https://ClinicalTrials.gov/show/NCT04637867
1874,1874,Use of Angiotensin-(1-7) in COVID-19,Recruiting,Drug: Angiotensin-(1-7)|Drug: Placebo,All,"17 Years to 81 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,130.0,"August 5, 2020","February 28, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04633772
1875,1875,Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19),Withdrawn,Other: Olfactory retraining|Drug: corticosteroid nasal irrigation|Other: smell household Items|Other: Nasal Irrigation,All,"18 Years and older   (Adult, Older Adult)",Phase 4,0.0,"January 10, 2021","March 10, 2022",Canada,https://ClinicalTrials.gov/show/NCT04374474
1876,1876,Spironolactone in Covid-19 Induced ARDS,Not yet recruiting,Drug: Spironolactone 100mg|Drug: Placebo oral tablet,All,"18 Years and older   (Adult, Older Adult)",Phase 4,60.0,"April 21, 2020","October 21, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04345887
1877,1877,Non-contact Endoscopy at Covid-19 Outbreak,Completed,Device: Non-contact MCE system,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,5.0,"March 16, 2020","April 9, 2020",China,https://ClinicalTrials.gov/show/NCT04320953
1878,1878,Social Media and Covid19 Pandemic,Enrolling by invitation,Behavioral: survey,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,212.0,"May 1, 2020","May 8, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04378738
1879,1879,Characteristics in Post Covid-19 Patients,Recruiting,Other: Exercise,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20.0,"August 11, 2020","December 31, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04514705
1880,1880,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Biological: ChAdOx1 nCoV-19|Biological: Normal saline 0.9%,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,2130.0,"June 24, 2020",December 2021,South Africa,https://ClinicalTrials.gov/show/NCT04444674
1881,1881,The Seniors COvid-19 Pandemic and Exercise Study,Completed,Behavioral: Virtual Group Intervention|Behavioral: Personal Exercise Intervention,All,65 Years and older   (Older Adult),Not Applicable,241.0,"May 23, 2020","October 5, 2020",Canada,https://ClinicalTrials.gov/show/NCT04412343
1882,1882,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Recruiting,Other: blood sampling,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,"July 28, 2020","December 31, 2025",France,https://ClinicalTrials.gov/show/NCT04429594
1883,1883,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,Recruiting,Behavioral: Telehealth coaching sessions,All,65 Years and older   (Older Adult),Not Applicable,75.0,"July 28, 2020","July 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04492527
1884,1884,Convalescent Plasma to Stem Coronavirus (CSSC-001),Recruiting,Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,500.0,"June 10, 2020",January 2023,India,https://ClinicalTrials.gov/show/NCT04323800
1885,1885,Escin in Patients With Covid-19 Infection,Recruiting,Drug: Escin|Drug: standard therapy,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,120.0,"March 23, 2020","December 30, 2020",Italy,https://ClinicalTrials.gov/show/NCT04322344
1886,1886,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Drug: Nitric Oxide Gas,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,200.0,"March 21, 2020","March 21, 2022",Israel,https://ClinicalTrials.gov/show/NCT04306393
1887,1887,The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People,Enrolling by invitation,Dietary Supplement: Vitamin D3,All,"30 Years to 66 Years   (Adult, Older Adult)",Not Applicable,100.0,"October 5, 2020","February 20, 2021",Jordan,https://ClinicalTrials.gov/show/NCT04476745
1888,1888,At Home Monitoring for Patients With Covid19,Not yet recruiting,Device: Covidfree@home,All,"Child, Adult, Older Adult",Not Applicable,1000.0,"October 16, 2020",April 2023,Canada,https://ClinicalTrials.gov/show/NCT04453774
1889,1889,Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),Withdrawn,Other: Best Practice|Biological: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 3,0.0,"April 7, 2020","June 2, 2020",Georgia,https://ClinicalTrials.gov/show/NCT04361552
1890,1890,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,Terminated,Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,"April 5, 2020","October 8, 2020",Denmark,https://ClinicalTrials.gov/show/NCT04322773
1891,1891,A Comparison of 3D and 2D Telemedicine During Covid 19,Not yet recruiting,Other: 3D Telemedicine|Other: 2D Telemedicine,All,"1 Year to 95 Years   (Child, Adult, Older Adult)",Not Applicable,80.0,"June 30, 2020","December 31, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04359225
1892,1892,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,Biological: Mesenchymal stromal cells,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"June 12, 2020","September 30, 2022",Belgium,https://ClinicalTrials.gov/show/NCT04445454
1893,1893,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Drug: INO-4800|Device: CELLECTRA® 2000,All,"18 Years and older   (Adult, Older Adult)",Phase 1,120.0,"April 3, 2020",July 2021,United States,https://ClinicalTrials.gov/show/NCT04336410
1894,1894,"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",Recruiting,Biological: Blood sample|Biological: Serum tube collection,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,800.0,"June 5, 2020","December 15, 2020",France,https://ClinicalTrials.gov/show/NCT04420338
1895,1895,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Recruiting,Drug: Inhaled budesonide,All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 4,300.0,"April 21, 2020","October 18, 2020",Spain,https://ClinicalTrials.gov/show/NCT04355637
1896,1896,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Completed,Dietary Supplement: Ayurveda|Other: Usual Care,All,18 Years to 60 Years   (Adult),Not Applicable,32.0,"March 6, 2020","April 12, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04351542
1897,1897,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults",Recruiting,Drug: HFB30132A|Other: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,24.0,October 2020,July 2021,United States,https://ClinicalTrials.gov/show/NCT04590430
1898,1898,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,Recruiting,Diagnostic Test: conjunctival RT PCR,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,68.0,"May 15, 2020","November 15, 2020",France,https://ClinicalTrials.gov/show/NCT04397666
1899,1899,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,Drug: Tocilizumab|Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,"July 16, 2020","December 31, 2021",French Guiana,https://ClinicalTrials.gov/show/NCT04476979
1900,1900,Turkish of the SARS-CoV-2 Anxiety Scale,Recruiting,Other: survey work,All,18 Years to 60 Years   (Adult),Not Applicable,300.0,"July 24, 2020","December 24, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04490473
1901,1901,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers",Completed,Drug: Aerolized Hydroxychloroquine Sulfate|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,"June 25, 2020","August 17, 2020",United States,https://ClinicalTrials.gov/show/NCT04461353
1902,1902,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Recruiting,Other: Home-based exercise,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,70.0,"May 10, 2020",February 2021,Brazil,https://ClinicalTrials.gov/show/NCT04425005
1903,1903,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Recruiting,Procedure: Prone positioning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25.0,"April 1, 2020","May 1, 2020",France,https://ClinicalTrials.gov/show/NCT04344106
1904,1904,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,Recruiting,Biological: VPM1002|Biological: Placebo,All,"60 Years and older   (Adult, Older Adult)",Phase 3,2038.0,"June 18, 2020","September 30, 2021",Germany,https://ClinicalTrials.gov/show/NCT04435379
1905,1905,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Recruiting,Other: Questionnaires|Biological: blood test|Other: Maximal effort test|Device: actigraphy|Device: Neuromuscular evaluation,All,"35 Years to 80 Years   (Adult, Older Adult)",Not Applicable,82.0,"May 27, 2020",December 2021,France,https://ClinicalTrials.gov/show/NCT04363606
1906,1906,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Completed,Other: Tele-yoga therapy|Other: Primary care,All,18 Years to 60 Years   (Adult),Not Applicable,64.0,"March 30, 2020","July 6, 2020",India,https://ClinicalTrials.gov/show/NCT04466605
1907,1907,Feasibility and Benefits of Digital Services During the COVID19 Pandemic,Recruiting,Behavioral: Training session adressing information and health literacy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1230.0,"July 1, 2020","December 31, 2021",Germany,https://ClinicalTrials.gov/show/NCT04453475
1908,1908,Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID,Recruiting,Behavioral: exercise group|Other: control group,Male,"50 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40.0,"November 19, 2020","March 1, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04639349
1909,1909,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Recruiting,Behavioral: Internet-based self-help|Behavioral: Internet-based self-help after 3 weeks,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,80.0,"May 6, 2020",April 2021,Switzerland,https://ClinicalTrials.gov/show/NCT04380909
1910,1910,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,Behavioral: Meditation app usage,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"August 19, 2020","April 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04369378
1911,1911,Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,Recruiting,Behavioral: Brief Behavioral Activation with Mental Imagery|Behavioral: Minimal Attention Control Intervention,All,65 Years and older   (Older Adult),Not Applicable,154.0,"August 17, 2020",July 2021,Sweden,https://ClinicalTrials.gov/show/NCT04508868
1912,1912,Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,Recruiting,Drug: Symptomatic drugs|Drug: Bridge therapy|Behavioral: Mindfulness program,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,25.0,"June 15, 2020",July 2022,Italy,https://ClinicalTrials.gov/show/NCT04410536
1913,1913,"Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study",Enrolling by invitation,Other: Colgate periogard mouthwash|Other: Colgate Peroxyl mouthwash|Other: Colgate Total mouthwash|Other: Placebo mouthwash (water),All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,70.0,"June 11, 2020","August 30, 2021",Brazil,https://ClinicalTrials.gov/show/NCT04537962
1914,1914,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Recruiting,Other: Video Dance classes|Other: Unsupervised physical activities,All,"50 Years to 80 Years   (Adult, Older Adult)",Not Applicable,60.0,"May 1, 2020","December 30, 2024",Brazil,https://ClinicalTrials.gov/show/NCT04422353
1915,1915,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"Active, not recruiting",Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab,All,18 Years to 60 Years   (Adult),Phase 2|Phase 3,320.0,"April 8, 2020","August 1, 2020",Russian Federation,https://ClinicalTrials.gov/show/NCT04347031
1916,1916,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Recruiting,Biological: BCG Vaccine|Biological: Placebo Vaccine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,1800.0,"April 20, 2020",November 2021,United States,https://ClinicalTrials.gov/show/NCT04348370
1917,1917,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,Not yet recruiting,"Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,40.0,September 2020,July 2021,Colombia,https://ClinicalTrials.gov/show/NCT04390152
1918,1918,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Recruiting,Diagnostic Test: Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus,All,"Child, Adult, Older Adult",Not Applicable,80.0,"May 23, 2020","July 23, 2021",France,https://ClinicalTrials.gov/show/NCT04387253
1919,1919,Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,Recruiting,Other: Doppler Echo,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50.0,"April 24, 2020","October 30, 2020",France,https://ClinicalTrials.gov/show/NCT04363528
1920,1920,Anosmia and / or Ageusia and Early Corticosteroid Use,Recruiting,Drug: Early-Dexamethasone|Drug: Late dexamethazone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,300.0,"August 30, 2020","December 15, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04528329
1921,1921,Coping With 2020 - No Health Without Mental Health,Recruiting,Behavioral: Co-mestring (co-coping),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,400.0,"April 2, 2020","December 31, 2021",Norway,https://ClinicalTrials.gov/show/NCT04421612
1922,1922,Stay Well at Home: a Text-messaging Study Social Distancing,Recruiting,Behavioral: Uniform random message delivery|Behavioral: Reinforcement learning message delivery,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"April 17, 2020","April 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04473599
1923,1923,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Active, not recruiting",Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution,All,"18 Years and older   (Adult, Older Adult)",Phase 2,416.0,"April 18, 2020",September 2020,Brazil,https://ClinicalTrials.gov/show/NCT04343729
1924,1924,Emotional Freedom Technique (EFT) Effect on Nurses,Completed,Behavioral: Emotional Freedom Technique,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,80.0,"May 10, 2020","May 20, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04393077
1925,1925,Mask Adhesive Institutional Study,Not yet recruiting,Device: Mask with Mask Adhesive/Arm 1|Device: Mask without Mask Adhesive / Arm 2,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,30.0,"November 17, 2020","December 17, 2020",United States,https://ClinicalTrials.gov/show/NCT04644276
1926,1926,Study of Descartes-30 in Acute Respiratory Distress Syndrome,Recruiting,Biological: Descartes 30,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,30.0,"September 15, 2020","September 25, 2022",United States,https://ClinicalTrials.gov/show/NCT04524962
1927,1927,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Recruiting,Procedure: Awake Proning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,350.0,"June 10, 2020","August 30, 2021",Canada,https://ClinicalTrials.gov/show/NCT04350723
1928,1928,A Study of Ad26.COV2.S in Adults (COVID-19),Recruiting,Biological: Ad26.COV2.S|Biological: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,1045.0,"July 15, 2020","February 2, 2024",Belgium,https://ClinicalTrials.gov/show/NCT04436276
1929,1929,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Recruiting,Drug: Losartan,All,"18 Years and older   (Adult, Older Adult)",Phase 4,200.0,"March 27, 2020","December 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04340557
1930,1930,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Recruiting,Biological: UC-MSCs,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,16.0,"February 6, 2020","December 30, 2020",China,https://ClinicalTrials.gov/show/NCT04269525
1931,1931,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Recruiting,Biological: Convalescent Plasma 1 Unit|Biological: Convalescent Plasma 2 Units|Other: Standard of Care,All,"31 Days and older   (Child, Adult, Older Adult)",Phase 3,240.0,"April 16, 2020","March 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04376034
1932,1932,Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations,Recruiting,Behavioral: Motivational social support from nurse|Behavioral: Motivational social support from nurse with additional support from significant other|Behavioral: Attention control,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,225.0,"August 1, 2019",May 2023,United States,https://ClinicalTrials.gov/show/NCT03907891
1933,1933,Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome,Not yet recruiting,Other: Blood sampling|Other: Skin biopsy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,25.0,October 2020,December 2020,France,https://ClinicalTrials.gov/show/NCT04590209
1934,1934,Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions,Not yet recruiting,Biological: anti-SARS-CoV-2 human convalescent plasma,All,1 Month to 17 Years   (Child),Phase 1,30.0,August 2020,December 2024,United States,https://ClinicalTrials.gov/show/NCT04462848
1935,1935,A Study of a Candidate COVID-19 Vaccine (COV003),Recruiting,Biological: ChAdOx1 nCoV-19 single dose + paracetamol|Biological: MenACWY single dose + paracetamol|Biological: ChAdOx1 nCoV-19 two dose + paracetamol|Biological: MenACWY prime & saline placebo boost + paracetamol,All,"18 Years and older   (Adult, Older Adult)",Phase 3,10300.0,"June 2, 2020",September 2021,Brazil,https://ClinicalTrials.gov/show/NCT04536051
1936,1936,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),Not yet recruiting,Drug: L-ascorbic acid|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,January 2021,May 2021,United States,https://ClinicalTrials.gov/show/NCT04344184
1937,1937,Using PRP and Cord Blood in Treatment of Covid -19,Recruiting,Combination Product: stem cells,All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100.0,"May 25, 2020","September 1, 2020",Egypt,https://ClinicalTrials.gov/show/NCT04393415
1938,1938,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Drug: VC|Drug: Sterile Water for Injection,All,"18 Years and older   (Adult, Older Adult)",Phase 2,56.0,"February 14, 2020","March 29, 2020",China,https://ClinicalTrials.gov/show/NCT04264533
1939,1939,Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,Recruiting,Drug: REGN10933 + REGN10987|Drug: Placebo,All,"12 Years and older   (Child, Adult, Older Adult)",Phase 3,2000.0,"July 13, 2020","August 15, 2021",Georgia,https://ClinicalTrials.gov/show/NCT04452318
1940,1940,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,Other: HOME-CoV rule implementation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3133.0,"April 9, 2020","June 17, 2020",Belgium,https://ClinicalTrials.gov/show/NCT04338841
1941,1941,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Drug: Chloroquine diphosphate,All,"18 Years and older   (Adult, Older Adult)",Phase 2,278.0,"March 23, 2020","June 7, 2020",Brazil,https://ClinicalTrials.gov/show/NCT04323527
1942,1942,MR-Evaluation of Renal Function In Septic Patients,Recruiting,Other: Plasma expansion with Ringer's Acetate,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,April 2016,October 2025,Sweden,https://ClinicalTrials.gov/show/NCT02765191
1943,1943,"To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects",Recruiting,Drug: CT-P59|Drug: Placebo,All,19 Years to 55 Years   (Adult),Phase 1,32.0,"July 18, 2020","November 30, 2020","Korea, Republic of",https://ClinicalTrials.gov/show/NCT04525079
1944,1944,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults,Recruiting,Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,456.0,"April 23, 2020",November 2020,Germany,https://ClinicalTrials.gov/show/NCT04380701
1945,1945,Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections,Recruiting,Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation,All,"19 Years and older   (Adult, Older Adult)",Phase 2,20.0,"October 24, 2017","March 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT03331445
1946,1946,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Recruiting,Drug: Colchicine|Drug: Placebo oral tablet,All,"40 Years and older   (Adult, Older Adult)",Phase 3,6000.0,"March 23, 2020",December 2020,Brazil,https://ClinicalTrials.gov/show/NCT04322682
1947,1947,The COVID-19 ICU PRAYER Study,Recruiting,Behavioral: prayer,All,"18 Years to 110 Years   (Adult, Older Adult)",Not Applicable,1000.0,"June 1, 2020","August 31, 2020",United States,https://ClinicalTrials.gov/show/NCT04361838
1948,1948,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,Recruiting,Radiation: Angiography scanner,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"May 26, 2020","August 31, 2021",France,https://ClinicalTrials.gov/show/NCT04479540
1949,1949,A New Screening Strategy for 2019 Novel Coronavirus Infection,Not yet recruiting,Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy,All,"Child, Adult, Older Adult",Not Applicable,230.0,February 2020,March 2020,China,https://ClinicalTrials.gov/show/NCT04281693
1950,1950,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Recruiting,Behavioral: Mindfulness-Based Cognitive Therapy|Behavioral: Muscle Relaxation Therapy,All,"18 Years to 72 Years   (Adult, Older Adult)",Not Applicable,60.0,"October 19, 2020",December 2021,United States,https://ClinicalTrials.gov/show/NCT04540939
1951,1951,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,Drug: alpha one antitrypsin inhalation,All,"18 Years and older   (Adult, Older Adult)",Early Phase 1,150.0,"June 1, 2020","September 1, 2020",Saudi Arabia,https://ClinicalTrials.gov/show/NCT04385836
1952,1952,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Recruiting,Drug: Meplazumab for Injection,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,"February 3, 2020","December 31, 2020",China,https://ClinicalTrials.gov/show/NCT04275245
1953,1953,A Study of Ad26.COV2.S in Adults (COVID-19),Recruiting,Biological: Ad26.COV2.S|Biological: Placebo,All,"20 Years and older   (Adult, Older Adult)",Phase 1,250.0,"August 11, 2020","December 8, 2021",Japan,https://ClinicalTrials.gov/show/NCT04509947
1954,1954,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",Completed,Drug: EIDD-2801|Drug: Placebo,All,18 Years to 60 Years   (Adult),Phase 1,130.0,"April 10, 2020","August 11, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04392219
1955,1955,Effect of Positive Attitudes on Behavior and Wellness,Completed,Behavioral: Positive feedback,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,24.0,"June 15, 2020","July 30, 2020",United States,https://ClinicalTrials.gov/show/NCT04441632
1956,1956,"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",Suspended,Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500.0,"April 4, 2020","August 1, 2021",United States,https://ClinicalTrials.gov/show/NCT04341727
1957,1957,Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,Recruiting,Behavioral: Internet-based guided self-help based on CBT principles,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"May 14, 2020","June 30, 2021",Israel,https://ClinicalTrials.gov/show/NCT04394403
1958,1958,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Completed,Other: Deep Breathing training|Other: Compassion focused intervention,All,20 Years to 40 Years   (Adult),Not Applicable,69.0,"May 2, 2020","May 31, 2020",Italy,https://ClinicalTrials.gov/show/NCT04382560
1959,1959,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19","Active, not recruiting",Behavioral: Supportive Therapy SSI|Behavioral: Behavioral Activation SSI|Behavioral: Growth Mindset SSI,All,13 Years to 16 Years   (Child),Not Applicable,2409.0,"November 19, 2020","July 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04634903
1960,1960,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,"Active, not recruiting",Behavioral: SSE educational intervention|Other: Home sample collection of concerning mole with physician supervision|Behavioral: Active control:Healthy Living,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,1000.0,"July 2, 2020","December 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04420273
1961,1961,Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living',Not yet recruiting,Behavioral: Brief Skills for Safer Living,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,75.0,August 2020,August 2021,Canada,https://ClinicalTrials.gov/show/NCT04495543
1962,1962,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,Recruiting,Biological: T memory cells and NK cells,All,"up to 80 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,58.0,"September 4, 2020",March 2021,Spain,https://ClinicalTrials.gov/show/NCT04578210
1963,1963,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,Recruiting,Other: Sudarshan Kriya Yoga (SKY)|Other: Health Enhancement Program,All,"18 Years to 70 Years   (Adult, Older Adult)",Early Phase 1,60.0,"June 25, 2020","June 30, 2021",Canada,https://ClinicalTrials.gov/show/NCT04368676
1964,1964,Post-Pandemic Perception of Public Space in Singapore,Not yet recruiting,Other: Public space exposure,All,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,34.0,"June 1, 2020","December 31, 2020",Singapore,https://ClinicalTrials.gov/show/NCT04394039
1965,1965,A 3-month Cycle of Virtual Guided Tours to Promote Health in Older Community Members in a Context of COVID-19 Induced Social Isolation: a Pilot Study,Not yet recruiting,Other: Museum virtual guided tours,All,65 Years and older   (Older Adult),Not Applicable,40.0,"January 4, 2021","July 4, 2021",Canada,https://ClinicalTrials.gov/show/NCT04593433
1966,1966,Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome,Recruiting,Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,9.0,"June 17, 2020","June 30, 2025",Sweden,https://ClinicalTrials.gov/show/NCT04447833
1967,1967,Vitamin D3 Supplementation to Prevent Respiratory Tract Infections,Recruiting,Dietary Supplement: Vitamin D supplementation,All,"52 Years and older   (Adult, Older Adult)",Not Applicable,2099.0,"October 27, 2020",November 2021,Jersey,https://ClinicalTrials.gov/show/NCT04596657
1968,1968,Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects,Enrolling by invitation,Behavioral: Video about safety and effectiveness of adult seasonal flu vaccination|Behavioral: Message directing subjects to information on COVID-19 vaccine safety and efficacy,Male,18 Years to 51 Years   (Adult),Not Applicable,3350.0,"December 20, 2019","February 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04160975
1969,1969,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),Recruiting,Other: Meditation (1 x 20-minute guided audio training),All,"18 Years and older   (Adult, Older Adult)",Not Applicable,292.0,"October 28, 2020",March 2021,Australia,https://ClinicalTrials.gov/show/NCT04602286
1970,1970,"A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)",Recruiting,Drug: TAK-981|Drug: Standard of care,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,242.0,"October 1, 2018","October 1, 2023",United States,https://ClinicalTrials.gov/show/NCT03648372
1971,1971,CoV-PICS: A Virtual Post-ICU Clinic,Recruiting,Other: Medical Record Review - Inpatient Treatment|Other: Online Questionnaires,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,80.0,"September 29, 2020","July 30, 2021",United States,https://ClinicalTrials.gov/show/NCT04490278
1972,1972,Brief Video Interventions for Depression,Recruiting,Behavioral: Entrée: Cognitive skills|Behavioral: Entrée: Behavioral skills|Behavioral: Entrée: Interpersonal skills|Behavioral: Sampler skills,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,501.0,November 2020,November 2020,United States,https://ClinicalTrials.gov/show/NCT04643964
1973,1973,Mindfulness Training for Seniors,Completed,Behavioral: Mindfulness training (MT) Connect,All,"60 Years to 95 Years   (Adult, Older Adult)",Not Applicable,53.0,"May 13, 2020","August 4, 2020",United States,https://ClinicalTrials.gov/show/NCT04378803
1974,1974,Music Therapy in Frontline Healthcare Workers,Not yet recruiting,Behavioral: Music Therapy,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,20.0,"October 1, 2020","November 30, 2020",Canada,https://ClinicalTrials.gov/show/NCT04551274
1975,1975,Telemedical Risk Assessment and Preoperative Evaluation (TAPE),Recruiting,Device: TAPE-Software,All,"Child, Adult, Older Adult",Not Applicable,100.0,"April 20, 2020","November 30, 2020",Germany,https://ClinicalTrials.gov/show/NCT04518514
1976,1976,Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study,Recruiting,Other: Pulmonary tele-rehabilitation,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30.0,December 2020,January 2022,Canada,https://ClinicalTrials.gov/show/NCT04658979
1977,1977,Effects of a Face Mask on Oxygenation During Exercise,Completed,Other: Progressive cycling exercise test to exhaustion,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14.0,"September 14, 2020","October 15, 2020",Canada,https://ClinicalTrials.gov/show/NCT04557605
1978,1978,Video-Based Exercises and Well-Being During Social Isolation,Completed,Other: Video based aerobic exercise,All,18 Years to 35 Years   (Adult),Not Applicable,68.0,"April 6, 2020","June 3, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04335851
1979,1979,The Efficacy Comparing Daily and After-each-case Room Disinfection.,Completed,Other: after-each-case room disinfection|Other: daily room disinfection,All,"Child, Adult, Older Adult",Not Applicable,240.0,"May 25, 2020","June 10, 2020",China,https://ClinicalTrials.gov/show/NCT04399005
1980,1980,Effectiveness of Convalescent Immune Plasma Therapy,Completed,Other: Convalescent Immune Plasma,All,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,60.0,"May 15, 2020","June 17, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04442958
1981,1981,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Enrolling by invitation,Behavioral: self-care tools|Behavioral: lay telephone coaching,All,65 Years and older   (Older Adult),Not Applicable,176.0,"October 21, 2020","May 1, 2021",Canada,https://ClinicalTrials.gov/show/NCT04609371
1982,1982,Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease,Not yet recruiting,Dietary Supplement: Vitamin D 1000 IU|Drug: Placebo,All,18 Years to 30 Years   (Adult),Not Applicable,4400.0,"September 1, 2020","April 28, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04476680
1983,1983,Chat-based Support for Preventing Smoking Relapse,"Active, not recruiting",Behavioral: Chat-based instant messaging support|Behavioral: SMS message support|Behavioral: Self-help booklet,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,108.0,"June 2, 2020","June 30, 2021",Hong Kong,https://ClinicalTrials.gov/show/NCT04409496
1984,1984,Telemedicine for Follow-up of Systemic Lupus Erythematosus,Recruiting,Other: Telemedicine|Other: Standard care,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"May 1, 2020","December 31, 2021",Hong Kong,https://ClinicalTrials.gov/show/NCT04368299
1985,1985,Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions,Not yet recruiting,Drug: Dexamethasone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,980.0,"October 7, 2020","December 30, 2023",Spain,https://ClinicalTrials.gov/show/NCT04545242
1986,1986,Pre-exposure Prophylaxis for SARS-Coronavirus-2,"Active, not recruiting",Drug: Hydroxychloroquine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1500.0,"April 6, 2020",August 2020,United States,https://ClinicalTrials.gov/show/NCT04328467
1987,1987,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,Recruiting,Drug: Niclosamide|Drug: Placebo,All,18 Years to 45 Years   (Adult),Phase 1,28.0,"November 2, 2020","May 31, 2021",Germany,https://ClinicalTrials.gov/show/NCT04644705
1988,1988,Virtual Parental Presence on Induction,Not yet recruiting,Other: Use of Facetime with child and parents during induction,All,4 Years to 12 Years   (Child),Not Applicable,184.0,October 2020,December 2022,Canada,https://ClinicalTrials.gov/show/NCT04574219
1989,1989,Project Resurgence Communication Trial,Completed,Other: Communication type,All,"Child, Adult, Older Adult",Not Applicable,11120.0,"June 15, 2020","July 17, 2020",United States,https://ClinicalTrials.gov/show/NCT04418947
1990,1990,Self-compassion for Chronic Pain Virtual Group Treatment Program,Recruiting,Behavioral: Self-Compassion for Chronic Pain Virtual Group Treatment Program,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,28.0,"May 25, 2020","March 31, 2021",Canada,https://ClinicalTrials.gov/show/NCT04413006
1991,1991,PH94B in the Treatment of Adjustment Disorder With Anxiety,Not yet recruiting,Drug: PH94B,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,30.0,November 2020,September 2021,United States,https://ClinicalTrials.gov/show/NCT04404192
1992,1992,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Enrolling by invitation,Other: impliminting Online Distance Learning,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180.0,"September 1, 2020","February 28, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04372693
1993,1993,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Drug: Tocilizumab,All,"18 Years and older   (Adult, Older Adult)",Phase 2,228.0,"March 30, 2020","December 31, 2021",France,https://ClinicalTrials.gov/show/NCT04331808
1994,1994,Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,Enrolling by invitation,Behavioral: Brief cognitive behavioral therapy|Behavioral: Crisis intervention therapy,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,236.0,"June 30, 2020","December 30, 2020",Honduras,https://ClinicalTrials.gov/show/NCT04394455
1995,1995,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Active, not recruiting",Drug: Opaganib|Drug: Placebo,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,40.0,"July 2, 2020",December 2020,Israel,https://ClinicalTrials.gov/show/NCT04414618
1996,1996,A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy,Recruiting,Drug: Anakinra,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,"October 30, 2019",October 2022,United States,https://ClinicalTrials.gov/show/NCT04148430
1997,1997,Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,Recruiting,Device: MakAir,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,117.0,"July 20, 2020",December 2020,France,https://ClinicalTrials.gov/show/NCT04475185
1998,1998,Telerehabilitation in Oncology Patients,Enrolling by invitation,Other: Therapeutic Exercise and Education,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30.0,"July 1, 2020",December 2020,Spain,https://ClinicalTrials.gov/show/NCT04547634
1999,1999,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Enrolling by invitation,Behavioral: Technology based social interactions|Other: No research related technology based social interactions,All,"Child, Adult, Older Adult",Not Applicable,150.0,"June 2, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04480112
2000,2000,The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm,Enrolling by invitation,Dietary Supplement: 300 mg of omega3-FA,All,"30 Years to 66 Years   (Adult, Older Adult)",Not Applicable,100.0,"October 2, 2020","February 10, 2021",Jordan,https://ClinicalTrials.gov/show/NCT04483271
2001,2001,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,"Active, not recruiting",Other: DIG Axial|Other: DIG Tilted|Other: CIG Axial|Other: CIG Tilted,All,"50 Years to 65 Years   (Adult, Older Adult)",Not Applicable,56.0,"July 11, 2018",August 2020,Egypt,https://ClinicalTrials.gov/show/NCT04475913
2002,2002,Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial,"Active, not recruiting",Other: Virtual Care and Remote Automated Monitoring,All,"40 Years and older   (Adult, Older Adult)",Not Applicable,905.0,"April 23, 2020",January 2021,Canada,https://ClinicalTrials.gov/show/NCT04344665
2003,2003,Tele-Yoga Therapy for Chronic Pain,Completed,Other: Tele-Yoga Therapy,All,18 Years to 60 Years   (Adult),Not Applicable,18.0,"March 25, 2020","June 15, 2020",United Kingdom,https://ClinicalTrials.gov/show/NCT04457388
2004,2004,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,"Active, not recruiting",Behavioral: Video Chat +Personalized Feedback|Behavioral: Video Chat + Basic Feedback|Behavioral: Discussion Board for Social Support +Basic Feedback|Behavioral: Discussion Board for Social Support+Personalized Feedback,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"September 23, 2020","September 15, 2021",United States,https://ClinicalTrials.gov/show/NCT04514900
2005,2005,A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults,Recruiting,Drug: Icosapent ethyl,All,"50 Years and older   (Adult, Older Adult)",Phase 4,16500.0,"August 7, 2020","February 28, 2023",United States,https://ClinicalTrials.gov/show/NCT04505098
2006,2006,Digital Cardiac Counseling Trial: DCC Trial,Recruiting,Other: Digital cardiac Counseling,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,394.0,"June 5, 2020","December 31, 2022",Netherlands,https://ClinicalTrials.gov/show/NCT04393636
2007,2007,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Recruiting,Behavioral: Mindfulness,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50.0,"March 15, 2020",December 2021,Italy,https://ClinicalTrials.gov/show/NCT04389372
2008,2008,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine,Recruiting,Behavioral: Mindfulness,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,25.0,"September 15, 2020",December 2021,Italy,https://ClinicalTrials.gov/show/NCT04604977
2009,2009,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,Completed,Behavioral: brief mindfulness based intervention|Behavioral: Progressive muscle relaxation,All,"22 Years and older   (Adult, Older Adult)",Not Applicable,146.0,"July 7, 2020","September 5, 2020",Saudi Arabia,https://ClinicalTrials.gov/show/NCT04656626
2010,2010,DigiVis: Self-testing Vision App for Telephone Consultations,Not yet recruiting,Device: DigiVis visual acuity app,All,"5 Years to 85 Years   (Child, Adult, Older Adult)",Not Applicable,250.0,"July 24, 2020","January 1, 2021",United Kingdom,https://ClinicalTrials.gov/show/NCT04482387
2011,2011,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,Behavioral: Lifestyle change promotion program|Behavioral: Mindfullness based cognitive program|Behavioral: Written Information,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,186.0,"January 13, 2020","July 12, 2022",Spain,https://ClinicalTrials.gov/show/NCT04428099
2012,2012,Prednisolone in Early Diffuse Systemic Sclerosis,Recruiting,Drug: Prednisolone 5 mg|Drug: Placebo oral capsule; From August 2020 'no additional treatment',All,"18 Years and older   (Adult, Older Adult)",Phase 2,72.0,"December 21, 2017",September 2021,United Kingdom,https://ClinicalTrials.gov/show/NCT03708718
2013,2013,Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety,Enrolling by invitation,Other: Aerobic Exercises,Female,18 Years to 25 Years   (Adult),Not Applicable,40.0,"December 10, 2020","February 25, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04662021
2014,2014,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,"Active, not recruiting",Combination Product: Insulin film|Device: Fast dissolving film,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,40.0,"December 1, 2020","January 15, 2021",Egypt,https://ClinicalTrials.gov/show/NCT04657809
2015,2015,The Effect of Clear Masks in Improving Patient Relationships,Recruiting,Behavioral: Transparent mask|Behavioral: Typical surgical covered mask,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"September 3, 2020",December 2020,United States,https://ClinicalTrials.gov/show/NCT04595695
2016,2016,A Smartphone Intervention for Relational and Mental Well Being,Completed,Behavioral: Intervention,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,1765.0,"April 4, 2020","August 3, 2020",United States,https://ClinicalTrials.gov/show/NCT04629755
2017,2017,Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,Recruiting,Other: Phone call,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,130.0,"June 12, 2020","October 12, 2021",France,https://ClinicalTrials.gov/show/NCT04470869
2018,2018,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old),Recruiting,Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group,All,"60 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,50.0,"August 19, 2020","December 31, 2021",China,https://ClinicalTrials.gov/show/NCT04550351
2019,2019,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Recruiting,Drug: Sodium bicarbonate|Other: Standard of Care,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40.0,"October 5, 2020",March 2021,United States,https://ClinicalTrials.gov/show/NCT04530448
2020,2020,Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia,Recruiting,Drug: Methylprednisolone|Other: Usual Care,All,"18 Years and older   (Adult, Older Adult)",Phase 2,90.0,"December 2, 2019",July 2022,United States,https://ClinicalTrials.gov/show/NCT03852537
2021,2021,Telerehabilitation in Lung Surgery Patients,Recruiting,"Other: Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|Other: Exercise booklet",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40.0,"October 1, 2020","May 1, 2021",Turkey,https://ClinicalTrials.gov/show/NCT04568564
2022,2022,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Drug: Hydroxychloroquine Sulfate,All,"18 Years and older   (Adult, Older Adult)",Phase 4,53.0,"March 25, 2020","March 3, 2025",Norway,https://ClinicalTrials.gov/show/NCT04316377
2023,2023,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B,All,"18 Years and older   (Adult, Older Adult)",Phase 2,127.0,"February 10, 2020","March 31, 2020",Hong Kong,https://ClinicalTrials.gov/show/NCT04276688
2024,2024,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Not yet recruiting,Drug: Botulinum Neurotoxin|Drug: Placebo,All,"10 Years to 75 Years   (Child, Adult, Older Adult)",Phase 1,45.0,"July 15, 2020","October 15, 2020",United States,https://ClinicalTrials.gov/show/NCT04439825
2025,2025,Virtual White Boards for Patient Satisfaction,Not yet recruiting,Device: e-ink screen|Behavioral: Treatment as usual,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,"August 20, 2020","April 17, 2021",United States,https://ClinicalTrials.gov/show/NCT04497922
2026,2026,Global Mental Health of Urban Mothers,Not yet recruiting,Behavioral: Web-based psychosocial peer-to-peer support,Female,"18 Years and older   (Adult, Older Adult)",Not Applicable,200.0,"November 1, 2020",June 2023,China,https://ClinicalTrials.gov/show/NCT04363177
2027,2027,Lessening Organ Dysfunction With VITamin C,Recruiting,Drug: Vitamin C|Other: Control,All,"18 Years and older   (Adult, Older Adult)",Phase 3,800.0,"November 8, 2018","December 31, 2022",Canada,https://ClinicalTrials.gov/show/NCT03680274
2028,2028,Inhaled NO for the Treatment of Viral Pneumonia in Adults,Recruiting,Device: LungFit™,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,90.0,"November 25, 2020","September 7, 2021",Israel,https://ClinicalTrials.gov/show/NCT04606407
2029,2029,"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",Recruiting,Drug: Drug: NA-831 - 0.10 mg/kg|Drug: Placebo- 0.10 mg/kg|Drug: Drug: NA-831 - 0.20 mg/kg|Drug: Placebo- 0.20 mg/kg|Drug: Drug: GS-5734 - 1.00 mg/kg|Drug: Placebo- 1.00 mg/kg|Drug: Drug: GS-5734 - 2.00 mg/kg|Drug: Placebo- 2.00 mg/kg|Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|Combination Product: Placebo 0.10 mg + 1.00 mg/kg|Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|Combination Product: Placebo 0.20 mg + 2.00 mg/kg,All,21 Years to 50 Years   (Adult),Phase 1,45.0,"September 15, 2020","March 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04480333
2030,2030,Universal Anti-Viral Vaccine for Healthy Elderly Adults,Not yet recruiting,Drug: AlloStim,All,65 Years and older   (Older Adult),Phase 1|Phase 2,40.0,"January 6, 2021","December 31, 2021",United States,https://ClinicalTrials.gov/show/NCT04441047
2031,2031,Remote Blood Pressure Monitoring With the Wearable SENBIOSYS Photoplethysmographic Device,Not yet recruiting,Device: Sensbiosys,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30.0,"May 1, 2020","June 1, 2020",Switzerland,https://ClinicalTrials.gov/show/NCT04379986
2032,2032,PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock,Recruiting,"Other: Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,150.0,"March 15, 2019","March 15, 2024",Belgium,https://ClinicalTrials.gov/show/NCT04107402
2033,2033,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,Drug: Pioglitazone,All,"18 Years and older   (Adult, Older Adult)",Phase 4,10.0,"May 21, 2020","December 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04473274
2034,2034,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Drug: Hydroxychloroquine|Other: Placebo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1309.0,"March 17, 2020","May 20, 2020",Canada,https://ClinicalTrials.gov/show/NCT04308668
2035,2035,Coronavirus Smell Therapy for Anosmia Recovery,Not yet recruiting,Drug: Budesonide|Behavioral: High-Concentration Essential Oil|Drug: Placebo|Behavioral: Low-Concentration Essential Oil,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,200.0,"June 1, 2021","December 31, 2023",United States,https://ClinicalTrials.gov/show/NCT04422275
2036,2036,Acceptance and Commitment Therapy Delivered by Automated Software Messaging,Completed,Behavioral: Software Messaging,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,90.0,"April 5, 2020","June 1, 2020",United States,https://ClinicalTrials.gov/show/NCT04329897
2037,2037,Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness,Recruiting,Behavioral: Mindfulness Alone (MO) Intervention|Behavioral: Mindfulness + Compassion Intervention (MC),All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,120.0,"May 25, 2020",May 2021,United States,https://ClinicalTrials.gov/show/NCT04414826
2038,2038,Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions,Completed,Drug: FAVIR 200 MG FT|Drug: AVIGAN 200 mg FT,Male,18 Years to 40 Years   (Adult),Phase 1,30.0,"June 5, 2020","June 13, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04444986
2039,2039,Comparison of VieScope vs. Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions,Completed,Device: The standard Macintosh laryngoscope|Device: The Vie Scope laryngoscope,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,35.0,"January 20, 2020","February 25, 2020",Poland,https://ClinicalTrials.gov/show/NCT04363775
2040,2040,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,Recruiting,Behavioral: Intervention group CoronaCope,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,120.0,"June 10, 2020",August 2021,Sweden,https://ClinicalTrials.gov/show/NCT04424212
2041,2041,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions","Active, not recruiting",Drug: AVICOD 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets,Male,18 Years to 55 Years   (Adult),Phase 1,30.0,"November 13, 2020","December 20, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04651959
2042,2042,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Completed,Drug: FAVICOVIR 200 mg Film Tablet|Drug: AVIGAN 200 mg Film Tablets,Male,20 Years to 40 Years   (Adult),Phase 1,30.0,"May 14, 2020","June 19, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04406194
2043,2043,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Completed,Drug: FAVIRA 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets,Male,20 Years to 40 Years   (Adult),Phase 1,30.0,"May 28, 2020","June 18, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04400682
2044,2044,The Cognitive and spOrt Virtual EPIC Training Study for Cardiovascular Diseases,Recruiting,Behavioral: Physical exercise training|Behavioral: Cognitive training,All,"50 Years to 100 Years   (Adult, Older Adult)",Not Applicable,118.0,"May 18, 2020","December 1, 2022",Canada,https://ClinicalTrials.gov/show/NCT04661189
2045,2045,"The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions","Active, not recruiting",Drug: ATAFENOVIR 200 MG KAPSUL|Drug: ARBIDOL 100 MG KAPSUL,Male,20 Years to 40 Years   (Adult),Phase 1,18.0,"July 9, 2020","August 20, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04476719
2046,2046,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions",Completed,Drug: Test: Favipiravir 200 mg (LOQULAR)|Drug: Reference: Favipiravir 200 mg (Avigan),Male,20 Years to 40 Years   (Adult),Phase 1,30.0,"June 23, 2020","August 8, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04407000
2047,2047,Azithromycin-Prevention in Labor Use Study (A-PLUS),Recruiting,Drug: Azithromycin|Drug: Placebo,Female,18 Years to 45 Years   (Adult),Phase 3,34000.0,"September 1, 2020","September 1, 2023",Bangladesh,https://ClinicalTrials.gov/show/NCT03871491
2048,2048,"Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions","Active, not recruiting",Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Test|Drug: Lopinavir 200Mg/Ritonavir 50Mg FT Reference,Male,20 Years to 40 Years   (Adult),Phase 1,30.0,"April 30, 2020","June 20, 2020",Turkey,https://ClinicalTrials.gov/show/NCT04386876
2049,2049,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,Completed,Biological: MSCs-derived exosomes,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,24.0,"February 15, 2020","July 31, 2020",China,https://ClinicalTrials.gov/show/NCT04276987
2050,2050,Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients,Recruiting,Drug: Crizanlizumab,All,6 Months to 17 Years   (Child),Phase 2,100.0,"October 1, 2018","November 20, 2024",Belgium,https://ClinicalTrials.gov/show/NCT03474965
